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Abstract 
 
In recent years, rhodium(III)-catalysed C-H activation methodologies have come to the fore and 
proved to be an invaluable and powerful synthetic tool for the preparation of heterocycles. C-H 
activation using rhodium(III)-catalysed processes with internal oxidants has considerably 
improved the accessibility of these scaffolds. Furthermore, the alkynes and alkenes used to 
intercept the arylmetal species in the aforementioned systems have been either electronically 
neutral or electron-deficient.   
 
Chapter 1 outlines the investigation of electron-rich substrates, using vinyl esters as acetylene 
synthons and vinyl ethers as acetaldehyde enolate/acyl anion equivalents. From this study, a 
competing rhodium-catalysed Lossen rearrangement was identified and the regiochemical 
preference of vinyl ether substrates was determined. The preliminary screening identified the 
formation of a 3,4-unsubstituted isoquinolone from the reaction of vinyl acetate with the acyl 
hydroxamates. 
 
As a result, the synthesis of 3,4-unsubstituted isoquinolones, using vinyl acetate, a cheap bulk 
chemical, as an acetylene equivalent was explored. The procedure works well for a range of 
substituted N-(pivaloyloxy)benzamide derivatives; in total, 17 examplar 3,4-unsubstituted 
isoquinolones were prepared with an average yield of 75%. Heterocyclic pivaloyl hydroxamates 
were also tolerated in the reaction. These conditions offer distinct advantages over traditional 
methods. The utility of the procedure was demonstrated in the synthesis of two intermediates 
towards hepatitis C virus inhibitors. The ensuing chapter describes the optimization of this 
methodology using aryl ketoximes for the synthesis of 3,4-unsubstituted isoquinolines. 
 
To conclude, the final chapter describes the isolation and attempted optimisation of a highly 
fluorescent tetracyclic imide. Mechanistic studies used to determine the formation of the imide 
identified putative intermediates, however the synthetic procedure could not be optimised 
further. Using a novel strategy, via a key C-H activation/annulation reaction of a range of 
bespoke alkynes and N-(pivaloyloxy)benzamides, a library of nine imides was prepared. 
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Chapter 1 
 
Introduction 
1.1 C-H Activation 
 
Transition metal-catalysed cross-coupling methodologies represent one of the most powerful 
classes of chemical reactions in organic chemistry. Recognised by the scientific community as a 
highly versatile tool in synthetic disconnections, Heck, Negishi and Suzuki were awarded the 
Nobel prize for their contribution to the field for the development of palladium-catalysed cross-
coupling reactions.1–7 As the field has matured, new disconnections and novel catalysts have 
been identified for a variety of systems. Despite these well-established and robust protocols, the 
influence of economic and environmental factors has intensified the search for atom-efficient 
and environmentally green protocols. The advent of novel C-H activation methodologies, 
whereby the typically inert and ubiquitous C-H bond can be utilised instead of either an 
organometallic coupling partner or an aryl halide, has identified a powerful alternative. This 
emerging field is constantly evolving to encompass new areas that include heterocyclic 
synthesis, chiral C-H activation, sp, sp2 and sp3 hybridised systems, double C-H activation (C-H 
to C-H coupling) and many more. The aim of this introduction is to outline the origin of C-H 
activation in reference to the oxidative Heck reaction, to highlight examples of heterocyclic 
synthesis based on rhodium catalysis and finally, to discuss the recent developments of redox-
neutral systems. 
 
1.2 The oxidative Heck reaction 
 
In 1967, Fujiwara and Moritani discovered the oxidative Heck reaction from the coupling of 
styrene 4 with benzene 3 in acetic acid using a styrene-palladium chloride complex 28 to give 
trans-stilbene 1 (Scheme 1.1).9 This was the first reaction of its kind that utilised a C-H bond in 
a cross-coupling reaction with an alkene. The reaction highlighted the potential to streamline 
target-orientated synthesis by obviating the requirement to prefunctionalise starting materials. In 
order to reduce the stoichiometric palladium loading, investigation of suitable co-oxidants were 
undertaken. Fujiwara and Moritani found that addition of copper(II) acetate or silver(I) acetate 
under an oxygenated atmosphere would allow the reaction of styrene 4 and benzene 3 to 
proceed catalytically with respect to both palladium and copper/silver (Scheme 1.1).10 
 
	   2 
 
Scheme 1.1. aYields with respect to the palladium catalyst. 
 
Shue published a communication on the coupling of benzene 3 and styrene 4 using oxygen as 
the sole oxidant, which effectively reduced the catalyst loading to one mol% (Scheme 1.2).11 
Following optimisation studies on a number of oxidation systems, Fujiwara et al. identified tert-
butyl peroxide with benzoquinone as the ideal system (Scheme 1.2).12 The reaction of benzene 3 
with various cinnamates 5 proceeded to give good yields of the unsaturated products 6 and 7. 
The increase in the catalytic turnover number was attributed to the dual role of benzoquinone as 
an oxidant to regenerate palladium(II) from palladium(0) and to prevent palladium(0) 
nanoparticle aggregates forming in the reaction by coordination.13  
 
Scheme 1.2. aYield with respect to the palladium catalyst. 
 
1.3 Catalytic cycles 
 
The classic Heck reaction proceeds via the coupling of an aryl/vinyl halide with an alkene to 
furnish an alkenylated aromatic. The catalytic cycle proceeds by the oxidative insertion of a 
palladium(0) species I into the aryl/vinyl halide (or pseudohalide) C-X bond to give a 
palladium(II) salt II. Coordination of the alkene substrate III followed by syn-addition results in 
the alkylated palladium complex IV. Subsequent syn-β-hydride elimination releases the coupled 
alkene (typically the trans-alkene is favoured) and the palladium(II) salt V, which can undergo 
reductive elimination to regenerate the active palladium(0) catalyst I (Pathway A, Scheme 1.3). 
HPh
AcOH, reflux
Pd(OAc)2 (0.1 eq.)
[O] (0.1 eq.)
benzene−AcOH 
(4:1, 0.2 M)
O2 (50 atm)
reflux, 8 h [O]
Cu(OAc)2 446%a
AgOAc  245%a
2
1
23%a
Ph
1
Pd
Cl Cl
Cl
Pd
Cl
Ph
Ph
solvent
3
Ph 4
HPh
31100%a 1
Ph
Shue
Pd(OAc)2 (1 mol%)
O2,100 °C, 5 h
Ph
Ph
Pd(OAc)2 (1 mol%)
BQ (10 mol%)
tBuOOH (2 eq.)
AcOH—Ac2O 
(3:1, 0.75 M)
90 °C, 12 h 6 R = OEt 72%
7 R = Me 74%
R
O
5
O
R
4
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Scheme 1.3 
 
The oxidative Heck reaction follows the same reaction pathway with two exceptions. The active 
palladium(II) catalyst VI oxidatively inserts into the C-H bond via a base-promoted concerted 
metallation-deprotonation (CMD) pathway, using one of the σ-donor ligands, to generate the 
intermediate II.14 At this stage the cycle mimics the catalytic cycle of the Heck reaction until the 
palladium(0) species I forms. In order to complete the catalytic cycle an oxidant is required to 
reoxidise the palladium(0) I to palladium(II) VI (Pathway B, Scheme 1.3).  
 
The key challenge in the design of an oxidative Heck system lies in selecting a single C-H bond 
and identifying an oxidant that is suitable to use in conjunction with the substrates and metal-
catalyst. The metal catalyst can be influenced to insert into a specific C-H bond by means of a 
directing group, i.e. one that is capable of coordinating to the metal. This interaction guides the 
catalyst into the proximity of the desired C-H bond, ensuring that this position is kinetically 
favoured. This interaction can be used to achieve excellent regioselectivity in reactions. In 
comparison to the broad range of directing groups available, the oxidant selection is somewhat 
limited, with optimised systems having been identified for palladium, rhodium and ruthenium 
catalysts.  
 
  
Pd0Ln
R1 PdIILn
X
R2
R1 PdIILn
X
R2
PdIILn
X
R2 H
R1
R1
R2
H
PdIILn
X
II
I
III
IV
V
Base
BaseHX
PdIIX2Ln
[O]
VI
R1-H
R1 PdIILn
X II
HX
Pd0Ln
R1-X
R1 PdIILn
X II
I
Pathway
 A or B
-oxidative insertion
-C-X bond
Pd0Ln
I
Pathway A - Heck Reaction
Pathway B - Oxidative Heck Reaction
-Oxidant required
-Concerted Metalation-Deprotonation (CMD)
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1.4 Rhodium-mediated oxidative Heck reactions 
 
Over the past decade there have been numerous reports of rhodium(III)-mediated oxidative 
Heck reactions with particular emphasis on one precatalyst, pentamethylcyclo-
pentadienylrhodium(III) chloride dimer ([Cp*RhCl2]2). Associated benefits over the existing 
palladium catalysts included lower catalyst loadings, higher selectivity for the mono-olefinated 
versus the bis-olefinated products and broader alkene scope. Glorius et al. have used this 
catalyst to couple acetanilide derivatives 8 to a number of electron-rich and poor styrene 
derivatives, resulting in a variety of trans-stilbene type products.15 A comparison of the rhodium 
and the palladium-catalysed coupling of 3-methylacetanilide 8a to n-butyl acrylate reveals an 
increase in the yield of the stilbene derivative 9 to 98% from the 91% previously reported by de 
Vries using their optimised palladium system (Scheme 1.4).16 The rhodium complex 
[Cp*RhCl2]2 was used sparingly (0.5 mol%) with two equivalents of copper(II) acetate oxidant 
and silver hexafluoroantimonate (AgSbF6, 2 mol%) as a chloride ion scavenger. Under these 
reaction conditions a range of alkenes were coupled to substituted acetanilides 8 to afford 
excellent yields of the ortho-alkenylated products 9-13 (48-98%). 
 
Scheme 1.4 
 
Lower yields were observed when sterically encumbered olefins were chosen. Halide functional 
groups were tolerated, both in the acetanilide and the styrene substrates; proto-debromination 
products or Heck products (from the reaction of the aryl halide) were not detected in the 
reactions. This can often be an issue when using palladium catalysts. Under a mild pressure 
(2 bar), ethylene was coupled to 8a to give the styrene derivative 11 (48% yield), although a 
higher catalyst loading was required (2.5 mol%). The preparation of styrenes via the 
palladium(II)-catalysed oxidative Heck reaction had previously been acknowledged to be 
challenging, poorly selective and only feasible under harsh conditions.10,17,18 
 
  
NHAc
[Cp*RhCl2]2 (0.5 mol%)
AgSbF6 (2 mol%)
Cu(OAc)2 (2.1 eq.)
t-AmylOH (0.2 M) 
120 °C, 16 h
NHAcR1
R2
R2
(1.5 eq.)
Pd(OAc)2 (6 mol%)
BQ (1 eq.)
TsOH (0.5 eq.)
AcOH—toluene
(2:1, 0.4 M) 
20 °C, 16 h
NHAcMe
O
OnBu
CO2nBu
(1 eq.)
8
9
91%
R1 = Me   R2 = CO2nBu 98% 9
R1 = Me   R2 = Ph 88% 10
R1 = Me   R2 = H 48%a 11
R1 = CF3  R2 = Ph 65% 12
R1 = Cl     R2 = Ph 67% 13 
a2.5 mol% Rh
8a R1 = m-Me
R1
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1.5 Heterocycle formation using C-H activation with alkynes 
 
The rhodium-catalysed oxidative Heck reaction has been thoroughly exemplified with a range 
of directing groups, including ureas, carbamates, ketones and amides, to prepare unsaturated 
products from a range of alkenes.19 Using similar conditions, C-H annulation protocols were 
developed for the synthesis of heterocyclic scaffolds, using internal alkynes. For example, 
Glorius et al. utilised primary benzamides 15 to direct the insertion of styrene derivatives to 
afford a range of trans-stilbene products 17 (Scheme 1.5).20 Using similar conditions, Rovis 
et al. prepared 12 exemplar isoquinolones 14 from the C-H activation/annulation of secondary 
benzamides 16 with diphenyl acetylene (Scheme 1.5).21  
 
Scheme 1.5 
 
Fagnou22 et al. reported the synthesis of acetyl-protected indoles 19 from acetanilide 8 and a 
range of unsymmetrical internal alkynes. Excellent regioselectivity was observed for installation 
of the aromatic at the 2-position, for example with 1-phenyl-1-propyne 18 (Scheme 1.6). 
Electron-donating and withdrawing groups were tolerated on the acetanilide 8, with the 
corresponding indoles 19 isolated in high yields.  
 
Scheme 1.6 
 
Glorius23 et al. were able to prepare penta- and tetra-substituted pyrroles, 20 and 22, from 
enamine derivatives 21 (Scheme 1.7). Interestingly, the nature of the proximal directing group 
was observed to influence product formation. Substituting the ester for the nitrile resulted in 
α-functionalisation of the enamine, opposed to the γ-selectivity observed with the ester. Further 
investigation identified the ester as a crucial factor to achieve allylic sp3 C-H bond activation. 
 
R1 = H
[Cp*RhCl2]2 (0.5 mol%)
AgSbF6 (2 mol%)
Cu(OAc)2 (2.1 eq.)
t-AmylOH (0.2 M) 
120 °C, 16 h
R3
R3
(1.5 eq.)
R2
N
H
O
NH2
O
R1
R2
R1 = Me
[Cp*RhCl2]2 (2.5 mol%)
Cu(OAc)2•H2O (2.1 eq.)
t-AmylOH (0.2 M) 
110 °C, 16 h
Ph
(1.25 eq.)
N
O
R2
Ph
PhPh
14 17
12 examples
40-86%
12 examples
40-86%
Me
15 R1 = H
16 R1 = Me
Ph
Me
[Cp*RhCl2]2 (2.5 mol%)
AgSbF6 (10 mol%)
Cu(OAc)2 (2.1 eq)
                
t-AmylOH (0.2 M)
120 oC, 1 h
N
Me
Ph
Ac8 18 19
NHAc
H
9 examples
92-82%
R1 R1
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Scheme 1.7 
 
Fagnou24 and Miura25 have each published similar work on the oxidative coupling of aryl 
aldimines 23 and ketimines 26 with symmetrical and unsymmetrical alkynes furnishing 
isoquinolines 24 and 27 (Scheme 1.8). The reaction of N-tert-butylbenzaldimine derviatives 23 
resulted in the loss of isobutylene via the isoquinolinium salt 25 formed post-cyclisation. Li et 
al. expanded the scope to include N-substituted benzamidines 28 and alkynes, leading to 
1-(alkylamino)- and 1-(arylamino)-isoquinolines 29 with yields ranging from 38-97%. These 
C-H activation protocols provide an attractive route for the synthesis of substituted 
isoquinolines, a ubiquitous motif found in natural products and pharmaceutical/agrochemical 
compounds.26 
 
Scheme 1.8 
 
The oxidative Heck reaction, and the variants based on these systems, has been shown to 
tolerate a wide substrate scope, both in terms of the directing groups used and suitable coupling 
partners. Systems using ruthenium, palladium and rhodium have been developed, however these 
systems rely on stoichiometric oxidants, which are typically metal-based. This leads to the 
generation of expensive, environmentally unfriendly waste streams. Often high temperatures, 
achieved by super heating solvents in sealed tubes, are required for reaction completion. These 
factors inherently limit this methodology to small-scale synthesis. 
R  = CO2Et
[Cp*RhCl2]2 (2.5 mol%)
AgSbF6 (10 mol%)
Cu(OAc)2 (2.1 eq.)
                  
DCE (0.2 M)
120 oC, 16 h
Hα
R
NH
Ac
N
Ac
Et
Ph
21
Hγ
PhEt
EtO2C
R  = CN
[Cp*RhCl2]2 (2.5 mol%)
AgSbF6 (10 mol%)
Cu(OAc)2 (2.1 eq.)
                  
DCE (0.2 M)
120 oC, 16 h
N
Ac
Et
Ph
Ph Et
NC
70%
20
60%
22
NH
HN
R2 [RhCp*Cl2]2 (4 mol%)
Cu(OAc)2 (2.1 eq.)
THF, 85 °C
28
[Cp*RhCl2]2 (0.5 mol%)
Cu(OAc)2•H2O (2.1 eq.)
DMF, 80 oC , 2 h
N
HN
R4
R3
R1
R4R3
R1
N
[Cp*Rh(MeCN)3][SbF6]2
(2.5 mol%)
Cu(OAc)2 (2.1 eq.)
DCE, 85 °C, 16 h
23
N
R4
R3
R1
R4R3
R1
NH N
R3
R4
26 27R4R3
Ph R2
R1
R2
24
R1
11 examples
30-81%
10 examples
32-99%
28 examples
38-97%
via:
N
R4
R3
R1
25
29
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1.6 Redox-neutral C-H activation 
 
The discovery and development of redox-neutral systems using ‘internal oxidants’ has had a 
significant impact on the field of C-H activation chemistry.19,27–29 The internal oxidant refers to 
a cleavable bond in the starting material which can act as an oxidant for the metal catalyst. 
Significant benefits include: mild and simple reaction conditions, no external oxidants, which 
avoids the use of stoichiometric copper acetate and silver salts,30–32 excellent functional group 
tolerance, high regioselectivity and low catalyst loadings.  
 
Wu and Cui et al. were the first to identify the potential in using the cleavage of an N-O bond to 
provide an oxygen atom transfer reagent.33 Using a palladium-catalysed system, quinoline-
N-oxides 30 were used to simultaneously direct C-H activation in the C2-position and provide 
an oxidant for the catalytic cycle, to furnish twelve alkenylated quinolines 32 (27-95% yields) 
using ethyl acrylate 31 in the oxidative Heck reaction (Scheme 1.9). Based on this concept, 
Harwig et al. have subsequently used oxime esters 33 to prepare a series of substituted 
indoles 34 via an intramolecular C-H amination.  
 
Scheme 1.9 
 
In rapid succession, the groups of Fagnou34,35 and Glorius36 reported a rhodium-catalysed 
system using internal oxidants, treating benzhydroxamic ethers with alkenes and alkynes to 
afford ortho-alkenylated benzamides 17 and isoquinolones 35, respectively (Scheme 1.10). 
Using electron-rich and electron-deficient N-methoxybenzamide derivatives 36, Fagnou 
exemplified the synthesis of substituted isoquinolones 35. Unsymmetrical alkynes reacted with 
good regioselectivity in favour of the sp2 group adopting the 3-position; for example,	  treatment 
of the N-methoxybenzamide 36 with 1-phenyl-1-propyne furnished 4-methyl-3-
phenylisoquinolone as the single regioisomer. Using the same hydroxamate ether 36, with a 
lower catalyst loading of 1 mol% (compared with 2.5 mol% required with the alkynes), Glorius 
reported the synthesis of thirty-five exemplar 2-alkenylbenzamides 17, using substrates that 
included styrene derivatives, a ferrocenyl-substituted alkene, butyl acrylate and ethylene. The 
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added advantage of these systems was the control over mono- versus disubstitution. Previously, 
a carefully selected substitution pattern using steric shielding would have been required to 
suppress the double olefination.36  
 
 
Scheme 1.10 
 
During their mechanistic studies, Glorius et al. postulated a seven-membered rhodacycle 
intermediate 37 that underwent a β-hydride elimination, via II, to afford the alkenylated 
benzamides 17 (Scheme 1.11). Based on this hypothesis they reasoned that coordination 
saturation of the rhodium catalyst, via I, could divert the reaction pathway away from the 
β-hydride elimination and towards reductive elimination of the C-N bond. 
 
 
Scheme 1.11 
 
By exchanging the methoxy group with a pivaloyl group the reactions of 
N-(pivaloyloxy)benzamide derivatives 39 with a range of alkenes furnished the 
dihydroisoquinolones 38, supporting their hypothesis (Scheme 1.12). To unambiguously rule 
out the stilbene 17 as an intermediate in the cyclisation reaction, a control experiment was 
carried out. Treatment of 17 under the standard reaction conditions did not form the 
dihydroisoquinolone 38 (Scheme 1.11). 
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Scheme 1.12 
 
A comprehensive optimisation study of the internal oxidant was subsequently reported by 
Fagnou et al. (Figure 1.1).34 The rationale behind the substrate selection was two-fold; to 
investigate internal oxidants bearing better leaving groups, and to use groups that could stabilise 
intermediates in the catalytic cycle.34 In order to standardise the reactions, a diaryl alkyne 
(diphenylacetylene 40) and a dialkyl alkyne (4-octyne 41) were screened against a number of 
substrates (entries 1-11) using the standard reaction conditions. A marked increase in reactivity 
was observed with carbonyl-containing internal oxidants (entries 4-8), particularly in the 
reactions using 4-octyne 41 as the substrate. The reactions of the dialkyl alkyne showed a 
marked improvement in yield compared to their previous system using stoichiometric copper 
acetate as an external oxidant.35 Nitrogen-containing leaving groups (entries 10 and 11) failed as 
internal oxidants.34  
 
 
 
Figure 1.1 
 
Continuing with their optimal substrate, N-(pivaloxyloxy)benzamide 43, Fagnou et al. repeated 
their previous reactions where they had used N-methoxybenzamide 42 to illustrate the superior 
activity of this new substrate in redox-neutral systems (Table 1.1).34 The optimised conditions 
improved upon those previously reported by Glorius et al.,36 (cf. Scheme 1.12) by reducing the 
catalyst loading (from 2.5 to 0.5 mol%) and the temperature (from 80 °C in ethanol to room 
temperature in methanol). Fagnou et al. compared their previous results using 
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N-methoxybenzamide 42 to those using N-(pivaloyloxy)benzamide 43, which showed a marked 
improvement on the reaction yields with less reactive dialkylsubstituted alkynes, for example 
1-phenyl-1-propyne and 4-octyne (entries 1-4, Table 1.1). Increasing the catalyst loading to 
2.5 mol% facilitated the coupling of terminal alkynes with N-(pivaloyloxy)benzamide 43, a 
result which had previously been unachievable using external oxidant based systems. Previous 
to this report, examples of annulation protocols using copper acetate as an oxidant were limited 
to internal alkynes, resulting in disubstituted heterocycles. The restriction stems from the 
copper(I)-catalysed Glaser coupling, whereby terminal alkynes preferentially dimerize than 
react to afford a mono-substituted heterocycle.34 Fagnou et al. utilised their copper-free 
conditions with terminal alkynes, which gave the corresponding 3-substituted isoquinolones 35, 
as single regioisomers, albeit using a higher catalyst loading of 2.5 mol% (entries 6-9). These 
systems have now become the archetype for many rhodium based redox-neutral strategies.29  
 
 
Entry R1 R2 R3 Temp (°C) 
Cat. Loading 
(mol%) 
Yield 
1 Me Ph Me 60 2.5 61a 
2 Piv Ph Me rt 0.5 92 
3 Me nPr nPr 60 2.5 12a 
4 Piv nPr nPr rt 0.5 70 
5 Piv nhex H rt 0.5 92 
6 Piv (CH2)2OH H 60 2.5 85 
7 Piv CO2Me H 60 2.5 49 
8 Piv TMS H rt 2.5 75 
9 Piv cyclopropane H rt 2.5 95 
aCsOAc (0.3 eq.) 
Table 1.1 
 
N
H
O
OR1
R3
R2
NH
O
R2
R3
[Cp*RhCl2]2 (0.5 mol%)
CsOAc (2.0 eq.)
MeOH (0.2 M)
rt, 16 h 3542 R1 = Me 
43 R1 = Piv
	   11 
1.7 Mechanistic studies 
 
1.7.1 Experimental data 
 
To investigate the true role of the internal oxidant, Glorius et al. used a competition experiment 
to determine whether the reaction proceeded via an intra or intermolecular oxidation 
(Scheme 1.13).36 Under the standard conditions, using equimolar amounts of two distinct 
N-methoxybenzamide derivatives 44 and 45 with 1-methyl-4-vinylbenzene 46, the observed 
high recovery of 45 was indicative that the N-OMe bond acts as an internal oxidant.  
Scheme 1.13	  
Fagnou et al. highlighted the superiority of N-methoxybenzamide 42 as a directing group 
compared with benzamide 48 through a deuterium incorporation study (A and B, 
Scheme 1.14).35 Only 25% deuterium incorporation was identified using benzamide 48 
compared with 90% with N-methoxybenzamide 42, indicating higher rhodation of the C-H 
bond. On addition of diphenylacetylene 40, no deuterium was incorporated in the recovered 
starting material 42 or product 49, thus signifying an irreversible C-H insertion in the presence 
of the alkyne 40 (C), compared with reversible rhodation in its absence (B).35 
Scheme 1.14 
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The availability of a coordinating nitrogen in the directing group proved to be crucial in order to 
facilitate C-H insertion. A trial reaction, using standard conditions, with N-methyl-N-
methoxybenzamide and styrene resulted in unreacted starting material.36 Furthermore, all 
attempts using rhodium(I) catalysts, RhCl(PPh3)3 and [RhCl(cod)]2, in place of [Cp*RhCl2]2 
were unsuccessful.36 
Both Fagnou and Glorius conducted deuterium kinetic isotope effect (DKIE) studies to 
determine the rate-limiting step in the C-H activation mechanism (Scheme 1.15). For 
N-methoxybenzamide 42 a primary DKIE of 1.0 ±0.1 was found. In contrast, N-(pivaloyloxy)-
benzamide 43 was found to have a DKIE of 14.6 ±0.1, suggesting that C-H insertion is the rate 
determining step with this substrate.34,36  
	  
Scheme 1.15 
1.7.2 Computational data 
 
In an attempt to rationalise the difference in reactivity the N-methoxy- and N-(pivaloyloxy)-
benzamide, 42 and 43, Xia et al. reported a computational elucidation of the divergent reaction 
pathways of the –OMe and –OPiv catalytic cycles.37 Using density functional theory (DFT) 
calculations, reaction pathways of N-methoxybenzamide 42 and N-(pivaloyloxy)benzamide 43 
were calculated, using ethylene as a model substrate. The initial N-H deprotonation, C-H 
activation and olefin insertion steps were observed as the same for both substrates 42 and 43. 
Xia’s report describes the formation of the active catalyst, Cp*Rh(OAc)2, from the dimer 
[RhCp*Cl2]2 and CsOAc, followed by deprotonation of the NH bond I by one of the acetate 
ligands, leading to the displacement of one molecule of acetic acid II (Scheme 1.16). Previous 
reports had postulated [Cp*RhOAc]+ as the active catalyst, however Xia et al. claim their 
calculations eliminate this complex as the reactive catalyst and additionally rule out C-H 
cleavage prior to the N-H deprotonation.  
The C-H insertion proceeds via a concerted-metallation deprotonation mechanism (CMD).14,38 
The C-H bond is polarised as a result of an agostic interaction, which consequently increases the 
O
N
H
OMe Me
Ph
O
NH
Ph
Me
[Cp*RhCl2]2 (2.5 mol%)
CsOAc (0.3 eq.)
MeOH (0.2 M)
60 °C, 4 min42
D5/H5
O
N
H
OPiv Me
Ph
O
NH
Ph
Me
[Cp*RhCl2]2 (0.5 mol%)
CsOAc (0.3 eq.)
MeOH (0.2 M)
rt, 30 min43
D5/H5
42 8.9 (± 0.4) x 10-5 M/s
42-d5 8.8 (± 0.8) x 10-5 M/s
kH/D = 1.0 ± 0.1
43 4.8 (± 0.2) x 10-5 M/s
43-d5 0.33 (± 0.01) x 10-5 M/s
kH/D = 14.6 ± 0.1
	   13 
acidity of the proton. The C-H bond is then deprotonated by the resting acetate ligand to give 
III. Release of acetic acid from the rhodium complex III reveals a vacant site for coordination 
of the olefin substrate IV. From their calculations, the intermediate III was slightly higher in 
energy that the free substrate and catalyst, indicating the reversibility of the NH 
deprotonation/C-H activation processes for substrates 42 and 43. On insertion of the rhodium 
into the alkene, Xia et al. calculated the formation of the puckered intermediate VI, formed as a 
result of weak coordination with the π-electrons of the C1 and C2 aryl ring. Dissociation from 
the aryl ring from the rhodium centre alleviates the bond strain to form a seven membered 
intermediate VII. The calculated intermediate VI from the mechanistic pathway of 
N-methoxybenzamide 42 was shown to be more stable than the resultant seven-membered ring 
VII, which is possibly a result of the unsaturated coordination of the rhodium centre.37 In 
comparison, the intermediate VII is more stable than VI, with the N-(pivaloyloxy)benzamide 
43, due to the stabilising interaction of the pendent carbonyl (in the pivaloyl group) with the 
rhodium centre.  
	  
Scheme 1.16 
The seven-membered rhodacycle VII, formed after the olefin insertion, represents a key 
intermediate.	   At this stage the internal oxidant directs the reaction pathway. The 
N-(methoxy)benzamide continues through a β-hydride elimination step VIII via a rhodium-
hydride intermediate IX (Scheme 1.17). Transfer of the hydride to the nitrogen results in the 
rhodium(I) species X. In order to regenerate the catalyst, their calculations suggest the 
assistance of a molecule of acetic acid drawing the methoxy group away from the nitrogen XI, 
causing a formal covalent bond to form between the rhodium catalyst XII and the nitrogen, 
resulting in a cationic rhodium(III) species XIII. Their calculations eliminated the possibility of 
a formal 1,2-migration of the methoxy from the nitrogen to rhodium from the intermediate X, 
due to a large activation barrier.  
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Scheme 1.17 
As Fagnou34 and Glorius36 had postulated, the N-(pivaloyloxy)benzamide is able to stabilise the 
seven-membered rhodacycle XV through weak coordination of the carbonyl group 
(Scheme 1.18). Xia et al. postulated that an acyloxy transfer via the transition state XVI affords 
a rhodium(V)-nitrene intermediate XVII. Empirically, a rhodium(V) oxidation state has not 
been observed, only the more common rhodium(I) and rhodium(III) states. Subsequent C-N 
bond formation (reductive elimination) leads to regeneration of the rhodium(III) species XVIII.  
	  
Scheme 1.18 
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1.8 Redox-neutral strategies 
 
These seminal reports by Glorius36 and Fagnou34,35 laid the foundations for redox-neutral 
strategies and have since spurred a plethora of C-H activation systems for the synthesis of 
diverse heterocycles and functionalised aromatics.29 These systems have now been developed 
for ruthenium catalysts,39,40 using similarly mild conditions in solvents including water.41 
Strategies have been developed based on a tethered internal oxidant-directing group motif, 
whereby examples using RN-O, RO-N and RN-N bonds have been exemplified (A, Scheme 
1.19). Furthermore, the methodology has been extended to external oxidants, based on N-N and 
N-O substrates (B, Scheme 1.19), as milder oxidants, compared with copper(II) acetate. These 
approaches have been outlined accordingly. 
 
Scheme 1.19 
 
1.9 Ligand and directing group modification for control of stereoselectivity and 
regioselectivity 
 
The groups of Cramer42 and Rovis43 independently reported asymmetric variants of the 
annulation protocol using modified cyclopentadienyl ligands to effectively bias the coordination 
sphere (Scheme 1.20). These elegant strategies rely on the fixed Cp ligand controlling the 
arrangement of the substrates and other ligands around the metal centre, which makes the 
development of catalytic asymmetric variants enormously challenging. Cramer et al. developed 
a series of modified Cp-ligands 50 incorporating three key features: a) a steric shield to control 
positional selectivity of the incoming reactant (RC); b) a position lock to ensure stable 
conformation of the Cp-ligand; and c) a large pendent group to control the orientation of the 
substrates on the metal centre.42 Using benzoyl peroxide to generate the rhodium(III) catalyst in 
situ, they were able to catalyse the annulation of N-(pivaloyloxy)benzamide derivatives 39 with 
terminal or cyclic alkenes to prepare a range of dihydroisoquinolones 38 with excellent 
enantioselectivity (89:12-97:3 er).  
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Scheme 1.20 
 
Evolution of this strategy led to the development of a second-generation catalyst 53, used for 
the intramolecular asymmetric hydroarylation of 1,1-disubstituted alkenes tethered to a phenolic 
N-methoxybenzamide derviative 51 to create quaternary stereogenic centres (Scheme 1.21).44 
Typically N-methoxybenzamide derivatives react with alkenes to produce the unsaturated 
product via β-elimination (cf. Scheme 1.11), however in this system, the lack of β-hydrogens 
resulted in a mixture of the isoquinolone 54 (via cyclisation) and the dihydrobenzofuran 52 (via 
protonolysis); the latter was accelerated by the addition of pivalic acid. Cramer et al. 
exemplified this strategy with 15 illustrative examples, each with excellent enantiomeric control 
(91:9-96:4 er). 
 
Scheme 1.21 
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Streptavidin to foster their C-H activation protocol. Since the advent of bioengineering, 
metalloenzymes (enzymes that incorporate metal co-factors) have become powerful hosts for a 
wide range of chemical transformations, particularly in asymmetric catalysis,45 owing to their 
intricately tailored chiral environment. Amino acid residues that are not directly coordinated to 
the metal co-factor are available to interact with other substrates through non-covalent 
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interactions, this is defined as the second coordination sphere.46 These dormant residues can be 
employed to alter the active site in order to meet the transformations requirements. Rovis and 
Ward et al., employed this strategy in the design of their bifunctional engineered Streptavidin 
using the biotinylated rhodium(III) complex, [RhCp*biotinCl2]2, for asymmetric C-H activation 
(Scheme 1.22).43 Having successfully docked the rhodium catalyst to the protein, using a biotin 
tether, the catalytic activity was optimised using a proximal glutamate residue (installed by site-
specific mutagenesis of Streptavadin (SavMutant), whose activity was accelerated by addition 
of a proximal lysine residue to ensure full deprotonation of the glutamic carboxylate. The 
carboxylate ligand significantly reduces the activation energy of the concerted metalation-
deprotonation mechanism by stabilising the transition state, compared with the system using an 
exogenous acetate. Treatment of N-(pivaloyloxy)benzamide 43 with acrylates in a 3-
morpholinopropane-1-sulfonic acid buffer solution (MOPS) in MeOH furnished the 
corresponding dihydroisoquinolones 38 with good enantiomeric ratios (61-95%, er 73:27 – 
93:7). Both Rovis and Cramer’s approaches require highly specialised ligands to achieve 
intricate control of the coordination sphere, which reflects the difficulty involved in chiral C-H 
activation.	  	  
 
	  	  
 
Scheme 1.22 
 
Regioselectivity is determined by the balance of three factors including the steric environment 
of the activated C-H bond (A, Scheme 1.23), the electronics and the size of the groups on the 
reacting alkene/alkyne. Typically, non-symmetrical alkenes/alkynes prefer to coordinate to 
rhodium with the larger group occupying the α-position in the rhodacycle (B). When electronics 
govern the system, the electron-donating group prefers to be β-substituted to rhodium in the 
metallocycle, presumably to stabilise the electron-poor metal (C).47  
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Scheme 1.23 
 
Rovis et al. developed a sterically bulky di-tert-butylcyclopentadienyl ligand (Cpt) 55 to 
enhance the regioselectivity of alkene and alkyne migratory insertion events, delivering 
regioselectivities (generally >10:1) modestly above those achievable by Cp* ligated Rh 
complexes (<6:1) with alkyne substrates (Table 1.2).48,49 The Cpt ligand was particularly 
effective for regiocontrol over alkene substrates, which typically react with poor 
regioselectivitiy, possibly due to competing electronic and steric effects. Using their modified 
catalyst 55 with N-(pivaloyloxy)benzamide 43, Rovis et al. were able to control the migratory 
insertion step with enhanced regioselectivity compared with the Cp* system, furnishing 
3-substituted dihydroisoquinolones as the major isomer.  
 
Entry Alkene Yield % (Cpt) 
Cp* 
A:B 
Cpt 
A:B 
1  85 1.6:1 5.1:1 
2 
 
95 2.3:1 14:1 
3 
 
85 1.6:1 8:1 
4 
 
80 1.4:1 12:1 
5 
 
89 2:1 14:1 
6 
 
93 1:1 11:1 
Table 1.2 
 
Previous attempts to use nicotinamide derivatives in rhodium-catalysed C-H 
activation/annulation have resulted in low yields, due to the electron-poor nature of the ring,21 
and poor regioselectivity for the C2 and C4 positions.50,51 Huckins and Bercot utilised the 
nicotinamide N-oxide derivative 56 to simultaneously improve the C2 selectivity on the pyridine 
ring and to increase the electron density in the ring system (Scheme 1.24).52 This dual activation 
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generally improved the reaction yields and significantly improved the C2:C4 (A:B, Scheme 
1.24) regioselectivity of the reaction compared with the 3-N-(pivaloyloxy)nicotinamides 57 
e.g. from 1.9:1 to >20:1 (A:B) of 58 and 59 using norbornadiene and 1.7:1 to 17:1 of 60 and 61 
using 4-octyne.  
 
 
Scheme 1.24 
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1.10 Substrate scope 
 
The internal oxidant strategy was employed by Park et al. in the synthesis of the indolizidine 
motif, a scaffold which is relevant to natural products and pharmaceuticals (Scheme 1.25).53,54 
To effectively control the regiochemistry of the annulation step, the alkyne substrate was 
tethered to the internal oxidant group of the hydroxamic ester 62. The rhodium-catalysed 
intramolecular annulation furnished the pyridone 63 with a pendant hydroxyl group. This was 
subsequently used to assemble the indolizidine motif 64 via an intramolecular Mitsunobu 
reaction. Reduction of the pyridone 65, followed by an oxidative coupling, furnished the 
pentacyclic scaffold 66. Utilising this methodology, Park et al. reported the total synthesis of 
the phenanthroindolizidine alkaloids: (±)-septicine 65b, (±)-antofine 66a and (±)-tylophorine 
66b. 
 
 
 
Scheme 1.25 
 
Aside from alkenes and alkynes, numerous substrates have been reported as suitable coupling 
partners using this N-O based redox-neutral strategy. Glorius et al. exemplified the synthesis of 
isoquinolones from allenes 67 with cyclometallated intermediates generated from 
N-(pivaloxyloxy)benzamide derivatives 39 with [Cp*RhCl2]2 (Scheme 1.26).50 A range of 4-Z-
alkyenylated dihydroisoquinolones 38 were prepared using a selection of monosubstituted 
allenes, with high regio- and stereoselectivity. Glorius et al. proposed the Z-selectivity arises 
from the rhodium approaching the least sterically encumbered face of the allene (A, 
Scheme 1.26). When sterically congested N-(pivaloxyloxy)benzamides or allenes were 
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employed, the resultant isoquinolones 70-72 formed, suggested steric interference outweighed 
electronic factors (B, Scheme 1.26).50  
 
Scheme 1.26 
 
Allenylation of N-methoxybenzamide derivatives 36, using similar methodology, allowed Ma et 
al. to prepare poly-substituted allenyl-silyl-benzamides 74 using mild conditions, with excellent 
yields (Scheme 1.27).55 These products could be diversified further to the corresponding 
isoquinolones, furans and alkynes.  
 
 
Scheme 1.27 
 
C-H Activation can be used as a powerful tool for installing additional functional groups, which 
can offer a handle for versatile and divergent syntheses, which is particularly desirable for rapid 
library development. Glorius et al. realised the potential of combining C-H activation with 
N-methyliminodiacetic acid (MIDA) boronates to introduce a synthetic handle for Suzuki-
Miyaura cross-coupling reactions (Scheme 1.28). MIDA boronates are bench and air stable 
(unlike many boronic acids), simply prepared and are compatible with a wide range of common 
synthetic reagents. They can be used directly in cross-coupling reactions, however they are less 
reactive than the corresponding boronic acid. Deprotection to reveal the corresponding reactive 
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boronic acid in situ can be achieved using mild, basic conditions. Based on the difference in 
reactivity, Burke et al. developed an iterative Suzuki-Miyaura cross-coupling reaction.56 
Treatment of alkynyl MIDA boronates 75 with N-(pivaloyloxy)benzamide derivatives 39 using 
[Cp*RhCl2]2 furnished a range of 3-B-MIDA substituted isoquinolones 76. Additional 
copper(II) acetate (0.4 equivalents) was required in order to achieve full conversion to the 
products. Only terminal alkynes were tolerated using these reaction conditions, highlighting a 
limitation of the substrate scope. The isoquinolone-boronates were subsequently coupled with a 
selection of aryl-bromides using standard Suzuki-Miyaura coupling conditions to afford 
3-arylated isoquinolones 77 with excellent yields.  
 
Scheme 1.28 
 
In the same vein, Molander et al. found vinyltrifluoroborate 78 to be an efficient coupling 
partner with the hydroxamate ester 39 under these rhodium-catalysed conditions, this time 
observing selectivity for the 4-position (Scheme 1.29). The dihydroisoquinolones 79 were 
further diversified by oxidation to give the 4-hydroxydihydroisoquinolones, and 
protodebromination to afford 3,4-unsubtituted dihydroisoquinolones.57 The latter example was 
used for the preparation of corydaldine 80, a naturally occurring alkaloid used in Chinese and 
Indian traditional medicine.58 Unsubstitued-dihydroisoquinolones had previously been prepared 
using N-(pivaloyloxy)benzamide and ethylene as a coupling partner.34,36 
 
Scheme 1.29 
 
Numerous methodologies have been developed using hydroxamic esters with various substrates 
to assemble diverse heterocyclic rings (Scheme 1.30). Using diazoesters, Rovis et al. 
exemplified the synthesis of isoindolinones 81 (A).59 The groups of Glorius60 and Cui61 
extended the substrate scope to include α,β-unsaturated aldehydes/ketones and vinyl diazoesters 
to prepare azepinones 82 and 83, structural motifs commonly found in natural products 
(B and C). Fagnou et al. had previously prepared 3-substituted isoquinolones using terminal 
alkenes (cf. Table 1.1). An alternative synthesis, reported by Rovis et al., used activated 
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cyclopropenes to prepare 4-substituted isoquinolones 84.62 Treatment of diynes with 
N-(pivaloxyloxy)benzamide 43 furnished 3-alkynlated isoquinolones 85, which could be used 
as a functional handle for a range of diverse chemical transformations, including a sequential 
reaction with either another equivalent of N-(pivaloyloxy)benzamide 43 or with an unsaturated 
α-β-unsaturated oxime 87 to furnish fused bis-isoquinolones 86 or isoquinolone-pyridines 88, 
respectively.63 
 
Scheme 1.30 
 
The first example using internal oxidants with ketoximes was reported by Chiba et al. for the 
synthesis of isoquinolines from O-acetyl ketoximes 89 with alkynes (Scheme 1.31).64 Nineteen 
isoquinolines 90, bearing electron-donating or electron-withdrawing groups, were prepared with 
an excellent average yield of 82%, reflecting the high substrate tolerance of these reaction 
conditions. Unsymmetrical alkynes reacted with good regiocontrol in favour of the larger group 
adopting the 3-position; for example,	  treatment of O-acetyl acetophenone oxime with 1-phenyl-
1-propyne furnished 1,4-dimethyl-3-phenylisoquinoline as a single regioisomer. Using the same 
strategy, Rovis et al. used α,β-unsaturated oximes 87 and ketoximes 91 to prepare a range of 
pyridines and isoquinolines (Scheme 1.31).49  
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Scheme 1.31 
Whilst investigating the mechanism of the reaction, Chiba et al. used the chalcone oxime 
isomers 93 and 95, to determine the reactive isomer. The E-oxime 93 reacted with 
diphenylacetylene 40 to give the corresponding isoquinoline 94, unlike the Z-oxime 95, which 
deacetylated to give 96 under the reaction conditions (A, Scheme 1.32). This is presumably due 
to the availability of the lone pair of electrons on the nitrogen required to coordinate to the metal 
centre to facilitate C-H activation. The possibility of the reaction proceeding via a 6π-
electrocyclisation was deemed to be implausible, based on an observation using the substrate 97 
(B, Scheme 1.32). The oxime 97 was subjected to the standard reaction conditions, however 
only the deacetylated starting material 98 was observed. Addition of 4-octyne 41 to the reaction 
resulted in formation of the isoquinoline 99 and deacetylated starting material 98. 
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1.11 Variants of the N-O strategy 
 
 
The introduction of these rhodium-catalysed redox-netural systems has naturally evolved to 
encompass alternative substrates functionalised with cleavable N-O bonds. In the examples 
illustrated thus far the nitrogen from the N-O cleavage is incorporated into the final product, 
however, the oxygen-containing moiety is usually lost to the reaction medium. Lu et al. have 
developed a methodology to prepare ortho-hydroxyphenyl-substituted enamides 102 from 
N-phenoxy-acetamide 101 with alkynes, successfully incorporating both elements of the 
internal oxidant (16 examples, 32-83% yields, Scheme 1.33).65 A side reaction in their 
synthesis, using ester-substituted alkynes, was identified as the formation of benzofuran 100. By 
careful manipulation of the reaction additives and reaction solvent (addition of acetic acid in 
dichloromethane), fifteen exemplar benzofurans were prepared (Scheme 1.33). A solvent screen 
revealed the preferential formation of benzofurans when non-coordinating or bulky polar 
solvents, such as toluene, tert-butanol or dichloromethane, were used. In contrast, polar co-
ordinating solvents resulted in formation of the ortho-hydroxyphenyl enamides 102.  
 
Scheme 1.33 
 
A control experiment eliminated the intermediary enamide 102 in the formation of the 
benzofuran 100, which suggested two separate mechanistic pathways. In weak coordinating 
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solvents, Lu et al. postulated the pathway A (Scheme 1.33). Coordination of a solvent molecule 
to the rhodium(III) centre I would create an 18 electron complex which would reductively 
eliminate to form the rhodium(I) intermediate II. Oxidative insertion III, followed by acid 
promoted dissociation from the product would furnish the enamide 102. In contrast, in non-
coordinating solvents, the nitrogen coordinated to the rhodium(III) centre in the 16 electron 
complex could be protonated to afford the intermediate IV (pathway B, Scheme 1.33). An 
intramolecular substitution V, mediated by acetic acid, would furnish the benzofuran 100. 
Following this study, Lu et al. found that under similar conditions the reaction of alkenes with 
N-phenoxy-acetamide 101 generated the ortho-alkenylated phenols 103 (Scheme 1.34).66  
 
 
Scheme 1.34 
 
Recognising the inherent difficulty of functionalising tertiary anilines at the ortho-position, due 
to their propensity to react at the para-position in classical SEAr chemistry in order to avoid 
steric repulsion, You et al. developed a system whereby oxidised tertiary anilines would have a 
dual role as a traceless ortho-directing group (unlike acetanilides which would require an 
additional step to deprotect the aniline) and an internal oxidant for the reaction. Using their 
optimised conditions they were able to alkenylate twenty N-oxidised anilines 104 to give the 
corresponding unsaturated products 105 with N-substituents including N,N-dimethyl, a 
benzylated derivative and cyclic anilines (Scheme 1.35).67 Only a trace of the product was 
observed with the N,N-diethyl derivative, suggesting that steric hindrance is still a limitation in 
these reactions.  
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1.12 Redox-neutral systems based on N-N cleavage 
 
Based on the initial internal oxidant optimisation study by Fagnou et al. (Scheme 1.36),34 
functional groups with N-N bonds were deemed unreactive under the reaction conditions 
employed (cf. Figure 1.1). Further development has however identified hydrazines, hydrazones 
and nitroso-based directing groups to act as suitable internal oxidants for this C-H activation 
methodology. 
 
Huang and Zhu have used N-nitroso-compounds 107 and alkynes to furnish N-substituted 
indoles 106 (Scheme 1.36). These were the first reported N-alkyl indole syntheses using a C-H 
activation protocol. Starting with the active catalyst, [RhCp*(OAc)2]2, Huang et al. were able to 
utilise simple conditions in order to furnish the indoles 106,68 in comparison to Zhu’s protocol,69 
although a super-heated solvent system was required in order to obtain good yields. 
 
 
Scheme 1.36 
 
An alternative approach to indole synthesis using an N-N bond cleavage was developed by 
Glorius et al.70 using hydrazines 108 as their starting materials (Scheme 1.37). Under acidic 
conditions, in a sealed system, the hydrazines 108 reacted with a diverse range of alkynes to 
furnish substituted indoles. This approach offers an alternative substrate precursor compared 
with the traditional Fisher-indole synthesis that relies on the condensation of an aromatic 
hydrazine with an aldehyde/ketone. Unsymmetrical alkyl-aryl substituted alkynes reacted to 
preferentially install the aryl group in the 2-position of the indole. 
 
 
Scheme 1.37 
 
The synthetic utility of this approach was further explored to include isoquinolines 111 prepared 
from hydrazones 110 (Scheme 1.38). Cheng et al. commented on the importance of the acetic 
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acid in the reaction medium, based on their postulated mechanism which would involve the 
protonation of the N,N-dimethyl group in order improve it as a leaving group.71  
 
 
Scheme 1.38 
 
1.13 Intermolecular N-O/N-N oxidants 
 
A plethora of systems have been developed using a tethered internal oxidant and directing 
group, where they are combined in a single functional group (e.g. ketoximes, hydroxamate 
esters etc.). Glorius et al. reported an intermolecular example where the directing group has 
been separated from the N-O based oxidant for the ortho-C-H amination of 2-phenyl 
pyridines 112 and N-methoxybenzamides derivatives 36 (Scheme 1.39).72 Using a specifically 
designed and optimised electron-deficient aryloxycarbamate 113 as an external oxidant, the 
aromatic substrates were aminated to afford Boc-protected anilines 114 and 115, under mild 
conditions. Alternative protecting groups, including Cbz- and Fmoc-protected carbamates, were 
tolerated under the reaction conditions. N-Methoxybenzamide derivatives 36 were tolerated 
under the reaction conditions, where the N-O bond of the carbamate was selectively cleaved 
over the hydroxamic ether N-O bond. Further diversification of these substrates could be 
achieved using a subsequent internal-oxidant based C-H activation step, however this was not 
exemplified in their report. 
 
 
Scheme 1.39 
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require external oxidants that equally generate unwanted waste. Chang et al. used 
p-toluenesulfonyl azide 116 as a nitrogen source for the sulfoamidation of phenyl pyridines 112, 
purines 118a,b, a pyrazole 119 and ketoximes 120a-c (Scheme 1.40).73 The reaction was 
observed to tolerate electron-rich and electron-deficient aromatic systems, and the use of the 
azide 116 results in the generation of nitrogen as the stoichiometric waste. Although this 
synthetic approach could be challenging to perform on scale, due to the evolution of gas and the 
risks associated with azides, this methodology would prove to be synthetically useful to 
medicinal chemists for the preparation of libraries of compounds.  
 
Scheme 1.40 
 
1.14 Summary 
 
The work outlined above illustrates the potential for succinct, atom-efficient processes to 
construct heterocyclic scaffolds using internal oxidants. The aforementioned systems employ 
mild conditions and negate the generation of excessive metal waste (typically copper and 
silver), highlighting the potential for large-scale synthesis using these catalytic systems. 
Excellent control over regioselectivity and stereoselectivity has been exemplified through ligand 
design and tailored reaction conditions. Strategies based on the cleavage of N-O or N-N bonds, 
either appended to the directing group or used as an external, milder oxidant, have led to the 
assembly of structures, such as indoles, isoquinolines and isoquinolones; scaffolds which are 
prevalent in natural products, agrochemicals and pharmaceuticals.	   Such powerful C-H 
activation methodologies will undoubtedly prove to be invaluable in future synthetic protocols.  
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1.15 Project Aims 
 
A principle aim of the project is to develop a rhodium(III)-catalysed C-H activation protocol 
suitable for electron-rich alkenes — substrates that have not been as extensively explored in 
comparison to electron-deficient and electron-neutral alkenes and alkynes. Incorporation of an 
internal oxidant based system could provide a mild, expedient route to these compounds, 
compared with traditional syntheses. Currently, very little is understood about the regioisomeric 
preference of electron-rich alkenes, particularly in systems that employ internal oxidants. The 
initial aim of the project is to investigate the regioselectivity and reactivity of vinyl acetates and 
vinyl ethers as acyl anion or enolate equivalents under rhodium(III) C-H activation conditions, 
using an internal oxidant which favours a β-hydride elimination pathway (Scheme 1.41). 
Reaction via an enolate equivalent would provide a route to the α-aryl carbonyl motif, one that 
is difficult to achieve using traditional methodologies. 
	   
Scheme 1.41. Enamines and enol ethers/esters used as enolate equivalents using a directing group that 
favours β-hydride elimination. 
 
Additionally, exploitation of the divergent pathways observed for various internal oxidants 
could be used with these electron-rich alkenes as a way of constructing heteroaromatic 
compounds with a functional handle for further diversification (Scheme 1.42).  
 
 
Scheme 1.42. Reductive elimination of enamines and enol ethers/esters to afford functionalised 
heterocycles. 
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Chapter 2 
Rhodium-mediated C-H activation-annulation reactions with electron-rich alkenes 
2.1 Introduction 
In recent years, C-H activation methodologies using the rhodium catalyst, [Cp*RhCl2]2, have 
been shown to tolerate a breadth of alkene and alkyne substrates with a variety of directing 
groups to furnish a myriad of heterocycles, generally with excellent yields. However, external 
oxidant-based systems, using [Cp*RhCl2]2, rely on stoichiometric metal oxidants and precious 
metal additives, generally in sealed systems using super-heated solvents. As they stand, these 
systems are limited to small-scale synthesis and are not applicable for the large-scale 
manufacture of fine chemicals/pharmaceuticals. On the other hand, systems using internal 
oxidants allow for milder reaction conditions, lower catalyst loadings, and the reactions 
themselves produce organic-based waste products. The lower catalyst loadings and the 
inexpensive organic starting materials have great potential for process scale-up. Therefore 
continuous development of the existing systems is important if economically viable synthetic 
routes are to be used.  
Reactions of this type have been thoroughly exemplified using electron-deficient and electron-
neutral alkenes and alkynes. However, there is a paucity of examples using electron-rich alkenes 
(e.g. enamines and enols). To our knowledge, there was only a single example in the literature 
using an electron-rich alkene in a C-H coupling reaction of this type; Fagnou and co-workers 
used N-(pivaloyloxy)benzamide 43 in a reaction with 2,3-dihydrofuran 121, an enol ether to 
give the dihydroisoquinolones 122 and 123 (>20:1 of 122:123, Scheme 2.1).34  
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This reaction allowed us to envisage a way to utilise this system for the coupling of electron-
rich alkenes, with the potential to capture enol equivalents as a way of achieving the α-aryl 
carbonyl motif (Scheme 2.2).  
 
Scheme 2.2 
Examples of natural products and medicinal remedies that display this α-aryl carbonyl bond 
include atropine 124, gustastatin 125 and naproxen 126 (Figure 2.1). Atropine 124, an alkaloid 
isolated from Atropa Belladonna, is used as an anticholinergic agent at muscarinic receptors;74 
gustastatin 125, has potential capabilities as a human cancer cell growth inhibitor;75 and 
naproxen 126 is a nonsteroidal anti-inflammatory drug.76 
 
Figure 2.1 
Despite its presence in numerous natural products and pharmaceutical agents, current methods 
of installing the α-aryl carbonyl motif suffer from multi-step sequences or installation of 
requisite disposable functionality, which is often expensive and environmentally unfriendly. 
The original aim of this investigation was to develop a C-H activation methodology for the 
coupling of enol/enolate equivalents with aromatic systems in order to introduce the α-aryl 
carbonyl motif. 
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2.2 Results and discussion 
To commence our study, benzhydroxamic acid 127 and a range of hydroxamic esters 42, 43 and 
128 were prepared according to literature procedures,35,36 and subsequently treated with three 
illustrative enol/enamine equivalents (n-butyl vinyl ether, N-vinyl pyrrolidinone and vinyl 
acetate) using the conditions reported by the groups of Glorius and Fagnou; [RhCp*Cl2]2 
(1 mol%) with cesium acetate (30 mol%) in methanol at 60 °C.34,36  
Reactions of benzhydroxamic acid 127 and N-(methoxy)benzamide 42 with n-butyl vinyl ether 
129 were unsuccessful (entries 1 and 2, Table 2.1). In contrast, N-(acetoxy)- and 
N-(pivaloyloxy)benzamide, 128 and 43, furnished the benzylic ether dihydroisoquinolone 130 
as a single regioisomer, with a yield of 32% and 35% respectively (entries 3 and 4). The 
hemiaminal 131 was not observed in the 1H NMR spectrum of the crude reactions. The 
regiochemistry of the isomer 130 was confirmed by 1H NOESY NMR (Appendix 1.1).  
 
   Time Product (%) 
Entry R No. (h) A B 
1 H  127 16 - - 
2 Me  42 16 - - 
3 Ac  128 48 32 - 
4 Piv  43 48 35 - 
Table 2.1. Yields of isolated products. 
Reactions using N-vinyl pyrrolidinone 132 with the benzhydroxamic acid/esters 42, 43, 127 and 
128, were unsuccessful. Recovered N-vinyl pyrrolidinone and a single side product were 
isolated from the crude reaction using N-(acetoxy)- and N-(pivaloyloxy)benzamides, 128 and 
43. This isolated side product had also been observed in the crude 1H NMR spectrum of the 
previous reactions with n-butyl vinyl ether 129. Analysis of the product identified the 
compound as methyl phenyl carbamate 133, presumably formed via a competing Lossen 
rearrangement (Scheme 2.3).77–79 
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2.3 The Lossen rearrangement 
 
The base-mediated, thermal Lossen rearrangement typically requires benzhydroxamic acid 
derivatives as substrates.77–79 Initial deprotonation of the hydroxamate ester 134 is followed by a 
rearrangement of a transient acyl nitrenoid 135 to give the intermediate isocyanate 136 
(Scheme 2.4).  
 
Scheme 2.4  
 
Despite the toxicity associated with isocyanates, they are highly reactive, valuable intermediates 
that can be readily transformed via trapping of a nucleophile or, in the case of water as the 
nucleophile, degradation to the respective amine under aqueous conditions. Under our reaction 
conditions, solvent trapping with methanol furnished the methyl phenyl carbamate 133. 
 
In order to identify whether this reaction in our system was base or catalyst-induced, time-
dependent 1H NMR experiments were undertaken (Figure 2.2). The control reaction, using 
N-(pivaloyloxy)benzamide 43 and cesium acetate (30 mol%) in deuterated methanol-d4, showed 
only unreacted starting material after four hours. Addition of the rhodium catalyst 
([RhCp*Cl2]2, 1 mol%) led to 100% conversion to the methyl phenyl carbamate-d4 133 within 
four hours at 60 °C, suggesting a metal-catalysed Lossen rearrangement.  
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Figure 2.2. Time-dependent 1H NMR study in MeOD-d4 (500 MHz, 60 °C) Mesitylene singlets appear at δ 
6.75 and 2.23 (internal standard). Spectrum A shows an authentic sample of methyl phenyl carbamate-d4 
in MeOD-d4. 
 
Complexation of the hydroxamate ester 43 with the rhodium catalyst would reduce the pKa of 
the NH proton, allowing for deprotonation (by cesium acetate) and subsequent rearrangement to 
give the isocyanate 136 (Scheme 2.5). Hydroxamic acids are known to facilitate coordination to 
certain metal ions;80 this interaction has been exploited in drug molecules whereby the 
hydroxamic acid is crucial for selectivity when there is a metal ion in an active site.81,82 To lend 
further credibility to our theory, Roithová et al. reported a metal-assisted Lossen rearrangement, 
using basic salts of zinc and potassium, where the reaction proceeds via the metallated 
hydroxamate.80,83 
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Scheme 2.5 
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2.4 Optimisation study of enol ether substrates 
An optimisation study was undertaken to simultaneously reduce the reaction time, increase the 
yield of the desired product and decrease the formation of the Lossen product. Temperature, 
substrate equivalents and reaction concentration were chosen as the three variables in an 
optimisation study. The upper and lower limits were selected as 30 °C and 50 °C, 1.5 and 5 
equivalents of n-butyl vinyl ether 129 and reaction concentrations of 0.2 M and 1.0 M. For each 
of the experiments a 1H NMR spectrum of the crude reaction mixture was taken after 16 hours 
to assess the conversion to methyl phenyl carbamate 133, isoquinolone 137 and the ratio of 
regioisomers 130 and 131. Each reaction was subsequently purified to obtain isolated yields of 
the dihydroisoquinolones. In order to monitor the reproducibility of the reactions, a mid-point 
experiment (40 °C, 0.6 M and 3.25 equivalents of n-butyl vinyl ether) was repeated to evaluate 
the continuity across the reaction series. Table 2.2 outlines the results collated from analysis of 
the 1H NMR spectra of the crude reactions and the isolated yields of the regioisomers 130 and 
131. Significantly more carbamate 133 was observed at 50 °C (entry 5-8) compared with the 
reactions at 30 °C (entry 1-4). Additionally, the 1H NMR data indicated that higher temperatures 
led to formation of the isoquinolone 137, presumably from the thermal degradation of the 
benzylic ether 130 and/or the aminoacetal derivative 131. 
 
 
  
Variables 
Ratio of products 
(by 1H NMR) Ratio 
Yielda 
 % 
Entry Temp (°C) Conc (M) Equiv 129 A B C D (A-C):D A+B 
1 30 0.2 1.5 75 21 0 4 96:4 50 
2 30 0.2 5 73 25 0 2 98:2 76 
3 30 1 1.5 83 16 0 1 99:1 69 
4 30 1 5 77 22 0 1 99:1 74 
5 50 0.2 1.5 45 10 5 40 60:40 33 
6 50 0.2 5 59 16 6 19 81:19 51 
7 50 1 1.5 66 11 14 9 91:9 49 
8 50 1 5 62 19 14 5 95:5 64 
9 40 0.6 3.25 71 26 0 3 97:3 62 
10 40 0.6 3.25 71 25 0 4 94:4 68 
 
Table 2.2. aYields of isolated products. 
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Following purification by flash column chromatography, traces of the isoquinolone 137 were 
observed in the 1H NMR spectra of the benzylic ether 130 (the major regioisomer). Comparison 
of the RF values revealed similarities between the isoquinolone 137 and the major regioisomer 
130. To unambiguously identify which regioisomer eliminated butanol to form the isoquinolone 
137, two pure samples (>95% purity by 1H NMR) of regioisomers 130 and 131 were stirred 
with silica gel in CDCl3 overnight (Scheme 2.6). The results indicated that the isoquinolone had 
formed from the aminoacetal 131, not from elimination from the benzylic ether 130. 
 
 
Scheme 2.6. 
 
A reduction in temperature (30 °C) and use of excess n-butyl vinyl ether (5 eq.) produced the 
highest yield of 76% in 16 hours (cf. entry 2, Table 2.2) and 74% at a higher reaction 
concentration (1 M) (cf. entry 4, Table 2.2). Using the optimised conditions outlined in entry 4, 
the reaction was repeated with a ten-fold reduction in the rhodium precatalyst loading to 
0.1 mol% (Scheme 2.7). Disappointingly, complete conversion was not achieved after 72 hours. 
Analysis of the 1H NMR spectrum of the crude reaction mixture revealed 20% unreacted 
N-(pivaloyloxy)benzamide 43, 64% conversion to the regioisomers 130 and 131 and 6% 
conversion to the methyl phenyl carbamate 133. The material was purified to give 59% of the 
two regioisomers. Although full conversion was not achieved, a ten-fold reduction in catalyst 
loading produced 59% of the desired product with a turnover number (TON) of 590 compared 
with 74 from the reaction with 1 mol% of the catalyst (entry 4). 
 
 
Scheme 2.7. Reduction in catalyst loading from 1 mol% to 0.1 mol%. 
 
The conditions used in entry 2 (cf. Table 2.2) were applied to the reaction of ethyl vinyl ether 
138 with N-(pivaloyloxy)benzamide 43, resulting in an 87% yield of a 3:1 mixture of 4-ethoxy 
and 3-ethoxy-3,4-dihydroisoquinolin-1(2H)-ones 139 and 140 (Scheme 2.8). 
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Scheme 2.8 
 
2.5 Regiochemical considerations 
 
Curiously, the regioselectivity observed throughout the experimental design study contrasted 
with the regioselectivity that Fagnou et al.34 had reported with an analogous example 
(2,3-dihydrofuran 121), wherein the aminoacetal regioisomer 122 was reported as the major 
product (Scheme 2.9). This difference in regioselectivity of the disubstituted versus the 
monosubstituted alkene would suggest a contrasting influence of steric effects versus electronic 
preference. 
 
Scheme 2.9.34 Repeat of Fagnou’s conditions to investigate the regioselectivity of 2,3-dihydrofuran 121. 
 
In order to verify the regioselectivity observed in Fagnou’s study,34 the reported reaction 
conditions were repeated with 2,3-dihydrofuran 121 and N-(pivaloyloxy)benzamide 43  to 
meticulously investigate the structural assignment (Scheme 2.10). The spectral data reported in 
their study and the spectral data of the major regioisomer, isolated from our preparative 
experiment, matched accordingly. However, analysis of the 1H NOESY NMR spectrum of the 
same material revealed inconsistencies with their assignment. The 1H NOESY spectrum 
revealed two key interactions: a correlation between a doublet (δ 4.85 ppm Hd) with an aromatic 
proton and an overlapping ddd, resembling a broad triplet (δ 4.85 ppm Hc) with the NH proton, 
suggesting the regioisomer 123 (Scheme 2.10). Isolation and 1H NOESY NMR analysis of the 
minor regioisomer revealed additional evidence for our assignment of the aminoacetal 122 as 
the minor regioisomer. The doublet Ha (δ 5.57 ppm) appeared downfield of the corresponding 
doublet Hd (δ 4.85 ppm) (Scheme 2.10). The downfield shift was expected considering its 
deshielded position at the junction of two electronegative heteroatoms. Additionally the 1H 
NOESY NMR spectrum identified a correlation between the same doublet (HA) with the NH 
proton (Appendix 1.1). 
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Scheme 2.10  
 
Final confirmation of the structure was obtained via the collection of crystallographic data of 
the major regioisomer 123 (Figure 2.3, Appendix 1.1), validating our regiochemical assignment 
compared to the hemiaminal structure reported by Fagnou et al. (cf. Scheme 2.9).34 
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2.6 C-H activation/annulation with vinyl esters 
Having optimised the annulation reaction using vinyl ethers, we were interested in exploring 
alternative electron-rich alkenes. Using the aforementioned screening conditions for vinyl ethers 
(see Table 2.1), the analogous O-acetylated compounds from vinyl acetate were expected to 
form (Table 2.3). However, the sole products from the reactions, using the benzhydroxamic acid 
and the N-(acetoxy/pivaloyloxy)benzamide, were isoquinolone 137 and the methyl phenyl 
carbamate 133 (entries, 1, 3 and 4). Decreasing the reaction temperature to 45 °C supressed the 
competing Lossen rearrangement to afford the isoquinolone 137 with a yield of 87% (entry 6). 
Conducting the reaction at room temperature produced the same yield, however the reaction 
required 72 hours to reach completion (entry 5). The isoquinolone product presumably arises 
from elimination of acetic acid from a dihydroisoquinolone intermediate 142 and is the 
synthetic equivalent of a direct hydroxamate/alkyne annulation reaction using acetylene as the 
alkyne. Gaseous ethylene has been used by the groups of Fagnou35 and Glorius36 to furnish 
3,4-dihydroisoquinolones. However, to our knowledge, the use of gaseous alkynes in annulation 
reactions has not been investigated, and given the hazards and operational difficulties associated 
with such a process, the availability of a synthetic equivalent would be of great utility. 
 
   Temp. 
Isolated 
Yield 
Conversion 
 1H NMR 133 
Entry R No (°C) (%) (%) 
1 H  127 60 26 17 
2 Me  42 60 - 0 
3 Ac  128 60 79 15 
4 Piv 43 60 69 11 
5 Piv 43 rt 87a 0 
6 Piv 43 45 87 0 
 
Table 2.3. a72 hours. 
 
Based on our previous observations and the reported ineffectiveness of the benzhydroxamic 
acid 127 as an internal oxidant,34 the formation of the isoquinolone was surprising (entry 1, 
Table 2.3). In the presence of vinyl acetate and cesium acetate, we rationalised that the 
benzhydroxamic acid 127 could be acetylated during the reaction, thus forming the more 
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reactive substrate, N-(acetoxy)benzamide 128. Analysis of the final crude reaction mixture by 
1H NMR indicated the presence of the Lossen product 133, isoquinolone 137 and starting 
material 127. Further investigation using a 1H NMR time-course experiment identified that 
N-(acetoxy)benzamide 128 was formed in situ, before any signals corresponding to the 
isoquinolone 137 and methyl phenyl carbamate 133 were observed, supporting our proposition 
(Figure 2.4).  
 
 
 
Figure 2.4. A) An authentic sample of N-(acetoxy)benzamide 128 in MeOD-d4 
 B) ‘Zero hour’ 1H NMR spectrum of the reaction. C) ‘One hour’ 1H NMR spectrum. D) ’16 hour’ final 
1H NMR spectrum. Diagnostic peaks are highlighted in colour. 
 
The various reaction components were monitored in a time course 1H NMR study, over a period 
of 16 hours, using trimethoxybenzene as an internal standard (Figure 2.5). Within the first 15 
minutes, depletion of the benzohydroxamic acid 127 (60%) coincided with formation of 
N-(acetoxy)benzamide 128 (31%), when the yield plateaued. Formation of the products (the 
Lossen-derived carbamate 133 and the isoquinolone 137) were identified after 40 minutes as the 
concentration of N-(acetoxy)benzamide 128 began to decrease. After 16 hours the isoquinolone 
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137 and carbamate 133 were formed with yields of 17% and 10%, respectively. The delay in 
product formation, which coincided with a decrease in the transient hydroxamic ester, suggests 
that 128 is the true reactive species in the rhodium-catalysed annulation reactions.  
 
 
Figure 2.5. 1H NMR study of the formation and consumption of N-(acetoxy)benzamide 128 in situ. 
Legend: SM (127), product (137), Lossen (133) and N-(acetoxy)benzamide (128). 
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2.7 A divergent mechanistic pathway 
 
Based on our previous results with N-methoxybenzamide 42 in the internal oxidant screens, the 
isolation of unreacted starting material was expected; however a new product was identified, 
due to its strong blue fluorescence observed on examination of the TLC plate under a UV lamp 
(Scheme 2.11). Isolation of the tetracylic imide 143 returned a meagre 6% yield (the remaining 
crude reaction mixture contained unreacted starting material), however we were interested in 
optimising the synthesis due to the potential application of blue fluorescent compounds in 
organic light emitting diodes (oLEDs) and photovoltaic devices. Analysis of the compound 
identified the structure as isoindolo[2,1-b]isoquinoline-5,7-dione 143, which had previously 
been reported via different synthetic routes (discussed in Chapter 5) without mention of its 
fluorescent properties.84–88 
 
Scheme 2.11 
 
The divergent mechanistic pathways of O-acylated hydroxamic acids (128 and 43) compared 
with N-methoxybenzamide 42 are well documented,34,37,89,90 rationalising the formation of 143 
as being a novel compound. Subsequent mechanistic studies, route optimisation and 
fluorometry data are discussed in Chapter 5. 
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2.8 Rate study: a comparison of reactivity 
 
In order to compare the rate of the Lossen rearrangement to the C-H activation reaction, a time 
course 1H NMR experiment at 333 K (60 °C) was undertaken (Figure 2.6). Using 
trimethoxybenzene as an internal standard, the reactions were monitored over 16 hours, 
(Figure 2.6). In less than four hours, the reaction of n-butyl vinyl ether 129 and 
N-(pivaloyloxy)benzamide 43 at 60 °C was complete (A, Figure 2.6). Within the first hour, 23% 
of the desired product 130 had formed and slowly increased to 26% over the next hour. In 
contrast, the formation of the methyl phenyl carbamate 133 rapidly increased to 40% over the 
first hour, continuing to rise to 58% by the end of the reaction. It should be noted that the 
reaction yield of 130 for the preparative experiment (1 mmol scale) was 35% (see Table 2.1). 
The difference in yield could be attributed to the scale of the reaction. To compare the reactivity 
of the alkene substrates, a reaction using vinyl acetate 141 and N-(pivaloyloxy)benzamide 43 
was monitored (B, Figure 2.6).  
 
  
Figure 2.6. 1H NMR experiment (500 MHz, 333K, MeOD-d4) to monitor the formation of methyl phenyl 
carbamate 133 compared to 4-butoxy-3,4-dihydroisoquinolin-1(2H)-one 130 (reaction A) or 
isoquinolone 137 (reaction B). Average values plotted for reaction B from two iterations.  
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After eight hours, the starting material had been consumed to give the isoquinolone 137 (36%) 
and the Lossen carbamate 133 (32%). In the first hour, 20% of the isoquinolone had formed 
with only 5% of the carbamate 133 present.  
The rate at which the Lossen product formed in the butyl vinyl ether reaction was significantly 
faster than the reaction with vinyl acetate. After one hour, 4% of the carbamate had formed in 
reaction B, compared to 40% in reaction A. It should be noted that the reaction yield of the 
isoquinolone 137 for the preparative experiment (1 mmol scale) was 69% (see Table 2.3) 
compared with this yield of 32%, which could be a result of the scale of the reaction. One could 
argue that the acetate group of vinyl acetate prevents electron donation into the vinylic portion 
of the molecule compared with n-butyl vinyl ether, which has increased electron density due to 
the inductive effect of the alkyl chain. Another possibility could be the accelerating effect of 
coordination of the acyl group of vinyl acetate to the rhodium centre (see Section 3.6.3 for 
further discussion). This difference in reactivity suggests electron-rich alkenes are not 
favourable substrates under these reaction conditions.  
Interestingly, within the first ten minutes of both reactions, the desired annulated products were 
identified in the ‘zero hour’ 1H NMR spectra with no trace of the methyl phenyl carbamate in 
the reaction with vinyl acetate and only 6% present in the reaction with butyl vinyl ether, 
indicating rapid reaction of the vinylic substrates. Based on this observation, the two preparative 
reactions were repeated at room temperature. Reaction of vinyl acetate with N-(pivaloyloxy)-
benzamide 43 gave an encouraging yield of 87% (compared to a 76% yield at 30 °C, entry 2, 
Table 2.2), however the reaction took 72 hours to complete. Increasing the temperature to 45 °C 
reduced the reaction time to 16 hours, with yield of 87% (cf. Table 2.2). The reaction of n-butyl 
vinyl ether at room temperature furnished the dihydroisoquinolone products with a 77% yield of 
the two regioisomers (3:1, 130:131) over 72 hours. 
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2.9 Conclusion  
 
In summary, both reactions with vinyl esters and vinyl ethers were optimised to afford high 
yields, by selection of the internal oxidant and optimisation of the reaction conditions. The acyl 
hydroxamates, N-(acetoxy)- and N-(pivaloyloxy)benzamide, were identified as the most reactive 
substrates, however a competing reaction (Lossen rearrangement) was identified using these 
acylated hydroxamates. Based on the inactivity of the N-methoxybenzamide derivative, the 
reactivity of the benzhydroxamic acid was suprising. A 1H NMR time-course study revealed in 
situ formation of N-(acetoxy)benzamide from the reaction of benzhydroxamic acid and vinyl 
acetate, suggesting the true reactive species. 
 
The competing Lossen rearrangement was identified as a rhodium-catalysed process (using a 1H 
NMR study), which was subsequently minimised by a reduction in the reaction temperature. 
Using experimental design, the annulation of butyl vinyl ether with N-(pivaloyloxy)benzamide 
was optimised from 35% to 76%. The annulation of vinyl acetate to give 3,4-unsubstituted 
isoquinolones was optimised from 69% to 86% by decreasing the reaction temperature to 45 °C. 
 
Finally, the regiochemical preference of vinyl ethers to form the benzylic ether 
dihydroisoquinolones was confirmed with 1H NMR NOESY studies and X-ray diffraction 
analysis on a single crystal of 123, to disprove a previously reported assignment.35 Comparison 
of the rates of reaction of the vinyl enol ethers versus the vinyl enol esters suggests that 
electron-rich substrates are less favourable under these reaction conditions. 
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Chapter 3 
 
Rhodium(III)-catalysed synthesis of isoquinolones 
 
3.1 Introduction 
 
Isoquinolin-1(2H)ones are of significant interest due to their prevalence in alkaloidal natural 
products and synthetic therapeutic agents;91–95 illustrative examples include anti-cancer agents 
144,91 biological ligands 145,93 respiratory medicines 146,96 and hepatitis C intermediates 14797 
(Figure 3.1).  
 
Figure 3.1  
 
Traditional approaches to isoquinolones from monofunctionalised arene starting materials 
include thermal rearrangement/electrocyclisations of cinnamoyl azides 148,98–100 intramolecular 
Friedel-Crafts reactions of benzamidoalkyl acetals 149,101 or multi-step approaches involving 
reaction of ortho-lithiated benzamide derivatives 150 with α-dicarbonyl compounds 151 
(Scheme 3.1).102  
 
Scheme 3.1 
Alternative routes require ortho-difunctionalised benzene precursors from which the 
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copper107 catalysts have been developed for cross-coupling reactions with 2-halobenzamides 
152 with alkynes to afford substituted isoquinolones. These systems were rapidly surpassed by 
atom-efficient C-H activation protocols;21,108,109 eliminating the requirement for bespoke 
halogenated starting materials e.g. 153. Rhodium-catalysed C-H activation protocols typically 
require stoichiometric copper acetate as an oxidant to complete the catalytic cycle. Additionally, 
harsh conditions are required for C-H activation and large quantities of metal waste are 
generated. These systems have been superseded by the introduction of benzoyl hydroxamic 
ester derivatives as substrates by the groups of Fagnou34,35 and Glorius,36 allowing for mild 
conditions and organic based waste streams. 
Although substituted isoquinolones have been thoroughly exemplified, 3,4-unsubstituted 
isoquinolones have not. To our knowledge, there are only two transition-metal catalysed 
examples, both of which rely on an annulation step with norbornadiene followed by a retro-
Diels-Alder reaction to form the 3,4-unsubstituted isoquinolone (Scheme 3.2). Lautens et al.104 
used benzyl-protected 2-halobenzamides 154 in their palladium-catalysed annulation reaction at 
130 °C, using norbornadiene as a co-solvent, to furnish seven isoquinolones 156 with an 
average yield of 42%. Fagnou et al.35 reported a two-step synthesis to prepare the fused 
norbornene dihydroisoquinolone product 157 (91% yield) using an ‘internal oxidant’ based 
system, followed by a thermal retro-Diels-Alder reaction at 170 °C to give the corresponding 
isoquinolone 137. 
 
Scheme 3.2 
Avoiding these high temperature rearrangements and incorporating a C-H activation protocol, 
using our rhodium-catalysed coupling of substituted N-(pivaloyloxy)benzamides with vinyl 
acetate, would offer a beneficial alternative. This reaction is the synthetic equivalent of a direct 
hydroxamate/alkyne annulation reaction using acetylene as the alkyne. To our knowledge, the 
use of gaseous alkynes in C-H activation/annulation reactions has not been investigated. Given 
the hazards and operational difficulties associated with such a process, the availability of a 
cheap and convenient synthetic equivalent such as vinyl acetate would be highly useful.110   
N
H
O
OPiv
NH
O
N
H
O
Bn NH
O
Cl
R R R
Pd(OAc)2 (10 mol%)
PtBu3HBF4 (22 mol%)
Cs2CO3 ( 2 eq.)
PhMe:norbornadiene 8:1
130 °C, 16 h
156
7 examples
42% average yield
91% 157
ethylene glycol
170 °C, 16 h
–
–
96% 137
[Cp*RhCl2]2 (0.5 mol%)
CsOAc (2 eq.)
norbornadiene (1.1 eq)
MeOH (0.2 M)
rt, 16 h
155
43
154
NH
NH
O
O
	   50 
3.2 Results and discussion: isoquinolone series 1 
 
Having optimised the conditions for the synthesis of isoquinolones, we inferred that the 
methodology could be analogously applied to simple substituted aryl rings. A facile synthetic 
route was identified for the preparation of the pivalate substrates 160-167 from benzoic 
acids/acid chlorides, an ideal feedstock considering the low-cost and diverse substitution 
patterns commercially available (Table 3.1). Acid chlorides were either purchased or prepared 
from the equivalent acid using the Vilsmeier reagent,111 generated from oxalyl chloride and 
catalytic N,N’-dimethylformamide. Subsequent reaction with O-(pivaloyloxy)ammonium 
chloride 158112 or O-(pivaloyloxy)ammonium triflate35 (prepared by literature procedures), in 
either tetrahydrofuran with triethylamine or ethyl acetate−water (2:1) with potassium carbonate 
(Schotten-Baumann conditions), furnished the desired N-(pivaloyloxy)benzamide derivatives 
160-167 (A, Scheme 3.3, 16-81% yield, Table 3.1).  
 
 
Scheme 3.3 
 
Low yields of 161 and 162 were attributed to disubstitution of the amide 159 (A, Scheme 3.3). 
Despite increasing the equivalents of O-(pivaloyloxy)ammonium chloride 158 from 1 to 1.5 the 
side product was still identified in the reaction. It was subsequently found that replacing 
potassium carbonate with sodium hydrogen carbonate circumvented this disubstitution issue 
(see examples in Chapter 5). An alternative procedure, starting with the benzhydroxamic acid, 
furnished the product following acylation using pivaloyl chloride in tetrahydrofuran with 
triethylamine (B, Scheme 3.3). With a library of substrates in hand, the materials were reacted 
with vinyl acetate (1.5 equivalents) using the standard conditions: [Cp*RhCl2]2 (1 mol%) and 
cesium acetate (30 mol%) in MeOH (0.2 M) at 45 °C for 16 hours (Table 3.1). To commence 
our study, para-substituted substrates were selected in order to avoid issues of regiocontrol 
(Table 3.1). Electron-deficient p-cyano- 161, p-acetyl-, 162 and p-trifluoromethyl-N-
(pivaloyloxy)-benzamides 163 reacted to give excellent 81%, 99% and 71% yields of 169, 170 
and 171, respectively. 
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Entry R Yield A (%) No. Yield B (%)d No. 
1 H 88c 160 87 168 
2 CN 16b 161 81 169 
3 Ac 20a 162 99 170 
4 CF3 99b 163 71 171 
5 OMe 81b 164 31, 63e 172 
6 F 44b 165 68 173 
7 Br 62b 166 70 174 
8 I 47b 167 83 175 
 
a) PivONH2HCl (1.1 eq.), K2CO3 (2 eq.), EtOAc–H2O (2:1, 0.2 M), 0 °C, 3 h; b) PivONH2HCl (1.1 eq.), 
NEt3 (2.0 eq.), THF (0.2 M), 0 °C, 3 h; c) Prepared according to a literature procedure from 
benzhydroxamic acid (1.0 eq.), pivaloyl chloride (1.0 eq), NEt3 (1.2 eq.), THF, rt, 16 h.36 d) Standard 
conditions for annulation: [Cp*RhCl2]2 (1 mol%), CsOAc (30 mol%), MeOH (0.2 M), vinyl acetate 
(1.5 eq.), 45 °C, 16 h. d) 30 °C, 0.4 M. 
 
Table 3.1. Preparation of starting materials 160-167 and subsequent reaction with vinyl acetate to 
afford a library of isoquinolones 168-175 using the rhodium(III)-catalysed C-H 
activation/annulation protocol. 
 
Under the standard conditions, the electron-rich p-methoxy-N-(pivaloyloxy)-benzamide 164 
furnished the isoquinolone 172 with a poor yield of 31% (entry 5, Table 3.1), with the 
remaining starting material rearranging to the Lossen carbamate. Electron-donating groups are 
reported to accelerate the Lossen rearrangement by increasing the electron density at the N-O 
bond, which consequently facilitates the release of the pivalate anion.113,114 Additionally, 
Glorius et al. used a competition experiment to compare the reactivity of electron-deficient and 
electron-rich aromatic systems.36 4-Acetyl-N-methoxybenzamide 176 and 4-methoxy-N-
methoxy-benzamide 177 were treated with styrene 4 under their standard reaction conditions 
(Scheme 3.4). After 7 minutes, the reactions were quenched and analysis of the 1H NMR 
spectrum of the crude material revealed 28% conversion to the 4-acetyl-stilbene derivative 178 
and only 9% of the 4-methoxy-stilbene product 179, suggesting C-H insertion into electron-rich 
systems is less favourable. 
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Scheme 3.4. Glorius’ competition experiment with electronically different substrates 176 and 177.36 
 
To supress the competing reaction, the temperature was reduced to 30 °C and the concentration 
doubled to 0.4 M, which led to an improved yield of 63% of the isoquinolone 172 (entry 5). 
Halogenated substrates were tolerated under the reaction conditions (entries 6-8). 
Dehalogenated products were not observed in the crude reaction mixtures, rendering the 
products suitable for further cross-coupling reactions. 
 
To investigate regiochemical effects in non-symmetrically substituted substrates, eight 
3-substituted-N-(pivaloyloxy)benzamide derivatives were prepared 180-187 (Table 3.2). As 
predicted, in the reactions of substrates 180 and 181, C-H activation occurred at the less-
hindered position para- rather than ortho- to the phenyl/N-Boc substituent, giving 188 and 189 
as single regioisomers (entries 1 and 2). The reactions of the meta-brominated 182 and meta-
chlorinated 183 substrates gave predominantly the 7-bromoisoquinolone 190 and 
7-chloroisoquinolone 191 by reaction at the less-hindered site (entries 3 and 4). In contrast, the 
meta-fluorinated substrate 184 produced an inseparable mixture of regioisomers in favour of the 
contiguously substituted product (71%, 192a:192b, 2:1). The ortho-directing effect of strongly 
electronegative substituents on rhodium-mediated C-H activation has been previously 
reported.38,115 Given the irreversibility of the C-H insertion step under these conditions, in this 
case it is almost certainly a kinetic preference.35 This effect was also observed with the meta-
methoxy derivative 185 which gave a 2:3 mixture of regioisomers 193a:193b, while the 
protocatechuic acid derivatives 186 and 187 furnished the contiguously substituted 
isoquinolones 194b and 195b as single regioisomers (entries 7 and 8). 
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Entry R Yield SM % No. Product 
Ratiod 
a: b 
Yieldc 
a+b 
No 
1 HNBoc 62b 180 
 
1:0 81 188 
2 Ph 38a 181 
 
1:0 91 189 
3 Br 57a 182 
 
10:1 95 190 
4 Cl 85a 183 
 
98:2 66 191 
5 F 66b 184 
 
1:2 71 192 
6 OMe 76a 185 
 
3:2 76 193 
7 
 
83a 186 
 
0:1 53 194 
8 
 
73a 187 
 
0:1 48 195 
 
a) PivONH2HCl (1.1 eq.), K2CO3 (2 eq.), EtOAc–H2O (2:1, 0.2 M), 0 °C, 3 h; b) PivONH2HCl (1.1 eq.), NEt3 
(2 eq.), THF (0.2 M), 0 °C, 3 h; c) Standard conditions for annulation: [Cp*RhCl2]2 (1 mol%), CsOAc (30 mol%), 
MeOH (0.2 M), vinyl acetate (1.5 eq.), 45 °C, 16 h. d) Ratio of purified products. 
 
Table 3.2 
 
The protocatechuic acid derivatives 186/187 have reduced steric demands in comparison to the 
meta-methoxy derivative 185, in which the methoxy group is free to rotate, leading to a mixture 
of isomers. In total, 16 isoquinolones were prepared using the standard conditions as outlined in 
Table 3.1 and 3.2. 
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3.3 Heterocyclic series 2 
 
Having established a robust synthetic procedure for the preparation of isoquinolones, studies on 
heterocyclic analogues commenced. The starting materials 196-203 were prepared according to 
the procedures outlined in Section 3.1. The study began with thiophene derivatives, 
heterocycles electronically similar to the benzenoid substrates previously employed. Initial 
attempts using thiophene derivatives proved successful, albeit with lower yields compared with 
the benzenoid systems. The reactions of the thiophenyl substrate 196 and benzothiophenyl 
substrate 197 gave yields of 49% and 64%, respectively (entries 1 and 2, Table 3.3). To 
investigate the reactivity of the regioisomeric benzothiophene derivative, substrate 198 was 
prepared. Interestingly, no product was observed (entry 3). Analysis of the side products 
revealed a 70% conversion to the corresponding methyl carbamate (arising from methanol 
trapping the Lossen isocyanate formed in the reaction) and a further 15% of the free amide. 
Observation of the free amide was unexpected, as this would suggest an intermolecular N-O 
bond cleavage. The substrate scope was extended to include the benzofuran derivative 199, 
however the reaction required 48 hours to achieve an average yield of 38% (entry 4). Additional 
products isolated from the reaction included the free amide and the carbamate.  
 
Attempts to include N-heterocyclic compounds, using an N-methyl pyrrole derivative as the 
initial example, unfortunately, resulted in unreacted starting material. Similarly, the N-methyl 
indolyl derivative 200 furnished the product 207 in a low 16% yield. It became apparent that 
these relatively electron-rich systems were unsuitable for this rhodium-catalysed system. A 
recent study highlighted large rate differences in rhodium-mediated C-H activation reactions of 
various (hetero)aryl imines, the differing reactivity of substrates 196-200 appear in agreement 
with their finding.116 
 
To broaden the substrate scope, a nicotinamide derivative 201 and the N-oxide derivative 202 
(based on the reported enhanced reactivity of such substrates in C-H activation52) were added to 
the screening. After sixteen hours only unreacted starting material was identified in the crude 
reaction mixture of substrate 201 and 202, with no carbamate observed, potentially suggesting 
detrimental coordination of the rhodium. To probe this coordination effect, further investigation 
using the quinoline-3-carboxylic acid 203 was conducted. Potential dative coordination of the 
lone pair of electrons on the nitrogen would be disfavoured by the steric interaction of the C8 
hydrogen of the quinoline-based substrate. Interestingly, the quinoline derivative 203 did indeed 
furnish the benzo[b][1,6]-naphthyridin-1(2H)-one 208 with a yield of 51%. In total, five 
heterocyclic pyridones were prepared using this methodology. 
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Entry R 
Yield 
SM (%) 
No. Product 
Yield 
Product (%)d 
No. 
1 
 
40a 196 
 
49 204 
2 
 
25a 197 
 
64 205 
3 
 
42b 198 - - - 
4 
 
49a 199 
 
38e 206 
5 
 
35b 200 
 
16 207 
6 
 
25a 201 - - - 
7 
 
85c 202 - - - 
8 
 
45a 203 
 
51 208 
 
a) PivONH2HCl (1.1 eq.), K2CO3 (2 eq.), EtOAc–H2O (2:1, 0.2 M), 0 °C, 3 h; b) PivONH2HCl (1.1 eq.), NEt3 (2 
eq.), THF (0.2 M), 0 °C, 3 h; c) Prepared according to the literature procedure;52 d) Standard conditions for 
annulation: [Cp*RhCl2]2 (1 mol%), CsOAc (30 mol%), MeOH (0.2 M), vinyl acetate (1.5 eq.), 45 °C, 16 h; e) 48 h. 
 
Table 3.3. Formation of heterocyclic pyridones. 
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3.4 Substituted enol ester derivatives 
 
Having exemplified the reaction with a variety of hydroxamate esters, natural progression to the 
investigation of vinylic acetate derivatives ensued. The main objective was to incorporate α-
 and β-substituents to furnish more highly substituted isoquinolones. Our initial attempt, using 
isopropenyl acetate 209, produced 3-methylisoquinolin-1(2H)-one 215 in a disappointing 7% 
yield. The remainder of the starting material was converted to the methyl phenyl carbamate 133 
(Table 3.4, entry 1). Attempts to reduce the reaction temperature to room temperature resulted 
in a mixture of only unreacted starting material and the carbamate. Before expanding the scope, 
attempted optimisation of the reaction conditions was investigated, using isopropenyl acetate as 
the model substrate. 
 
The parameters selected for the optimisation study included: temperature (40-60 °C), reaction 
concentration (1-5 M) and substrate equivalents (1.5-5 eq.). The mid-point was repeated to 
verify continuity. The major product from each reaction was the carbamate 133, with only 
traces (confirmed by 1H NMR) of the desired product. In light of this observation, a number of 
alternative enol acetate derivatives 211-215 were tested. The corresponding aldehydes or 
ketones were used to prepare the derivatives shown in Table 3.4, using standard literature 
procedures.117,118  
 
Entry 1 2 3 4 5 6 
SM 
      
No. 209 211 212 213 214 215 
Product 
 
- - - - - 
No. 210      
Yield (%) 7 - - - - - 
Table 3.4 
 
Reactions of these alkenyl substrates (Table 3.4), at various temperatures, resulted in mixtures 
of unreacted starting material 43 and the methyl phenyl carbamate 133. Any attempt to increase 
the temperature above 45 °C led to full conversion to the carbamate 133. The reaction of 
α-acetoxy styrene 211 led to degradation to the starting phenylacetaldehyde, as well as 
benzamide and carbamate 133 (entry 2). Concerned that steric hindrance may have prevented 
N
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O
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coordination to the metal centre, a cyclic alkene, vinylene carbonate 216, was selected as a 
model substrate (Scheme 3.5). The tethered cis-arrangement would give some indication as to 
whether steric factors were playing a part in the substrate selectivity. Interestingly vinylene 
carbonate furnished 4-hydroxyisoquinolone 217 with a 78% yield as a single regioisomer 
(confirmed by the 1H NOESY NMR spectrum and literature data119).  
 
 
Scheme 3.5 
 
The substrate screen suggested 1,1-disubstituted and trans-1,2-disubstituted enol acetates were 
not accommodated in the reaction compared with monosubstituted and cis-1,2-cyclic alkenes. 
This was perhaps unsurprising, as Glorius36 and Fagnou34 reported only monosubstituted or 
1,2-cis-alkenes (e.g. 2,3,-dihydrofuran, norbornadiene and 1,3-cyclohexadiene) in their 
pioneering studies of intermolecular C-H activation/annulation protocols with 
N-(pivaloyloxy)benzamide.  
 
In summary, the oxidative rhodium-catalysed coupling of vinyl acetate to a variety of electron-
rich/deficient, aromatic and heteroaromatic, pivaloyl hydroxamates was successfully achieved. 
This synthesis presents a streamlined route for the preparation of 3,4-unsubstituted 
isoquinolones using an internal oxidant and mild reaction conditions. This method provides an 
attractive alternative to systems requiring external oxidants, which typically require superheated 
solvents with an excess of copper(II) acetate and silver(I) salts. Furthermore, the use of vinyl 
acetate, as a replacement for acetylene, offers a safe and cheap alternative and could find 
important application in the synthesis of isoquinolone-based compounds.  
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3.5 Methodology application: intermediates for Hepatitis C virus protease inhibitors 
 
3.5.1 Merck’s MK-1220 virus inhibitor 
 
Hepatitis C is a chronic viral infection that affects an estimated 170-200 million people 
worldwide120 and over time a significant portion of patients develop chronic liver disease. 
Current limitations with pharmaceutical therapeutics are their limited efficacy and often serious 
side effects. As a result very few patients complete their treatment. Merck recently identified 
MK-1220 218 as a potent and efficacious hepatitis C virus protease inhibitor with a potentially 
superior therapeutic profile (Figure 3.2).97  
 
Figure 3.2 
 
Despite the obvious challenges of preparing the macrocyclic ring, the methods for preparing 
individual fragments were additionally cumbersome. The heterocyclic fragment embedded in 
the macrocyclic structure is an ether-linked 6-methoxyisoquinoline, prepared from the 7-bromo-
6-methoxyisoquinolone 147 (Scheme 3.6). The key step in the reported three-step medicinal 
chemistry route required a thermal rearrangement (250 °C) of a cinnamoyl azide 219, resulting 
in an overall yield of 35% (A, Scheme 3.6).97 Based on the low yield of the cyclisation step 
(65%) and the high temperature required for the rearrangement, an alternative strategy was 
sought for the process route.121 Their survey of the literature identified the challenge of 
preparing this isoquinolone, particularly in achieving high regioselectivity for the cyclization 
step.121 These challenges were confirmed by the results of their exploration of potential routes, 
including an attempted bromination of 221, which resulted in the undesired regioisomer 222, 
and an attempted Friedel-Crafts cyclisation of 223 formed 224 instead of 147. Their final 
optimised 5-step synthesis, from the unsaturated tetrasubstituted intermediate 220, was achieved 
in 55% overall yield (B, Scheme 3.6).  
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Scheme 3.6 Key cyclisation steps from the discovery chemistry (A)97 and the optimised process 
route (B).121 
 
To investigate the application of this methodology to the synthesis of the intermediate 147, the 
corresponding 3-bromo-4-methoxy-N-(pivaloyloxy)benzamide 226 was prepared quantitatively 
from the cheap, commercially available benzoic acid 225 (Table 3.5). Using our standard 
conditions, the desired regioisomer 147 was observed and isolated with a yield of 46% 
(entry 1). The remaining starting material had rearranged to form the corresponding carbamate 
as a consequence of the competing Lossen rearrangement. By reducing the temperature of the 
reaction to 30 °C (entry 2) and increasing the concentration to 0.4 M (entry 3), the yield was 
improved from 46% to 85%. Additionally, the product was isolated as a single regioisomer. Our 
approach reduced the number of synthetic steps from five (for the process route) to three, 
resulting in a higher overall yield of 85%.  
 
Entry Conc. (M) Temp. (°C) Time (h) Yield (%) 
1 0.2 45 16 46 
2 0.2 30 48 72 
3 0.4 30 16 85 
 
Table 3.5 
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3.5.2 Bristol-Myers-Squibbs asunaprevir and analogues 
 
Asunaprevir 227, a Bristol-Myers-Squibb drug currently in phase III clinical trials for the 
treatment of hepatitis C virus infection, and its analogues rely on a 4-methoxy-7-
chloroisoquinoline fragment for improved activity relating to cardiovascular events.122 
Preparation of asunaprevir and its analogue 228 originate from three key fragments, one of 
which is 1,7-dichloro-4-methoxyisoquinoline 229 which is tethered to the core molecule via an 
SNAr reaction with N-Boc-hydroxyproline (Figure 3.3).122 
 
 
Figure 3.3. 
 
Scola et al.123 reported the synthesis of 4-hydroxy-7-chloroisoquinolone 235, the precursor to 
the key fragment 229, in five-steps with an overall yield of 41% (Scheme 3.7). Using a Heck 
reaction with butyl vinyl ether, followed by hydrolysis, the acetophenone derivative 232 was 
subsequently brominated to afford the α-halo carbonyl 233. Displacement of the bromine via a 
SN2 reaction with sodium diformylamide furnished the cyclisation precursor 234, which was 
immediately treated with methanol and acetic acid to afford the 4-hydroxy-7-
chloroisoquinolone 235 (78% yield over two steps). 
 
  Scheme 3.7 
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Having previously shown that our C-H activation/annulation chemistry would furnish the 
7-chloroisoquinolone 191a (66% yield, see Table 3.2) in two steps from the commercially 
available 3-chlorobenzoyl chloride 236, it was evident that using the same 3-chloro-
N-(pivaloyloxy)benzamide 183 with vinylene carbonate 216, instead of vinyl acetate, would 
furnish the 4-hydroxy-7-chloroisoquinolone 235 in a more succinct synthesis than that 
developed by Scola et al.124 Pleasingly, 4-hydroxy-7-chloroisoquinolone 235 was isolated as a 
single regioisomer (65%) using our standard C-H activation conditions (Scheme 3.8). Using our 
optimised methodology the number of steps required to prepare the isoquinolone 235 was 
reduced from the original six-step route (with an overall yield of 41%) to a two-step route with 
an overall yield of 55%. 
 
Scheme 3.8 
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3.6 Mechanistic considerations 
 
3.6.1 Deuterated vinyl esters 
 
Following our optimisation and exemplification of the isoquinolone synthesis (cf. Section 3.1) 
we were interested in the determining the mechanism of the reaction and specifically in probing 
the regiochemistry of the reaction with vinyl esters. In order to gain a better insight into the 
electronic preferences of the rhodium catalyst, further examination of the regiochemical 
outcome, with respect to the acetate portion, was undertaken (Scheme 3.9). 
 
Scheme 3.9 
 
Preparation of regiospecifically isotopically-labelled vinyl acetate 141 would provide further 
information about the regiochemical preference (Scheme 3.10). To acquire this information 
either the α-monodeuterated 238 or β-bisdeuterated 237 vinyl acetate would have to be 
prepared.  
 
Scheme 3.10 
 
Vinyl acetate is typically prepared on an industrial scale by oxidative condensation of ethylene 
and acetic acid using oxygen in the presence of a palladium catalyst.125,126 This approach would 
be unsuitable for our labelling study, as we would need to be able to differentiate between the 
two carbon atoms in the alkene (Scheme 3.10). Surprisingly, the synthesis of regiospecifically 
labelled vinyl acetate was unknown. Three different approaches were identified; acylation of 
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deuterated acetaldehyde (A, Scheme 3.11), acylation of heptenoic acid followed by ring closing 
metathesis to give vinyl acetate (B) and finally, alkenylation of a formyl anhydride (C). 
 
Scheme 3.11 
 
An initial literature search for the acylation of acetaldehyde 239 indicated a lack of examples, 
presumably owing to the propensity of the acetaldehyde enolate towards polymerisation. 
However, a report published by Sladkov and Petrov identified a viable strategy.127 Predicting a 
difficult separation of the desired vinyl ester product from the reaction medium, due to its low 
boiling point, lauryl chloride 240 was used instead of acetyl chloride to provide a stable, non-
volatile substrate to separate. Firstly vinyl laurate was used instead of vinyl acetate in our 
standard C-H activation/annulation conditions. The isoquinolone was obtained with a yield of 
86%, indicating no detrimental effect with the substitution. Addition of lauryl chloride to a 
solution of formaldehyde and pyridine at 0 °C, with subsequent heating, unfortunately, did not 
yield the desired vinyl laurate 241 (Scheme 3.12). Instead a complex mixture of products was 
obtained.  
 
Scheme 3.12 
 
Based on the failed reaction (Scheme 3.12) and the paucity of similar preparative techniques 
using these substrate types, route B was investigated (Scheme 3.13). A route was envisaged 
starting from the reduction of 6-heptenoic acid to the deuterated aldehyde 244. Acylation of the 
corresponding enolate 243 followed by a ring closing metathesis would provide the desired 
deuterated vinyl ester 237 with elimination of cyclopentene 242. Significant literature precedent 
exists for the ring-closing metathesis of enol esters with terminal alkenes. These have been 
shown to work effectively for the formation of cyclic enol ethers using molybdenum128,129 and 
ruthenium130–133 based catalysts.  
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Scheme 3.13 
 
Following the successful reduction of the unsaturated acid 245 to the bis-deuterated alcohol 246 
(100% D, by 1H NMR), using lithium aluminium deuteride, attempts were made to oxidise the 
unsaturated compound to the aldehyde 244 (Scheme 3.14). Both Dess-Martin periodinane134 and 
Swern135 oxidation led to the formation of several side products. The oxidation mediated by 
pyridinium chlorochromate (PCC) gave a 65% yield of the aldehyde 244, which was not 
sufficient for the multi-step synthesis. Tetrapropylammonium perruthenate (TPAP) successfully 
furnished the aldehyde 244 on a smaller scale (65%); however scale up resulted in the formation 
of multiple side products. Based on the assumption that sufficient material would be required to 
screen several conditions for the metathesis step, an alternative approach was considered. 
 
Preparation of the Weinreb amide 247 from the acid chloride (prepared using 6-heptenoic acid 
245 and the Vilsmeier reagent111) produced several by-products (Scheme 3.14). Fortunately, 
formation of the desired product 247 was realised via the mixed anhydride generated from 
isobutyl chloroformate, obtained with a yield of 96%. Reduction of the Weinreb amide 247 
using lithium aluminium deuteride gave the deuterated aldehyde with a yield of 85% (100% D 
by 1H NMR). Acylation of the aldehyde using potassium bis(trimethylsilyl)amide (KHMDS) 
and hexanoyl chloride furnished the enol ester 248 with a modest yield of 32% (E:Z 1.8:1). 
 
Scheme 3.14 
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Grubbs 1st and 2nd generation catalysts G2-G4 Table 3.6). The reactions were monitored by 
1H NMR over two hours. Unreacted starting material was observed using both G1 and G3 
(entries 1 and 3). Promisingly, the product 249 and cyclopentadiene 242 were observed in the 
reactions using the catalysts G2 and G4 (entries 2 and 4). In both reactions, the product 
conversion ceased after the first hour, suggesting catalyst poisoning. The reaction in deuterated 
dichloromethane-d2 at a lower temperature resulted in only 5% conversion to product (entry 5).  
 
 
Entry Catalyst 
1H NMR ratio 
248:249 
1 G1 100:0  
2 G2 84:16 
3 G3 100:0 
4 G4 87:13 
5 G2 95:5a 
6 G2 89:11b 
1H NMR ratio of 248:249 from the crude reaction mixture. 
 aDCM-d2 (0.16 M), 45 °C. bEthylene bubbled through the reaction. 
 
Table 3.6 
 
Enol ethers are used to terminate ring-opening metathesis polymerisation reactions (ROMP) by 
formation of the ruthenium Fisher carbene complex 251.133,136 The Fisher carbene is more stable 
than the intermediate alkylidene (or methylidene) 250 that is formed during the alkene 
metathesis i.e. the equilibrium should favour the formation of species 251 (Scheme 3.15). 
Concerned that the product 249 was inhibiting catalytic activity, the reaction was repeated with 
ethylene gas bubbling through the solvent,137,138 however the yield was not improved (entry 6, 
Table 3.6)  
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Scheme 3.15 
 
Following the unsuccessful attempts using the metathesis strategy, we decided to move on to 
our third approach. Petasis et al.139 reported a methylenation of the cyclic anhydride 252 to 
produce the vinyl lactone 253 (and the bis-vinyl cyclic ether 254) using dimethyl titanocene 
(A, Scheme 3.16). Using this method we reasoned that treatment of a formyl anhydride 255 
with deuterated dimethyl titanocene-d6 could provide the required vinyl ester 237 (B, 
Scheme 3.16).  
 
Scheme 3.16 
 
Following a procedure by Naef et al.,140 the formyl anhydride 258 was prepared from formic 
acid 256 and hexanoyl chloride 257 in dimethylaniline (57%, Scheme 3.17). The alkylating 
reagent, dimethyl titanocene-d6 260, was synthesised from titanocene dichloride 259 and 
deuterated methyllithium to give the product in a solution of toluene (the concentration was 
determined by 1H NMR).141 Isolation of the compound was avoided due to the reported 
instability of the complex when exposed to moisture and light.139 The dimethyl titanocene 
solution 260 was added immediately to succinic anhydride, as a trial reaction, to identify 
whether the complex was active. Analysis of the crude 1H NMR spectra indicated traces of the 
desired allylic product 261, however the majority of the material remained unreacted. 
Benzaldehyde was used as an alternative substrate to test the dimethyl titanocene solution 260; 
consumption of the aldehyde was observed by 1H NMR, however no vinylic peaks 
corresponding to the deuterated styrene 262 were observed, suggesting an issue with the 
dimethyl titanocene reagent 260.  
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Scheme 3.17 
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3.6.2 A vinyl ester surrogate 
 
Following our failed attempts to prepare deuterated vinyl acetate, we decided to focus on a 
deuterated substrate that would be easier to synthesise than vinyl acetate. 
O-Vinyl-N,N’-diisopropylcarbamate 265 was selected as an analogous reactant (Scheme 3.18). 
The material was simply prepared following a procedure by Clayden et al.142 via a lithium-
mediated decomposition of tetrahydrofuran 263 to give the lithium acetaldehyde enolate 264, 
which was subsequently acylated using N,N’-diisopropyl carbamoyl chloride to afford the 
desired product 265 (83%). Selective incorporation of a deuteron at the α-position was achieved 
by directed lithiation using sec-BuLi, followed by a quench using deuterium chloride in 
deuterium oxide to afford 265-d1 (87% D by 1H NMR). 
 
Scheme 3.18 
 
To assess whether the vinyl carbamate was a suitable alternative for vinyl acetate, the non-
deuterated carbamate 265 was used under the standard reaction conditions (Scheme 3.19). The 
reaction produced the isoquinolone 137 as the sole product with a reasonable yield of 50% 
(compared to 87% with vinyl acetate). Unfortunately, attempts with the deuterated variant 
265-d1 produced the isoquinolone 137-d1 with a yield of 5%. Several iterations of the reaction 
with different batches of the starting material resulted in the same yield, suggesting catalyst 
poisoning. Despite the poor yield, the isoquinolone 137-d1 was isolated and the regioselective 
incorporation of the deuteron in the 3-position was confirmed by 1H NMR (85% D by 1H 
NMR).  
 
Scheme 3.19 
 
Assuming the regioselectivity of O-vinyl-N,N’-diisopropylcarbamate 265 is comparable to that 
of vinyl acetate, the isolated product suggests the reaction proceeds through an aminoacetal 
intermediate. This result contrasts with the regioselectivity observed using vinyl ethers which 
furnished the benzylic ethers  as the major regioisomer (Figure 3.4). 
O LiO
N
iPr
iPr
O
O
N
iPr
iPr
O
ODnBuLi (1.5 eq.)
rt, 16 h DMPU (1 M)
0 °C to rt, 
4 h 83%265
i)  sBuLi (1 eq.)
TMEDA (1 eq.)
THF (0.9 M)
-78 °C, 1 h
ii) DCl in D2O
96% (87% D by 1H NMR)
265-d1
(iPr)2NCOCl
(1 eq.)
263 264
N
iPr
iPr
O
OH/D
N
H
O
O
O
[Cp*RhCl2]2 (1 mol%)
CsOAc (30 mol%)
MeOH (0.2 M), 45 °C, 
16 h
NH
O
H/D
137:  H = 50%
137-d1:  D = 5%
43265: H
265-d1: D
	   69 
 
Figure 3.4 
 
3.6.3 Factors influencing regiochemical preference of alkenyl substrates 
 
Once the regiochemical preference for the enol ether substrates and vinyl acetate had been 
established (cf. Section 2.4 and 3.6.2), we were interested to find out whether the carbonyl 
moiety has a role in the regioselectivity of the reaction. N-Boc-dihydropyrrole 266 was selected 
as a model substrate for the study. Using the standard conditions, N-Boc-dihydropyrrole 266 
and N-(pivaloyloxy)benzamide 43 furnished the aminal 267, with a yield of 45% (Scheme 
3.20). The regioisomer was confirmed by a 1H NMR NOESY spectrum and an X-ray structure 
of a single crystal of 267 (Scheme 3.20 and Appendix 2.2).  
  
Scheme 3.20 Regioisomer 267 confirmed with an X-ray crystal structure. 
Having observed a similar selectively with the O-vinyl-N,N-diisopropyl carbamate 265-d1, as 
our vinyl acetate surrogate (see Scheme 3.19), we considered potential interactions between the 
carbonyl group and the rhodium catalyst. Xia et al. reported the carbonyl-stabilised key 
intermediate I, by computational calculations using DFT methods, with ethylene as a model 
substrate (Figure 3.5).37 Based on the rhodacycle II, it is possible to imagine an alternative 
stabilisation occurring via the carboxyl group of the pyrrole III or vinyl acetate IV, through a 
five-membered intermediate. 
 
Figure 3.5 
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3.7 Conclusion 
In summary, a robust, efficient C-H activation protocol for the synthesis of isoquinolones from 
simple hydroxamate/oxime esters using vinyl acetate as an acetylene equivalent has been 
established. This protocol avoids the necessity for gaseous acetylene in order to achieve the 
desired 3,4-unsubstituted isoquinolones and provides an effective and facile synthetic route 
compared with existing procedures.  
 
In total, sixteen exemplar 3,4-unsubstituted isoquinolones, bearing electron-
donating/withdrawing groups, were prepared with an average yield of 75%. Oxygen and sulfur-
based heterocycles were also tolerated, however nitrogen-containing aromatics proved to be less 
reactive. Despite this observed trend, five heterocyclic examples were successfully prepared.  
 
The limitations of the reaction conditions were brought to light when our attempts to react 
various substituted vinylic acetate derivatives with N-(pivaloyloxy)benzamide under rhodium 
catalysis proved unsuccessful (only cyclic alkenes were tolerated under the existing reaction 
conditions). Comparison of vinyl ethers to vinyl acetate indicated a significant difference in 
reactivity, which we believe is a result of either the increased electron density in the vinylic 
portion of the molecule or the coordination of the acyl group to the rhodium centre. Generally, 
electron-rich substrates (with regards to the aromatic or vinylic reactant) had a detrimental 
effect on the activity of the catalyst.  
 
Having failed to prepare selectively-deuterated vinyl acetate, we were able to use a deuterated 
surrogate (O-vinyl-N,N’-diisopropylcarbamate) in order to assess the regiochemical preference. 
The results contrasted with those found using n-butyl vinyl ether, suggesting an additional 
interaction between the carbonyl of the vinyl acetate and the metal centre (also observed using 
N-Boc-dihydropyrrole). 
 
Finally, the utility of this methodology was exemplified with the succinct synthesis of two 
intermediates for hepatitis C virus protease inhibitors, MK-1220 and asunaprevir. Excellent 
regioselectivity meant that the desired intermediates were simply prepared using our optimised 
methodology. 
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Chapter 4 
 
Rhodium(III)-catalysed synthesis of isoquinolines 
 
4.1 Introduction 
 
Isoquinolines are prevalent scaffolds in pharmaceutical agents, natural products and other fine 
chemicals;143–149 there are over 400 members in the isoquinoline alkaloid family alone.148 
Traditional syntheses of isoquinolines from mono-substituted arene precursors include the well-
established Bischler-Napieralski,150 Pictet-Spengler,151 Pictet-Gams,152 and Pomeranz-Fritsch 
reactions (Scheme 4.1).153,154 In each case the key cyclisation step proceeds via an SEAr 
mechanism, which inherently limits the substrate scope to electron-rich aromatic systems. To 
address this limitation, alternative approaches using ortho-disubstituted aromatic precursors as 
templates for annulation of the heterocyclic component have been developed. The primary 
approach is to install alkenes/alkynes ortho- to an imine or imine precursor, (typically using 
cross-coupling methodologies with ortho-halogenated substrates) which can undergo an 
electrophilic-induced intramolecular cyclisation to afford isoquinolines.155–161 Larock et al. 
utilised cross-coupling methodology of 2-iodobenzaldeyde imines with internal alkynes to give 
a range of isoquinolines.162,163 Other methods include reactions using benzyne with vinyl amines 
and 2-azidoacrylates164 with α-diazocarbonyl compounds.165 Despite broadening the variety of 
substrates available, atom economy is still a drawback in the design of these new systems.  
 
Scheme 4.1 
 
In recent years, numerous C-H activation/annulation approaches to isoquinolines have been 
developed using various rhodium, ruthenium and palladium catalysts.24,25,166–168 This chemistry 
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combines the synthetic flexibility of using mono-substituted arene precursors while obviating 
the requirement for electronic activation towards SEAr chemistry inherent in the classical 
approaches named above. The process involves conversion of a C-H bond to a C-C bond and 
hence to facilitate catalytic turnover an oxidant is required, which, in the case of rhodium, is 
typically stoichiometric copper acetate. Alternative protocols based on ‘internal’ oxidants have 
been developed by the groups of Fagnou34 and Chiba.64 Using ketoximes as superior directing 
groups allows for milder conditions, while cleavage of the N-O bond maintains the active 
rhodium(III) catalyst without generating metal-based waste streams.39,49,64,160,169–171 Recent work 
by Cheng et al. identified hydrazones (cleaving N-N bonds) as a new oxidizing direction groups 
for the synthesis of isoquinolines.71 
 
Having established a novel and robust synthetic procedure for the preparation of 
3,4-unsubstituted isoquinolones (Section 3.1), application of this methodology was extended to 
the synthesis of isoquinolines. Chiba et al.64 have demonstrated a similar protocol, reacting 
internal alkynes with acetylated oximes to afford isoquinolines. However acetylene has not been 
used in this type of reaction, which encouraged us to proceed with our investigation using vinyl 
acetate as an acetylene equivalent. 
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4.2 Results and discussion 
 
To commence the investigation, ketoximes 268-271 were examined using the previously 
developed reaction conditions (entries 1-4, Table 4.1).110 Disappointingly, the ketoxime reacted 
to give <5% of the corresponding isoquinoline 272. Competing deacylation of ketoximes esters 
270 and 271 resulted in the formation of ketoxime 268 (entries 3 and 4). Increasing the reaction 
temperature to 60 °C improved the yield of the reactions with O-acetylated oxime 271 from 3% 
to 24% (entry 8). 
 
 
Entry Reactant R 141 (eq.) Conc. (M) Temp. (°C) 1H NMR yield (%)a 
1 268 H 1.5 0.2 45 5 
2 269 Me 1.5 0.2 45 0 
3 270 Piv 1.5 0.2 45 5 
4 271 Ac 1.5 0.2 45 3 
5 268 H 1.5 0.2 60 4 
6 269 Me 1.5 0.2 60 0 
7 270 Piv 1.5 0.2 60 4 
8 271 Ac 1.5 0.2 60 24 
9 271 Ac 1.5 0.2 60 10 
10 271 Ac 1.5 0.2 60 2b 
11 271 Ac 1.5 0.2 60 0c 
12 271 Ac 1.5 2 60 19 
13 271 Ac 5 2 60 48 
14 271 Ac 10 2 60 75 
15 271 Ac 20 2 60 30 
16 271 Ac neat 2 60 0 
17 271 Ac 10 2 60 79 
18 271 Ac 10 1 60 56 
a[Cp*RhCl2]2 (1 mol%), CsOAc (0.3 eq.), MeOH, 60 °C, 48 h; b1 eq. of CsOAc instead of 0.3 eq; 
cK2CO3 (1 eq.) was used instead of CsOAc. Trimethoxybenzene was used as an internal standard. 
Table 4.1  
 
Proceeding with O-acetylated ketoxime 271, the number of equivalents of cesium acetate was 
increased from 0.3 to 1 equivalent, however this had a detrimental effect on the yield, where the 
oxime 268 was again observed in the 1H NMR of the crude reaction (entries 9 and 10). Fagnou 
et al.35 observed an improved yield when cesium acetate was replaced with potassium carbonate 
when using the O-pivaloyl ketoxime 270 with diphenyl acetylene, however under these 
conditions again only the deacylated oxime 268 was observed. To avoid increasing the catalyst 
N OR
OAc N
[Cp*RhCl2]2] (1 mol%)
CsOAc (30 mol%)
MeOH141 (eq.)
268-271
272
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loading, the concentration of the reaction was increased ten-fold to 2 M, and the number of 
equivalents of vinyl acetate were investigated (entries 12-16). This screening revealed that 10 
equivalents of vinyl acetate were necessary to obtain an optimal yield of 75% (entry 14 and 17). 
Given the low cost and volatility of vinyl acetate (ensuring simple purification), we considered 
the excessive addition of the substrate to be acceptable. Reducing the concentration to 1 M 
reduced the yield from 79% to 56% of the isoquinoline (entries 17 and 18). With our optimized 
conditions in hand, the scope of the reaction utilizing a broad range of substrates was 
investigated, the results of which are summarized in Table 4.2 and 4.3.  
 
Substrates 273-282 were prepared from the corresponding acetophenones by formation of the 
(E)-oxime using hydroxylamine in refluxing ethanol–pyridine.64 Subsequent acetylation of the 
crude oxime, using acetic anhydride and catalytic 4-dimethylaminopyridine (DMAP) in 
pyridine, furnished the desired products with overall yields for the two steps ranging from 44 to 
95% (Table 4.2).64 To commence the substrate scoping, ortho- and para-derivatives were 
considered to avoid issues of regiocontrol. Electron-deficient p-nitro- and p-trifluoromethyl-O-
acetylated oximes reacted to afford the corresponding isoquinolines, 283 and 284, in good yield, 
however introduction of a methyl group reduced the yield of 285 to 44%. Halogens were well 
tolerated, with 8-fluoro- 286 and 6-chloro-, bromo-, and iodoisoquinolines (287-289) being 
formed in reasonable to good yields (41-72%, Table 4.2). Using the mixture of E- and Z-
naphthylisoquinoline ketoxime isomers 280 (3:1, E-:Z-), we were expecting a maximum yield 
of 75%, based on the study reported by Chiba et al.64 (cf. Scheme 1.32). The 
naphthylisoquinoline 280 reacted to give the tricylic isoquinoline 290 with a yield of 24%. The 
LCMS of the crude reaction identified peaks corresponding to unreacted starting material (the 
E- and Z-isomers), two separate peaks for the E- and Z-deacylated starting materials and the 
product peak (entry 9, Table 4.2). The relative signals were difficult to quantify from the 1H 
NMR spectrum of the crude reaction. Electron-rich groups had a detrimental effect on the yield, 
with the ortho- and para-methoxy derivatives reacting to give 14% and 9% of the 
corresponding isoquinolines 291 and 292, respectively (entries 10 and 11). The poor yields 
observed from reactions using electron-rich substrates paralleled the trend observed with the 
synthesis of isoquinolones (Section 3.1). 
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Entry SM Yield SM % No. Product 
Yield 
(%) 
No. 
1 
 
80 271 
 
57 272 
2 
 
95 273 
 
83 283 
3 
 
80 274 
 
82 284 
4 
 
82 275 
 
44 285 
5 
 
44 276 
 
41 286 
6 
 
74 277 
 
60 287 
7 
 
78 278 
 
72 288 
8 
 
81 279 
 
64 289 
9 
 
87 
(E:Z, 3:1) 
280 
 
24 290 
10 
 
82 281 
 
14 291 
11 
 
94 282 
 
9 292 
 
Table 4.2 
 
O-Acetylated meta-substituted oximes were investigated to probe regiochemical effects in non-
symmetrically substituted substrates (Table 4.3). The 3-bromo 293 and 3-fluoroketoximes 294 
reacted to give regioisomeric mixtures of the 7- to 5-substituted isoquinolines (2.7:1 298a:298b 
(50%) and 1:5 299a:299b (47%), respectively). As predicted, the meta-methylated derivative 
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295 gave a regioisomeric ratio significantly in favour of C-H activation at the less-hindered 
position (10:1 300a:300b, 52%). In contrast to the methyl example, the meta-methoxy 
derivative was isolated as a 1:1.4 regioisomeric ratio of 301a:301b in favour of reaction at the 
sterically congested ortho-position. The ortho-directing effect of electronegative substituents in 
rhodium-catalysed C-H activation has been previously noted.35 To illustrate this effect, the 
(3,4-methylenedioxy)acetophenone ketoxime 297 was prepared (to remove steric bias from the 
C-H selectivity), which pleasingly, furnished solely the contiguously substituted 
isoquinoline 302. 
 
 
 
Entry R Yield SM % No. Product 
Ratioa 
a:b 
Yield 
a+b 
No. 
1 
 
97 293 
 
2.7:1 50 298 
2 
 
73 294 
 
1:5 47 299 
3 
 
90 295 
 
10:1 52 300 
4 
 
94 296 
 
1:1.4 58 301 
5 
 
77 297 
 
- 36 302 
Table 4.3 aRatio of purified products. 
 
Substrates 303-306 were prepared in order to assess the tolerance of varied substituents at the 
α-position, in addition to an example of C-H activation of a heterocyclic example 307. 
Replacing the α-methyl substituent with various functional groups proved mostly unsuccessful 
(entries 1-3, Table 4.4), with the exception of the tetralone derivative 306 which furnished the 
tetracyclic isoquinoline 308 with a yield of 11%, indicating potential for optimisation (entry 4). 
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Unfortunately only a trace of the fused thienopyridine 309 was identified from the reaction 
mixture by 1H NMR analysis (entry 5). 
 
 
Entry SM No. Product 
Yield 
(%) 
No. 
1 
 
303 - 0 - 
2 
 
304 - 0 - 
3 
 
305 - 0 - 
4 
 
306 
 
11 308 
5 
 
307 
 
trace 309 
Table 4.4 
 
In summary, the rhodium(III)-catalysed synthesis of 3,4-unsubstituted isoquinolines was 
optimised and exemplified with seventeen representative compounds. To ensure the catalyst 
loading was maintained at 1 mol%, the equivalents of vinyl acetate were increased to ten-fold in 
order to maximise the yield. Considering the wide availability of methyl ketones as precursors, 
coupled with the low cost of vinyl acetate, this methodology presents a significant alternative to 
the current methods available for preparing 3,4-unsubstituted isoquinolines.  
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 4.3 Methodology application: decumbenine B 
 
Having observed a single regioisomer in the reaction of 3,4-(methylenedioxy)acetophenone 
ketoxime derivative 297, we were interested in applying our methodology to the corresponding 
aldoxime 312 in the hope of preparing the isoquinoline intermediate 310 used in Orito’s 
synthesis of decumbenine B. This naturally occurring alkaloid was isolated from the plant 
tubers of Corydalis decumbens and has been used for the treatment of hypertension, rheumatoid 
arthritis and sciatic neuraligia.96 The first total synthesis of decumbenine B, reported by Zhu et 
al., required 18 steps from piperonal.172 The route was succeeded by a ten-step linear synthesis 
by Orito173 and then by an improved seven-step convergent procedure by Larock.162,163 The 
intermediate isoquinoline 310, prepared by Orito et al.,173 relies on a key Pictet-Gams 
cyclisation, resulting in a yield of 22% over five steps (Scheme 4.2).  
 
Scheme 4.2 Orito et al., synthesis of decumbenine B.173 
 
By application of the previously developed methodology, the aldoxime 312 was converted to 
the intermediate isoquinoline 310 as a single regioisomer with a yield of 26% (21% over three 
steps from piperonal, Scheme 4.3). The remaining starting material had rearranged to give the 
corresponding nitrile 313. Attempts to optimize the conditions by increasing the catalyst and 
base loading proved unsuccessful. Exchange of the O-acetyl ketoxime for the O-pivaloyl 
ketoxime group resulted in 100% conversion to the corresponding nitrile 313. This result was 
perhaps unsurprising as aldoximes are susceptible to elimination to nitriles; examples include 
reactions catalyzed by ruthenium,174,175 palladium,176–178 copper,179 among others.180–183 
Although disappointing for the intended purpose, the potential for a rhodium-catalysed 
rearrangement of ketoximes has been identified and is currently under investigation, as nitriles 
are valuable intermediates in chemical synthesis.  
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Scheme 4.3 
 
4.4 Conclusion 
 
In conclusion, a C-H activation protocol has been optimised and developed for the synthesis of 
seventeen 3,4-unsubstituted isoquinolines. Electron-deficient ketoximes were particularly 
effective substrates under these conditions, however, electron-rich derivatives were less 
reactive, leading to competing deacetylation of the starting materials. The synthetic utility of 
vinylic esters as acetylene synthons has broad application in the synthesis of heterocycles. To 
demonstrate the application of this methodology, a three-step synthesis of the decumbenine B 
intermediate 310 was achieved. Additionally, a rhodium-catalyzed rearrangement of aldoximes 
to nitriles was identified. 
 
4.5 Future work 
 
The isoquinoline alkaloids have been identified as potent therapeutic agents for a host of 
anticancer, antimalarial and antiviral applications, to name but a few.149,184 The most prevalent 
scaffolds within this class of compounds are based on natural berberine and palmatine, and the 
synthetic coralyne, of whose analogues have been extensively studied (Figure 4.1).149 A 
common motif embedded in these structures is a 3-arylisoquinoline. 
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Larock et al.162,163 reported a succinct synthesis of decumbenine B using a key palladium-
catalysed coupling of terminal acetylenes 315 with 2-iodobenzalimines 314 to furnish 
3-arylisoquinolines (Scheme 4.4), significantly improving access to these scaffolds. The 
drawback of this system is the requirement for a halogenated starting material to undergo the 
cross-coupling reaction.  
 
Scheme 4.4 
 
Using a similar disconnection, a C-H activation annulation would offer an alternative, succinct 
pathway for the synthesis of these alkaloidal scaffolds and their analogues (Scheme 4.5). This 
methodology will be investigated in due course. 
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Chapter 5 
 
Synthesis of tetracylic fluorescent imides 
 
5.1 Introduction 
 
 
5.1.1 A divergent mechanistic pathway revisited 
 
Whilst screening the reactions of hydroxamic esters (see Section 2.6), an unexpected product 
was isolated from the rhodium(III)-catalysed reaction of N-methoxybenzamide 42 with vinyl 
acetate 141 (Figure 5.1). The isoindolo[2,1-b]isoquinoline-5,7-dione 143 was isolated with a 
low yield of 6%, along with unreacted starting material.85 Investigation of the spectrochemical 
properties of the molecule identified a strong blue fluorescence (λabs 375 nm, λemis 413 nm, 
dichloromethane). The ability to simply tailor the fluorescence of a key scaffold for a particular 
purpose is highly attractive. Based on the structure of the tetracyclic imide 143, one could 
envisage tuning the fluorescent and physical properties (in terms of solubility and/or 
crystallinity) by modification of the aromatic rings using various substituents.   
  
 
Figure 5.1. Absorbance and emission spectra for imide 143 in dichloromethane. 
 
  
OAc
N
O O[Cp*RhCl2]2 (1 mol%)
CsOAc (30 mol%)
MeOH (0.4 M)
60 °C, 48 h141 6% 143
N
H
O
OMe
42
0	  
500000	  
1000000	  
1500000	  
2000000	  
2500000	  
3000000	  
0	  
0.05	  
0.1	  
0.15	  
0.2	  
0.25	  
0.3	  
0.35	  
0.4	  
250	   350	   450	   550	  
Fl
uo
re
sc
en
ce
	  
Ab
so
rb
an
ce
	  
Wavelength	  (nm)	  
	   82 
5.1.2 Application of aromatic fluorescent molecules 
 
 
In recent years the development of luminescent and π-functionalised materials, for application 
in organic semi-conductors185,186 and electroluminescent organic materials,187–193 has driven the 
demand for succinct, efficient syntheses of polycyclic and heterocyclic compounds. This class 
of polycyclic aromatic compounds are of particular interest due to their stability, their 
fluorescent properties in the solid state and their ability to transport charge.194 The basic 
requirements for organic electroluminescent materials are the capability to undergo charge 
transfer to an electrode, the ability to transport charge and to fluoresce efficiently.187  
 
Fluorescent compounds are particularly attractive for use in organic light-emitting diodes 
(oLEDs). Many green and red-light emitting diodes have been developed, however highly 
efficient and stable blue-light emitters are still rare.195 Fluorene-based polymers are commonly 
used in blue-light emitting materials, due to their good thermal stability and solubility and their 
photoluminescent quantum yield.196–198 For example, Chen and Kieffer et al. developed fluorene 
based polymers 323-325 for oLED applications (Scheme 5.1).195 The carbazole derivative 318 
was prepared via an Ullman coupling of carbazole 316 and 4-iodoaniline 317. The oligomeric 
strands 320-322 were prepared by a Buchwald-Hartwig coupling of the aniline 318 with the 
dibromofluorene 319 to afford the intermediates 320-322 with yields of 53-68%. A subsequent 
Suzuki coupling furnished the final oligomers, which displayed high photoluminescent quantum 
yields (ranging from 59-64% in chloroform) with λmax emission values of 493 nm for 323 and 
324 and 446 nm for 325. 
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In recent years, white polymer light-emitting diodes (WPLEDs) have received attention due to 
their potential application in backlight and full-colour displays with colour filters.199 Wang et al. 
incorporated three primary colour emitters (blue (λmax 445 nm), green (λmax 515 nm) and red 
(λmax 624 nm)) in a single polymer 330 to cover the whole visible range spectrum from 400 to 
700 nm (Scheme 5.2). Generally in a macromolecule, the energy from the shorter wavelength 
fluorophore will transfer to the longer wavelength emitter, causing emission only from the latter 
to be observed. To circumvent this issue, Wang et al. decreased the green and red emissive 
components, with respect to the blue fluorene to ensure this transfer of energy was compensated 
for, ensuring separate blue, green and red emission. The polymer was assembled via a Suzuki 
polymerisation coupling of the brominated monomers 326, 328 and 329 with the fluorene 
boronic acid 327.  
 
Scheme 5.2 
 
In biological systems, fluorescence microscopy is one of the most widely used approaches for 
high-resolution, non-invasive imaging of live organisms.200 Exogenous organic fluorophores are 
the most commonly used tags for fluorescence-based imaging. Shorter-wavelength fluorophores 
are infrequently used as longer wavelength dyes are widely available and are less likely to cause 
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photodamage to labelled biomolecules.201 Many cells autofluoresce when exposed to UV light 
and therefore eliminate the requirement for UV sensitive exogenous fluorophores. Despite these 
considerations, blue-fluorescent probes can provide a contrasting colour that can be easily 
distinguished from the longer wavelength probes (that are typically green, yellow, orange and 
red). Multicolour assays are often used for immunofluorescence, in situ hybridization and 
neuronal tracing, and nucleic acid/protein microarrays.201 Aside from Cascade blue® 331, most 
blue fluophores for biological imaging are based on the coumarin scaffold, for example Alexa 
Fluor® 350 332, 4-amino-4-methyl-coumarin (AMCA-X) 333 and Pacific Blue™ 334 
(Figure 5.2). 
 
Figure 5.2 
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5.1.3 Assembly of polyaromatic scaffolds via rhodium(III)-catalysed C-H activation 
 
In the past decade, numerous reports of polyaromatic or heteroaromatic scaffolds have been 
explored, due to the demand for novel conducting materials. C-H activation methodology has 
proved highly useful in the synthesis of these scaffolds. Numerous examples of rhodium(III)-
catalysed cleavage of C-H/N-H or C-H/O-H bonds with subsequent annulation reactions with 
alkynes have been reported for the synthesis of polycyclic compounds.109,202–207 For example, 
Cheng et al. reported the synthesis of highly substituted naphthyridine-based 
polyheteroaromatic compounds 336 from N-hydroxbenzamidines 335 with diphenyl acetylene 
40 (Scheme 5.3).202 Using copper(II) acetate and the oxime (N-O) bond as a source of an 
internal and external oxidant, they were able to achieve three C-H bond insertions to form the 
pentacyclic fused core.  Derivatives of the polyaromatic compound 336 displayed absorbance 
maxima from 380-450 nm and fluorescence maxima from 500-530 nm.  
 
Scheme 5.3 
 
Using a combination of an internal and external oxidant, Shi et al. utilised the oxidative 
rhodium(III)-catalysed annulation of aryl ketoximes 337 with three units of phenyl acetylene 40 
to form sterically congested 1-methyl-4-phenyl-3-tetraphenylnaphthyl isoquinolines 338, with 
an average yield of 72% across 12 examples (Scheme 5.4).170 
 
 
Scheme 5.4 
 
NH2
N OH
[Cp*Rh(MeCN)3][SbF6]2
 (6 mol%)
Cu(OAc)2 (4.5 eq.)
t-AmylOH (0.07 M)
 130 °C, 18 h
N
NR1
R1
336
13 examples
63-86%
λabs = 380-450 nm
λemis = 500-530 nm
40
335
N
OMe
H
Ph
Ph
Ph
Ph
Ph
H
H
[Cp*RhCl2]2 (2.5 mol%)
Cu(OAc)2 (2 eq.)
NaOAc (0.5 eq.)
MeOH, 110 °C, 2 h
N
Ph
Ph
Ph
Ph
Ph
338
averaged yield 72%
12 examples
RR
337 40
	   86 
The groups of Song206 and Miura109 reported the synthesis of fused isoquinolone scaffolds 339 
from the rhodium(III)-catalysed annulation of benzamides 15 with diphenylacetylene 40 
(Scheme 5.5) using silver carbonate and copper acetate as oxidants, respectively.  
 
 
Scheme 5.5 
 
Under Miura’s copper(II)-rhodium(III) conditions, annulation of the phenyl-substituted 
benzamide derivatives 340 with diphenyl acetylene substrates 341 furnished a range of 
isoquinoline-1-(2H)ones 342. These structures displayed fluorescence in the solid state within a 
range of 370-420 nm,109 however, the tetracyclic compounds 339 (Scheme 5.6) did not 
fluoresce. 
 
Scheme 5.6 
 
Based on a similar isoquinolone framework, Zhang et al.208 used the internal oxidant strategy, 
using the N-(acetoxy)benzamide derivative 343 with diphenylacetylene 40 to construct the 
pyrido[3,4-g]-isoquinoline framework 344. To improve the solubility, the isoquinolone 344 was 
alkylated with bromohexane to afford a mixture of the N- and O- alkylated products, 345-347. 
The compounds fluoresced in a similar region to one another (at approximately 470 nm) and 
were found to have quantum yields ranging from 0.092-0.25 in solution (using quinine in 1N 
H2SO4 as a standard), with lower values observed in the solid state (0.033-0.22) (Table 5.1). 
Interestingly, the fluorescent yield diminished with the gradual transformation of the pyridine 
ring to the cyclic amide (345 to 346 to 347).  
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Entry Compounds Absorption λmax (nm) Fluorescence λmax (nm) Φsolution Φsolid 
1 345 278, 362 447, 470 0.25 0.22 
2 346 266, 356 472, 470 0.098 0.07 
3 347 258, 354 469, 469 0.092 0.033 
 
Table 5.1 
 
Considering the vast application of fluorescent molecules, both in the field of material 
chemistry and in biological application, the ability to tune the fluorescent and physical 
properties of a fluorescent scaffold would be a highly desirable attribute. 
 
  
N
H
O
OAc
H
N
O
AcO
[Cp*RhCl2]2 (5 mol%)
CsOAc (3 eq.)
MeOH (0.1 M)
60 °C, 16 h
PhPh
343
NH
O
HN
O
344
NaH, DMF
80 °C, 16 h
N
O
N
O
347
C6H13
H13C6
N
O
N
O
346
C6H13N
O
N
O
345
C6H13
H13C6 H13C6
41% 30% 27%
C6H13Br
	   88 
5.2 Mechanistic studies 
 
The tetracyclic imide 143 had been previously reported, however the compound was never fully 
characterized.84–88,90 Additionally, there is no reference to its fluorescent properties. The existing 
synthetic routes require harsh conditions with step-wise procedures.  Godfrey et al. reported the 
synthesis of the imide 143 via a thermal cyclisation at 240 °C of the diammonium salt of 
2,2’-dicarboxy-desoxybenzoin 348 in diphenylamine (Scheme 5.7).90   
 
 
Scheme 5.790 
 
The pursuit of this route for the synthesis of the tetracyclic imide scaffold would be of interest, 
as the scope for tailoring the fluorescent properties towards a variety of applications would be 
of interest. In order to optimise the yield using this methodology, further understanding of the 
mechanism was required. Based on the structure of the imide 143, it was apparent that two units 
of the N-methoxybenzamide derivative 42 had reacted with one unit of vinyl acetate, however 
the mechanism of the reaction was not evident. A route via activation of the isoquinolone 137 
was rejected based on the full recovery of the starting material 137 upon resubjection to the 
reaction conditions with both the N-methoxybenzamide derivative 42 and the more reactive 
N-(pivaloyloxy)benzamide 43 (Scheme 5.8). The latter substrate resulted in a rearrangement to 
the corresponding methyl phenyl carbamate via the Lossen rearrangement. 
 
 
Scheme 5.8 
 
In a separate study within the Marsden group, a C-H activation reaction using vinyl ethers/esters 
with acetophenone 349, catalysed by [Cp*RhCl2]2 with copper(II) acetate as a stoichiometric 
oxidant, was in development (Scheme 5.9). A trace of 2-vinylacetophenone 350 was observed 
when vinyl laurate 241 was treated with acetophenone 349, presumably via elimination of lauric 
acid from the rhodacycle I. 
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Scheme 5.9 
 
Despite the fact that the directing group and oxidant system was different to the system using 
N-methoxybenzamide 42 and vinyl acetate 141, the formation of 2-vinyl-N-methoxy-
benzamide 351 and 2-vinyl-benzamide 352 were investigated as putative intermediates 
(Scheme 5.10). The following mechanistic studies were carried out by Michael Watt within the 
Marsden group. To commence this study, vinyl acetate 141 was replaced with 
2-vinylbenzamide 351 and 2-vinyl-N-methoxybenzamide 352 (Scheme 5.10). Interestingly, the 
formation of imide 143 was not observed in the reaction using 2-vinyl benzamide 351, however, 
the reaction of 2-vinyl-N-methoxy benzamide 352 with N-methoxybenzamide 42 gave the imide 
143 and the stilbene-derivative 353 with yields of 25% and 30%, respectively.  
 
Scheme 5.10 
 
The stillbene derivative 353 was found to be highly insoluble in methanol, and only sparingly 
soluble in DMF and DMSO. The intermediate 353 was isolated and re-subjected to the reaction 
conditions above, however more aggressive heating under microwave conditions (80 °C) were 
used to aid solubility (Scheme 5.11). The imide was isolated with a yield of 18%, suggesting the 
stilbene derivative 353 as a possible reaction intermediate. In order to generate significant 
quantities of the stilbene 353, the cyclisation precursor to the imide 143, the 
addition/elimination reaction of N-methoxybenzamide 42 with vinyl acetate 141 to generate 
2-vinyl-N-methoxybenzamide 352 would have to be high yielding. The 6% yield of the isolated 
imide 143 from the initial reaction of N-methoxybenzamide 42 with vinyl acetate 141 would 
suggest that this was not the case.   
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Based on these putative intermediates, a catalytic cycle for the formation of the tetracyclic imide 
was proposed. Initial formation of N-methoxy-2-vinylbenzamide 352 could proceed via 
elimination of acetic acid from the rhodacycle II (Scheme 5.12)  
 
Scheme 5.12 
 
Coordination of the rhodium(III) active catalyst, [Cp*Rh(OAc)2] to N-methoxybenzamide 42, 
followed by coordination of the vinylic substrate 352 would result in the formation of the seven-
membered rhodacycle III (Scheme 5.13). Subsequent β-hydride elimination from the six-
membered IV rhodacycle (via a ligand exchange), followed by N-OMe bond cleavage could 
furnish the stilbene 353 intermediate. These initial steps follow the classic rhodium(III)-
catalysed oxidative Heck mechanism. 
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Insertion of the catalyst into the alkenyl C-H bond could proceed via two pathways, either 
through formation of the six-membered rhodacycle V or by insertion into the adjacent C-H 
bond, to form the seven-membered rhodacycle VI. In order to distinguish the aromatic rings, a 
fluorine atom was introduced into the N-(pivaloyloxy)benzamide substrate in a study carried out 
by a co-worker (Scheme 5.14). Had the fluorine been incorporated into the isoquinolone portion 
of the imide, it would have suggested a seven-membered rhodacycle VI, and vice versa for the 
six-membered rhodacycle V (Scheme 5.13). The reaction of 4-fluoro-N-(methoxy)benzamide 
356 and 2-vinyl-N-methoxy benzamide 352 furnished the imide 360, suggesting the formation 
of a six-membered rhodacycle 358 followed by reductive elimination to form 360. Subsequent 
release of ammonia from cyclisation of the exo-cyclised lactam 359 would give the imide 360.  
 
Scheme 5.14 
 
Additional literature evidence would suggest this pathway was favoured. A report by Glorius et 
al. identified the intramolecular cyclisation reaction of the ortho-benzamide stilbene 361 to give 
the exo-cyclised lactam 362 (via 363) under rhodium(III)-catalysed system using copper(II) 
acetate as an oxidant (Scheme 5.15).20  
 
Scheme 5.15 
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This short study revealed potential intermediates in the catalytic system. Attempted optimisation 
of the original reaction conditions however proved futile based at least in part on the poor 
solubility of these compounds (see Scheme 5.10). The alternative reaction, starting from the 
N-methoxy-2-vinyl benzamide derivative 352, improved the yield of the imide from 6% to 25%, 
however there were recurrent issues with the solubility of the product and intermediate stilbene 
derivatives.   
 
We envisaged an alternative approach, exploiting the well-established rhodium(III)-catalysed C-
H activation/annulation of hydroxamate esters 366 with unsymmetrical alkyl-aryl internal 
alkynes 367 to prepare substituted isoquinonolones 365, bearing an ortho-carboxylate on the 
pendent phenyl ring (Scheme 5.16). Subsequent cyclisation of the intermediate isoquinolone 
365, could provide the target imide 364 in two steps from the starting materials.  
 
 
Scheme 5.16 
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used in these annulation protocols.  
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variety of aliphatic terminal alkynes to choose from. Additionally, introduction of an aliphatic 
group at the C4 position could address the solubility issues, previously observed with the former 
routes. We were confident that introduction of a group at this position would not impact the 
planar π-system responsible for the fluorescent properties of the molecule. Careful design of the 
substrates could be used to tailor the fluorescent properties of the molecule, resulting in a 
diverse library of imides. 
 
5.3 Optimisation and synthesis of novel imides 
 
With a new synthetic approach in hand, a range of ortho-carboxyl-substituted phenylalkyne 
substrates were prepared. Methyl 2-(oct-1-yn-1-yl)benzoate 370 was prepared via a Sonogashira 
reaction of methyl 2-iodobenzoate with 1-octyne (Scheme 5.18).209 Pleasingly, the subsequent 
reaction of the alkyne 370 and N-(pivaloyloxy)benzamide 43, using the rhodium catalyst, 
[Cp*RhCl2]2, employed by Fagnou et al.35 gave a mixture of the desired imide 372 and the 
uncyclised isoquinolone 371 as a 1:1 mixture with a yield of 87% (1H NMR yield using 
mesitylene as an internal standard). Gratifyingly, the undesired regioisomer was not observed in 
the 1H NMR spectrum of the crude reaction mixture. 
 
	  
Scheme 5.18 
 
Interestingly, observation of the ortho-carboxyl-substituted isoquinolone 371 in deuterated 
chloroform over 24 hours revealed a slow conversion to the cyclised imide 372, presumably 
aided by residual acid in the chloroform (Figure 5.3). Full conversion to the product was 
achieved after one week in chloroform. 
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Figure 5.3 
 
Based on this observation, the methanol from the crude reaction mixture was removed in vacuo 
and the residue redissolved in acetonitrile with p-toluenesulfonic acid and heated to 80 °C to 
achieve full conversion to the imide 372 (Scheme 5.19). An attempt to purify the crude reaction 
mixture by column chromatography resulted in poor recovery of the imide, with most of the 
product hydrolysing to form the corresponding acid 373 on the column.  
 
 
Scheme 5.19 
 
The instability of the imide in nucleophilic solvents became apparent from a 1H NMR study in 
deuterated methanol  (Figure 5.4). On dissolution in deuterated methanol-d4, the 1H NMR 
spectrum indicated a 3:1 ratio of the imide 372 and the uncyclised isoquinolone 371. The 
alcoholysis of the imide in deuterated MeOD-d4 was monitored over six hours at 23 °C and 
50 °C at 30 minute intervals (Figure 5.4). Within the time taken to heat the sample to 50 °C 
within the 1H NMR machine, the imide had undergone 100% conversion to the ring-opened 
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isoquinolone 371. The reaction monitored at room temperature indicated an initial 25% 
conversion to the corresponding isoquinolone, rising to 84% over six hours. The stability of the 
imide in nucleophilic solvents is of fundamental importance if these scaffolds are to have 
application as a fluorescent unit in aqueous environments.  
 
 
 
 
Figure 5.4 
 
Polar aprotic solvents were screened as alternative reaction solvents, in the hope of isolating the 
imide as the sole product from the reaction. The conditions screened in Table 5.2 resulted in a 
lower yield of the mixture of products, 371 and 372, compared to the reaction in methanol 
(Table 5.2, entry 1). Reactions in tetrahydrofuran and 1,4-dioxane were unsuccessful (entries 2 
and 3). The reaction in acetonitrile gave an improved yield of 50% (entry 4), however the most 
promising result was achieved using a solvent blend of acetonitrile and methanol (9:1) which 
gave a 1:0.3 ratio of the imide 372 to the methyl ester derivative 371 with a combined yield of 
75% (entry 7). The yield was however still lower than the methanolic system (entry 1), which 
re-focussed effort towards optimising the purification step. 
  
N
O O
hex
NH
O
hex
OCD3O
MeOD-d4 (0.2 M)
Δ , 6 h
372 371
0	  
20	  
40	  
60	  
80	  
100	  
0	   60	   120	   180	   240	   300	   360	  
Co
nv
er
si
on
	  %
	  
Time	  (min)	  
50	  °C	   23	  °C	  
	   96 
 
 
 
Entry Solvent 
1H NMR yield % 
371 and 372 
Ratio 372:371 
1 MeOH 87 1:1.3 
2 THF 6 1:0 
3 Dioxane 0 - 
4 MeCN 50 1:0 
5 MeCN:MeOH (3:1) 64 1:1.3 
6 MeCN:MeOH (9:1) 75 1:0.3 
 
Table 5.2 
 
Chromatography, including HPLC and standard flash silica chromatography proved 
unsuccessful, with poor recovery of the imide 372 and uncyclised product 371, with additional 
hydrolysed acid 373 observed. Treatment of the crude reaction mixture from the initial 
rhodium-catalysed annulation reaction (using conditions in entry 1, Table 5.2) with 2M HCl in 
ether led to precipitation of the imide 372, which could be isolated from the reaction mixture 
and subsequently recrystallized from ethyl acetate to afford the pure product 372, albeit with a 
lower yield of 53%. The solubility of the imide 372 in a variety of organic solvents, including 
tetrahydrofuran, dichloromethane, and acetonitrile, was significantly improved compared with 
the original imide 143 lacking the hexyl chain.  
 
5.4 Improving the imide stability 
 
Aware that the instability of the imide might complicate or compromise any potential 
application as a fluorophore, we were interested to see if the scaffold could be modified to 
circumvent this issue. Introduction of an electron-donating group ortho- to the carboxyl group 
could reduce its electrophilicity, making it less susceptible to nucleophilic attack (Scheme 5.21). 
The difficulty with the design of suitable alkyne substrates was that three contiguously 
substituted functional groups were required to achieve our target molecule, in the following 
order: a (pseudo)halide for the Sonogashira coupling; an ester to complete the cyclisation; and 
an electron-donating group to potentially decrease the electrophilicity of the adjacent carboxyl 
group.  
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In order to test the hypothesis, the synthesis of the ortho-propoxy alkyne 386 was undertaken 
(Scheme 5.21). Alkylation of methyl salicylate 381 with bromopropane catalysed by lithium 
iodide, followed by hydrolysis of the ester gave the 2-propoxybenzoic acid 382 (83% over two 
steps).210 To install an ortho-iodide for the subsequent Sonogashira coupling, we envisaged a 
route using ortho-lithiation of 382, followed by addition of an electrophilic iodine source. 
Benzoic acids are commonly used as strong ortho-directing groups in lithiation chemistry.211 
However, Mortier et al. observed competing reaction pathways for the ortho-lithiation of 2-
methoxybenzoic acid 374, whereby sec-BuLi could either attack the lithiated benzoic acid 
functionality (CO2Li), to form the corresponding sec-butyl ketone 378 on work up, or displace 
the alkoxy group via an addition-elimination sequence to form the 2-sec-butylbenzoic acid 
(neither of which were quantified in the report, Scheme 5.20).212 Addition of N,N,N’,N’-
tetramethylethylenediamine (TMEDA) (one equivalent) successfully suppressed the addition-
elimination reaction, resulting in yields of 71% with methyl iodide and 46% using iodine. 
Similar examples with various electrophiles using ortho-lithiated-2-alkoxybenzoic acids have 
been reported in the literature with similar yields.211,213  
 
 
Scheme 5.20 
 
Ortho-lithiation with a sec-BuLi-TMEDA complex, followed by iodination produced a mixture 
of the desired product 384 and the sec-butyl ketone 383 (identified as 1.75:1 mixture of 
384:383, observed in the 1H NMR spectrum of the crude reaction mixture). The mixture was 
taken through to the next step, as attempted purification of the acid resulted in a low recovery 
(Scheme 5.21).212,214 Esterification provided methyl 2-iodo-6-propoxy benzoate 385 with a yield 
of 32% over 2 steps. A subsequent Sonogashira coupling,209 using PdCl2(PPh3)2 (2 mol%) with 
copper(I) iodide (5 mol%), gave the target alkyne 386 with a yield of 90%. Application of the 
rhodium-catalysed annulation conditions furnished the model imide 387. The 1H NMR 
spectrum of the crude reaction mixture indicated 100% conversion to the products, with a 4:1 
ratio of the imide 387 to the methyl ester isoquinolone derivative, unlike the 1:1 ratio observed 
from the crude reaction without the propoxy group (cf. Scheme 5.18). The poor recovery of the 
imide 387 (28%) from the precipitation method may have been a result of the solubilising 
propyl group. 
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Scheme 5.21 
 
The analogue bearing the free hydroxyl group 393 was subsequently developed as a more 
readily accessible alternative (Scheme 5.22). 2,6-Dihydroxybenzoic acid 388 was protected as 
the isopropylidene acetal 389 before treatment with triflic anhydride to afford the Sonogashira 
precursor 390. Application of the previous cross-coupling conditions in triethylamine were 
unsuccessful, owing to the insolubility of the starting material. Switching the solvent from 
triethylamine to acetonitrile at 80 °C, with diethylamine as a base, gave the desired product 391 
with a yield of 62%.215 Using the standard C-H activation conditions, the annulation with 
N-(pivaloyloxy)benzamide 43 furnished the corresponding isoquinoline 392 with an excellent 
yield of 96%. A benefit of this strategy over the previous was the facile purification of the 
cyclisation precursor 392, which could be isolated with high purity by column chromatography, 
ensuring simple purification after the final cyclisation step. Treatment of the isoquinolone 392 
with sodium hydride furnished the imide 393 with a yield of 63%. The phenolic handle offers 
an additional point of diversification, however, this was not investigated in this study. 
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Scheme 5.22 
 
Comparison of the rate of ring-opening of the imide of the ortho-propoxy derivative 387 with 
the parent imide 372 at different temperatures was qualitatively investigated (Figure 5.5). The 
imides were heated in deuterated methanol-d4 for 30 minutes at various temperatures. The 
ortho-propoxy imide 387 had not undergone ring opening at room temperature (compared to the 
parent imide 372 with 35%) and only 30% at 60 °C (at 100% for 372). The rate of alcoholysis 
of the parent imide was significantly faster than the propoxy derivative. Although alcoholysis 
had not been prevented entirely, the stability of the imide had significantly improved in 
comparison to the parent imide.  
 
 
Figure 5.5 
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5.5 Extension of the conjugated π-system 
 
The ability to tune the fluorescent properties on a particular scaffold, using various functional 
groups, is highly advantageous in the design of bespoke materials. For example, photovoltaic 
devices absorb in the visible light to IR region to maximise absorbance from sunlight,194 
whereas organic light emitting diodes can be tailored to a specific wavelength to emit particular 
colours. Biological sensors range from blue/green emitters (450-550 nm) to near-infrared (600-
700 nm), based on the requirements of the biological system under investigation, or indeed the 
laser source used for excitation.201  
 
The fluorescent properties of an aromatic system can be altered significantly by substitution. 
Both the nature and position of a substituent can alter the photochemical properties. Extension 
of the conjugated π-system is a well-established method to induce a bathochromic shift in 
fluorescence and absorbance. Additionally, a larger degree of conjugation generally increases 
the fluorescence quantum yield.216 Functional groups bearing non-bonding electrons can 
increase the molar absorption coefficient and bathochromatically shift (red shift) the absorption 
and fluorescence spectra to longer wavelengths. These groups are known as auxochromes, and 
there are two main categories; acidic (-COOH, -OH, -SO3H) and basic (-NH2, -NR2). 
Auxochromes extend the conjugated π-system and therefore raise the energy of the HOMO and 
lower the energy of the LUMO, so that less energy is required for an electronic transition, 
therefore a bathochromic shift is observed.  
 
Investigation into substitution effects on the photochemical properties began, by introducing 
substituents that would effectively extend the aromatic π-system and incorporate auxochromes 
(-OH and -NR2). To commence the investigation of imides with extended π-systems, the 
naphthyl derivative 397 was prepared from the reaction of N-(pivaloyloxy)-2-naphthamide 396 
with the bicyclic alkyne 391 (Scheme 5.23). Rhodium(III)-catalysed C-H activation/annulation 
furnished a mixture of regioisomers (crude ratio of 70:11:19 of 397:398:399) which were 
separated to give a yield of 51% of 397, mixed fractions of 397:398 (5:2, 27%) and 1% of 399. 
The undesired regioisomers were not fully characterised, however diagnostic peaks of the H10 
proton were observed in the 1H NMR spectrum. The major regioisomer 397 was subsequently 
treated with sodium hydride in tetrahydrofuran to afford the naphthylimide 400 with a yield of 
69%. 
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Scheme 5.23 
 
To investigate the effect of electron-donating groups, two examples with auxochrome groups 
(-OH and NR2) were prepared. The N-(pivaloyloxy)-biphenylamino derivative 405 was 
prepared in three steps via a key Suzuki coupling of 4-(dimethylamino)phenylboronic acid 401 
with ethyl 4-bromobenzoate 402 to furnish the biphenyl intermediate 403 with a yield of 79% 
(Scheme 5.24).217 Following hydrolysis of the ester 403, the acid 404 was converted to the acid 
chloride for the reaction with N-(pivaloyl)ammonium triflic acid under Schotten-Baumann218,219 
conditions to furnish the substrate 405 with a yield of 45%. 
 
Scheme 5.24 
 
With the substrate 405 in hand, the imide precursor 406 was prepared, via the standard reaction 
conditions, as a 4:1 mixture of regioisomers of the desired isoquinolone 406 to the regioisomer 
407, which were separated by column chromatography and fully characterised (Scheme 5.25). 
Treatment of the imide precursor 406 with sodium hydride furnished the desired imide 408 with 
a yield of 50%.  
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Scheme 5.25 
 
The para-hydroxy derivative 416 was subsequently prepared for a comparison to the ortho-
phenolic imide 393 previously prepared (see Scheme 5.26). The alkyne 414 was prepared via 
ortho-lithiation of 4-methoxybenzoic acid 409, with subsequent iodination to afford the 2-iodo-
4-methoxybenzoic acid derivative 410. Demethylation of the methoxy group was achieved 
using boron tribromide to afford 2-iodo-4-hydroxybenzoic acid 411, which was used without 
further purification. Acid-catalysed esterification furnished the methyl ester 412 with a yield of 
76% over two steps. The phenol 412 was subsequently protected as the methoxymethyl ether 
413 prior to the Sonogashira coupling reaction, which gave the alkyne 414 with a yield 67%. 
 
Scheme 5.26 
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The alkyne 414 was treated with N-(pivaloyloxy)benzamide 43 using the standard rhodium(III)-
catalysed annulation procedure to afford the MOM-protected imide 415 with a yield of 35%. 
Deprotection of the phenol was achieved under acidic conditions to give the para-phenolate 
derivative 416 with a yield of 62%. 
 
 
Scheme 5.27 
 
Fluorescent compounds can be incorporated into polymeric semi-conducting materials for light 
harvesting in photovoltaic cells and printed organic thin-film transistors.220–222 Polythiophene 
structures are very common motifs in semi-conductors as they have high photostability and 
conduct charge efficiently.223 They are of particular interest due to ideal solution phase 
processing and good film-forming properties.194 In the interest of extending the π-system, two 
model compounds 423 and 424 substituted with a thiophene ring, were prepared by a co-worker 
in the Marsden group via the rhodium-catalysed annulation methodology (Scheme 5.28). A 
Suzuki coupling of 2,5-dibromothiophene 418 with methyl 4-boronic benzoate 417 gave the 
para-substituted bromothiophene derivative 419. Hydrolysis of the ester 419 to the acid 420, 
followed by acid chloride formation and reaction with the O-pivaloylhydroxylamine triflic acid 
salt gave the N-(pivaloyloxy)-substrate 421, with a yield of 51% over three steps. Using two 
methyl 2-alkynyl benzoate substrates 370 and 386, the thiophene substituted imides 423 and 
424 were prepared with yields of 32% and 28%, respectively. 
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Scheme 5.28 
 
The synthesis of aromatic based semi-conductors is typically achieved using transition-metal 
catalysed polymerisation.224,225 The palladium-catalysed Suzuki coupling is the most common 
method as the polymerisation step is high yielding, largely unaffected by the presence of water 
and generally requires low catalyst loadings.226–229 A disadvantage of the system is that reaction 
times normally exceed 48 hours for high molecular weight polymers. Additionally two halides 
and two boronic acid equivalents are extruded from the reaction, generating excess waste. 
 
A polymerisation strategy utilising C-H activation could provide an atom-efficient method for 
the polymerisation of aromatic monomers. For example, Marks et al. reported the synthesis of 
5,5’-bis(4-n-hexylphenyl)-2,2’-bithiophene (dH-PTTP) 428 for phenylene-thiophene-based 
organic field-effect transistors via a key Stille coupling of the organostannane 426 with 
1-bromo-4-n-hexylbenzene 427 (Scheme 5.29).230 Fagnou et al. illustrated the effectiveness of 
palladium catalysed C-H activation for the formation of the thiophene dimer 428 via a single 
step direct arylation of the dithiophene 425 using 1-bromo-4-n-hexylbenzene 427, avoiding the 
requirement to prefunctionalise the starting material 425 with an improvement in yield of 87%, 
compared with 60% over two steps.231  
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Scheme 5.29231 
 
To our knowledge, there are no existing methodologies using rhodium(III)-catalysed C-H 
activation/annulation reactions using internal or external oxidants to mediate a polymerisation 
reaction. Using our methodology, we were interested in investigating a strategy using block co-
polymerisation (-(A-B-B-A)n-), via an A2B2 strategy, using a dimeric unit of the 
N-(pivaloyloxy)benzamide derivative 429 with a bis-alkynyl acetonide substrate 430 
(Scheme 5.30). A system of this kind would only generate by-products such as pivalic and 
acetic acid from the C-H activation step, and hydrogen and acetone in the subsequent 
cyclisation to prepare 432. 
 
 
Scheme 5.30 
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To commence the investigation, the dimeric imide 435 was proposed as a model for the 
polymerisation reaction (Scheme 5.31). To prepare the substrate for the rhodium-catalysed C-H 
activation/annulation reaction the biphenyl-4,4’-dicarboxylic acid 433 was converted to the 
biphenyl-N-(pivaloyloxy)-derivative 429 with a yield of 91%. Under the C-H 
activation/annulation conditions, the fused bis-isoquinolone precursor 434 was prepared with a 
yield of 69%, although a higher catalyst loading and reaction temperature (to solubilise the 
intermediate 434) were required to achieve full conversion to the product. Disappointingly, the 
attempted cyclisation of the substrate 434 was unsuccessful. Reaction monitoring revealed 
formation of the mono-cyclised product, with no further conversion on addition of excess 
sodium hydride. The termination of the reaction at this point may have been a result of the 
insolubility of the intermediate product in the reaction medium, observed as a suspension in 
solution. By switching the solvent from tetrahydrofuran to N,N’-dimethylformamide, in the 
hope of solubilising the intermediate monocyclised product (identified by LCMS), it was hoped 
that the issue would be circumvented. However, this was unsuccessful and the same outcome 
was observed. In future, these issues could be circumvented by addition of aliphatic groups on 
the aromatic ring systems to aid solubility. 
 
 
Scheme 5.31 
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In summary, nine imides were prepared using the rhodium(III)-catalysed C-H activation/-
annulation route via the ortho-methyl ester isoquinolone 438 or the acetonide isoquinolone 436, 
followed by cyclisation using sodium hydride (Scheme 5.32). Introduction of the electron-
donating phenol group or ethers significantly improved the stability of the imide to ring-opening 
in nucleophilic solvents and was achieved using the acetonide derivatives 436. To extend the 
π-system, with the intention of modifiying the spectrochemical properties, various 
N-(pivaloyloxy)benzamide derivatives were prepared to incorporate a naphthyl, thiophene and 
phenyl aniline moiety into the imide. The spectrochemical and electrochemical data are reported 
herein.  
 
Scheme 5.32 
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5.6 Fluorescence and absorbance properties 
  
With a variety of imides in hand, we were interested in investigating the effect of the 
substituents on the photochemical properties. To commence the study, the absolute quantum 
yield (ΦF) of the parent imide was measured in dichloromethane. The fluorescence quantum 
yield is a measure of fluorescence efficiency i.e. the ratio of photos absorbed to photons emitted 
through fluorescence. The value is an indication of the probability of deactivation of the excited 
state via a non-radiative mechanism. Fluorescence quantum yields are typically measured 
against a well-studied standard, which has a known and high quantum yield. The ratio of the 
integrated fluorescence of the sample versus the standard can very simply provide the quantum 
yield of the sample compound. 
 
 Fluorescence measurements are normally collected at very low concentration solutions (10-5 or 
10-6 M) in order to minimise re-absorption effects, and multiple readings are taken at different 
concentrations to ensure linearity. At higher concentrations, aggregation of the compound in 
solution can lead to self-quenching, where the fluorescence of one molecule is absorbed by 
another and is therefore not detected, causing non-linear effects.232 
 
Whilst working with these low concentrations the compounds and solvent must be of high 
purity and glassware must be scrupulously clean to ensure no contaminants effect the 
fluorescent readings. The standard is generally selected so as to have a similar absorbance and 
emission wavelength of the sample of interest. Based on the wavelength (λmax) of the 
absorbance and fluorescence maxima of the imide 372 (λabs 384 nm, λemis 420 nm), 
9,10-diphenyl-anthracene (λabs 375 nm, λemis 410 nm) was selected as a standard, as its reported 
quantum yield is close to unity (0.95 in cyclohexane, which was later corrected to 0.97 in 
dichloromethane for our study, see Experimental 6.11).233 The quantum yield of imide 372 was 
calculated as ΦF 0.44, using equation (1), with the values of the gradient obtained from a plot of 
the integrated fluorescence versus absorbance (Figure 5.6). The molar absorption coefficient (ε) 
for the imide 372 was calculated as 2.34 x 104 M-1cm-1 at λabs 383 nm (see Experimental 6.11).  
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 ϕX= ϕSt
GradientX
GradientSt
  (1) 
 
ϕX= 0.97
1.22×108 
2.71×108
  
 
ϕX=0.44 
 
Figure 5.6. Quantum yield calculation for imide 372 
 
The photochemical properties of the imides were subsequently measured in order to compare 
the effect of various substituents on the parent imide scaffold. The absorbance spectrum features 
multiple peaks, which can be assigned to various Franck-Condon vibronic transitions. When 
there is little difference to the nuclear configuration of the molecules in its excited state (ν’) 
compared to the ground state (ν’’), the operation of the Franck-Condon principle will mean that 
the 0-0 transition is the most intense, although ν’=1, 2, 3 etc. will still exist (Figure 5.7).234 In 
solution, any vibrational excitation is rapidly lost through collisions with solvent molecules and 
emission therefore occurs from the ν’=0 level of the excited electronic state. Therefore the 0-0 
transition was used to compare the imides (Table 5.3 and Figure 5.8). 
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Figure 5.7. Potential energy curves highlighting the individual vibrational energy levels and their 
involvement in absorption (A) from the ν’ = 0 level of the ground electronic state and the emission (B) 
from the ν’ = 0 level of the electronically excited state.234 
 
A bathochromic shift was observed with all of the substituted imides except for the para-
hydroxy imide derivatives 415 and 416, which were slightly shifted into the blue region (~7 nm, 
G and H, Table 5.3 and Figure 5.8). The largest bathochromic shift of 24 nm was observed for 
the naphthyl derivative 400 (F). The 0-0 transitions were smaller than the original imide 372 
(A), however not by a significant factor (1-4 nm). Generally, small Stokes shifts are detrimental 
to fluorescence, as photons are reabsorbed before the radiative pathway can occur, which is 
known as fluorescent quenching.201 In biological dyes Stokes shifts of >100 nm are highly 
desirable to reduce interference in order to observe a strong fluorescent signal.235 Characteristic 
absorption peaks were observed for the thiophene ring of imides 423 and 424 at 320 and 331 
nm (C and D, Figure 5.8), respectively. 2-Phenylthiophene and 2-(α-naphthyl)-thiophene absorb 
at 283 nm (cyclohexane) and 296 nm (ethanol),236 indicating a significant bathochromic shift 
due to the increased conjugation of the imide ring. Three characteristic absorbances were 
measured for the naphthyl unit of imide 400 (F), at 375, 357 and 340 nm, which are 
significantly red shifted compared to the absorbance peaks of naphthalene, which absorbs at 
220, 275 and 310 nm.237 Molar absorptivity values and relative quantum yields (Φrel) were 
calculated from single values to give a relative comparison to the parent imide 372. No 
significant differences were observed in the quantum yield of imides 387, 393 and 400, however 
the thiophene derivatives, 423 and 424, and the para-hydroxy imides 415 and 416 indicated a 
much lower yield (Φrel ~0.15). This result was surprising, as conjugation of the π-system 
typically increases the quantum yield. This could be a result of the thiophene twisting out of the 
plane of the conjugated π-system, which could be investigated using other thiophene-substituted 
derivatives. 
 
  
A	   B	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Imide Entry 
Absorbance (nm) 
ν’’à ν’ 
Fluorescence (nm) 
ν’à ν’’ 
ν’à ν’’ 
0à0 
(nm) 
ε =A/cl 
(104 M-1cm-1) 
Φrel 
 
0à1 0à0 0à0 0à1 
372 A 383* 403 418 439 15 2.34 0.44 
387 B 392 413* 427 442 14 2.81 0.32 
424 C 395 416* 428 452 12 3.28 0.15 
423 D 390* 408 422 446 14 2.07 0.15 
393 E 394 416* 427 449 11 2.68 0.45 
400 F 408 429* 441 466 12 3.14 0.44 
415 G 377* 398 409 433 11 2.51 0.17 
416 H 375* 396 407 431 11 2.01 0.15 
 
Table 5.3. Data for the 0à1 and 0à0 absorption and emission peaks, including the v’ (0à0) to 
v’’ (0à0) shift in dichloromethane. Molar absorptivity (ε) is given from a single measurement at the λmax 
(abs), indicated by the asterix*.  The Φrel is given in relation to the quantum yield measured for imide A. 
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Figure 5.8. Normalised absorption and emission spectra for compounds A-D in dichloromethane. Spectra 
A is labelled with the vibration transitions of 0-0 and 0-1 of the groud state (ν’) and the excited electronic 
state (ν’’) 	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Figure 5.8 cont. Normalised absorption and emission spectra for compounds E-H in dichloromethane. 
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5.7 Cyclic voltammetry 
 
Cyclic voltammetry is commonly used to characterise the electrochemical properties of 
conducting polymers. In order to conduct efficiently, without degradation of the polymer, the 
redox system must be reversible. This analytic technique can be used to: i) identify the formal 
redox potentials of a species; ii) determine whether the process is reversible; iii) determine the 
electron stoichiometry of a system.238,239 A voltammogram is obtained by measuring the current 
at the working electrode during the cyclical potential scan rate (versus a reference electrode e.g. 
the saturated calomel electrode (SCE)). Unlike linear sweep voltammetry (E0 to E1, A, Figure 
5.9), cyclic voltammetry continues with a reverse scan (from E1 to E2), to complete the cycle. 
During the scan the current is recorded and as potential and current are both functions on time, 
they can be interrelated. In the forward scan, as the potential approaches that of the anodic 
oxidation potential the current begins to rise and a peak (ipA) is observed (B, Figure 5.9). On the 
reverse cycle (E1 to E2), the respective reduction reaction begins and the peak cathodic current 
(ipC) and the associated peak potential (EpC) can be obtained. 
  
A	   	   	   	   	   	   B	  
 
Figure 5.9 
 
The formal reduction potential (E0’) for a reversible couple is centred between EpA and EpC. The 
peak separation can provide important information about the electrochemical reversibility of a 
redox system. The Nernst equation (equation 2) can be used to determine the electron 
stoichiometry of a system. The number of electrons transferred in the electrode reaction (n) for a 
reversible couple can be determined from the separation between the peak potentials 
(equation 4). Therefore a one-electron process will exhibit a ΔEp value of 0.059 V. 
  E=E0'- RT
nF
ln Q     (2) 
    E=E0'- 2.303 × RT
nF
log [R]
[O]
  (3)1 
    E =
 EpA+EpC
2
= 0.059
n
log [R]
[O]
  (4) 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  The Nernst equation is more commonly written in base-10 log form, therefore a conversion factor of 
2.303 is applied.	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The cyclic voltammograms of the imide 372, 387, 423 and 424 were measured to determine 
whether the imides would undergo reversible reduction, and therefore give some indication as to 
whether these scaffolds would be suitable in a conducting polymer. The voltammograms were 
collected at different scan rates to ensure consistency of the two reduction peaks. All potentials 
quoted were referenced to an internal ferrocene/ferrocenium standard and were obtained at 
varying scan rates (ν) of 20-1000 mVs-1 (Figure 5.10). For example, the ferrocene/ferrocenium 
couple under these conditions was observed at +0.45 ≤ E1/2 ≤ 0.46 V versus Ag/AgCl, providing 
two observed reduction potentials of the imide 372 at – 1.33 V and – 1.79 V (vs Fc/Fc+) (taken 
at the midpoint). 
 
Figure 5.10.  Cyclic voltammograms of the parent imide 372 (1.0 mM) in non-aqueous media 
(CH3CN/[nBu4N]BF4 0.10 M), ν = 20-1000 mVs-1, T = 298 K, [Fc] = 1.0 mM; EpC1 and  EpC2 
ascribed to the imide reduction. 
 
Each imide was measured to assess the first (EpC1) and second cathodic reduction peak (EpC2) in 
order to evaluate the reversibility of the reduction process and compare the formal reduction 
potential (E0’) (Table 5.4, for voltammograms see Experimental 6.12). Unsuprisingly, the 
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electron-rich propoxy substituted imides 387 and 424 (entries 2 and 4) were harder to reduce 
than their counterparts 372 and 423 (entries 1 and 3). Extension of the π-system by addition of 
the thiophene substituent reduced the EpC2 values by approximately 0.06 V (both in the case of 
the 387 and 424). 
 
Entry Entry EpC1 (V) ΔEpC1 (V) EpC2 (V) ΔEpC2 (V) 
1 372 -1.33 0.066 -1.79 0.048 
2 387 -1.38 0.053 -1.80 0.058 
3 423 -1.33 0.031 -1.73 0.031 
4 424 -1.37 0.014 -1.74 0.014 
      Table 5.4 
 
In all cases, the ΔEpC1 values were <0.06 V (bar the ΔEpC1 value of imide 372, entry 1), 
suggesting two reversible reduction processes. Although the reduction potentials are 
significantly lower, i.e. harder to reduce, than those used in photovoltaic materials (for example 
the perylene bis(imides) reported by Lemmetyinen et al.240 range from ΔEpC1 values of -0.90 V 
to -1.15 V, and ΔEpC2 values of -1.35 V to -1.18 V), there is still potential to reduce the value by 
further π-conjugation. 
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5.8 Metal complexes 
 
In biological systems, metal ions are responsible for normal cell functioning. Perturbations in 
ion concentration or localizations have been shown to contribute to ageing and disease.241 The 
advent of confocal light microscopy, used in cell imaging, has spurred efforts towards 
identification of small fluorescent molecules that can be used in situ to monitor cellular events. 
Synthetic fluorophores can be used to visualize the presence of specific metal ions, both within 
the cell organelles and in the extracellular medium. Further understanding of their role in 
cellular processes will undoubtedly contribute towards the discovery of new treatments for a 
variety of human disorders.241 Effective fluorescent probes must fulfil certain criteria in order to 
be of effective use: the sensor must be selective for a particular ion over those in much higher 
cellular concentration (e.g. Na+, K+, Mg2+ and Ca2+); dyes with absorption and emission spectra 
within the visible light region are desirable, in order to minimize sample damage and reduce 
autofluorescence; high quantum yields, water solubility and low toxicity are mandatory; and 
‘turn on’ emission increase or shift in the absorption and emission are preferable over ‘turn-off’ 
emission quenching to maximise spatial resolution.241 
 
With this application in mind, we were interested in exploring the possibility of the tetracyclic 
imide 372 acting as a ligand for a host of metals. Encouragingly, the mass spectrum revealed the 
formation of a species with two ligands centred around a sodium ion (Figure 5.11). Based on the 
rigid conformation of the tetracyclic aromatic 372, and the availability of the oxygen lone pairs, 
it was possible to imagine the imide acting as a bidentate ligand to the sodium metal to give the 
metal complex 439. Based on this observation, we were encouraged to screen alternative metal 
complexes. 
 
Figure 5.11. High-resolution mass spectrum of imide 372 (ESI+). 
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A selection of metal salts were chosen, based on their characteristic colour changes when 
coordinated to various ligands and their solubility in ethyl acetate. The intention of the 
qualitative screen was to identify colour changes on addition of the colourless solution of the 
imide 372 (sample A, Figure 5.12). A colour change would signify coordination of the imide to 
the metal. Copper tetrafluoroborate, cobalt tetrafluoroborate, zinc triflate and europium triflate 
were tested in the screening. The solution of copper tetrafluoroborate displayed a colour change 
from blue (sample B) to bright green (sample C) on addition of the imide 372. Colour changes 
were also observed with cobalt tetrafluoroborate solution (from pink (sample D) to orange 
(sample E)) and europium triflate (colourless (sample G) to yellow (sample H)) on addition of 
the imide 372 (sample A). The colourless solution of zinc triflate in ethyl acetate changed to a 
light blue (sample F) on addition of the imide solution. Having identified coordination of the 
imide to the metals, the samples were exposed to UV light to observe the effect on fluorescence. 
All of the samples were exposed to a standard UV lamp (λ = 254/365 nm), however only a 
single sample (F) diplayed fluorescence.  
 
 
Figure 5.12. All solutions in ethyl acetate:  
A) 372; B) Cu(BF4)2; C) 372 and Cu(BF4)2; D) Co(BF4)2; E) 372 and Co(BF4)2; 
 F) 372 and Zn(OTf)2; G) Eu(OTf)3; H) 372 and Eu(OTf)3. 
 
To investigate the fluorescent properties of the zinc complex, UV/Vis and fluorimetry data were 
collected upon titrating zinc triflate into the solution of imide. Unfortunately, at low 
concentrations (10-5 and 10-6 M), only the absorbance and fluorescence of the imide 372 were 
observed, suggesting dissociation of the complex. At lower concentrations the complex is not 
present at appreciable levels which is indicative of a small association constant (Figure 5.13).  
 
 
Figure 5.13. Solutions A-C contain imide: Zn(OTf)2 (2:1) at A) 10-4; B) 10-5 M; C)10-6 M; D) Solution of 
imide 372 at 10-6 M under a UV lamp (λ 365 nm). 
A	   B	   C	   D	   E	   F	   G	   H	  
A	   B	   C	   D	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To qualitatively assess the shift in fluorescence, a titration at a higher concentration of 10-4 M 
was executed (Figure 5.14). A bathochromic shift of the fluorescence maxima (λmax) from 
440 nm to 462 nm was observed. Suprisingly, the fluorescence continued to shift until 2.14 
equivalents of zinc triflate had been added. The fluorescence spectra indicates the lack of a clear 
isosbestic point, suggesting a non-linear relationship between zinc(II) triflate and the imide 372 
at varying concentrations.  
 
Figure 5.14. A titration study in spectrophotometric grade DCM.  A mixed solution of the imide 372 with 
Zn(OTf)2 was titrated into the solution of the imide 372 (2×10-4 M). Emission measured at an excitation 
wavelength of λ=383 nm. Legend indicates the equivalents of Zn(OTf)2 added. 
 
In a separate study, multiple crystallisation trials were prepared in various solvents, using a 2:1 
ratio of the imide 372 to zinc triflate (based on the stoichiometry of the sodium dimer [M2Na+] 
observed in the mass spectrum). The zinc complex 440 was isolated from slow evaporation of a 
solution of acetone, from which the crystal structure of the zinc complex was confirmed (Figure 
5.15). Peak shifts in the 1H NMR and IR spectrum were observed however the complex, 
unsurprisingly, could not be identified by high-resolution mass spectrometry (HRMS).  
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Bond 
372 
Bond length (Å) 
440 
Bond length (Å) 
C5-O 1.221 1.219 
C5-N 1.399 1.398 
C7-O 1.206 1.233 
C7-N 1.424 1.407 
 
Figure 5.15. X-ray crystal structure of the imide 372 and the zinc complex 440. Image of the samples 
fluorescing in the solid state. 
 
Comparison of the X-ray crystal structures of the free imide 372 with the complexed imide 440 
revealed key differences in the bond lengths of the C7-O and C7-N bond. The C7-N bond is 
shortened from 1.424 Å (in 372) to 1.407 Å (in 440), as the C7-O bond is lengthened from 
1.206 Å to 1.233 Å, suggesting delocalisation of electrons from the nitrogen into the carboxyl 
group in the complexed imide. The isoquinolone portion of the imide is mainly unaffected in the 
complex. The bite angle (O-Zn-O) of the zinc in the complex was 86.15° (see Appendix for 
X-ray crystal structures). 
 
Considering the weak binding of the neutral imide ligand 372 to the zinc(II) centre, our 
attention turned to neutral zinc complexes, whereby the ligand could covalently bind to the 
metal. Deprotonation of the para- and ortho-hydroxy imides, 416 and 393, in the presence of a 
zinc(II) source could lead to the formation of neutral zinc complexes 441 and 442 (Scheme 
5.33). 
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Scheme 5.33 
 
With the phenolic imides in hand, investigation into the formation of neutral zinc complexes 
commenced (Scheme 5.34). Treatment of the ortho-hydroxy imide 393 with half an equivalent 
of Zn(OTf)2 in DCM containing triethylamine produced a colour change from bright yellow to 
orange, which was encouraging based on a previous observation: the intermediate sodium 
phenolate imide 443, formed via deprotonation of the acetonide isoquinolone 392, was observed 
as an orange solution. On addition of acid (to reprotonate the phenolate anion), the solution 
changed colour from orange to bright yellow to give the imide 393 in its protonated form. 
Despite this observation, no discernable products were observed either from reaction sampling 
or from the final crude reaction. The identical reaction with the para-hydroxy imide 416 was 
equally unsuccessful.  
 
Scheme 5.34 
 
Alternative combinations of bases and solvents were examined with both imides, however 
despite observing the colour change, any reaction monitoring of the reaction mixture and the 
crude reaction (by LCMS (ESI+), TLC or HRMS (ESI+ and ESI-) revealed only the unreacted 
N
hex
O O
OH416
[Zn2+]
N
hex O
O
N
hexO
O
Zn
441O
O
N
hex
O O
393
[Zn2+]
N
hex O
O
N
hexO
O
Zn
442
OH
O
O
base
base
N
hex
O O
393
Zn(OTf)2 (0.5 eq.)
N
hex O
O
N
hexO
O
Zn
441
OH
O
O
NEt3 (2 eq.)
DCM
N
hex
O O
ONH
hex
O
O
OO
NaH (2 eq.)
THF (0.02 M)
 0 °C - rt, 2 h
392 443
N
hex
O O
OH
393
H+
Na
orange solution yellow solution
Previous observations:
	   122 
imide. To simplify the reaction conditions, diethylzinc was employed to simultaneously act as a 
base and a source of zinc(II).242,243 Evolution of ethane gas as the only by-product would ensure 
that purification of a resulting complex would be simplified. On addition of the diethylzinc (0.5 
equivalents added as a 1 M solution in hexanes), to the homogeneous solution of the imide 393 
in tetrahydrofuran (THF) a colourless precipitate formed, which was subsequently filtered from 
the reaction. The solid proved to be insoluble in all solvents, including DMSO, suggesting it 
was either inorganic material or potentially polymeric organic material. 
 
Petrus and Sobota reported a crystal structure of the tetrameric cluster complex from the 
reaction of diethylzinc with methyl salicylate in their study of catalyst preparation for 
polymerisation reactions (Scheme 5.35).243 Treatment of the cluster 444 with pyridine led to the 
formation of the monomeric zinc species 445. Coordination of the ligand 381 to the metal 
centre, via the lone pair of electrons on the carbonyl atom and a covalent phenolic bond, would 
be equivalent to the mode in which the imide 393 could potentially bind to the zinc. 
Unfortunately, treatment of the insoluble precipitate from the previous reaction using the 
imide 393 with pyridine made little difference to the solubility of the material even on heating. 
 
Figure 5.35243 
 
In summary, coordination of the parent imide 372 with various metal salts was confirmed by 
qualitative colour changes, however fluorescence was only observed with zinc(II) triflate. 
Attempts to characterise the complex in solution were unsuccessful due to weak binding, 
however at higher concentrations crystals were grown to confirm the structure by X-ray 
crystallography. The crystal structure confirmed the 2:1 ratio of ligand 440 to zinc, which was 
previously proposed based on the sodium dimer in the mass spectrum. Attempted formation of 
neutral-zinc complexes were unsuccessful.   
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5.9 Conclusion 
 
 
In summary, a fluorescent tetracyclic imide was identified and isolated from the rhodium(III)-
catalysed annulation of N-(methoxy)benzamide with vinyl acetate. Subsequent mechanistic 
investigations identified putative intermediates, giving an indication as to the formation of the 
imide in the reaction. Based on the structure of the highly fluorescent molecule, the potential for 
tailoring the spectrochemical properties of the system, by addition of susbstituents, seemed 
promising. However, the initial synthetic routes suffered from issues with solubility and 
optimisation of yields proved futile. 
 
An alternative approach, using the rhodium(III)-catalysed annulation of N-(pivaloyloxy)-
benzamide derivatives with 2-alkynyl benzoate esters was identified a succinct route to the same 
scaffold. Using this approach the solubility and substrate scope was simultaneously addressed 
using bespoke starting materials. The starting materials were simply prepared from benzoic acid 
derivatives, and the alkynes assembled via a Sonogashira coupling.  
 
Rhodium(III)-catalysed annulation of the 2-alkynyl benzoate esters resulted in formation of the 
desired isoquinolone and imide. Issues with the imide stability in nucleophilic solvents were 
addressed by incorporation of an ortho-electron-donating group to reduce the electrophilicity of 
the adjacent carboxyl group. 
 
In total, nine imides were prepared using this methodology, including examples with 
auxochromic groups (-OH and –NR2) and conjugated π-systems (naphthyl and thiophene 
derivatives). Their spectrochemical properties were subsequently investigated. A study of the 
quantum yield (Φ) of the parent imide 372 gave a value of Φrel 0.44 (in dichloromethane). 
Substitution on the parent imide using hydroxyl and π-conjugated systems led to bathochromic 
shifts in the absorbance and emission values. The electrochemical properties of four 
representative imides were analysed and found to have two reversible reduction peaks, which 
was promising for future tailoring towards semi-conductor applications. 
 
Finally, a zinc-imide complex was prepared from a 2:1 mixture of the parent imide and zinc(II) 
triflate, however isolation proved cumbersome due to the weak binding. Attempts to prepare 
neutral zinc complexes from the ortho- and para-hydroxy imides were unsuccessful. 
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5.10 Future work 
 
The application scope for this imide scaffold is plentiful, based on these preliminary findings. 
Using our methodology, the scaffold offers three points for diversification, which could be 
exploited to serve a particular application (Figure 5.16). Further modifications could be made to 
the aromatic core to tune the fluorescent and physical properties of the scaffold towards semi-
conductor or biological applications. The modification of the side chain has not been fully 
explored, but could be used to tether additional components to the fluorophore. The 
interconversion of the fluorescent imides to the non-fluorescent isoquinolones could be 
exploited as a pH sensitive fluorescent switch. Studies into the rate of interconversion at 
different pH levels and the behaviour in various solvents would provide additional information 
for this potential application.   
 
Figure 5.16 
 
The initial foray into a C-H activation polymerisation methodology, using the biphenyl-N-
(pivaloyloxy)-derivative 429 (see Scheme 5.31) proved unsuccessful, based on the solubility of 
the intermediate mono-cyclised imide. However, introduction of additional lipohilic groups to 
the precursors could potentially circumvent this issue to allow the formation of a polymeric 
material with the fluorescent imide embedded in the chain (see Scheme 5.30).  
 
The observed fluorescence of the imide with zinc highlighted the potential for alternative 
fluorescent metal-imide complexes. Studies are currently underway collaboratively with the 
group of Dr Patrick McGowan to investigate the synthesis of titanium-imide complexes for use 
in cell line imaging for anti-cancer agents.  
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 Chapter 6 
 
Experimental 
 
6.1 General methods 
 
All experiments were conducted in oven-dried glassware, under a dry nitrogen atmosphere with 
anhydrous solvents, unless otherwise stated. Hygroscopic cesium acetate (CsOAc) was stored in 
a desiccator. Anhydrous solvents were obtained from the solvent purification system (SPS). 
Anhydrous methanol was stored on 3Å molecular sieves. All other solvents and reagents were 
obtained from commercial sources and used without further purification. O-(Pivaloyl)-
hydroxylammonium chloride112 and O-(pivaloyl)-hydroxylamine triflic acid34 were prepared 
according to literature procedures. 
Flash silica chromatography was performed using Fischer Matrix silica gel (35-70 µm particles) 
and thin layer chromatography was carried out using pre-coated silica plates (Merck silica 
Kieselgel 60F254). Spots were visualised using UV fluorescence (λmax = 254 nm) or chemical 
staining with potassium permanganate. All chromatography eluents were HPLC grade and used 
without purification. Petrol refers to petroleum ether (b.p. 40-60°C). 
Proton (1H) and carbon (13C{1H}) nuclear magnetic resonance spectra were recorded using a 
Bruker DPX 300, a Bruker DRX 500 or a Bruker Avance 500 spectrometer using an internal 
deuterium lock.  1H NMR chemical shifts (δ) are quoted in ppm downfield of tetramethylsilane 
or residual solvent peaks and coupling constants (J) are quoted in Hz.  13C{1H} NMR spectra 
were recorded with broadband proton decoupling at 75 MHz and 125 MHz.  NMR spectra were 
processed using MestreNova software. Assignments were made on the basis of chemical shift 
and coupling data, using COSY and DEPT where necessary.  Infra-red spectra were recorded on 
a Perkin Elmer Spectrum One FT-IR spectrometer, with absorption reported in wavenumbers 
(cm-1). High-resolution electrospray mass spectra (ESI-MS) were measured on a Bruker 
MicroTOF-Q or Bruker MaXis Impact spectrometer in positive mode. Melting points were 
determined using a Griffin D5 variable temperature apparatus and are uncorrected. 
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6.2 1H NMR studies 
 
1H NMR study of the Lossen rearrangement 
 
N-(Pivaloyloxy)benzamide (22 mg, 0.10 mmol), CsOAc (6 mg, 0.3 mmol) and [Cp*RhCl2]2 
(0.6 mg, 1 µmol) for B and C) were weighed into a NMR tube fitted with a Young’s tap under 
an N2 atmosphere. To each NMR tube was added mesitylene (14 µL, 0.10 mmol), followed by 
MeOD (0.5 mL, 0.2 M).  The tubes were sealed and shaken and reactions A and B were heated 
to 60 °C.  1H NMR analysis was taken at the following time points: 0, 1, 2, 3 and 4 hours.  After 
this time the reactions A and C contained unreacted starting material and reaction B showed 
>95% conversion to the methyl phenyl carbamate. 
 
1H NMR study of the annulation reactions of vinyl acetate and butyl vinyl ether 
 
 
N-(Pivaloyloxy)benzamide (22 mg, 0.10 mmol), CsOAc (6 mg, 0.3 mmol), trimethoxybenzene 
(5.6 mg, 0.03 mmol) and vinyl acetate (14 µL, 0.15 mmol) or butyl vinyl ether (20 µL, 
0.15 mmol) were dissolved in MeOD-d4 (0.5 mL, 0.2 M) in a septum-topped vial under an N2 
atmosphere. To each NMR tube (fitted with a Young’s tap),  [Cp*RhCl2]2 (0.6 mg, 1 µmol) was 
added followed by the solution containing the remaining reactant. The tubes were sealed, 
shaken and the reactions were heated to 60 °C (333 K) in the 1H NMR machine.  1H NMR 
spectra were acquired at regular time intervals to compare the rate of product formation 
(isoquinolone or 4-butoxy,3,4-dihydroisoquinolones) versus the Lossen rearrangement. 
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1H NMR study of in situ formation of N-(acetoxy)benzamide 
 
 
Benzhydroxamic acid (14 mg, 0.10 mmol), CsOAc (6 mg, 0.3 mmol), trimethoxybenzene 
(5.6 mg, 0.033 mmol) and vinyl acetate (14 µL, 0.15 mmol) were dissolved in MeOD-d4 
(0.5 mL, 0.2 M) in a septum-topped vial under an N2 atmosphere. To each NMR tube (fitted 
with a Young’s tap),  [Cp*RhCl2]2 (0.6 mg, 1 µmol) was added followed by the reaction 
solution containing the remaining reactant. The tube was sealed, shaken and the reaction was 
heated to 60 °C (333 K) in the 1H NMR machine.  1H NMR spectra were acquired at regular 
time intervals to identify the formation of N-(acetoxy)benzamide in situ. 
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6.3 Alkenyl substrate scope 
 
Optimisation study for vinyl ethers 
 
N-(Pivaloyloxy)benzamide (221 mg, 1.00 mmol), n-butyl vinyl ether (194 µL, 1.50 mmol or 
647 µL, 5.00 mmol), [Cp*RhCl2]2 (6 mg, 1 mol%) and CsOAc (58 mg, 30 mol%) were 
dissolved in MeOH (5.0 mL, 0.2 M or 1.0 mL, 1.0 M) under N2 in a sealed vessel.  After 16 
hours the reaction solution was concentrated in vacuo (1H NMR spectra were taken from the 
crude samples) and purified by flash silica chromatography using 50% EtOAc in hexane with 
5% NEt3.  The desired fractions were concentrated and analysed.   
 
 
 Variables 
Yield % 
(by  1H NMR) 
Ratio Isolated Yield % 
Entry Temp (°C) Conc (M) X (Eq.) A B C D (A+B+C):D A+ B 
1 30 0.2 1.5 75 21 0 4 24 :1 50 
2 30 0.2 5 73 25 0 2 49:1 76 
3 30 1 1.5 83 16 0 1 99:1 69 
4 30 1 5 77 22 0 1 99:1 74 
5 50 0.2 1.5 45 10 5 40 3:2 33 
6 50 0.2 5 59 16 6 19 81:9 51 
7 50 1 1.5 66 11 14 9 91:9 49 
8 50 1 5 62 19 14 5 19:1 64 
9 40 0.6 3.25 71 26 0 3 97:3 62 
10 40 0.6 3.25 71 25 0 4 24:1 68 
Table 2.2 
4-Butoxy-3,4-dihydroisoquinolin-1(2H)-one 130 
Isolated as a brown oil.  Yields from the optimisation study are outlined in Table 
2.2.  δH (300 MHz, CDCl3) 8.09 (1H, dd, J 7.6, 1.2, H8), 7.54 (1H, td, J 7.5, 1.4, 
H6), 7.47-7.43 (2H, m, H5 and H7), 7.13 (1H, br s, NH), 4.50-4.48 (1H, m, H4), 
3.70 (1H, ddd, J 12.8, 4.1, 2.6, H3), 3.62 (1H, ddd, J 12.8, 5.8, 3.4, H3), 3.56 (1H, 
dt, J 9.0, 6.5, OCH2), 3.45 (1H, dt, J 9.0, 6.6, OCH2), 1.60-1.52 (2H, m, OCH2CH2), 1.31-1.40 
(2H, m, O(CH2)2CH2), 0.88 (3H, t, J 7.4, O(CH2)3CH3); δC (75 MHz, CDCl3) 165.9 (CqO), 138.7 
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MeOH (0.2 M - 1.0 M)
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(Cq), 132.1 (C6), 128.7 (C7), 128.3 (Cq), 128.0 (C8), 126.7 (C5), 72.4 (C4), 68.9 (C3), 44.7 
(OCH2), 31.7 (OCH2CH2), 19.3 (O(CH2)2CH2), 13.9 (O(CH2)3CH3); HRMS (ESI+): m/z 
calculated for formula C13H17NNaO2 [MNa+]: 242.1151; found 242.1158; IR (νmax, film, cm-1): 
3255, 3064, 2870, 1944, 1668, 1473, 1090. 
3-Butoxy-3,4-dihydroisoquinolin-1(2H)-one 131 
 
Isolated as an orange oil.  Yields from the optimisation study are outlined in 
Table 2.2.  δH (500 MHz, CDCl3) 8.49 (1H, br s, NH), 8.08 (1H, dd, J 7.7, 
1.2, H8), 7.47 (1H td, J 7.5, 1.4, H6), 7.35 (1H, td, J 7.5, 1.0, H7), 7.24 (1H, 
dd, J 7.5, 1.0, H5), 4.88 (1H, td, J 4.5, 2.5, H3), 3.58 (1H, dt, J 9.2, 6.7, OCH2), 3.38 (1H, dt, J 
9.0, 6.5, OCH2), 3.29 (1H, dd, J 16.4, 4.5, H4), 3.10 (1H, dd, J 16.4, 4.5, H4), 1.51-1.45 (2H, m, 
OCH2CH2), 1.31-1.23 (2H, m, O(CH2)2CH2), 0.85 (3H, t, J 7.5, O(CH2)3CH3); δC (75 MHz, 
CDCl3) 167.0 (CqO), 136.5 (Cq), 132.7 (C6), 128.1 (C7), 127.8 (C5), 127.5 (Cq), 126.9 (C8), 80.3 
(C3), 67.1 (C4), 33.8 (OCH2), 31.5 (OCH2CH2), 19.2 (O(CH2)2CH2), 13.7 (O(CH2)3CH3); 
HRMS (ESI+): m/z calculated for formula C13H17NNaO2 [MNa+]: 242.1151; found 242.1142; IR 
(νmax, film, cm-1): 2956, 2889, 1652, 1475, 1343, 1228. 
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4-Ethoxy- and 3-ethoxy-3,4-dihydroisoquinolin-1(2H)-one. 
Ethyl vinyl ether (481 µL, 5.00 mmol) was added to a solution of N-(pivaloyloxy)benzamide 
(221 mg, 1.00 mmol), CsOAc (57.0 mg, 0.30 mmol) and [Cp*RhCl2]2 (6 mg, 1 mol%) in MeOH 
(5.00 mL, 0.20 M) that was left stirring overnight at 30 °C for 16 hours. The crude reaction 
mixture was concentrated in vacuo and purified by flash silica chromatography using 10% 
hexane in EtOAc with 5% NEt3 to give two regioisomers 139 (134 mg, 65%) and 140 (45.6 mg, 
22%) as orange amorphous solids.  Samples of the solids were cystallised from hexane–EtOAc. 
4-Ethoxy-3,4-dihydroisoquinolin-1(2H)-one 139 
Major regioisomer.  M.p. 130-132 °C (hexane–EtOAc); δH (300 MHz, CDCl3) 
8.11 (1H, dd, J 7.4, 1.4, H8), 7.55 (1H, td, J 7.4, 1.4, H6), 7.47 (1H, td, J 7.6, 1.4, 
H7), 7.42 (1H, d, J 7.3, 1.4, H5), 6.10 (1H, br s, NH), 4.50 (1H, t, J 4.6, H4), 3.76-
3.45 (4H, m, OCH2 and H3), 1.22 (3H, t, J 7.0, CH3); δC (75 MHz, CDCl3) 165.5 
(CqO), 138.1 (Cq), 132.1 (C6), 128.8 (C7), 128.4 (Cq), 128.2 (C8), 126.9 (C5), 72.3 (C4), 64.5 
(C3), 44.9 (OCH2), 15.4 (OCH2CH3); HRMS (ESI+): m/z calculated for formula: C11H14NO2 
[MH+] 192.1023; found 192.1023; IR (νmax, solid, cm-1): 3302, 2890, 1605, 1439, 1113. 
3-Ethoxy-3,4-dihydroisoquinolin-1(2H)-one 140 
 
Minor regioisomer.  M.p. 130-132 °C (hexane–EtOAc); δH (300 MHz, 
CDCl3) 8.09 (1H, d, J 8.0, H8), 7.48 (1H, td, J 7.5, 3.7, H6), 7.36 (1H, t, J 
7.5, H7), 7.25 (1H, d, J 7.1, H5), 6.61 (1H, br  s, NH), 4.89 (1H, td, J 4.4, 2.3, 
H3), 3.65 (1H, dq, J 9.1, 7.0, OCH2CH3), 3.43 (1H, dq, J 9.1, 7.0, OCH2CH3),  
3.32 (1H, dd, J 15.9, 4.5, H4), 3.11 (1H, d, J 16.4, H4), 1.15 (3H, t, J 7.0, OCH2CH3); 
δC (75 MHz, CDCl3) 160.1 (CqO), 136.4 (Cq), 132.6 (C6), 128.6 (C7), 127.9 (Cq), 127.7 (C5), 
127.0 (C8), 80.3 (C3), 62.6 (OCH2), 34.0 (C4), 15.1 (CH3); HRMS (ESI+): m/z calculated for 
formula: C11H13NNaO2 [MNa+] 214.0838; found 214.0833; IR (νmax, solid, cm-1): 3282, 2925, 
1650, 1490, 1033. 
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Verification of regiochemistry: repeat of Fagnou experiment.34  
 
 
Dihydrofuran (83 µL, 1.1 mmol) was added to a solution of N-(pivaloyloxy)benzamide 
(221 mg, 1.00 mmol), CsOAc (384 mg, 2.00 mmol) and [Cp*RhCl2]2 (3 mg, 0.5 mol%) in 
MeOH (5 mL, 0.2 M).  The solution was left to stir at room temperature for 24 hours.  The 
material was concentrated and purified using flash silica chromatography with 8% isopropanol 
in toluene to separate a mixture of regioisomers (145 mg, 77%, 123) and (5 mg, 3%, 122). 
 
2,3,3a,4-Tetrahydrofuro[3,2-c]isoquinolin-5(9bH)-one 123 
 
Isolated as a cream solid (145 mg, 77%). RF 0.08 (8% isopropanol in toluene).  
δH (300 MHz, CDCl3) 8.16 (1H, dd, J 7.3, 1.2, H6), 7.61-7.45 (3H, m H7, H8, 
H9), 6.00 (1H, br s, NH), 4.85 (1H, d, J 4.6, H9b), 4.36-4.34 (1H, m, H3a), 
4.13-3.99 (2H, m, H2), 2.52-2.39 (1H, m, H3), 2.19-2.09 (1H, m, H3); 
δC (75 MHz, CDCl3) 164.8 (C5), 135.3 (Cq), 132.7 (C8), 129.4 (C7), 129.1 (C9), 128.0 (C6), 127.4 
(Cq), 72.2 (C9b), 66.7 (C2), 54.3 (C3a), 34.9 (C3); HRMS (ESI+): m/z calculated for formula: C11-
H11NNaO2 [MNa+] 212.0682; found 212.0680; IR (νmax, solid, cm-1): 3196, 2957, 1668, 1456, 
1335, 1040. 
 
1,3a,4,9b-Tetrahydrofuro[2,3-c]isoquinolin-5(2H)-one 122 
 
Isolated as an orange oil (5 mg, 3%). RF 0.15 (8% isopropanol in toluene), δH 
(300 MHz, CDCl3) 8.07 (1H, dd, J 7.8, 1.3, H6), 7.45 (1H, td, J 7.5, 1.4, H8), 
7.31 (1H, td, J 7.6, 1.1, H7), 7.23 (1H, dd, J 7.6, 0.5, H9), 6.76 (1H, br s, NH), 
5.51 (1H, dd, J 6.0, 1.6 H3a ), 3.98-3.99 (2H, m, H2), 3.48 (1H, ddd, J 14.4, 
8.3, 6.2, H9b), 2.50-2.38 (1H, m, H1), 2.12-2.00 (1H, m, H1).  Insufficient material to obtain a 
good quality 13C spectrum. HRMS (ESI+): m/z calculated for formula C11H11NNaO2 [MNa+] 
212.0682; found 212.0689; IR (νmax, solid, cm-1): 3254, 2935, 1695, 1471, 1190, 1042. 
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6.4 Preparation of hydroxamate esters 
N-Methoxybenzamide 4234 
A solution of O-methylhydroxylamine hydrochloride (1.50 g, 18.0 mmol) and 
potassium carbonate (4.18 g, 30.0 mmol) in EtOAc–water (2:1, 270 mL) was 
cooled to 0 °C in an ice bath.  Benzoyl chloride (1.7 mL, 15 mmol) was added 
dropwise into the reaction, ensuring the temperature was maintained at 0 °C.  Following the 
addition, the solution was warmed to room temperature and left stirring overnight.  After 16 
hours, the reaction solution was diluted with EtOAc (100 mL) and washed with water (100 mL) 
and brine (100 mL).  The organic layer was dried with MgSO4, filtered and concentrated in 
vacuo to give N-methoxybenzamide as a colourless solid (1.43g, 69%).  RF 0.45 (9:1 EtOAc–
petrol); δH (500 MHz, CDCl3) 8.72 (1H, br s, NH), 7.74 (2H, d, J 7.2, ArH), 7.54 (1H, t, J 7.7, 
ArH), 7.45 (2H, t, J 7.7, ArH), 3.90 (3H, s, MeO); δC (75 MHz, CDCl3) 166.6 (CqO), 132.1 (C4-
), 131.9 (Cq), 128.7 (C3 and C5), 127.1 (C2 and C6), 64.6 (MeO); HRMS (ESI+): m/z calculated 
for formula C8H10NO2 [MH+]: 152.0706; found 152.0708.  Spectral data consistent with the 
literature.34 
 
N-Acetoxybenzamide 12834  
A solution of benzhydroxamic acid (0.7 g, 5 mmol), 2 M NaOH (2.30 mL), 
and acetic anhydride (0.60 mL, 5.5 mmol) in DCM (15 mL) was stirred at 
room temperature for 16 hours.  After this time the reaction mixture was 
diluted with EtOAc (20 mL) and the organic layer was sequentially washed with 1 N HCl 
(20 mL), water (2 × 20 mL) and brine (20 mL).  The organic layer was dried over MgSO4, 
filtered and concentrated in vacuo to give N-acetoxybenzamide, which was recrystallised from 
Et2O–pentane to give colourless crystals (0.75 g, 83%).  RF 0.44 (50% hexane–EtOAc); δH (500 
MHz, CDCl3) 9.45 (1H, br s, NH), 7.82 (2H, d, J 7.2, ArH), 7.58 (1H, t, J 7.6, ArH), 7.48 (2H, 
t, J 7.9, ArH), 2.31 (3H, s, Me); δC (75 MHz, CDCl3) 169.2 (CqO), 166.4 (CqO), 132.8 (C4), 
130.7 (Cq), 128.8 (C3 and C5), 127.5 (C2 and C6), 18.4 (Me); HRMS (ESI+): m/z calculated for 
formula C9H9NNaO3 [MNa+]: 202.0475; found 202.0469.  IR (νmax, solid, cm-1): 3143, 2957, 
1792, 1651, 1313, 1198, 1021, 895, 693.  Spectral data consistent with the literature.34 
N-(Pivaloyloxy)benzamide 43244 
 
A solution of benzhydroxamic acid (1.47 g, 10.7 mmol), NEt3 (1.30 mL, 
11.0 mmol) and pivaloyl chloride (1.30 mL, 11.0 mmol) in THF (60 mL, 
0.18 M) was stirred at room temperature for 16 hours.  The reaction 
mixture was diluted with EtOAc (50 mL) and washed with 1 N HCl (50 mL), water (2 x 50 mL) 
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and brine (50 mL).  The organic layer was dried over MgSO4 and concentrated in vacuo to give 
an amorphous cream solid.  The material was crystallised from Et2O–pentane to give a 
colourless microcrystalline powder, N-(pivaloyloxy)benzamide (2.08 g, 88%). M.p. 170-172 °C 
(Et2O–pentane, [lit. M.p. 169-170 °C]244); RF 0.80 (50% EtOAc in hexane); δH (500 MHz, 
CDCl3) 9.30 (1H, br s, NH), 7.83 (2H, d, J 7.9, H2 and H6), 7.58 (1H, t, J 7.9, H4), 7.48 (2H, t, J 
7.9, H3 and H5), 1.38 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 177.0 (COC(CH3)3), 166.8 (CONH), 
132.7 (C4), 131.0 (C1), 128.8 (C3 and C5), 127.5 (C2 and C6), 38.5 (COC(CH3)3), 27.1 
(COC(CH3)3); HRMS (ESI+): m/z calculated for formula C12H15NNaO3 [MNa+]: 244.0944; 
found 244.0939. IR (νmax, solid, cm-1): 3240, 2975, 1781, 1650, 1516, 1482, 1369, 1267, 1068, 
1025.  Spectral data consistent with the literature.244  
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General Procedure (A) for the synthesis of hydroxamic esters 
 
Oxalyl chloride (1.2 eq.) was added to a solution of the benzoic acid derivative (1 eq.) in 
anhydrous DCM (0.2 M) with DMF (2 drops).  The solution was stirred at room temperature for 
3 hours, after which time the solvent was removed in vacuo to afford the crude acid chloride.  
The intermediate was diluted in EtOAc (5 mL) and transferred to a flask containing 
O-(pivaloyl)hydroxylammonium chloride (1.1 eq.) and K2CO3 (2 eq.) dissolved in a 2:1 mixture 
of EtOAc–H2O (0.2 M) at 0 °C.  After 2 hours, the reaction was quenched with sat. NaHCO3 
(50 mL) and extracted with EtOAc (50 mL).  The two phases were separated and the organic 
layer was washed with brine (50 mL).  The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo.  The final compound was purified by crystallisation or flash silica 
chromatography. 
 
General Procedure (B) for the synthesis of hydroxamic esters 
 
Oxalyl chloride (1.2 eq.) was added to a solution of the benzoic acid derivative (1 eq.) in 
anhydrous DCM (0.2 M) with DMF (2 drops).  The mixture was stirred at room temperature for 
3 hours, after which time the solvent was removed in vacuo to afford the crude acid chloride.  
The intermediate was diluted in THF (5 mL) and transferred to a flask containing 
O-(pivaloyl)hydroxylammonium chloride (1.1 eq.) and NEt3 (2 eq.) in THF (0.2 M) at 0 °C.  
After 2 hours, the reaction was concentrated in vacuo and the residue was re-diluted with sat. 
NaHCO3 (50 mL) and EtOAc (50 mL).  The two phases were separated and the organic layer 
was washed with brine (50 mL).  The organic layer was dried over MgSO4, filtered and 
concentrated in vacuo.  The final compound was purified by crystallisation or flash silica 
chromatography. 
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4-Cyano-N-(pivaloyloxy)benzamide 161  
 
The final compound was isolated as a colourless solid (459 mg, 37%), 
by flash column chromatography using 10-20% EtOAc in hexane, 
from 4-cyanobenzoic acid (736 mg, 5.00 mmol) following general 
procedure B.  A sample was taken and crystallised from CDCl3.  RF 0.33 (9:1 hexane–EtOAc); 
m.p. 103.4-105.5 °C (CDCl3); δH (500 MHz, CDCl3) 9.30 (1H, br s, NH), 7.92 (2H, d, J 8.5, H2 
and H6), 7.78 (2H, d, J 8.6, H3 and H5), 1.37 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 176.8 
(COC(CH3)3), 165.0 (CONH), 134.8 (C1), 132.6 (C3 and C5), 128.2 (C2 and C6), 117.7 (CN), 
116.2 (C4), 38.5 (COC(CH3)3), 27.0 (COC(CH3)3); HRMS (ESI+): m/z calculated for formula C-
13H14N2NaO3 [MNa+] 269.0897; found 269.0895; IR (νmax, solid, cm-1): 3223, 2982, 2234, 1781, 
1648, 1519, 1480, 1398, 1366, 1308, 1281, 1064. 
4-Acetyl-N-(pivaloyloxy)benzamide 162 
 
The final compound was isolated as a colourless solid (105 mg, 10%), 
by flash column chromatography using 30% EtOAc in hexane, from 
4-acetylbenzoic acid (329 mg, 2.00 mmol) following general 
procedure A.  δH (300 MHz, CDCl3) 9.72 (1H, s, NH), 7.98 (2H, d, J 8.4, H2 and H6), 7.87 (2H, 
d, J 8.4, H3 and H5), 2.61 (3H, s, COCH3), 1.34 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 197.5 
(COCH3), 176.9 (COC(CH3)3), 165.6 (CONH), 140.0 (C4), 134.8 (C1), 128.6 (C3 and C5), 127.8 
(C2 and C6), 38.5 (COC(CH3)3), 27.0 (COC(CH3)3), 26.9 (COCH3); HRMS (ESI+): m/z 
calculated for formula C14H17NNaO4 [MNa+] 286.1050; found 286.1048; IR (νmax, solid, cm-1): 
3209, 2975, 1779, 1682, 1514, 1070. 
4-(Trifluoromethyl)-N-(pivaloyloxy)benzamide 163 
 
The final compound was isolated as a colourless crystalline solid 
(813 mg, 60%), by crystallisation from Et2O–pentane, from 
4-(trifluoromethyl)benzoic acid (1.36 g, 4.69 mmol) following general 
procedure B.  M.p. 121-124 °C (Et2O–pentane); δH (300 MHz, CDCl3) 9.53 (1H, br s, NH), 7.91 
(2H, d, J 8.1, H2 and H6), 7.71(2H, d, J 8.2, H3 and H5), 1.36 (9H, s, (CH3)3); δC (75MHz, 
CDCl3) 177.1 (COC(CH3)3), 165.5 (CONH), 134.5 (q, J 32.9, C4), 134.3 (C1), 128.1 (C2 and 
C6), 126.0 (q, J 3.7, C3 and C5), 123.6 (q, J 272.8, CF3), 38.6 (COC(CH3)3), 27.1 (COC(CH3)3); 
HRMS (ESI+): m/z calculated for formula C13H15F3NO3 [MH+] 290.0999; found 290.0997; IR 
(νmax, solid, cm-1): 2978, 1780, 1663, 1582, 1323, 1128, 1065, 1016. 
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4-Methoxy-N-(pivaloyloxy)benzamide 164  
 
The desired compound was isolated as a colourless crystalline solid 
(613 mg, 81%), by crystallisation from CHCl3, from 
4-methoxybenzoyl chloride (510 mg, 3.00 mmol) following general 
procedure B.  M.p. 149-150 °C (CHCl3); δH (300 MHz, CDCl3) 9.27 (1H, br s, NH), 7.81 (2H, 
d, J 9.0, H2 and H6), 6.96 (2H, d, J 9.0, H3 and H5), 3.88 (3H, s, OMe), 1.38 (9H, s, (CH3)3); 
δC (75 MHz, CDCl3) 177.3 (COC(CH3)3), 166.7 (CONH), 163.2 (C4), 129.5 (C2 and C6), 123.0 
(C1), 114.1 (C3 and C5), 55.5 (OMe), 38.5 (COC(CH3)3), 27.1 (COC(CH3)3); HRMS (ESI+): m/z 
calculated for formula C13H17NNaO4 [MNa+] 274.1050; found 274.1045; IR (νmax, solid, cm-1): 
3259, 2974, 1774, 1605, 1494, 1318, 1260, 1073, 1028. Spectral data consistent with the 
literature.34  
4-Fluoro-N-(pivaloyloxy)benzamide 165   
 
The final compound was isolated as a colourless microcrystalline 
powder colourless microcrystalline powder (317 mg, 44%), by flash 
column chromatography using 20% EtOAc in hexane, from 
4-fluorobenzoic acid (420 mg, 3.00 mmol) following general procedure B.  δH (300 MHz, 
CDCl3) 9.26 (1H, br s, NH), 7.86 (2H, dd, J 8.7, 5.3, H2 and H6), 7.17 (2H, t, J 8.6, H3 and H5), 
1.38 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 177.1 (COC(CH3)3), 165.9 (CONH), 165.4 (d, J 
252.8, C4), 130.0 (d, J 9.2, C2 and C6), 127.0 (d, J 3.3, C1), 116.1 (d, J 22.1, C3 and C5), 38.5 
(COC(CH3)3), 27.2 (COC(CH3)3); HRMS (ESI+): m/z calculated for formula C12H14FNNaO3 
[MNa+] 262.0850; found 262.0847; IR (νmax, solid, cm-1): 3194, 2976, 1784, 1652, 1602, 1493, 
1237, 1075. 
4-Bromo-N-(pivaloyloxy)benzamide 166  
 
The final compound was isolated as a colourless microcrystalline 
powder (924 mg, 62%), by flash column chromatography using 10-
50% EtOAc in hexane, followed by a crystallisation using EtOAc–
hexane, from 4-bromobenzoic acid (1.01 g, 5.00 mmol) following general procedure B.  RF 0.28 
(20% EtOAc in hexane); M.p. 141-142 °C (EtOAc–hexane); δH (500 MHz, CDCl3) 9.24 (1H, br 
s, NH), 7.69 (2H, d, J 8.7, H2 and H6), 7.62 (2H, d, J 8.7, H3 and H5), 1.37 (9H, s, (CH3)3); 
δC (75 MHz, CDCl3) 177.0 (COC(CH3)3), 165.8 (CONH), 132.1 (C3 and C5), 129.7 (C1), 129.0 
(C2 and C6), 127.6 (C4), 38.5 (COC(CH3)3), 27.0 (COC(CH3)3); HRMS (ESI+):  calculated for 
formula C12H1479BrNNaO3 [MNa+] 322.0049; found 322.0050; IR (νmax, solid, cm-1): 3165, 
2980, 1779, 1644, 1480, 1069.  Spectral data consistent with the literature.245  
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4-Iodo-N-(pivaloyloxy)benzamide 167 
 
The final compound was isolated as a colourless crystalline solid 
(489 mg, 47%), by crystallisation from EtOAc–hexane, from 
4-iodobenzoyl chloride (799 mg, 3.00 mmol) following general 
procedure B.  M.p. 152-153 °C (EtOAc–hexane); δH (300 MHz, MeOD-d4) NH peak missing, 
7.78 (2H, d, J 8.6, H2 and H6), 7.46 (2H, d, J 8.6, H3 and H5), 1.24 (9H, s, (CH3)3); δC (75 MHz, 
MeOD-d4) 177.5 (COC(CH3)3), 167.2 (CONH), 139.2 (C3 and C5), 132.3 (Cq), 130.1 (C2 and 
C6), 100.2 (C4), 39.4 (COC(CH3)3), 27.5 (COC(CH3)3); HRMS (ESI+): m/z calculated for 
formula C12H14INNaO3 [MNa+] 369.9911; found 369.9903; IR (νmax, solid, cm-1): 3140, 2971, 
1781, 1648, 1584, 1475, 1007, 1004. Spectral data consistent with the literature.36  
tert-Butyl (3-((pivaloyloxy)carbamoyl)phenyl) carbamate 180 
 
The desired compound was isolated as a colourless amorphous 
solid (628 mg, 62%), by flash column chromatography using 
20% EtOAc in hexane, from 3-((tert-butoxycarbonyl)-
amino)benzoic acid (1.01 g, 3.00 mmol) following general procedure B.  δH (300 MHz, CDCl3) 
9.39 (1H, br s, NH), 7.85 (1H, s, H2), 7.55 (1H, d, J 7.6, H4), 7.48 (1H, d, J 7.6, H6), 7.38 (1H, t, 
J 7.8, H5), 6.58 (1H, s, NH), 1.52 (9H, s, OC(CH3)3), 1.36 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 
177.1 (CO2tBu), 166.4 (COC(CH3)3), 152.9 (CONH), 139.0 (C3), 131.7 (C1), 129.5 (C5), 122.6 
(C4), 122.0 (C6), 117.4 (C2), 81.1 (OC(CH3)3), 38.5 (C(CH3)3), 28.4 (OC(CH3)3), 27.1 
(C(CH3)3); HRMS (ESI+): m/z calculated for formula C17H24N2NaO5 [MNa+] 359.1577; found 
359.1571; IR (νmax, solid, cm-1): 3288, 2978, 1781, 1727, 1672, 1591, 1543, 1480, 1236, 1159, 
1078. 
N-(Pivaloyloxy)-[1,1’-biphenyl]-3-carboxamide 181 
 
The desired compound was isolated as a colourless amorphous 
solid (223 mg, 38%), by flash column chromatography using 20% 
EtOAc in petrol, from 3-biphenylcarboxylic acid (490 mg, 
2.00 mmol) following general procedure A.  RF 0.33 (20% EtOAc in petrol); δH (300 MHz, 
CDCl3) 9.33 (1H, s, NH), 8.05 (1H, t, J 1.6, ArH), 7.82-7.76 (2H, m, ArH), 7.63-7.58 (2H, m, 
ArH), 7.55-7.35 (4H, m, ArH), 1.38 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 177.1 (COC(CH3)3), 
166.8 (CONH), 142.0 (C3), 139.8 (Cq), 131.5 (C1), 131.4, 129.3, 129.0, 128.0, 127.2, 126.3, 
126.1, 38.5 (COC(CH3)3), 27.1 (COC(CH3)3); HRMS (ESI+): m/z calculated for formula: C18H-
20NO3 [MH+] 298.1438; found 298.1436; IR (νmax, solid, cm-1): 3038, 2975, 1786, 1652, 1514, 
1077. 
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3-Bromo-N-(pivaloyloxy)benzamide 182 
 
The desired compound was isolated as a colourless amorphous solid 
(850 mg, 57%) by flash column chromatography using 20% EtOAc in 
hexane, from 3-bromocarboxylic acid (1.01 g, 5.00 mmol) following 
general procedure A.  RF 0.13 (20% EtOAc in hexane); δH (300 MHz, CDCl3) 9.27 (1H, s, NH), 
7.96 (1H, t, J 1.6, H2), 7.80-7.63 (2H, m, H4 and H6), 7.35 (1H, t, J 7.9, H5), 1.36 (9H, s, 
(CH3)3); δC (75 MHz, CDCl3) 176.7 (COC(CH3)3), 165.1 (CONH), 135.5 (C4), 132.6 (C1), 130.7 
(C5), 130.3 (C2), 126.0 (C6), 122.8 (C3), 38.5 (COC(CH3)3), 27.2 (COC(CH3)3); HRMS (ESI+): 
m/z calculated for formula C12H1479BrNNaO3 [MNa+] 322.0049; found 322.0053; IR (νmax, solid, 
cm1): 3251, 2816, 1784, 1660, 1301, 1068. 
 
3-Chloro-N-(pivaloyloxy)benzamide 183 
 
The desired compound was isolated as a colourless crystalline solid 
(1.09 g, 85%), by crystallisation from EtOAc–pentane, from 
3-chlorobenzoyl chloride (640 µL, 5.00 mmol) following general 
procedure A.  In this reaction O-pivaloylhydroxyamine triflic acid35 (1.47 g, 5.50 mmol) was 
used instead of O-pivaloylhydroxyamine hydrochloric acid.  RF 0.6 (10% EtOAc in hexane); 
M.p. 89-92 °C (EtOAc–pentane); δH (300 MHz, CDCl3) 9.73 (1H, s, NH), 7.75 (1H, t, J 1.7, 
H2), 7.64 (1H, d, J 7.7, H6), 7.48 (1H, ddd, J 8.0, 2.0, 1.0, H4), 7.34 (1H, t, J 7.9, H5), 1.32 (9H, 
s, (CH3)3); δC (75 MHz, CDCl3) 177.0 (COC(CH3)3), 165.4 (CONH), 135.0 (C1), 132.7 (C3 and 
C4), 130.2 (C5), 127.9 (C2), 125.6 (C6), 38.6 (COC(CH3)3), 27.1 (COC(CH3)3); HRMS (ESI+): 
m/z calculated for formula C12H1435ClNNaO3 [MNa+] 278.0554; found 278.0548;  IR (νmax, 
solid, cm-1): 3190, 2971, 1782, 1660, 1569, 1516, 1476, 1465, 1302, 1270, 1229, 1154, 1068, 
1027. 
3-Fluoro-N-(pivaloyloxy)benzamide 184   
 
The desired compound was isolated as a colourless amorphous solid 
(474 mg, 66%) by flash column chromatography using 20% EtOAc in 
hexane, from 3-fluorobenzoic acid (420 mg, 3.00 mmol) following 
general procedure B.  δH (300 MHz, CDCl3) 9.30 (1H, s, NH), 7.61-7.56 (1H, m, H6), 7.55-7.50 
(1H, m, H2), 7.47 (1H, td, J 8.0, 5.4, H5), 7.31-7.29 (1H, m, H4), 1.39 (9H, s, (CH3)3); 
δC (75 MHz, CDCl3) 177.1 (COC(CH3)3), 165.5 (CONH), 162.8 (d, J 248.7, C3), 133.1 (d, J 7.0, 
C1), 130.7 (d, J 7.9, C5), 123.1 (d, J 3.2, C6), 119.9 (d, J 21.2, C4), 115.0 (d, J 23.3, C2), 38.6 
(COC(CH3)3), 27.3 (COC(CH3)3); HRMS (ESI+): m/z calculated for formula C12H14FNNaO3 
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[MNa+] 262.0850; found 262.0847; IR (νmax, solid, cm-1): 3194, 2976, 1784, 1652, 1602, 1493, 
1237, 1075. 
3-Methoxy-N-(pivaloyloxy)benzamide 185 
 
The desired compound was isolated as an amorphous solid (984 mg, 
76%), by flash column chromatography using 20% EtOAc in hexane, 
from 3-methoxybenzoic acid (760 mg, 5.00 mmol) following general 
procedure A.  δH (300 MHz, CDCl3) 9.41 (1H, s, NH), 7.25 (3H, m, H2, H5 and H6), 6.98 (1H, 
dt, J 9.8, 3.4, H4), 3.74 (3H, s, OMe), 1.37 (9H, s, (CH3)3); δC  (75 MHz, CDCl3) 177.0 
(COC(CH3)3), 166.6 (CONH), 159.8 (C3), 132.1 (C1), 129.8 (C5), 119.3 (C4 or C6), 119.2 (C4 or 
C6), 112.3 (C2), 55.5 (OMe), 38.5 (COC(CH3)3), 27.0 (COC(CH3)3); HRMS (ESI+): m/z 
calculated for formula C13H17NNaO4 [MNa+] 274.1050; found 274.1055; IR (νmax, solid, cm-1): 
3550, 3212, 2970, 1783, 1667, 1067. 
N-(Pivaloyloxy)benzo[d][1,3]dioxole-5-carboxamide 186 
 
The desired compound was isolated as a colourless crystalline solid 
(663 mg, 83%), by crystallisation using EtOAc, from piperonylic acid 
(498 mg, 3.00 mmol) following general procedure A.  M.p. 141-
142 °C (EtOAc); δH (300 MHz, CDCl3) 9.17 (1H, s, NH), 7.39 (1H, dd, J 8.1, 1.7, H6), 7.29 
(1H, d, J 1.7, H4), 6.86 (1H, d, J 8.1, H7), 6.05 (2H, s, OCH2O), 1.36 (9H, s, (CH3)3); 
δC (75 MHz, CDCl3) 177.2 (COC(CH3)3), 166.4 (CONH), 151.4 (OCq), 148.1 (OCq), 124.8 (C1), 
122.6 (C6), 108.3 (C4), 107.9 (C7), 101.9 (OCH2O), 38.5 (COC(CH3)3), 27.0 (COC(CH3)3); 
HRMS (ESI+): m/z calculated for formula C13H15NNaO5 [MNa+] 288.0842; found 288.0848; IR 
(νmax, solid, cm-1): 3215, 2971, 1771, 1645, 1479, 1263, 1094. 
N-(Pivaloyloxy)-2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamide 187 
 
The desired compound was isolated as a colourless microcrystalline 
solid (565 mg, 73%) by flash column chromatography using 33% 
EtOAc in hexane, followed by crystallisation from hexane–EtOAc, 
from 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylic acid (500 mg, 2.77 mmol) following 
general procedure A.  M.p. 126-129 °C (hexane–EtOAc); δH (300 MHz, CDCl3) 9.29 (1H, br s, 
NH), 7.37-7.29 (2H, m, H5 and H7), 6.89 (1H, d, J 8.4, H8), 4.34-4.21 (4H, m, O(CH2)2O), 1.35 
(9H, s, (CH3)3); δC (75 MHz, CDCl3) 177.2 (COC(CH3)3), 166.3 (CONH), 147.6 (OCq), 143.6 
(OCq), 123.9 (C1), 121.1 (C7), 117.6 (C5), 117.0 (C8), 64.6 (O(CH2)2O), 64.1 (O(CH2)2O), 38.5 
(COC(CH3)3), 27.0 (COC(CH3)3); HRMS (ESI+): m/z calculated for formula C14H17NNaO5 
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[MNa+] 302.0999; found 302.0998; IR (νmax, solid, cm-1): 3208, 2976, 1777, 1645, 1488, 1288, 
1062. 
 
Heterocyclic pivalate esters 
N-(Pivaloyloxy)thiophene-2-carboxamide 196 
 
The desired compound was isolated as a colourless amorphous solid 
(455 mg, 40%) by flash column chromatography using 10% EtOAc in 
hexane, from 2-thiophene carboxylic acid (641 mg, 5.00 mmol) following general procedure A.  
RF 0.22 (10% EtOAc in hexane); δH (300 MHz, CDCl3) 9.18 (1H, s, NH), 7.67 (1H, dd, J 3.8, 
1.2, H3), 7.59 (1H, dd, J 5.0, 1.2, H5); 7.13 (1H, dd, J 5.0, 3.8, H4), 1.38 (9H, s, (CH3)3); 
δC (75 MHz, CDCl3) 177.1 (COC(CH3)3), 161.9 (CONH), 133.6 (C2), 131.7 (C3), 130.5 (C5), 
127.9 (C4), 38.5 (COC(CH3)3), 27.0 (COC(CH3)3); HRMS (ESI+): m/z calculated for formula: 
C10H13NNaO3S [MNa+] 250.0508; found 250.0502; IR (νmax, solid, cm-1): 3208, 2938, 1784, 
1625, 1478, 1245, 1070. 
N-(Pivaloyloxy)benzo[b]thiophene-2-carboxamide 197  
 
The desired compound was isolated as a colourless amorphous solid 
(356 mg, 25%) by flash column chromatography using 30-50% EtOAc 
in hexane, from benzothiophene-2-carboxylic acid (891 mg, 
5.00 mmol) following general procedure A.  RF 0.41 (50% EtOAc in hexane); δH (300 MHz, 
CDCl3) 9.33 (1H, br s, NH), 7.93 (1H, s, H3), 7.90-7.87 (2H, m, H4 and H7), 7.51-7.40 (2H, m, 
H5 and H6), 1.38 (9H, s, (CH3)3); δC (75 MHz, CDCl3) 177.0 (COC(CH3)3), 162.0 (CONH), 
138.6 (CqS), 133.2 (CqS), 127.6 (C6), 127.0 (C5), 125.5 (C4), 125.1 (C7), 122.7 (C3), 38.5 
(COC(CH3)3), 27.0 (COC(CH3)3), one quaternary peak missing; HRMS (ESI+): m/z calculated 
for formula C14H15NNaO3S [MNa+] 300.0665; found 300.0654; IR (νmax, solid, cm-1): 3170, 
2970, 1781, 1632, 1528, 1064. 
N-(Pivaloyloxy)benzofuran-2-carboxamide 199 
 
The desired compound was isolated as a colourless crystalline solid 
(258 mg, 49%) by crystallisation from EtOAc, from benzo[b]furan-2-
carboxylic acid (416 mg, 2.00 mmol) following general procedure A.  
M.p. 111-115 °C (EtOAc); δH (300 MHz, CDCl3) missing NH peak, 7.70 (1H, d, J 7.8, H4), 
7.59 (1H, s, H3), 7.53 (1H, d, J 8.2, H7), 7.50-7.43 (1H, m, H6), 7.32 (1H, t, J 7.4, H5), 1.38 (9H, 
s, (CH3)3); δC (75 MHz, CDCl3) 176.6 (COC(CH3)3), 157.2 (CONH), 155.2 (CqO), 146.2 (CqO), 
127.8 (C6), 127.1 (Cq), 124.2 (C5), 123.0 (C4), 112.8 (C7), 112.1 (C3), 38.6 (COC(CH3)3), 27.2 
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(COC(CH3)3); HRMS (ESI+): m/z calculated for formula: C14H15NNaO4 [MNa+] 284.0893; 
found 284.0889; IR (νmax, solid, cm-1): 3128, 2971, 1787, 1653, 1072. 
1-Methyl-N-(pivaloyloxy)-1H-indole-2-carboxamide 200 
 
The desired compound was isolated as a colourless amorphous 
solid (392 mg, 35%) by flash column chromatography using 0-5% 
EtOAc in hexane, from 1-methyl-1H-indole-2-carboxylic acid 
(718 mg, 4.10 mmol) following general procedure B.  RF 0.28 (20% EtOAc in hexane); δH (300 
MHz, CDCl3) 9.27 (1H, s, NH), 7.67 (1H, d, J 8.0, H4), 7.44-7.36 (2H, m, H5 and H7), 7.18 (1H, 
ddd, J 7.9, 6.3, 1.5, H6), 7.08 (1H, s, H3), 4.04 (3H, s, NMe), 1.39 (9H, s, (CH3)3); δC (75 MHz, 
CDCl3) 177.2 (COC(CH3)3), 162.0 (CONH), 139.4 (C1), 127.2 (Cq), 125.9 (Cq), 125.0 (C6), 
122.3 (C4), 120.8 (C5), 110.2 (C3), 106.1 (C7), 38.5 (COC(CH3)3), 31.4 (NMe), 27.1 
(COC(CH3)3); HRMS (ESI+): m/z calculated for formula C15H18N2NaO3 [MNa+] 297.1210; 
found 297.1211; IR (νmax, solid, cm-1): 3179, 2973, 1783, 1660, 1520, 1464, 1267, 1114, 1073, 
1028. 
N-(Pivaloyloxy)isoquinoline-3-carboxamide 203 
 
The desired compound was isolated as a colourless crystalline solid 
(365 mg, 45%), by crystallisation from DCM, from quinoline-3-
carboxylic acid (520 mg, 3.00 mmol) following general procedure B.  
M.p. 154-156 °C (DCM); δH (300 MHz, CDCl3) 10.24 (1H, br s, NH), 9.24 (1H, d, J 2.0, H2), 
8.62 (1H, d, J 1.8, H4), 8.09 (1H, d, J 8.5, H5), 7.82 (1H, t, J 7.1, H7), 7.78 (1H, d, J 7.1, H8), 
7.59 (1H, app t, J 7.3, H6), 1.36 (9H, s, (CH3)3);  δC (75 MHz, CDCl3)  176.9 (COC(CH3)3), 
164.9 (CONH), 149.4 (NCq), 147.8 (C2), 136.8 (C4), 131.9 (C7), 129.2 (C5), 128.9 (C8), 127.8 
(C6), 126.7 (Cq), 124.0 (Cq), 38.5 (COC(CH3)3), 27.0 (COC(CH3)3); HRMS (ESI+): m/z 
calculated for formula C15H16N2O3 [MH+] 273.1234; found 273.1230; IR (νmax, solid, cm-1): 
3096, 1765, 1695, 1523, 1291, 1079. 
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6.5 Preparation of isoquinolone derivatives  
 
General Procedure (C) for the synthesis of isoquinolones 
 
Vinyl acetate (138 µL, 1.50 mmol) was added to a solution of [Cp*RhCl2]2 (0.01 eq.), CsOAc 
(0.3 eq) and the N-(pivaloyloxy)benzamide derivative (1 eq.) in MeOH (0.2 M) in a vial under a 
nitrogen atmosphere.  The reaction was heated to 45 °C for 16 hours, after which time the 
solvent was removed in vacuo and the crude material was purified by recrystallisation or flash 
silica chromatography. 
Isoquinolin-1(2H)-one 168 
 
The product was triturated with a 2:1 mixture of Et2O–MeOH (5 mL) and 
crystallised from MeOH.  The desired compound was isolated as a colourless 
solid (126 mg, 87%) from N-(pivaloyloxy)benzamide (221 mg, 1.00 mmol) 
following general procedure C. δH (500 MHz, DMSO-d6) 11.25 (1H, br s, NH), 8.19 (1H, d, J 
9.0, H8), 7.69-7.66 (2H, m, H6 and H5), 7.65-7.47 (1H, m, H7), 7.19 (1H, d, J 9.0, H3), 6.54 (1H, 
d, J 9.0, H4); δC (75 MHz, DMSO-d6) 161.8 (C1), 137.8 (Cq), 132.3 (C6), 128.9 (C3), 126.6 (C8), 
126.3 (C5 or C7), 126.2 (C5 or C7), 126.0 (Cq), 104.6 (C4); HRMS (ESI+): m/z calculated for 
formula C9H8NO [MH+]: 146.0600; found 146.0606; IR (νmax, solid, cm-1): 3286, 3158, 2852, 
1633, 1548, 1475, 1343, 1228. Spectral data consistent with the literature.35  
6-Cyanoisoquinolin-1(2H)-one 169 
 
The product was triturated with a 2:1 mixture of Et2O–MeOH (5 mL) and 
crystallised from MeOH.  The desired compound was isolated as a pale 
yellow solid (68 mg, 81%) from 4-cyano-N-(pivaloyloxy)benzamide 
(120 mg, 0.49 mmol) following general procedure C.  M.p. 307-312 °C (MeOH); δH (300 MHz, 
DMSO-d6) 11.62 (1H, s, NH), 8.28 (1H, d, J 8.4, H8), 8.25 (1H, s, H5), 7.81 (1H, dd, J 8.3, 1.4, 
H7), 7.35-7.29 (1H, m, H3), 6.62 (1H, d, J 7.1, H4); δC (75 MHz, DMSO-d6) 160.9 (C1), 137.9 
(Cq), 131.3 (C3), 131.0 (C5), 128.4 (Cq), 128.0 (C7), 127.9 (C8), 118.3 (CN), 114.6 (C6), 103.6 
(C4); HRMS (ESI+): m/z calculated for formula C10H7N2O [MH+] 171.0553; found 171.0575; IR 
(νmax, solid, cm-1): 3307, 2227, 1652, 1539, 1498, 1460, 1337, 1235.  
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6-Acetylisoquinolin-1(2H)-one 170 
 
The product was filtered from the crude reaction mixture and washed with 
MeOH–Et2O (1:4) (5 mL).  The desired compound was isolated as a tan 
amorphous solid (48 mg, 99%) from 4-acetyl-N-(pivaloyloxy)-benzamide 
(68 mg, 0.25 mmol) following general procedure C.  δH (300 MHz, DMSO-d6) 11.79 (1H, s, 
NH), 8.28 (1H, d, J 1.2, H5), 8.26 (1H, d, J 8.3, H8), 7.93 (1H, dd, J 8.3, 1.2, H7), 7.29 (1H, d, J 
7.1, H3 ), 6.68 (1H, d, J 7.1, H4), 2.67 (3H, s, COCH3); δC (75 MHz, DMSO-d6) 198.0 (COCH3), 
161.4 (C1), 139.3 (Cq), 138.0 (Cq), 130.1 (C3), 128.6 (Cq), 127.2 (C7), 127.1 (C5), 124.5 (C8), 
104.8 (C4), 27.0 (COCH3); HRMS (ESI+): m/z calculated for formula C11H10NO2 [MH+] 
188.0706; found 188.0699; IR (νmax, solid, cm-1): 3299, 2911, 1751, 1692, 1542, 1461, 1347, 
1267, 1186. 
6-(Trifluoromethyl)isoquinolin-1(2H)-one 171 
 
The product was triturated with a 2:1 mixture of Et2O–MeOH (5 mL) and 
crystallised from CHCl3.  The desired compound was isolated as a pale 
yellow crystalline solid (151 mg, 71%) from 4-trifluoromethyl-N-
(pivaloyloxy)benzamide (289 mg, 1.00 mmol) following general procedure C.  RF 0.2 (50% 
EtOAc in hexane); M.p. 176-181 °C (CHCl3); δH (300 MHz, CDCl3) 11.6 (1H, br s, NH), 8.53 
(1H, d, J 8.4, H8), 7.86 (1H, s, H5), 7.71 (1H, dd, J 8.4, 1.4, H7), 7.29 (1H, d, J 7.1, H3), 6.65 
(1H, d, J 7.1, H4); δC (75 MHz, CDCl3) 163.7 (C1), 138.2 (Cq), 134.5 (q, J 32.4, C6), 129.3 (C3), 
128.6 (C8), 128.3 (Cq) 123.8 (q, J 272.9, CF3), 123.8 (q, J 3.9, C5), 123.0 (q, J 3.2, C7), 106.6 
(C4); HRMS (ESI+): m/z calculated for formula C10H7F3NO [MH+] 214.0474; found 214.0475; 
IR (νmax, solid, cm-1): 3299, 2911, 1751, 1692, 1542, 1461, 1347, 1267, 1186. 
6-Methoxyisoquinolin-1(2H)-one 172 
 
Vinyl acetate (138 µL, 1.50 mmol) was added to a solution of [Cp*RhCl2]2 
(6 mg, 0.01 mmol), CsOAc (58 mg, 0.3 mmol) and 4-methoxy-N-
(pivaloyloxy)benzamide (251 mg, 1.00 mmol) in MeOH (2.5 mL, 0.4 M) in 
a vial under a nitrogen atmosphere.  The reaction was heated to 30 °C for 16 hours, after which 
time the solvent was removed in vacuo. The product was isolated by flash column 
chromatography using a solvent gradient of 50% EtOAc in hexane followed by a solvent swap 
to 5% MeOH in DCM.  The product was crystallised from EtOAc to afford colourless 
crystalline needles (110 mg, 63%).  M.p. 179-181 °C (EtOAc); δH (300 MHz, CDCl3) 11.12 
(1H, br s, NH), 8.33 (1H, d, J 8.9, H8), 7.15 (1H, d, J 7.1, H3), 7.08 (1H, dd, J 8.9, 2.5, H7), 6.91 
(1H, d, J 2.5, H5), 6.48 (1H, d, J 7.2, H4), 3.92 (3H, s, OMe); δC (75 MHz, CDCl3) 163.9 (CqO), 
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163.0 (CqO), 140.3 (Cq), 129.3 (C8), 128.3 (C3), 116.5 (C7), 107.0 (C5), 106.4 (C4), 55.5 (OMe), 
missing a quaternary carbon; HRMS (ESI+): m/z calculated for formula C10H9NNaO2 [MNa+] 
198.0525; found 198.0529; IR (νmax, solid, cm-1): 3162, 1605, 1468, 1231. 
6-Fluoroisoquinolin-1(2H)-one 173 
 
The product was triturated with a 4:1 mixture of Et2O–MeOH (5 mL) and 
crystallised from acetone.  The desired compound was isolated as pale yellow 
crystalline needles (40 mg, 71%) from 4-fluoro-N-(pivaloyloxy)-benzamide 
(239 mg, 1.00 mmol) following general procedure C.  M.p. 207-210 °C (acetone); δH (300 
MHz, DMSO-d6) 11.34 (1H, br s, NH), 8.22 (1H, dd, J 8.8, 6.1, H8), 7.49 (1H, dd, J 10.1, 2.5, 
H5), 7.32-7.27 (1H, m, H7), 7.23 (1H, d, J 7.1, H3), 6.54 (1H, d, J 7.2, H4); δC (75 MHz, DMSO-
d6) 164.3 (d, J 249.2, C6), 161.2 (C1), 140.3 (d, J 10.8, Cq), 130.5 (C3), 130.1 (d, J 10.3, C8), 
122.9 (d, J 1.5, Cq), 114.7 (d, J 23.7, H7), 110.9 (d, J 21.9, H5), 104.1 (d, J 3.1, H4); HRMS 
(ESI+): m/z calculated for formula C9H6FNNaO [MNa+] 186.0326; found 186.0323; IR (νmax, 
solid, cm-1): 3392, 2968, 1669, 1551, 1408, 1015.  Spectral data consistent with the literature.99  
6-Bromoisoquinolin-1(2H)-one 174 
 
The product was isolated by flash column chromatography using 50% EtOAc 
in hexane.  The desired compound was isolated as a colourless solid (186 mg, 
70%) from 4-bromo-N-(pivaloyloxy) benzamide (300 mg, 1.00 mmol) following general 
procedure C.  RF 0.4 (50% EtOAc in hexane). δH (300 MHz, DMSO-d6) 11.36 (1H, br s, NH), 
8.07 (1H, d, J 8.5, H8), 7.94 (1H, s, H5), 7.61 (1H, dd, J 8.5, 1.4, H7), 7.28-7.18 (1H, m, H3), 
6.52 (1H, d, J 7.1, H4); δC (75 MHz, CDCl3) 161.4 (C1), 139.6 (Cq), 130.5 (C7), 129.2 (C5), 
129.0 (C8), 128.4 (C3), 126.3 (C6), 124.9 (Cq), 103.6 (C4); HRMS (ESI+): m/z calculated for 
formula C9H679BrNNaO [MNa+] 245.9525; found 247.9505; IR (νmax, solid, cm-1): 2735, 1665, 
1632, 1239.  Spectral data consistent with the literature.246  
 
6-Iodoisoquinolin-1(2H)-one 175 
 
The product was triturated with a 2:1 mixture of Et2O–MeOH (5 mL) and 
crystallised from MeOH.  The desired compound was isolated as a cream 
amorphous solid (211 mg, 83%) from 4-iodo-N-(pivaloyloxy)-benzamide 
(347 mg, 1.00 mmol) following general procedure C.  M.p. decomposed at 231 °C (MeOH);  δH 
(300 MHz, DMSO-d6) 11.35 (1H, br s, NH), 8.12 (1H, s, H5), 7.90 (1H, d, J 8.4, H8), 7.78 (1H, 
d, J 8.2, H7), 7.20-7.18 (1H, m, H3), 6.49 (1H, d, J 7.1, H4); δC (75 MHz, DMSO-d6) 161.6 (C1), 
139.5 (Cq), 134.8 (C7), 134.5 (C5), 130.2 (C8), 128.5 (C3), 125.1 (Cq), 103.3 (C4), 100.7 (C6); 
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HRMS (ESI+): m/z calculated for formula C9H7INO [MH+] 271.9567; found 271.9571; IR (νmax, 
solid, cm-1): 3012, 2851, 1659, 1633, 1587, 1494, 1237. 
tert-Butyl (1-oxo-1,2dihydroisoquinolin-7-yl) carbamate 188a 
 
The product was purified by trituration with a 4:1 mixture of 
pentane–ethanol (5 mL) to afford a colourless amorphous solid 
(81 mg, 81%) from tert-butyl (3-((pivaloyloxy)carbamoyl)phenyl) 
carbamate (260 mg, 1.00 mmol) following general procedure C.  δH (300 MHz, DMSO-d6) 
11.10 (1H, br s, NH), 9.61 (1H, s, NH), 8.37 (1H, d, J 1.7, H8), 7.70 (1H, dd, J 8.6, 2.2, H6), 
7.54 (1H, d, J 8.6, H5), 7.08-6.97 (1H, m, H3), 6.45 (1H, d, J 7.0, H4), 1.50 (9H, s, O(CH3)3);  
δC (75 MHz, DMSO-d6) 161.6 (CO2C(CH3)3), 152.7 (C1), 137.9 (Cq), 132.6 (Cq), 126.8 (C3), 
126.7 (C5), 126.6 (Cq), 123.5 (C6), 114.2 (C8), 104.4 (C4), 79.3 (CO2C(CH3)3), 28.1 
(CO2C(CH3)3); HRMS (ESI+): m/z calculated for formula C14H16N2NaO3 [MNa+] 283.1053; 
found 283.1054; IR (νmax, solid, cm-1): 3355, 2993, 2980, 2932, 2834, 1694, 1663, 1564, 1522, 
1250, 1167. 
7-Phenylisoquinolin-1(2H)-one 189a 
 
The product was triturated with a 2:1 mixture of Et2O–MeOH (5 mL) and 
crystallised from EtOAc–hexane to afford pale yellow crystals (101 mg, 
91%) from N-(pivaloyloxy)(1,1’-biphenyl)-3-carboxamide (150 mg, 
0.50 mmol) following general procedure C. m.p. 223-226 °C (EtOAc–hexane); δH (300 MHz, 
CDCl3) 10.29 (1H, s, NH), 8.66 (1H, d, J 2.0, H8), 7.95 (1H, dd, J 8.3, 2.0, H6), 7.72 (2H, d, J 
7.1, H2’), 7.65 (1H, d, J 8.3, H5), 7.48-7.46 (3H, m, H3’ and H4’), 7.11 (1H, d, J 7.4, H3), 6.62 
(1H, d, J 7.4, H4); δC (75 MHz, CDCl3) 164.0 (C1), 140.0 (Cq), 139.9 (Cq), 137.2 (Cq), 131.8 
(C6), 129.1 (2C3’), 127.9 (C3), 127.5 (C8 or C4’), 127.4 (2C2’), 127.0 (C8 or C4’), 126.7 (Cq), 
125.5 (C5), 106.6 (C4); HRMS (ESI+): m/z calculated for formula C15H11NNaO [MNa+] 
244.0733; found 244.0724; IR (νmax, solid, cm-1): 3159, 2907, 1654, 1449, 1223. 
7-Bromoisoquinolin-1(2H)-one 190a 
 
A mixture of regioisomers were isolated from 3-bromo-N-
(pivaloyloxy)benzamide (300 mg, 1.00 mmol) following general procedure C.  
The products were isolated as an inseparable mixture of 7- and 5-
bromoisoquinolin-1(2H)-one, as a yellow amorphous solid, (9:1, 215 mg, 95%) following 
purification by flash column chromatography using 30% EtOAc in hexane as an eluent.  δH (500 
MHz, DMSO-d6) δ 11.42 (1H, s, NH), 8.25 (1H, d, J 2.1, H8), 7.84 (1H, dd, J 8.5, 2.2, H6), 7.64 
(1H, d, J 8.5, H5), 7.22 (1H, dd, J 6.8, 5.7, H3), 6.56 (1H, d, J 7.1, H4); δC (125 MHz, DMSO-d6) 
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161.4 (C1), 139.6 (Cq), 130.7 (C6), 129.2 (C3), 129.0 (C8), 128.4 (C5), 126.4 (Cq), 124.9 (Cq), 
103.6 (C4); HRMS (ESI+): m/z calculated for formula C9H779BrNO [MH+] 223.9706; found 
223.9703; IR (νmax, solid, cm-1): 3152, 3002, 2923, 1660, 1223. Spectral data consistent with 
literature values.247 
7-Chloroisoquinolin-1(2H)-one 191a 
The precipitate was filtered from the reaction and washed with a solution of 
pentane–MeOH (5 mL, 4:1).  The cream amorphous solid was recrystallised 
from isopropanol to afford a colourless crystalline solid (119 mg, 66%), from 3-chloro-N-
(pivaloyloxy)benzamide (256 mg, 1.00 mmol) following general procedure C.  The 
regioisomeric ratio of 7-chloroisoquinolin-1-(2H)-one compared with 5-chloroisoquinolin-1-
(2H)-one varied during the purification: crude reaction (4:1, 7-:5-), upon filtration (4:1, 7-:5-) 
and after crystallisation (98:2, 7-:5-).  M.p. decomposed at 190 °C (isopropanol); δH (300 MHz, 
DMSO-d6) 11.42 (1H, s, NH), 8.11 (1H, d, J 0.9, H7), 7.76-7.68 (2H, m, H5 and H6), 7.21 (1H, 
d, J 7.1, H3), 6.58 (1H, d, J 7.2, H4); δC (75 MHz, DMSO-d6) 160.8 (C1), 136.6 (Cq), 132.5 (C6), 
130.8 (Cq), 129.5 (C3), 128.6 (C5), 127.2 (C7), 125.7 (C8), 104.1 (C4); HRMS (ESI+): m/z 
calculated for formula C9H735ClNO [MH+] 180.0211; found 180.0208; IR (νmax, solid, cm-1): 
2998, 2914, 2855, 2704, 1659, 1632, 1602, 1541, 1493, 1472, 1430, 1344, 1298, 1233, 1152, 
1103, 1087, 1060. 
5-Chloroisoquinolin-1-(2H)-one 191b 
For reference from signals visible in the 1H NMR:  δH (300 MHz, DMSO-d6) 
11.42 (1H, s, NH), 8.17 (1H, d, J 7.0, H8), 7.84 (1H, dd, J 7.8, 1.1, H6), 7.47 
(1H, t, J 8.2, H7), 7.33 (1H, d, J 7.4, H3), 6.69 (1H, d, J 7.4, H4). 
7-Fluoroisoquinolin-1(2H)-one 192a and 5-fluoroisoquinolin-1(2H)-one 192b 
 
The products were isolated by trituration with a 9:1 mixture of 
pentane–ethanol (5 mL), the material was then recrystallised 
from acetone.  The desired compounds were isolated, as an 
inseparable mixture of regioisomers, as a colourless crystalline powder (170 mg, 71%, 2:1, 5-:7) 
from 3-fluoro-N-(pivaloyloxy)benzamide (588 mg, 1.50 mmol) following general procedure C. 
δH (300 MHz, acetone-d6) 10.35 (1H, br s, NH major and minor), 8.12-8.07 (0.66H, m, ArH 
major), 7.90 (0.33H, dd, J 9.6, 2.6, H8 minor), 7.74 (0.33H, dd, J 8.8, 5.2, H6 minor), 7.55 
(0.33H, peak obscured, H5 minor), 7.49 (1.32H, dd, J 8.4, 3.7, ArH major), 7.33 (0.66H, d, J 
7.3, H3 major), 7.23 (0.33H, d, J 7.4, H3 minor), 6.63 (0.66H, d, J, H4 major), 6.58 (0.33H, d, J 
7.4, H4 minor).  1H NMR consistent with the literature.10 δH (300 MHz, DMSO-d6) major signals 
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only 11.49 (1H, s, NH), 8.01 (1H, d, J 7.9, H8), 7.62-7.53 (1H, m, H6), 7.48 (1H, td, J 8.0, 5.5, 
H7), 7.33-7.23 (1H, m, H3), 6.58 (1H, d, J 7.2, H4); δC (75 MHz, DMSO-d6) 160.7 (d, J 2.9, Cq-
O), 156.9 (d, J 248.6, C-F), 130.1 (C3), 127.8 (d, J 4.0, Cq), 126.9 (Cq), 126.7 (d, J 7.9, C7), 
122.7 (d, J 3.6, C8), 117.2 (d, J 19.6, C6), 96.4 (d, J 5.7, C4). HRMS (ESI+): m/z calculated for 
formula C9H6FNNaO [MNa+] 186.0326; found 186.0318; IR (νmax, solid, cm-1): 3162, 2999, 
2861, 1633, 1549, 1480, 1352, 1247. 
 
7-Methoxyisoquinolin-1(2H)-one 193a and 5-methoxyisoquinolin-1(2H)-one 193b 
 
The products were isolated by flash column chromatography 
using 1% MeOH in EtOAc to afford an amorphous off-white 
solid containing an inseparable 3:2 mixture of 7-
methoxyisoquinolin-1(2H)-one 193a and 5-methoxyisoquinolin-1(2H)-one 193b (172 mg, 98%) 
from 3-methoxy-N-(pivaloyloxy)benzamide (251 mg, 1.00 mmol) following general 
procedure C. 13C spectral values consistent with the literature100 in CDCl3  however data 
reported below for spectra measured in MeOD-d4, which gave better signal separation.  δH (500 
MHz, MeOD-d4) missing NH peak, 7.86 (0.4H, d, J 8.1, H6 minor), 7.74 (0.6, d, J 2.6, H8 -
major), 7.59 (0.6H, d, J 8.7, H5 major), 7.46 (0.4H, t, J 8.1, H7 minor), 7.34 (0.6H, dd, J 8.7, 
2.7, H6 major), 7.23 (0.4H, d, J 8.3, H8 minor), 7.15 (0.4H, d, J 7.2, H3 minor ), 7.07 (0.6H, d, J 
7.1, H3 major), 6.96 (0.4H, d, J 7.3, H4 minor ), 3.97 (1.2H, s, OMe minor), 3.91 (1.8H, s, 3H, 
OMe major); δC (75 MHz, MeOD-d4) 164.8 (Cq), 160.3 (Cq), 156.1 (Cq), 134.0 (Cq), 130.8 (Cq), 
129.2 (C5 major), 128.3 (C7 minor), 128.2 (Cq), 128.0 (C3 minor), 126.4 (C3 major), 124.3 (C6 
major), 119.4 (C6 minor), 113.1 (C8 minor), 107.9 (C4 major and C8 major), 102.2 (C4 minor), 
56.4 (OMe), 56.0 (OMe). IR (νmax, solid, cm-1): 2828, 1653, 1258, 1057; HRMS (ESI+): m/z 
calculated for formula C10H10NO2 [MH+] 176.0706; found 176.0711.   
 
[1,3]-Dioxolo[4,5-f]isoquinolin-6(7H)-one 194b  
 
The product was filtered from the cooled reaction mixture and subsequently 
washed with a 3:7 mixture of MeOH–Et2O (5 mL).  The desired compound 
was isolated as a cream amorphous solid (101 mg, 53%) from 
N-(pivaloyloxy)benzo[d][1,3]dioxole-5-carboxamide (265 mg, 1.00 mmol) following general 
procedure C.  δH (300 MHz, CDCl3) 11.04 (1H, s, NH), 7.79 (1H, d, J 8.5, H5), 7.19-7.07 (2H, 
m, H4 and H8), 6.34 (1H, d, J 7.2, H9), 6.22 (2H, s, OCH2O); δC (75 MHz, CDCl3) 161.0 (C6), 
149.1 (CqO), 140.9 (CqO), 129.7 (C8), 121.0 (C5), 121.6 (Cq), 121.1 (Cq), 108.2 (C4), 102.3 
(O(CH2)2O), 96.9 (C9); HRMS (ESI+): m/z calculated for formula C10H8NO3  [MH+] 190.0499 
and C10H7NNaO3 [MNa+] 212.0318; found 190.0507 and 212.0315; IR (νmax, solid, cm-1): 3282, 
2844, 1688, 1663, 1633, 1442, 1270, 1236, 1048, 944. 
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2,3-Dihydro-[1,4]dioxino[2,3-f]isoquinolin-7(8H)-one 195b 
 
The product was triturated with a 9:1 mixture of pentane–ethanol (5 mL), then 
crystallised from EtOH.  The desired compound was isolated as a tan 
microcrystalline powder (97 mg, 48%) from N-(pivaloyloxy)-2,3-
dihydrobenzo[b][1,4]dioxine-6-carboxamide (279 mg, 1.00 mmol) following 
general procedure C.  M.p. decomposed at 225 °C (EtOH); 1H NMR (300 MHz, DMSO-d6) δ 
11.08 (1H, br s, NH), 7.67 (1H, d, J 8.8, H6), 7.12 (1H, dd, J 7.0, 5.6, H9), 6.99 (1H, d, J 8.8, 
H5), 6.54 (1H, d, J 7.3, H10), 4.42-4.31 (4H, m, O(CH2)2O); δC (75 MHz, DMSO-d6) 161.2 (C7), 
145.0 (CqO), 136.5 (CqO), 129.0 (C9), 128.9 (Cq), 120.2 (Cq), 119.7 (C6), 116.5 (C5), 97.6 (C10), 
64.2 (CH2), 64.1(CH2); HRMS (ESI+): m/z calculated for formula C11H10NO3[MH+] 204.0655; 
found 204.0649; IR (νmax, solid, cm-1): 3259, 2980, 1655, 1603, 1462, 1286, 1088. 
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Heterocyclic Pyridones 
Thieno[2,3-c]pyridin-7(6H)-one 204 
 
The product was purified by flash column chromatography using a solvent 
gradient of 10-100% EtOAc in hexane.  The desired compound was isolated as a 
colourless solid (74 mg, 49%) from N-(pivaloyloxy)thiophene-2-carboxamide 
(227 mg, 1.00 mmol) following general procedure C.  A sample was taken and crystallised from 
CDCl3.  M.p.  186-189 °C (CDCl3, [lit. value 195 °C]248); δH (300 MHz, CDCl3) 12.68 (1H, s, 
NH), 7.69 (1H, d, J 5.2, H2), 7.29 (1H, d, J 6.9, H5), 7.21 (1H, d, J 5.2, H3), 6.70 (1H, d, J 6.9, 
H4); δC (75 MHz, CDCl3) 161.4 (C7), 146.9 (Cq), 133.6 (C2), 129.5 (Cq), 129.4 (C5), 124.6 (C3), 
104.0 (C4); HRMS (ESI+): m/z calculated for formula C7H5NNaOS [MNa+] 173.9984; found 
174.0008; IR (νmax, solid, cm-1): 3100, 1627, 1526, 1480. 
Benzo[4,5]thieno[2,3-c]pyridine-1(2H)-one 205 
 
The product was isolated by trituration with MeOH (0.5 mL).  The desired 
compound was isolated as a colourless amorphous solid (23 mg, 64%) from N-
(pivaloyloxy)-benzo[b]thiophene-2-carboxamide (50 mg, 0.18 mmol) 
following general procedure C.  δH (300 MHz, DMSO-d6) 11.87 (1H, br s, NH), 8.33 (1H, d, J 
7.6, H8), 8.13 (1H, d, J 7.8, H5), 7.63 (1H, t, J 7.8, H6), 7.54 (1H t, J 7.8, H7), 7.49 (1H, d, J 6.8, 
H3), 7.20 (1H, d, J 6.8, H4); δC (75 MHz, DMSO-d6) 158.8 (CqO), 142.1 (SCq), 140.9 (SCq), 
135.0 (Cq), 131.4 (C3), 128.4 (Cq), 128.2 (C6), 125.0 (C7), 123.9 (C8), 123.6 (C5), 100.1 (C4); 
HRMS (ESI+): m/z calculated for formula C11H8NOS [MH+] 202.0321; found 202.0314; IR 
(νmax, solid, cm-1): 2949, 1652, 1610, 1464, 1235, 1056. 
Benzofuro[2,3-c]pyridine-1(2H)-one 206   
 
The reaction was heated to 45 °C for 48 hours, after which time the solvent 
was removed in vacuo. The product was triturated with a 1:4 mixture of 
MeOH–Et2O (5 mL) and subsequently crystallised from sec-butanol.  The 
desired compound was isolated as a colourless solid (70 mg, 38%) from N-
(pivaloyloxy)benzo[b]furan carboxamide (261 mg, 1.00 mmol) following general procedure C.  
M.p. decomposed above 260 °C (sec-butanol), (literature value 276 °C (ethanol));249  δH (300 
MHz, DMSO-d6) 11.90 (1H, br s, NH), 8.14 (1H, d, J  7.8, H5), 7.80 (1H, d, J 8.3, H8), 7.62 
(1H, t, J 7.4, H6), 7.45 (1H, t, J 7.7, H7), 7.36 (1H, d, J 6.7, H3), 6.99 (1H, d, J 6.7, H4); 
δC (75 MHz, DMSO-d6) 155.7 (CqO), 153.7 (CqO), 143.8 (CqO), 130.2 (C3), 129.5 (Cq), 129.0 
(C6), 123.7 (C7), 122.9 (Cq), 122.5 (C5), 112.5 (C8), 98.4 (C4); HRMS (ESI+): m/z calculated for 
NH
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formula C11H7NNaO2 [MNa+] 208.0369; found 208.0363; IR (νmax, solid, cm-1): 2876, 1699, 
1572, 1473, 1184. 
9-Methyl-2,9-dihydro-1H-pyrido[3,4-b]indol-1-one 207 
 
The product was isolated by flash silica chromatography using an eluent of 0-
100% EtOAc in hexane then recrystallised from CDCl3–Et2O.  The desired 
compound was isolated as a colourless solid (17 mg, 11%) from 1-methyl-N-
(pivaloyloxy)-1H-indole-2-carboxamide (214 mg, 0.78 mmol) following general procedure C.  
M.p. decomposed above 260 °C (CDCl3–Et2O); δH (500 MHz, CDCl3) 11.35 (1H, br s, NH), 
7.98 (1H, d, J 8.0, H5), 7.54 (1H, t, J 7.5, H7), 7.48 (1H, d, J 8.4, H8), 7.28 (1H, t, J 7.4, H6), 
7.13 (1H, d, J 6.8, H3), 6.99 (1H, d, J 6.7, H4), 4.36 (3H, s, NMe); δC (126 MHz, CDCl3) 158.2 
(CO), 141.1 (Cq), 127.3 (Cq), 127.1 (C7), 126.2 (Cq), 124.2 (C3), 121.7 (Cq), 121.5 (C5), 120.2 
(C6), 110.2 (C8), 101.4 (C4), 31.5 (NMe); HRMS (ESI+): m/z calculated for formula C12H11N2O 
[MNa+] 199.0866; found 199.0861; IR (νmax, solid, cm-1): 3140, 2955, 2854, 1642, 1458, 1351, 
1329, 1226. 
Benzo[b][1,6]naphthyridin-1(2H)-one 208 
 
After filtration from the reaction solution the solid precipitate was washed 
with a 1:4 mixture of EtOH–pentane (1 mL) and subsequently crystallised 
from isopropanol.  The desired compound was isolated as a colourless solid 
(24 mg, 51%) from N-(pivaloyloxy)isoquinoline-3-carboxamide (65 mg, 0.24 mmol) following 
general procedure C.  M.p. 288 °C (isopropanol, [lit. decomposed above 290 °C (DMF)]250); δH 
(300 MHz, DMSO-d6) 11.37 (1H, br s, NH), 9.25 (1H, s, H10), 8.24 (1H, d, J 7.9, H9), 8.06 (1H, 
d, J 8.5, H6), 7.90 (1H, t, J 8.5, H7), 7.63 (1H, t, J 7.5, H8), 7.47 (1H, dd, J 7.4, 5.8, H3), 6.68 
(1H, d, J 7.5, H4); δC (75 MHz, DMSO-d6) 162.5 (C1), 153.2 (Cq), 150.3 (Cq), 137.5 (C10), 133.5 
(C7), 132.4 (C3), 129.6 (C9), 128.1 (C6), 126.0 (C8), 125.9 (Cq), 120.8 (Cq), 106.1 (C4); HRMS 
(ESI+): m/z calculated for formula C12H9N2O [MH+] 197.0709; found 197.0704; IR (νmax, solid, 
cm-1): 3166, 3029, 2930, 1661, 1614, 1587, 1499, 1202. 
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Hepatitis C inhibitor intermediates 
 
3-Bromo-4-methoxy-N-(pivaloyloxy)benzamide 226  
 
Oxalyl chloride (480 µL, 5.50 mmol) was added to a solution of 3-
bromo-4-methoxybenzoic acid (1.16 g, 5.00 mmol) in DCM (25 mL, 
0.20 M) with cat. DMF.  The mixture was stirred at room 
temperature for 2 hours, then concentrated in vacuo to afford the crude acid chloride.  The crude 
acid chloride was diluted in EtOAc (5 mL) and transferred to a flask containing O-(pivaloyl)-
hydroxylamine triflic acid34 (1.47 g, 5.50 mmol) and NaHCO3 (840 mg, 10.0 mmol) dissolved 
in a 2:1 mixture of EtOAc–H2O (45 mL, 0.1 M) at 0 °C.  After 2 hours the reaction was 
quenched with sat. NaHCO3 (50 mL) and diluted with EtOAc (50 mL).  The two phases were 
separated and the organic layer was washed with brine (50 mL).  The organic layer was dried 
over MgSO4 and concentrated in vacuo to give 3-bromo-4-methoxy-N-(pivaloyloxy)benzamide 
(1.65g, quant.) (>95% pure by 1H NMR). A sample of the crude product (1 g) was purified by 
crystallisation from Et2O–pentane, recovery (0.65 g). RF 0.7 (33% EtOAc in pentane); M.p. 94-
96 °C (Et2O–pentane); δH (500 MHz, CDCl3) 9.65 (1H, br s, NH), 7.99 (1H, d, J 2.2, H6), 7.72 
(1H, dd, J 8.6, 2.2, H2), 6.86 (1H, d, J 8.6, H3), 3.91 (3H, s, OMe), 1.33 (9H, s, (CH3)3); δC (125 
MHz, CDCl3) 177.2 (CqO), 165.3 (C4-OMe), 159.3 (CqO), 132.9 (C2) 128.5 (C6), 124.3 (C1), 
112.0 (C3), 111.5 (C5), 56.5 (OMe), 38.6 (Cq(CH3)3), 27.1 ((CH3)3); HRMS (ESI+): m/z 
calculated for formula C13H1779BrNO4 [MH+] 330.0335; found 330.0335; IR (νmax, solid, cm-1): 
3167, 2976, 1772, 1648, 1597, 1560, 1510, 1481, 1461, 1443, 1397, 1370, 1311, 1268. 
 
7-Bromo-6-methoxyisoquinolin-1(2H)-one 147  
 
Vinyl acetate (69 µL, 0.75 mmol) was added to a solution of [Cp*RhCl2]2 
(3 mg, 5 µmol), CsOAc (28 mg, 0.15 mmol) and 3-bromo-4-methoxy-N-
(pivaloyloxy)benzamide (165 mg, 0.5 mmol) in MeOH (1.25 mL, 0.4 M) in 
a vial under a nitrogen atmosphere.  The reaction was heated to 30 °C for 16 hours, after which 
time the solvent was removed in vacuo. The product was triturated with a 1:4 mixture of 
MeOH–Et2O (2 mL) to afford a cream amorphous solid (108 mg, 85%).  A sample was 
crystallised from THF to afford colourless crystals.  RF 0.12 (33% EtOAc in pentane); M.p 
decomposed at 250 °C (THF); δH (500 MHz, DMSO-d6) 11.23 (1H, br s, NH), 8.26 (1H, s, H8), 
7.29 (1H, s, H5), 7.18 (1H, dd, J 6.7, 6.6, H3), 6.51 (1H, d, J 7.1, H4), 3.97 (3H, s, OMe); δC 
(125 MHz, DMSO) 160.5 (C6), 158.0 (C1), 139.3 (Cq), 131.1 (C8), 130.2 (C3), 120.7 (Cq), 110.2 
(C7), 107.6 (C5), 104.1 (C4), 56.6 (OMe); HRMS (ESI+): m/z calculated for formula 
Br
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C10H979BrNO2 [MH+] 253.9811; found 253.9812; IR (νmax, solid, cm-1): 2896, 2834, 1647, 1631, 
1594, 1494, 1464, 1449, 1426, 1381, 1346, 1279, 1256, 1246, 1219. 
 
4-Hydroxyisoquinolin-1(2H)-one 217 
 
Vinylene carbonate (95 µL, 1.5 mmol) was added to a solution of 
N-(pivaloyloxy)benzamide (221 mg, 1.00 mmol), CsOAc (57 mg, 0.30 mmol) 
and [Cp*RhCl2]2 (6 mg, 0.01 mmol)  in MeOH (5 mL, 0.2 M).  The solution was 
heated to 45 °C for 5 hours during which time a pale pink solid precipitated from the reaction.  
The MeOH was removed in vacuo and the solid was triturated with cold EtOH–diethyl ether 
(9:1, 10 mL) and the solid was filtered and collected under reduced pressure to afford a pale 
brown amorphous solid (126 mg, 78%). δH (300 MHz, DMSO-d6) 10.65 (1H, s, NH), 9.02 (1H, 
s, OH), 8.17 (1H, d, J 8.0, H8), 7.84 (1H, d, J 8.0, H5), 7.73 (1H, t, J 7.6, H6), 7.51 (1H, t, J 7.9, 
H7), 6.63 (1H, s, H3); δC (75 MHz, DMSO) 159.5 (CO), 134.8 (Cq), 133.4 (Cq), 131.7 (C6), 
126.9 (C8), 126.6 (C7), 125.9 (Cq), 121.3 (C5), 109.7 (C3); LCMS (ESI+): m/z calculated for 
formula C9H8NO2 [MH+] 162.1; found 161.9; IR (νmax, solid, cm-1): 3279, 2689, 1652, 1505, 
1343, 1241, 1083, 907, 821, 773, 675, 613, 555, 469.  Spectral data consistent with the 
literature.119  
 
4-Hydroxy-7-chloroisoquinolin-1-(2H)-one 235 
 
Vinylene carbonate (78 µL, 1.5 mmol) was added to a solution of 3-chloro-
N-(pivaloyloxy)benzamide (210 mg, 0.82 mmol), CsOAc (47 mg, 0.3 mmol) 
and [Cp*RhCl2]2 (5 mg, 0.01 mmol)  in MeOH (4.1 mL, 0.2 M).  The solution 
was heated to 45 °C for 16 hours during which time a pale pink solid precipitated from the 
reaction.  The pink solid was filtered from the reaction, and subsequently washed with a mixture 
of MeOH−Et2O (2 mL, 1:1), then ether (2 × 2 mL).  The pink solid was dried in vacuo at 80 °C 
to afford the amorphous product (104 mg, 65%). δH (300 MHz, DMSO-d6) 10.86 (1H, br s , 
NH), 9.17 (1H, s, OH), 8.11 (1H, d,  J 2.1, H8), 7.86 (1H, d, J 8.7, H5), 7.77 (1H, dd, J 8.7, 2.1, 
H6), 6.66 (1H, s, H3); δC (75 MHz, DMSO) 158.4 (C1), 134.5 (Cq), 132.1 (Cq), 132.0 (C6), 131.4 
(Cq), 127.1 (Cq), 126.0 (C8), 123.8 (C5), 110.3 (C3); LRMS (ESI+): m/z 161.9 [MH+]; IR (νmax, 
solid, cm-1): 3100, 2953, 1643, 1602, 1534, 1462, 1437, 1403, 1325, 1276, 1237, 1220, 1102, 
1073.  
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6.6 Deuterated enol carboxylate derivatives 
 
Heptan-1-ol-d2 246 
 
A suspension of LiAlD4 (203 mg, 4.80 mmol) in THF (10 mL) was cooled 
to 0 °C in a salt/ice bath.  6-Heptenoic acid (541 µL, 4.00 mmol) in THF 
(10 mL) was added dropwise to the suspension. The reaction was warmed slowly to room 
temperature and stirred for five hours.  The reaction was cooled to 0 °C and quenched with 
water (5 mL).  Diethyl ether (20 mL) and 1N HCl (20 mL) was added and the aqueous layer 
was extracted twice with diethyl ether (2 x 20 mL).  The organic layer was dried with MgSO4 
and concentrated in vacuo to give a colourless oil (395 mg, 85%, 100% D by 1H NMR).  δH 
(300 MHz, CDCl3) 5.91-5.70 (1H, m, H6), 5.07-4.89 (2H, m, H7), 2.13-2.01 (2H, m, H5), 1.57 
(2H, t, J 6.9, H2), 1.49-1.31 (4H, m, H3 and H4); δC (75 MHz, CDCl3) 138.9 (HC=CH2), 114.3 
(HC=CH2), 33.7, 22.4, 28.7, 25.2; IR (vmax, NaCl, film, cm-1) 3337, 2928, 2090, 1640, 1460, 
1134, 966, 909, 635; Unable to acquire HRMS for this sample. 
 
N-Methoxy-N-methylhept-6-enamide 247251 
 
Isobutyl chloroformate (203 µL, 1.56 mmol) was added dropwise to a 
solution of 6-heptenoic acid (211 µL, 1.56 mmol) in DCM (3 mL) with 
NEt3 (658 µL, 4.68 mmol) at -15 °C (EtOH/ice bath).  The solution was 
allowed to stir at 0 °C for 30 minutes to allow the mixed  anhydride to form.  The reaction was 
cooled again to – 20 °C (EtOH/ice bath) and N,O-dimethylhydroxylamine·HCl (197 mg, 2.03 
mmol) was added to the anhydride solution.  The reaction was allowed to warm to room 
temperature overnight.  The reaction was quenched with 1N HCl (20 mL) and the organic layer 
was washed with sat. NaHCO3 (20 mL), brine (20 mL), dried (MgSO4) and concentrated in 
vacuo.  The crude material was purified using flash silica chromatography with an EtOAc–
hexane eluent (1:1) to afford a colourless oil (256 mg, 96%).  δH (300 MHz, CDCl3) 5.82 (1H, 
ddt, J 17.0, 10.3, 6.6, H6), 5.05-4.93 (2H, m, H7), 3.69 (3H, s, NOCH3), 3.19 (3H, s, NCH3), 
2.43 (2H, t, H2), 2.12-2.05 (2H, m, H5), 1.71-1.61 (2H, m, H3), 1.50-1.39 (2H, m H4); δC (75 
MHz, CDCl3) 174.6 (CO), 138.7 (C7), 114.5 (C6), 61.2 (OMe), 33.6 (NMe), 32.2 (C2), 31.7 
(C5), 28.7 (C3), 24.1 (C4); HRMS (ESI+): m/z calculated for formula C9H17NNaO2 [MNa]+ 
194.1151; found 194.1179; IR (vmax, NaCl film, cm-1) 3494, 2937, 1667, 1415, 1177. Spectral 
data consistent with literature.251 
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Hept-6-enal-d1 244 
 
N-Methoxy-N-methylhept-6-enamide (267 mg, 1.56 mmol) in THF (10 mL) 
was added dropwise to a suspension of LiAlD4 (80 mg, 1.87 mmol) in THF 
(10 mL) at 0 °C.  The reaction was monitored by TLC.  After the starting material had been 
consumed (~3 hours) the reaction was quenched with water (5 mL).  The reaction was diluted 
with 1N HCl (20 mL) and extracted with Et2O (2 x 20 mL) and the organic phases were 
combined and washed with brine (20 mL), dried (Na2SO4) and concentrated in vacuo (<10 °C).  
At this stage an aqueous droplet formed in the solution (from dehydration of the acetal), the 
reaction was rediluted in Et2O (10 mL) and dried again using Na2SO4.  The solution was filtered 
and concentrated in vacuo to give a clear oil (150 mg, 85%, 100% D). δH (300 MHz, CDCl3) 
5.86-5.71 (1H, m, H6), 5.06-4.95 (2H, m, H7), 2.44 (2H, t, J 7.3, H2), 2.12-2.05 (2H, m, H5), 
1.71-1.61 (2H, m, H3), 1.49-1.39 (2H, m, H4); δC (75 MHz, CDCl3) 202.3 (t, J 25.9, OCq-D), 
138.2 (C7), 114.8 (C6), 43.4 (C2), 33.4 (C5), 28.3 (C3), 21.5 (C4); IR (vmax, NaCl film, cm-1) 
3077, 2931, 1736, 1641, 1439, 1261, 993, 910. Spectral data matches that of hept-6-enal (aside 
from the deuterated carbon peak).252 Unable to obtain a HRMS due to volatility of the sample. 
 
(E/Z)-Hepta-1,6-dien-1-yl hexanoate 248 
 
Following a modified procedure by Nishizawa et al.,253 KHMDS (3.3 mL, 
0.5 M solution in toluene, 1.66 mmol) was added dropwise to a solution 
of hept-6-enal-d1  (170 mg, 1.5 mmol) in THF (15 mL) at -78 °C.  
Following the addition the reaction was allowed to warm to 0 °C and 
stirred for a further half an hour.  The reaction was cooled again to -78 °C and hexanoyl 
chloride (230 µL, 1.65 mmol) was added dropwise to the solution.  The reaction was monitored 
by TLC and after 30 minutes the reaction was quenched with NaHCO3 (5 mL) and the aqueous 
solution was extracted with EtOAc (3 × 10 mL) and dried with MgSO4.  The crude reaction 
mixture was purified using a gradient of 0-5% EtOAc in hexane using flash silica 
chromatography to afford a colourless oil (100 mg, 32%, E:Z 1.8:1 ). δH (300 MHz, CDCl3) 
5.86-5.76 (1H, m, H6), 5.40 (0.64H, t, J 7.7, H2, E isomer) 5.04-4.95 (2H, m, 2H7), 4.87 (0.36 H, 
t, J 7.5, H2, Z isomer), 2.40 (0.36H, t, J 7.5, 2H2’, Z-isomer), 2.36 (1.28H, t, J 7.5, 2H2’, E-
isomer), 2.10-2.05 (2H, m, 2H5), 2.05-2.00 (1.28H, m, 2H3, E isomer), 2.16 (0.72H, q, J 7.3, 
2H3, Z isomer), 1.69-1.63 (2H, m, 2H3'), 1.49 (2H, q, J 7.5, 2H4), 1.37-1.30 (4H, m, 2H4’ and 
2H5’), 0.93-0.89 (3H, m, 3H6’); δC (75 MHz, CDCl3) 171.1 (CqO, E isomer), 170.9 (CqO, Z 
isomer), 138.5 (C6, Z isomer), 138.4 (C6, E isomer), 135.4 (C1D, t, J 17.3, E isomer), 134.0 (C1-
D, t, J 17.3, Z isomer), 114.8 (C7, E isomer), 114.6 (C7, Z isomer), 114.3 (C2, E isomer), 113.5 
(C2, Z isomer), 34.1 (C2’, Z isomer), 34.0 (C2’, E isomer), 33.0 (C5), 31.2 (C4’), 28.7 (C4), 26.6 
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(C3, E isomer), 24.4 (C3, Z isomer) 22.3 (C3' and C5') 13.9 (C6’); HRMS (ESI+): m/z calculated 
for formula C13H21DNaO2 [MNa]+ 234.1575; found 234.1565; IR (vmax, NaCl, film, cm-1) 2930, 
1751, 1652, 1458, 1160, 1114, 911; 
Vinyl N,N-diisopropylcarbamate 265 
 
Following a modified procedure by Clayden et al.,142 n-butyllithium (2.5 M in 
hexanes, 6.0 mL, 15 mmol) was added to THF (11 mL, 1.3 M) at room 
temperature.  After 16 hours N,N-diisopropyl carbamoyl chloride (1.6 g, 
10 mmol) was dissolved in DMPU (11 mL, 0.91 M) and added dropwise to a cooled solution 
(0 °C) containing the lithium ethenolate.  The reaction was warmed to room temperature over 
four hours.  The reaction was quenched with saturated NH4Cl and extracted with Et2O (3 x 25 
mL).  The organic layer was washed with water and dried over Na2SO4.  The solvent was 
removed in vacuo and purified by flash silica chromatography using 33% EtOAc in hexane to 
afford a clear oil (1.42 g, 83%).  RF 0.84 (50% EtOAc in hexane);  δH (300 MHz, CDCl3) 7.26 
(1H, dd, J  14.7, 5.6, C=CH-O), 4.77 (1H, dd, J 14.0, 1.4, OC=CH trans), 4.43 (1H, dd, J 6.3, 
1.4, OC=CH cis), 4.07 (1H, br s, CH-(Me)2), 3.86 (1H, br s, CH-(Me)2), 1.25 (12H, d, J 6.7, 
Me); δC (75 MHz, CDCl3) 152.7 (CO), 142.3 (C=C-O), 94.5 (C=C-O), 46.7 (C(Me)2), 45.8 
(C(Me)2), 20.4 (Me), 19.4 (Me); IR (νmax, film, cm-1): 3417, 2972, 1713, 1646, 1436, 1371, 
1316, 1144, 1048; HRMS (ESI+): m/z calculated for formula C9H18NO2 [MH+] 172.1332; found 
172.1328.  The 1H NMR spectral data corresponds to the literature values.254 
 
Vinyl N,N-diisopropylcarmabate-d1 265-d1 
 
sec-Butyllithium (1.4 M in hexanes, 1.40 mL, 1.90 mmol) was added dropwise 
to a solution of TMEDA (290 mL, 1.93 mmol) in THF (2 mL) at -78 °C.  After 
ten minutes O-vinyl-N,N-diisopropylcarbamate (300 mg, 1.75 mmol)  was 
added to the yellow solution.  After two hours at -78 °C, the reaction was quenched with DCl in 
D2O (35% wt solution, 100 mL, 2.47 mmol) and the solution was allowed to warm to room 
temperature.  The reaction was diluted with water and the product was extracted with Et2O (3 x 
20 mL).  The organic layers were combined and washed with brine (30 mL) and dried over Na2-
SO4.  The crude material was passed through a silica plug to remove base line impurities using 
50% EtOAc in hexane.  The solvent was concentrated in vacuo to afford a colourless oil (288 
mg, 96%, 87% D by 1H NMR).  RF 0.84 (50% EtOAc in  hexane);  δH (500 MHz, CD3CN) 7.20 
(0.13 H, dd, J 14.1, 6.3 Hz, 1H), 4.75 (1H, s, HHC=CD), 4.41 (1H, s, HHC=CD), 3.99 (2H, br 
s, CH(Me)2), 1.22 (12H, d, J 6.8, CH(Me)2); δC (126 MHz, CD3CN ) 153.5 (CO), 142.9 (t, J 
16.3, C=CD-O), 94.9 (C=CDO), 47.6 (C(Me)2), 46.8 (C(Me)2), 21.7 (Me), 20.7 (Me); IR (νmax, 
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film, cm-1): 2972, 1714, 1622, 1435, 1371, 1314, 1144, 1050.  HRMS (ESI+): m/z calculated for 
formula C9H16DNO2 [M2H+] 345.2748; found 345.2761.   
Isoquinolin-1(2H)-one-d1 137-d1 
 
The desired compound was isolated as a crude solid (10 mg, 6%, 85% D by 1H 
NMR) containing impurities (<90% pure) from N-(pivaloyloxy)benzamide 
(221 mg, 1.00 mmol) following general procedure C using mesitylene (46 µL, 
0.33 mmol) as an internal standard.  The 1H NMR of the crude reaction mixture 
indicated 10% conversion to the isoquinolone (5aD) (see spectrum).  The product was isolated 
as an amorphous solid (8 mg, 5%) by preparative TLC using 50% EtOAc in hexane.  δH (500 
MHz, CDCl3) 10.68 (1H, s, NH), 8.42 (1H, d, J 8.1, ArH), 7.67 (1H, t, J 8.1, ArH), 7.56 (2H, d, 
J 7.8, ArH), 7.51 (1H, t, J 7.1, ArH), 7.14 (0.15 H, d, J 7.1, H3), 6.55 (1H, s, H4). 
 
tert-Butyl 5-oxo-3a,4,5,9b-tetrahydro-1H-pyrrolo[2,3-c]isoquinoline-3(2H)-carboxylate 267 
 
N-Boc-2,3-dihydro-1H-pyrrole (172 µL, 1.50 mmol) was added to a 
solution of [Cp*RhCl2]2 (6 mg, 0.01 mmol), CsOAc (58 mg, 0.3 
mmol) and N-(pivaloyloxy) benzamide (221 mg, 1.00 mmol) in MeOH 
(5 mL, 0.2 M) in a vial under a nitrogen atmosphere.  The reaction was 
heated to 45 °C for 16 hours, after which time the solvent was removed in vacuo.  The crude 
material was purified by flash silica chromatography using an eluent of 50% EtOAc in hexane 
then crystallised from EtOAc–pentane to afford pale yellow crystals (131 mg, 45%).  M.p. 161-
165 °C (DCM–pentane); δH (500 MHz, 343K, DMSO-d6) 7.94 (1H, d, J 7.2, H6), 7.53 (1H, td, J 
7.3, 1.0, H8), 7.42-7.38 (2H, m, H7 and H9), 7.27 (1H, br s, NH), 5.51 (1H, d, J 6.4, H3a), 3.54 
(1H, dt, J 10.8, 6.7, H9b), 3.46-3.33 (2H, m, 2H2), 2.38-2.26 (1H, m, H1), 2.01-1.91 (1H, m, H1), 
1.47 (9H, s, tBu); δC (126 MHz, 343K, DMSO-d6) δ 161.9 (C5), 153.0 (CO2tBu), 138.3 (Cq), 
131.9 (C8), 127.3 (C7), 127.0 (C6), 126.8 (C9), 126.3 (Cq), 79.3 (OCtBu), 66.7 (C3a), 44.4 (C2), 
39.5 (C9b) 31.9 (C1), 27.8 (C(CH3)3). C9b is obscured by the DMSO signal but can be identified 
in the HMQC; HRMS (ESI+): m/z calculated for formula C16H21N2O3 [MH+] 289.1547; found 
289.1542; IR (νmax, solid, cm-1): 3585, 3518, 3199, 2955, 2849, 1705, 1650, 1464, 1387, 1284, 
1122. 
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6.7 Preparation of (E)-acetophenone oxime derivatives 
 
General procedure (D) for the synthesis of (E)-acetophenone O-acetyl oxime derivatives64 
 
 
To a stirred solution of hydroxylamine hydrochloride (1.5 eq.) in a pyridine–ethanol 
(1:2, 0.2 M) solution at 60 °C was added the acetophenone derivative (1 eq.).  After one hour the 
reaction mixture was partitioned between water (25 mL) and EtOAc (25 mL).  The aqueous 
layer was re-extracted with EtOAc (25 mL) and the organic layers were combined and washed 
with 1 N HCl (25 mL), brine (20 mL) and dried with MgSO4 and filtered.  The solvent was 
removed in vacuo to afford the crude oxime.  The product was added to a solution of acetic 
anhydride (2.2 eq.) in pyridine (1 M) with DMAP (cat.) at room temperature.  After 2 hours, the 
reaction was quenched with water (25 mL), extracted with EtOAc (2 × 25 mL).  The organic 
layers were combined and washed with 1 N HCl (25 mL), brine (25 mL) and dried with MgSO4.  
The solvent was removed in vacuo to afford the crude O-acetyl oxime, which was purified by 
crystallisation or flash column chromatography. 
 
(E)-Acetophenone O-acetyl oxime 271  
 
The desired compound was isolated as colourless needles (709 mg, 80%) from 
acetophenone (583 µL, 5.00 mmol) following general procedure D.  The crude 
material was crystallised from EtOAc–hexane.  M.p. 54-55 °C (EtOAc–hexane, 
[lit. 53-55 °C, EtOAc–hexane]64); δH (300 MHz, CDCl3) 7.74 (2H, d, J 8.2, H2 and H6), 7.50-
7.35 (3H, m, H3, H4 and H5), 2.39 (3H, s, CNCH3), 2.27 (3H, s, COCH3); δC (75 MHz, CDCl3) 
169.0 (COCH3), 162.5 (CNCH3), 134.9 (C1), 130.6 (C4), 128.6 (C3 and C5), 127.0 (C2 and C6), 
20.0 (COCH3), 14.4 (CNCH3); LCMS (ESI+): m/z calculated for formula C10H11NNaO2 [MNa+] 
200.1; found 200.1; IR (vmax, solid, cm-1) 3063, 2629, 1760, 1684, 1599, 1449, 1361, 1267. 
Spectral data consistent with the literature.64  
 
(E)-Acetophenone O-pivaloyloxime 270 
 
The desired compound was isolated as crystalline needles (745 mg, 68%) 
from (E)-acetophenone oxime (675 mg, 5.00 mmol) and pivalic anhydride 
(2.33 mL, 11.0 mmol) (instead of acetic anhydride) following general 
procedure D.  The product was purified by flash column chromatography using 0-30% EtOAc 
i) NH2OH•HCl (1.5 eq.)
EtOH−pyridine (2:1, 0.2 M)
60 °C, 1 h
ii) Ac2O (2.2 eq.), DMAP (cat.)
pyridine (1 M), 1 h, rt
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in hexane, followed by crystallisation from EtOAc–pentane. M.p. 51-53 °C (EtOAc–hexane); δH 
(300 MHz, CDCl3) 7.78-7.73 (2H, m, H2 and H6, 7.47 (3H, m, H3, H4 and H5), 2.38 (3H, s, 
CNCH3), 1.34 (9H, s, CO2(CH3)3); δC (75 MHz, CDCl3) 175.2 (CO2(CH3)3), 163.3 (CNCH3), 
135.1 (C1), 130.6 (C4), 128.7 (C3 and C5), 127.2 (C2 and C6), 39.0 (C(CH3)3), 27.5  (C(CH3)3), 
14.5 (CNCH3); LCMS (ESI+): m/z calculated for formula C13H17NNaO2 [MNa+] 242.1; found 
242.1; IR (νmax, solid, cm1): 2964, 1753, 1481, 1445, 1390, 1366, 1305, 1267, 1110, 1075, 1021.  
Spectral data consistent with the literature.34 
 
(E)-1-(4-Nitrophenyl)ethanone O-acetyl oxime 273 
 
The desired compound was isolated as a brown crystalline solid (1.05 g, 
95%) from 4’-nitroacetophenone (825 mg, 5.00 mmol) following general 
procedure D.  The crude material was crystallised from EtOAc–hexane. 
M.p. 124-128 °C (EtOAc–hexane); δH (300 MHz, CDCl3) 8.23 (2H, d, J 9.1, H3 and H5), 7.91 
(2H, d, J 9.1, H2 and H6), 2.42 (3H, s, CNCH3), 2.27 (3H, s, COCH3); δC (75 MHz, CDCl3) 
168.3 (COCH3), 160.5 (CNCH3), 149.0 (C4), 140.9 (C1), 128.0 (C2 and C6), 123.8 (C3 and C5), 
19.7 (COCH3), 14.4 (CNCH3); HRMS (ESI+): m/z calculated for formula C10H10N2NaO4 
[MNa+] 245.0533; found 245.0542; IR (vmax, solid, cm-1) 3429, 2304, 1771, 1645, 1517, 1191. 
 
(E)-1-(4-(Trifluoromethyl)phenyl)ethanone O-acetyl oxime 274  
 
The desired compound was isolated as colourless needles (980 mg, 80%) 
from 4’-trifluoromethylacetophenone (940 mg, 5.00 mmol) following 
general procedure D.  The crude material was crystallised from EtOAc–
hexane.   M.p. 43-44 °C (EtOAc–hexane), [lit. 42-44 °C, EtOAc–hexane]64); δH (300 MHz, 
CDCl3) 7.87 (2H, d, J  8.3, H3 and H5), 7.67 (2H, d, J 8.7, H2 and H6), 2.42 (3H, s, CNCH3), 
2.28 (3H, s, COCH3); δC (75 MHz, CDCl3) 168.6 (COCH3), 161.2 (CNCH3), 138.3 (C1), 132.3 
(q, J 32.3, C4), 127.4 (C2 and C6), 125.6 (q, J 3.8, C3 and C5), 19.8 (COCH3), 14.4 (CNCH3), 
missing CF3 quartet; HRMS (ESI+): m/z calculated for formula C11H10F3NNaO2 [MNa+] 
268.0556; found 268.0564; IR (vmax, solid, cm-1) 3397, 3063, 1773, 1615, 1328, 1200, 1064.  
Spectral data consistent with the literature.64  
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(E)-1-(p-Tolyl)ethanone O-acetyl oxime 275  
 
The desired compound was isolated as a pale yellow crystalline solid 
(787 mg, 82%) from 4’-methylacetophenone (666 µL, 5.00 mmol) following 
general procedure D.  The crude material was crystallised from EtOAc–
hexane.  M.p. 105-109 °C (EtOAc–hexane); δH (300 MHz, CDCl3) 7.64 (2H, 
d, J 8.3, H2 and H6), 7.21 (2H, d, J 8.5, H3 and H5), 2.38 (3H, s, CNCH3), 2.37 (3H, s, Me), 2.27 
(3H, s, COCH3); δC (75 MHz, CDCl3) 169.1 (COCH3), 162.4 (CNCH3), 140.9 (C1), 131.9 (C4), 
129.3 (C3 and C5), 126.9 (C2 and C6), 21.4 (Me), 19.9 (COCH3), 14.3 (CNCH3); HRMS (ESI+): 
m/z calculated for formula C11H13NNaO2 [MNa+] 214.0838; found 214.0839; IR (vmax, solid, cm-
1) 3036, 1756, 1681, 1370, 1200. 
 
(E)-1-(2-Fluorophenyl)ethanone O-acetyl oxime 276 
 
The desired compound was isolated as a colourless crystalline solid (429 mg, 
44%) from 2’-fluoroacetophenone (607 µL, 5.00 mmol) following general 
procedure D.  The product was purified by crystallisation from EtOAc–pentane. 
RF 0.67 (20% EtOAc in pentane); M.p. 44-47 °C (EtOAc–pentane).; δH (300 MHz, CDCl3) 7.55 
(1H, td, J 7.6, 1.8, H6), 7.44-7.35 (1H, m, H4), 7.17 (1H, dd, J 7.6, 1.0, H5), 7.09 (1H, dd, J 11.0, 
8.5, H3), 2.38 (3H, d, J 2.6, CNCH3), 2.24 (3H, s, COCH3); δC (75 MHz, CDCl3) 168.7 
(COCH3), 162.5 (CNCH3), 160.8 (d, J 251.0, C2), 132.0 (d, J 8.4, C4), 130.1 (d, J 3.0, C6), 124.4 
(d, J 3.5, C5), 123.8 (d, J 12.5, C1), 116.3 (d, J 21.7, C3), 19.8 (COCH3), 17.1 (d, J 5.3, CNCH3); 
HRMS (ESI+): m/z calculated for formula C10H11FNO2 [MH+] 196.0768; found 196.0765; IR 
(νmax, solid, cm-1): 3068, 2938, 1767, 1615, 1490, 1450, 1366, 1320, 1189. 
 
(E)-1-(4-Chlorophenyl)ethanone O-acetyl oxime 277   
 
The desired compound was isolated as pale yellow needles (1.07 g, 74%) 
from 4’-chloroacetophenone (646 µL, 4.18 mmol) following general 
procedure D.  The crude material was crystallised from EtOAc–hexane. M.p. 
88-92 °C (EtOAc–hexane); δH (300 MHz, CDCl3) 7.70 (2H, d, J 8.8, H2 and H6), 7.38 (2H, d, J 
8.8, H3 and H5), 2.37 (3H, s, CNCH3), 2.27 (3H, s, COCH3); δC (75 MHz, CDCl3) 168.8 
(COCH3), 161.4 (CNCH3), 136.8 (C4), 133.3 (C1), 128.9 (C3 and C5), 128.3 (C2 and C6), 19.8 
(COCH3), 14.3 (CNCH3); HRMS (ESI+): m/z calculated for formula C10H1035ClNNaO2 [MNa+] 
234.0292; found 234.0290; IR (vmax, solid, cm-1) 3054, 2987, 2305, 1768, 1617, 1491, 1421, 
1204. 
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(E)-1-(4-Bromophenyl)ethanone O-acetyl oxime 27864 
 
The desired compound was isolated as colourless needles (997 mg, 78%) 
from 4’-bromoacetophenone (995 mg, 4.18 mmol) following general 
procedure D.  The crude material was crystallised from EtOAc–hexane. M.p. 
94-96 °C (EtOAc–hexane, [lit. 95-97 °C, EtOAc–hexane]64); δH (300 MHz, CDCl3) 7.63 (2H, d, 
J 8.8, H2 and H6), 7.54 (2H, d, J 8.8, H3 and H5), 2.37 (3H, s, CNCH3), 2.27 (3H, s, COCH3); δC 
(75 MHz, CDCl3); 168.7 (COCH3), 161.4 (CNCH3), 133.7 (C1), 131.8 (C2 and C6), 128.5 (C3 
and C5), 125.2 (C4), 19.8 (COCH3), 14.2 (CNCH3); HRMS (ESI+): m/z calculated for formula 
C10H1079BrNNaO2 [MNa+] 277.9787; found 277.9780; IR (vmax, solid, cm-1) 3054, 2987, 2305, 
1767, 1421, 1204.  Spectral data consistent with the literature.64 
 
(E)-1-(4-Iodophenyl)ethanone O-acetyl oxime 279 
 
The desired compound was isolated as a brown crystalline solid (1.23 g, 81%) 
from 4’-iodoacetophenone (1.23 g, 5.00 mmol) following general procedure 
D.  The crude material was crystallised from EtOAc–hexane. M.p. 54-55 °C 
(EtOAc–hexane); δH (300 MHz, CDCl3) 7.75 (2H, d, J 8.7, H2 and H6), 7.48 (2H, d, J 8.7, H3 
and H5), 2.36 (3H, s, CNCH3), 2.26 (3H, s, COCH3); δC (75 MHz, CDCl3) 168.8 (COCH3), 
161.6 (CNCH3), 137.8 (C3 and C5), 134.3 (C1), 129.0 (C2 and C6), 97.3 (C4), 19.8 (COCH3), 
14.2 (CNCH3); HRMS (ESI+): m/z calculated for formula C10H10INNaO2 [MNa+] 325.9648; 
found 325.9659; IR (vmax, solid, cm-1) 3420, 3054, 2987, 2305, 1767, 1421, 1274. 
 
(E)- and (Z)-1-(Naphthalene-1-yl)ethanone O-acetyl oxime 280  
 
The desired compound was isolated as a colourless oil 
(984 mg, 87%) from 1’-acetonaphthone (760 µL, 5.00 
mmol) following general procedure D.  The product was 
purified by flash silica chromatography using 0-40% EtOAc 
in hexane to afford a mixture of the (E)- and (Z)-isomers 
(E:Z, 3:1).  RF 0.57 (20% EtOAc in pentane); δH (300 MHz, CDCl3) 7.98 (1H, dd, J 8.1, 1.0, H2, 
(E)-isomer), 7.78-7.71 (2H, m, ArH), 7.60-7.54 (0.35H, m, ArH (Z)-isomer), 7.46 (4H, m, 
ArH), 7.16 (0.3H, dd, J 7.1, 1.1, ArH, (Z)-isomer) 2.37 (3H, s, CNCH3 (E)-isomer), 2.35 (0.9H, 
s, CNCH3, (Z )-isomer)  2.17 (3H, s, COCH3); δC (75 MHz, CDCl3) 168.3 (COCH3, (E)-isomer), 
167.9 (COCH3, (Z)-isomer), 164.3 (CNCH3, (E)-isomer), 163.9 (CNCH3, (Z)-isomer), 133.3 (Cq, 
(E)-isomer), 133.2 (Cq, (Z)-isomer), 132.8 (Cq, (E)-isomer), 132.8 (Cq, (Z)-isomer), 132.8, 130.0 
(Cq), 129.6, 128.8, 128.2, 128.1, 128.0 (Cq), 126.5 (Cq), 126.5, 126.0, 125.8, 124.7, 124.6, 
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124.2, 122.9, 22.4 (COCH3, (Z)-isomer), 19.3 (COCH3, (E)-isomer), 18.7 (COCH3, (Z)-isomer), 
18.3 (COCH3, (E)-isomer); HRMS (ESI+): m/z calculated for formula C14H13NO2 [MNa+] 
228.1019; found 228.1013; IR (νmax, film, cm-1): 3061, 2247, 1759, 1627, 1509, 1429, 1366, 
1254, 1207, 1188. 
 
(E)-1-(2-Methoxyphenyl)ethanone O-acetyl oxime 281 
 
The desired compound was isolated as a colourless oil (850 mg, 82%) from 2’-
methoxyacetophenone (690 µL, 5.00 mmol) following general procedure D.  
The product was purified by flash silica chromatography using 0-40% EtOAc in 
hexane. RF 0.64 (20% EtOAc in pentane); δH (300 MHz, CDCl3) 7.32-7.21 (2H, m, H4 and H6), 
6.88-6.77 (2H, m, H3 and H5), 3.70 (3H, s, OMe), 2.23 (3H, s, COCH3), 2.12 (3H, s, CNCH3); 
δC (75 MHz, CDCl3) 168.5 (COCH3), 164.4 (C2), 157.2 (CNCH3), 130.9 (C4), 129.4 (C6), 124.8 
(C1), 120.2 (C5), 110.7 (C3), 55.1 (OMe), 19.4 (COCH3), 17.1 (CNCH3); LCMS (ESI+): m/z 
calculated for formula C11H13NNaO3 [MNa+] 230.1; found 230.1; IR (νmax, film, cm-1): 2839, 
2247, 1759, 1600, 1492, 1462, 1436, 1366, 1319, 1273, 1246, 1202, 1163, 1127, 1046, 1025.  
Spectral data consistent with the literature.64 
 
(E)-1-(4-Methoxyphenyl)ethanone O-acetyl oxime  282  
 
The desired compound was isolated as colourless needles (1.04 g, 80%) 
from 4’-methoxyacetophenone (750 mg, 5.00 mmol) following general 
procedure D.  The crude material was crystallised from EtOAc–hexane.  
M.p.  52-54 °C (EtOAc–hexane, [lit. 53-55 °C, EtOAc–hexane]64); δH (300 MHz, CDCl3) 7.70 
(2H, d, J 8.6, H2 and H6), 6.90 (2H, d, J 8.6, H3 and H5), 3.82 (3H, s, OMe) , 2.34 (3H, s, 
CNCH3), 2.24 (3H, s, COCH3); δC (75 MHz, CDCl3) 169.2 (COCH3), 161.9 (CNCH3), 161.6 
(C4), 129.7 (C2 and C6), 127.4 (C1), 113.9 (C3 and C5), 55.4 (OMe), 19.9 (COCH3), 14.2 
(CNCH3); HRMS (ESI+): m/z calculated for formula C11H13NNaO3 [MNa+] 230.0788; found 
230.0796; IR (vmax, film, cm-1) 3517, 2937, 2840, 2559, 1765, 1604, 1514, 1254, 1180, 834.  
Spectral data consistent with the literature.64 
 
(E)-1-(3-Bromophenyl)ethanone O-acetyl oxime 293 
 
The desired compound was isolated as a colourless oil (1.24 g, 97%) from 
3’-bromoacetophenone (661 µL, 5.00 mmol) following general procedure D.  
The product was purified by flash silica chromatography using 0-40% 
EtOAc in hexane.  RF 0.59 (20% EtOAc in pentane); δH (300 MHz, CDCl3) 7.84 (1H, t, J 1.7, 
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H2), 7.61 (1H, dd, J 7.9, 1.7, H6), 7.51 (1H, dd, J 7.9, 1.7, H4), 7.22 (1H, t, J 8.0, H5), 2.31 (3H, 
s, CNCH3), 2.21 (3H, s, COCH3); δH (75 MHz, CDCl3) 168.5 (COCH3), 161.1 (CNCH3), 136.8 
(C1), 133.4 (C4), 130.1 (C5), 129.8 (C2), 125.6 (C6), 122.7 (C3), 19.7 (COCH3), 14.3 (CNCH3); 
LCMS (ESI+): m/z calculated for formula C10H1079BrNO2 [MNa+] 278.0; found 278.0; IR (νmax, 
film, cm-1): 3066, 2933, 2250, 1764, 1557, 1418, 1365, 1310, 1297, 1269, 1190, 1070.  Spectral 
data consistent with the literature.64 
 
(E)-1-(3-Fluorophenyl)ethanone O-acetyl oxime 294 
 
The desired compound was isolated as a colourless crystalline solid (713 mg, 
73%) from 3’-fluoroacetophenone (613 µL, 5.00 mmol) following general 
procedure D.  The product was purified by flash silica chromatography using 
0-30% EtOAc in hexane and subsequently crystallised from pentane. RF 0.61 (20% EtOAc in 
pentane); M.p. 38-41 °C (pentane); δH (300 MHz, CDCl3) 7.53-7.42 (2H, m, H6 and H2), 7.36 
(1H, td, J 8.0, 5.8, H5), 7.12 (1H, tdd, J 8.3, 2.5, 0.8, H4), 2.36 (3H, s, CNCH3), 2.25 (3H, s, 
COCH3); δC (75 MHz, CDCl3) 168.8 (COCH3), 162.8 (d, J 246.5, C3), 161.4 (d, J 2.5, CNCH3), 
137.1 (d, J 7.8, C1), 130.3 (d, J 8.2, C5), 122.8 (d, J 3.0, C6), 117.6 (d, J 21.3, C4), 114.1 (d, J 
23.3, C2), 19.8 (COCH3), 14.4 (CNCH3); LCMS (ESI+): m/z calculated for formula C10H11FNO2 
[MH+] 196.0768; found 196.0767; IR (νmax, film, cm-1): 3075, 2937, 2766, 1580, 1435, 1367, 
1316, 1210, 1187. 
 
(E)-1-(3-Methylphenyl)ethanone O-acetyl oxime 295 
 
The desired compound was isolated as a colourless oil (857 mg, 90%) from 
3’-methylacetophenone (680 µL, 5.00 mmol) following general procedure D.  
The product was purified by flash silica chromatography using 0-30% EtOAc 
in hexane.  RF 0.65 (20% EtOAc in pentane); δH (300 MHz, CDCl3) 7.58 (1H, s, H2), 7.51 (1H, 
d, J 7.3, H6), 7.30-7.24 (2H, m, H4 and H5), 2.36 (3H, s, CNCH3), 2.35 (3H, s, Me), 2.25 (3H, s, 
COCH3); δC (75 MHz, CDCl3) 169.0 (COCH3), 162.6 (CNCH3), 134.7 (C3), 131.3 (C4), 129.8 
(C1), 128.4 (C5), 127.5 (C2), 124.1 (C6), 21.3 (Me), 19.7 (COCH3), 14.3 (CNCH3); LCMS 
(ESI+): m/z calculated for formula C11H13NaNO2 [MNa+] 214.1; found 214.1; IR (νmax, film, 
cm1): 3412, 3039, 2922, 2251, 1764, 1428, 1366, 1313, 1209, 1193, 1042. Spectral data 
consistent with the literature.178 
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(E)-1-(3-Methoxyphenyl)ethanone O-acetyl oxime 296 
 
The desired compound was isolated as a colourless oil (969 mg, 94%) 
from 3’-methoxyacetophenone (686 µL, 5.00 mmol) following general 
procedure D.  The product was purified by flash silica chromatography 
using 0-40% EtOAc in hexane.  RF 0.52 (20% EtOAc in pentane); δH (300 MHz, CDCl3) 7.24-
7.20 (3H, m, H2, H5 and H6), 6.93-6.88 (1H, m, H4), 3.74 (3H, s, OMe), 2.28 (3H, s, COCH3), 
2.17 (3H, s, CNCH3); δC (75 MHz, CDCl3) 168.8 (COCH3), 162.2 (C3), 159.5 (CNCH3), 136.1 
(C1), 129.4 (C5), 119.3 (C6), 116.2 (C4), 112.9 (C2), 55.2 (OMe), 19.6 (COCH3), 14.3 (CNCH3); 
LCMS (ESI+): m/z calculated for formula C11H13NNaO3 [MNa+] 230.1; found 230.0; IR (νmax, 
film, cm-1): 2940, 2837, 2251, 1762, 1577, 1428, 1366, 1320, 1236, 1194, 1041.  Spectral data 
consistent with the literature.64 
 
(E)-1-(Benzo[d][1,3]dioxol-5-yl)ethanone O-acetyl oxime 297  
 
The desired compound was isolated as colourless needles (854 mg, 77%) 
from 3',4'-(methylenedioxy)acetophenone (810 mg, 5.00 mmol) following 
general procedure D. The crude material was crystallised from EtOAc–
hexane. M.p. 108-110 °C (EtOAc–hexane); δH (300 MHz, CDCl3) 7.29 (1H, d, J 1.8, H4), 7.20 
(1H, dd, J 1.8, 8.2, H6), 6.80 (1H, d, J 8.2, H7), 5.99 (2H, s, OCH2O), 2.23 (3H, s, COCH3), 2.24 
(3H, s, CNCH3); δC (75 MHz, CDCl3) 169.0 (COCH3), 161.8 (CNCH3), 149.8 (CqO), 148.0 
(CqO), 128.8 (C5), 122.1 (C6), 108.1 (C4), 107.0 (C7), 101.6 (OCH2O ), 19.9 (COCH3), 14.3 
(CNCH3); HRMS (ESI+): m/z calculated for formula C11H11NNaO4 [MNa+] 244.0580; found 
244.0588; IR (vmax, solid, cm-1) 1756, 1591, 1439, 1214, 1032. 
 
 
  
N
OAc
O
O
N
OAc
MeO
	   164 
6.8 Preparation of isoquinoline library 
 
General procedure (E) for the synthesis of isoquinolines 
 
 
Vinyl acetate (922 µL, 10.0 mmol) was added to a solution of the acetylated oxime (1.00 mmol) 
in MeOH (0.5 mL, 2 M) with CsOAc (58 mg, 0.30 mmol) and [Cp*RhCl2]2 (6 mg, 0.01 mmol) 
in a septum-topped vial under nitrogen.  The reaction vials were sealed and heated to 60 °C for 
48 hours.  The crude reaction mixture was loaded on to a 5 g SCX column that was 
subsequently washed with MeOH (2 × 25 mL).  The product eluted with the secondary wash 
using 0.7 M NH3 in MeOH (2 × 25 mL) to give the clean product (>90% purity).  Products 
containing impurities were purified using flash silica chromatography. 
 
1-Methylisoquinoline 272 
 
The desired compound was isolated as a brown oil (82 mg, 57%) from (E)-
acetophenone O-acetyl oxime (177 mg, 1.00 mmol) following general procedure 
E.  δH (300 MHz, CDCl3) 8.37 (1H, d, J 5.7, H3), 8.08 (1H, d, J 7.6, H8), 7.77 
(1H, d, J 7.8 Hz, H5), 7.68-7.60 (1H, m, H6), 7.60-7.52 (1H, m, H7), 7.48 (1H, d, J 5.8, H4), 2.94 
(3H, s, CH3); δC (75 MHz, CDCl3) 158.6 (C1), 141.8 (C3), 135.8 (Cq), 129.9 (C6), 127.2 (C8 and 
Cq), 127.0 (C7), 125.6 (C5), 119.3 (C4), 22.4 (CH3); LRMS (ESI+): m/z 144.0 [MH+]; IR (vmax, 
film, cm-1) 2968, 1623, 1563, 1391. Data consistent with the literature.255 
 
1-Methyl-6-nitroisoquinoline 283 
 
The desired compound was isolated as a brown oil (156 mg, 83%) from (E)-1-
(4-nitrophenyl)ethanone O-acetyl oxime (222 mg, 1.00 mmol) following 
general procedure E.  δH (300 MHz, CDCl3) 8.72 (1H, d, J 2.0, H5), 8.56 (1H, 
d, J 5.8, H3), 8.36-8.24 (2H, m, H7 and H8), 7.69 (1H, d, J 5.8, H4), 3.02 (3H, s, CH3); δC (75 
MHz, CDCl3) 159.3 (C1), 148.0 (C6), 143.9 (C3), 135.2 (Cq), 129.1 (Cq), 127.8 (C8), 123.5 (C5), 
120.4 (C4 and C7), 22.7 (CH3); HRMS (ESI+): m/z calculated for formula C10H9N2O2 [MH+] 
189.0659; found 189.0660; IR (vmax, solid, cm-1) 3074, 1535, 1344, 906. 
 
  
[Cp*RhCl2]2] (1 mol%)
CsOAc (0.3 eq.)
MeOH (2 M), 60 °C
vinyl acetate (10 eq.)
N
R
OAc
N
R
N
N
O2N
	   165 
1-Methyl-6-(trifluoromethyl)isoquinoline 284 
 
The desired compound was isolated as a brown oil (174 mg, 82%) from (E)-1-
(4-(trifluoromethyl)phenyl)ethanone O-acetyl oxime (245 mg, 1.00 mmol) 
following general procedure E.  δH (300 MHz, CDCl3) 8.49 (1H, d, J 5.8, H3), 
8.22 (1H, d, J 8.8, H8), 8.09 (1H, dt, J 1.9, 1.0, H5), 7.75 (1H, dd, J 8.8, 1.8, H7), 7.57 (1H, d, J 
5.8, H4), 2.99 (3H, s, CH3); δC (75 MHz, CDCl3) δ 158.9 (C1), 143.2 (C3), 135.0 (Cq), 131.6 (q, J 
32.6, C6), 128.3 (Cq), 126.9 (C8), 124.9 (q, J 4.4, C5), 123.9 (q, J 271.0, CF3), 122.7 (q, J 3.1, 
C7), 119.6 (C4), 22.4 (CH3); HRMS (ESI+): m/z calculated for formula C11H9F3N [MH+] 
212.0682; found 212.0690; IR (vmax, solid, cm-1) 3060, 1590, 1574, 1340, 1237, 1127. 
 
1,6-Dimethylisoquinoline 285 
 
The desired compound was isolated as a brown oil (69 mg, 44%) from (E)-1-(p-
tolyl)ethanone O-acetyl oxime (191 mg, 1.00 mmol) following general 
procedure E. δH (300 MHz, CDCl3) 8.32 (1H, d, J 5.9, H3), 8.00 (1H, d, J 8.6, 
H8), 7.56 (1H, s, H5), 7.47-7.39 (2H, m, H4 and H7), 2.95 (3H, s, 1-Me), 2.53 (3H, s, 6-Me); δC 
(75 MHz, CDCl3) 158.0 (C1), 141.0 (C3), 140.6 (C6), 136.4 (C7), 129.6 (Cq), 126.2 (C5), 125.8 
(Cq), 125.6 (C8), 119.2 (C4), 21.9 (Me) 21.7 (Me); HRMS (ESI+): m/z calculated for formula 
C11H12N [MH+] 158.0964; found 158.0962; IR (vmax, solid, cm-1) 1643, 1631, 1403, 1258, 1037.  
 
8-Fluoro-1-methylisoquinoline 286 
 
The desired product was isolated as a brown oil (66 mg, 41%) from (E)-1-(2-
fluorophenyl)ethanone O-acetyl oxime (195 mg, 1.00 mmol) following general 
procedure E.  The material was purified by column chromatography using 
0-100% EtOAc in hexane without the use of an SCX column.  RF 0.73 (50% EtOAc in pentane); 
δH (300 MHz, CDCl3) 8.37 (1H, d, J 5.8, H3), 7.56-7.52 (2H, m, H5 and H6), 7.45 (1H, dd, J 5.8, 
2.7, H4), 7.22-7.14 (1H, m, H7), 3.05 (3H, d, J 7.0, Me); δC (75 MHz, CDCl3) 160.0 (d, J 256.8, 
C8), 156.8 (d, J 5.9, C1), 142.3 (d, J 1.8, C3), 138.5 (d, J 3.5, Cq), 130.4 (d, J 9.3, C6), 123.3 (d, J 
4.5, C5), 118.7 (d, J 3.7, C4), 118.4 (d, J 14.1, Cq), 112.4 (d, J 23.2, C7), 26.8 (d, J 10.7, Me); 
HRMS (ESI+): m/z calculated for formula C10H9FN [MH+] 162.0714; found 162.0709; IR (νmax, 
film, cm-1): 2932, 1629, 1565, 1385, 1346, 1325, 1260, 1223, 1118, 1017. 
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6-Chloro-1-methylisoquinoline 287 
 
The desired compound was isolated as a brown oil (106 mg, 60%) from (E)-1-
(4-chlorophenyl)ethanone O-acetyl oxime (211 mg, 1.00 mmol) following 
general procedure E.  δH (300 MHz, CDCl3) 8.40 (1H, d, J 5.8, H3), 8.04 (1H, 
d, J 9.0, H8), 7.77 (1H, d, J 2.1, H5), 7.52 (1H, dd, J 9.0, 2.1, H7), 7.41 (1H, d, J 5.8, H4), 2.93 
(3H, s, CH3); δC (75 MHz, CDCl3) 158.7 (C1), 143.0 (C3), 136.8 (Cq), 136.1 (C6), 128.0 (C7), 
127.4 (C8), 125.9 (C5), 125.7 (Cq), 118.4 (C4), 22.4 (CH3); HRMS (ESI+): m/z calculated for 
formula C10H935ClN [MH+] 178.0418; found 178.0421; IR (vmax, solid, cm-1) 3390, 3056, 1616, 
1562, 1089. 
 
6-Bromo-1-methylisoquinoline 288  
 
The desired compound was isolated as a brown oil (159 mg, 72%) from (E)-1-
(4-bromophenyl)ethanone O-acetyl oxime (256 mg, 1.00 mmol) following 
general procedure E.  δH (300 MHz, CDCl3) 8.38 (1H, d, J 5.8, H3), 7.96-7.90 
(2H, m, H5 and H8), 7.63 (1H, dd, J 9.0, 1.9, H7), 7.38 (1H, d, J 5.8, H4), 2.91 (3H, s, CH3); δC 
(75 MHz, CDCl3) 158.8 (C1), 142.7 (C3), 137.1 (Cq), 130.6 (C7), 129.3 (C5), 127.4 (C8), 125.9 
(Cq), 124.7 (C6), 118.3 (C4), 22.3 (CH3); HRMS (ESI+): m/z calculated for formula C10H979BrN 
[MH+] 221.9913; found 221.9915; IR (vmax, solid, cm-1) 1611, 1560, 1393, 1077. 
 
6-Iodo-1-methylisoquinoline 289 
The desired compound was isolated as a tan crystalline solid (172 mg, 64%) 
from (E)-1-(4-iodophenyl)ethanone O-acetyl oxime (303 mg, 1.00 mmol) 
following general procedure E.  The product was recrystallized from EtOAc–
hexane.  M.p. 132-134 °C (EtOAc–hexane);  δH (300 MHz, CDCl3) 8.41 (1H, d, J 5.9, H3), 8.24 
(1H, d, J 1.1, H5), 7.88-7.84 (2H, m, H7 and H8), 7.42 (1H, d, J 5.8, H4), 2.96 (3H, s, CH3); δC 
(75 MHz, CDCl3) 158.8 (C1), 142.7 (C3), 137.5 (Cq), 136.1 (C5), 136.0 (C7), 127.2 (C8), 126.3 
(Cq), 118.2 (C4), 97.1 (C6), 21.6 (CH3); HRMS (ESI+): m/z calculated for formula C10H9IN 
[MH+] 269.9774; found 269.9774; IR (vmax, solid, cm-1) 1607, 1558, 1392, 1072. 
 
1-Methylbenzo[h]isoquinoline 290 
 
The desired product was isolated as a brown oil (46 mg, 24%) from (E)- and 
(Z)-1-(naphthalene-1-yl)ethanone O-acetyl oxime (229 mg, 1.00 mmol) (E:Z, 
3:1) following general procedure E.  The material was purified by column 
chromatography using 0-100% EtOAc in hexane without the use of an SCX column.  RF 0.61 
N
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(50% EtOAc in pentane); δH (500 MHz, CDCl3) 8.89 (1H, d, J 8.5, H10), 8.59 (1H, d, J 5.3, H3), 
7.96 (1H, dd, J 7.8, 1.5, H7), 7.91 (1H, d, J 8.7, H5), 7.74 (1H, ddd, J 8.6, 7.0, 1.6, H9), 7.67 
(1H, d, J 8.7, H6), 7.67 (1H, ddd, J 8.0, 7.1, 1.1, H8), 7.60 (1H, d, J 5.3, H4), 3.35 (3H, s, Me); 
δC (75 MHz, CDCl3) 157.0 (C1), 143.1 (C3), 138.0 (Cq), 133.6 (Cq), 131.9 (C5), 130.5 (Cq), 
129.3 (C7), 127.2 (C10 and C9), 126.8 (C6 or C8), 126.0 (C6 or C8), 125.5 (Cq), 120.4 (C4), 30.3 
(Me); HRMS (ESI+): m/z calculated for formula C14H12N [MH+] 194.0964; found 194.0961; IR 
(νmax, film, cm-1): 2969, 2929, 1675, 1588, 1448, 1416, 1382, 1248. 
 
8-Methoxy-1-methylisoquinoline 291 
 
The desired product was isolated as a brown oil (23 mg, 14%) from (E)-1-(2-
methoxyphenyl)ethanone O-acetyl oxime (207 mg, 1.00 mmol) following 
general procedure E.  The material was purified by column chromatography 
using 0-100% EtOAc in hexane without the use of an SCX column.  RF 0.65 (50% EtOAc in 
pentane); δH (300 MHz, CDCl3) 8.31 (1H, d, J 5.7, H3), 7.53 (1H, t, J 8.0, H6), 7.40 (1H, d, J 
5.7, H4), 7.32 (1H, d, J 7.6, H5), 6.88 (1H, d, J 7.8, H7), 3.97 (3H, s, OMe), 3.10 (3H, s, Me); δC 
(75 MHz, CDCl3) 158.6 (C1 or C8), 158.2 (C1 or C8), 142.1 (C3), 138.9 (Cq), 130.3 (C6), 120.6 
(Cq), 119.5 (C5), 119.1 (C4), 106.4 (C7), 55.6 (OMe), 28.9 (Me); HRMS (ESI+): m/z calculated 
for formula C11H12NO [MH+] 174.0913; found 174.0910; IR (νmax, film, cm-1): 2970, 2934, 
1619, 1561, 1457, 1359, 1344, 1327, 1272, 1231, 1067.  
 
6-Methoxy-1-methylisoquinoline 292 
 
The desired compound was isolated as a brown oil (16 mg, 9%) from (E)-1-
(4-methoxyphenyl)ethanone O-acetyl oxime (207 mg, 1.00 mmol) following 
general procedure E.  δH (300 MHz, CDCl3) 8.32 (1H, d, J 5.8, H3), 8.02 (1H, 
d, J 9.2, H8), 7.44 (1H, d, J 5.9, H4), 7.23 (1H, dd, J 9.2, 2.6, H7), 7.06 (1H, d, J 2.5, H5), 3.95 
(3H, s, OMe), 2.92 (3H, s, CH3); δC (75 MHz, CDCl3) 160.9 (C6), 157.7 (C1), 141.4 (C3), 138.2 
(Cq), 127.6 (C8), 120.0 (C7), 119.0 (C4), 104.9 (C5), 55.5 (OMe), 21.6 (CH3), one Cq not 
observed; HRMS (ESI+): m/z calculated for formula C11H12NO [MH+] 174.0913; found 
174.0919; IR (vmax, solid, cm-1) 3249, 1619, 1514, 1251, 1179, 1029.  
 
7-Bromo-1-methylisoquinoline 298a and 5-bromo-1-methylisoquinoline 298b 
 
 The regioisomeric compounds were isolated as an inseparable 
1:2.7 mixture of 5-bromo-1-methylisoquinoline 298b and 7-
bromo-1-methylisoquinoline 298a in the form of a brown oil 
N
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(131 mg, 50%) from (E)-1-(3-bromophenyl)ethanone O-acetyl oxime (256 mg, 1.00 mmol) 
following the general procedure.  The material was purified by column chromatography using 
0-100% EtOAc in hexane without the use of an SCX column.  RF 0.58 (50% EtOAc in pentane); 
δH (300 MHz, CDCl3) 8.38 (1H, d, J 5.8, H3, major and minor), 8.20 (0.73H, d J 1.7, H8, major), 
8.03 (0.27H, dd, J 8.4, 0.9, H8, minor), 7.89 (0.27H, dd, J 7.5, 0.9, H6, minor), 7.81 (0.27H, d, J 
6.0, H4, minor), 7.69 (0.73H, dd, J 8.7, 1.8, H6, major), 7.61 (0.73H, d, J 8.7, H5, major), 7.42 
(0.73H, d, J 5.8, H4, major), 7.37 (0.27H, t, J 8.0, H7, minor), 2.93 (0.81H, s, Me, minor), 2.88 
(2.19H, s, Me major); δC (75 MHz, CDCl3) 159.0 (C1, minor), 157.8 (C1, major), 143.0 (C3, 
minor), 142.1 (C3, major), 135.1 (Cq, minor), 134.4 (Cq, major), 133.8 (C6, minor), 133.5 (C6, 
major), 129.0 (C5, major), 128.6 (Cq, minor), 128.5 (Cq, major), 128.1 (C8, major), 127.4 (C8, 
minor), 125.4 (C7, minor), 122.3 (C5, minor), 120.8 (C7, major), 119.0 (C4, major), 118.2 (C4, 
minor), 22.5 (Me, minor), 22.3 (Me, major);  HRMS (ESI+): m/z calculated for formula 
C10H979BrN [MH+] 221.9913; found 221.9912; IR (νmax, film, cm-1): 2919, 1579, 1557, 1488, 
1400, 1365, 1346, 1299, 1070. 
 
7-fluoro-1-methylisoquinoline 299a and 5-fluoro-1-methylisoquinoline 299b 
 
The regioisomeric compounds were isolated as an inseparable 
5:1 mixture of 5-fluoro-1-methylisoquinoline 299b and 7-fluoro-
1-methylisoquinoline 299a in the form of a brown oil (76 mg, 
47%) from (E)-1-(3-fluorophenyl)ethanone O-acetyl oxime (195 mg, 1.00 mmol) following the 
general procedure.  The material was purified by column chromatography using 0-100% EtOAc 
in hexane without the use of an SCX column.  RF 0.56 (50% EtOAc in pentane); δH (300 MHz, 
CDCl3) 8.42 (0.83H, d, J 5.9, H3, major), 8.35 (0.17H, d, J 5.8, H3, minor), 7.85 (0.83H, d, J 
8.5, H8, major), 7.80-7.74 (0.34H, m, H5 and H8, minor), 7.71 (0.83H, d, J 5.9, H4, major), 7.66 
(0.17H, dd, J 9.9, 2.4, H6, minor), 7.52-7.44 (0.83H, m, H7, major), 7.43-7.37 (0.17H, m, H4, 
minor ), 7.30 (0.83H, dd, J 9.8, 7.8, H6, major ), 2.93 (2.49H, s, Me, major), 2.88 (0.51H, s, Me, 
minor); δC (75 MHz, CDCl3) 160.8 (d, J 248.8, C7, minor), 158.4 (d, J 2.7, C1, major), 158.0 (d, 
J 5.7, C1, minor), 158.0 (d, J 253.3, C5, major), 141.9 (d, J 1.7, C3, major), 141.0 (d, J 2.6, C3, 
minor), 133.0 (Cq, minor), 129.8 (d, J 8.5, C5, minor), 128.3 (d, J 7.9, Cq, minor), 128.6 (d, J 
4.6, Cq, major), 126.8 (d, J 7.9, C7, major), 126.6 (d, J 17.5, Cq, major), 121.4 (d, J 4.4, C8, 
major), 120.5 (d, J 25.3, C6, minor), 119.0 (C4, minor), 113.5 (d, J 19.2, C6, major), 111.9 (d, J 
4.6, C4, major), 109.2 (d, J 21.1, C8, minor), 22.5 (Me, major), 22.1 (Me, minor); HRMS 
(ESI+): m/z calculated for formula C10H9FN [MH+] 162.0714; found 162.0718; IR (νmax, film, 
cm-1): 2970, 2926, 1632, 1591, 1498, 1414, 1389, 1356, 1237, 1156. 
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1,7-Dimethylisoquinoline 300a and 1,5-dimethylisoquinoline 300b 
 
 The regioisomeric compounds were isolated as an inseparable 
1:10 mixture of 1,5-dimethylisoquinoline 300b and 1,7-
dimethylisoquinoline 300a in the form of a brown oil (82 mg, 
52%) from (E)-1-(3-methylphenyl)ethanone O-acetyl oxime (193 
mg, 1.00 mmol) following the general procedure.  The material was purified by column 
chromatography using 0-100% EtOAc in hexane without the use of an SCX column.  RF 0.56 
(50% EtOAc in pentane); δH (300 MHz, CDCl3) 8.40 (0.09H, d, J 6.0, H3 minor), 8.31 (0.91H, 
d, J 5.8, H3), 7.96-7.91(0.09H, m, H8 minor), 7.84 (0.91H, d, J 1.5, H8), 7.67 (0.91H, d, J 8.3, 
H5), 7.60 (0.09H, d, J 6.1, H4 minor), 7.47 (1H, dd, J 8.4, 1.5, H6 and H6 or H7 minor), 7.44 (1H, 
d, J 5.7, H4 and H6 or H7 minor), 2.94 (0.27H, s, 1-Me minor), 2.91 (2.73H, s, 1-Me), 2.63 
(0.27H, s, 5-Me minor), 2.54 (2.73H, s, 7-Me); δC (75 MHz, CDCl3) Signals for major isomer 
only: 157.8 (C1), 140.8 (C3), 137.0 (C7), 134.2 (Cq), 132.3 (C6), 127.7 (Cq), 127.1 (C5), 124.6 
(C8), 119.2 (C4), 22.2 (1-Me), 22.1 (7-Me); HRMS (ESI+): m/z calculated for formula C11H12N 
[MH+] 158.0964; found 158.0961; IR (νmax, film, cm-1): 2919, 1589, 1561, 1434, 1411, 1366, 
1309, 1239. 
 
7-Methoxy-1-methylisoquinoline 301a and 5-methoxy-1-methylisoquinoline 301b 
 
Mixed fractions of 5-methoxy-1-methylisoquinoline 301b and 
7-methoxy-1-methylisoquinoline 301a (51 mg, 29%, 1:5) and 
pure fractions of 5-methoxy-1-methylisoquinoline 301b 
(49 mg, 29%) were isolated in the form of brown oils 
(combined yield: 100 mg, 58%, 1.4:1 ratio of 5-:7-) from (E)-1-(3-methoxyphenyl)ethanone O-
acetyl oxime (207 mg, 1.00 mmol) following the general procedure. The material was purified 
by column chromatography using 0-100% EtOAc in hexane without the use of an SCX column. 
δH (300 MHz, CDCl3) 8.38 (1H, d, J 5.9, H3, major), 8.27 (0.8H, d, J 5.7, H3, minor), 7.88 (1H, 
d, J 5.9, H4, major), 7.68 (0.8H, d, J 8.9, H5, minor), 7.65 (1H, d, J 8.5, 0.7, H8, major), 7.47 
(1H, t, J 8.1, H7, major), 7.41 (0.8H, d, J 5.7, H4, minor), 7.30 (0.8H, dd, J 8.9, 2.5, H6, minor), 
7.25 (0.8H, d, J 2.5, H8, minor), 6.97 (1H, dd, J 7.7, 0.7, H6, major), 3.98 (3H, s, OMe, major), 
3.93 (2.4H, s, OMe, minor), 2.93 (3H, s, Me, major), 2.89 (2.4H, s, Me, minor); δC (75 MHz, 
CDCl3)  158.2 (C1, minor), 158.0 (C1, major), 156.9 (C7, minor), 155.0 (C5, major), 141.5 (C3, 
major), 134.0 (C3, minor), 131.4 (Cq, minor), 128.8 (C5, minor), 128.7 (Cq, major), 128.6 (Cq, 
minor), 128.3 (Cq, major), 127.0 (C7, major), 122.7 (C6, minor), 119.1 (C4, minor), 117.5 (C8, 
major), 113.6 (C4, major), 107.4 (C6, major), 103.5 (C8, minor), 55.8 (OMe, major), 55.5 (OMe, 
minor), 22.8 (Me, major), 22.4 (Me, minor); HRMS (ESI+): m/z calculated for formula 
NN
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C11H12NO [MH+] 174.0913; found 174.0908. IR (νmax, film, cm-1): 2957, 2935, 2836, 1621, 
1585, 1495, 1446, 1412, 1389, 1353, 1261, 1248, 1181, 1041. 
 
6-Methyl-[1,3]dioxolo[4,5-f]isoquinoline 297b 
 
The desired compound was isolated as a brown oil (58 mg, 36%) after column 
chromatography using 10-30% EtOAc in hexane, from (E)-1-
(benzo[d][1,3]dioxol-5-yl)ethanone O-acetyl oxime  (221 mg, 1.00 mmol) 
following general procedure E.  δH (300 MHz, CDCl3) 8.31 (1H, d, J 5.9, H8), 7.74 (1H, d, J 8.7, 
H5), 7.47 (1H, d, J 5.9, H9), 7.26 (1H, d, J 8.7, H4), 6.22 (2H, s, OCH2O), 2.92 (3H, s, CH3); δC 
(75 MHz, CDCl3) 158.9 (C6), 146.5 (CqO), 141.6 (C8), 140.8 (CqO), 123.9 (Cq), 122.0 (Cq), 
120.6 (C4), 111.4 (C5), 110.9 (C9), 102.3 (OCH2O), 23.0 (CH3); HRMS (ESI+): m/z calculated 
for formula C11H10NO2 [MH+] 188.0706; found 188.0700; IR (vmax, solid, cm-1) 1646, 1594, 
1471, 1428, 1284, 1052. 
 
Decumbenine B intermediate 
(E)-Benzo[d][1,3]dioxole-5-carbaldehyde oxime256 
Hydroxylamine hydrochloride (1.73 g, 25.0 mmol) was added to a 
solution of piperonal (3.0 g, 20 mmol) in a solution of water/ice–EtOH 
(3:1, 20 mL, 1.0 M) at 0 °C. Sodium hydroxide (1.6 g, 40 mmol) in water (5 mL) was added to 
the reaction which was left to warm to room temperature.  After four hours, the reaction was 
complete (by TLC).  The aqueous layer was extracted with Et2O (30 mL).  The aqueous phase 
was cooled and acidified to pH 1 using 6 N HCl and extracted with Et2O (3 × 30 mL).  The 
organic layers were combined, dried with MgSO4, filtered and the solvent was removed in 
vacuo to afford a colourless amorphous solid (3.16 g, 96%) which was not purified further.  δH 
(300 MHz, CDCl3) 8.04 (1H, s, HCN), 7.50 (1H, s, OH), 7.17 (1H, d, J 1.5, H4), 6.96 (1H, dd, J 
8.0, 1.5, H6), 6.81 (1H, d, J 8.0, H7), 6.00 (2H, s, OCH2O); δC (75 MHz, CDCl3) δ 150.2 (HCN), 
149.5 (CqO), 148.4 (CqO), 126.5 (C5), 123.1 (C6), 108.5 (C7), 105.8 (C4), 101.6 (C2); LCMS 
(ESI+): m/z calculated for formula C8H8NO3 [MH+] 166.0; found 166.0; IR (νmax, solid, cm-1): 
3222, 3124, 2998, 2917, 1605, 1497, 1445, 1357, 1317, 1249, 1195, 1124, 1107, 1034.  Spectral 
data consistent with the literature.256,257 
(E)-Benzo[d][1,3]dioxole-5-carbaldehyde O-acetyl oxime 312 
Acetyl chloride (1.85 mL, 15.0 mmol) was added to a solution of  (E)-
benzo[d][1,3]dioxole-5-carbaldehyde oxime (1.65 g, 10.0 mmol) in 
pyridine (10 mL, 2.0 M) with catalytic DMAP (5 mg).  After 4 hours, 
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water (30 mL) was added to quench the reaction and the product was extracted with EtOAc (2 × 
50 mL).  The organic layers were combined and washed with 1 N HCl (50 mL), brine (50 mL), 
dried with MgSO4, filtered and concentrated in vacuo.  The crude material was crystallised from 
Et2O–pentane to afford a colourless crystalline solid (1.94 g, 73%).  M.p. 107-109 °C (EtOAc–
pentane); δH (300 MHz, CDCl3) 8.24 (1H, s, HCN), 7.35 (1H, d, J 1.6, H4), 7.08 (1H, dd, J 8.0, 
1.6, H6), 6.83 (1H, d, J 8.0, H7), 6.03 (2H, s, OCH2O), 2.22 (3H, s, COMe); δC (75 MHz, 
CDCl3) 168.9 (COMe), 155.6 (HCN), 151.0 (CqO), 148.6 (CqO), 125.3 (C6), 124.4 (C5), 108.6 
(C7), 106.7 (C4), 101.9 (C2), 19.8 (Me); HRMS (ESI+): m/z calculated for formula C10H10NO4 -
[MH+] 208.0604; found 208.0601; IR (νmax, solid, cm-1): 2914, 2855, 1757, 1596, 1508, 1493, 
1439, 1359, 1338, 1253, 1209, 1100, 1035, 1001. 
 
[1,3]Dioxolo[4,5-f]isoquinoline 310 
The desired compound was isolated as a brown amorphous solid (45 mg, 26%) 
from (E)-benzo[d][1,3]dioxole-5-carbaldehyde O-acetyl oxime (207 mg, 1.00 
mmol) following general procedure E. δH (300 MHz, CDCl3) 9.16 (1H, s, H6), 
8.43 (1H, d, J 5.8, H8), 7.60-7.57 (2H, m, H5 and H9), 7.29 (1H, d, J 8.7, H4), 
6.23 (2H, s, OCH2O); δC (75 MHz, CDCl3) 152.9 (C6), 147.1 (Cq-O3), 142.8 (Cq-O1), 140.3 (Cq), 
125.3 (Cq), 122.9 (C5), 121.8 (Cq), 112.7 (C9), 111.8 (C4), 102.5 (OCH2O); LRMS (ESI+): m/z 
174.1 [MH+]; IR (νmax, solid, cm-1): 2897, 1648, 1549, 1466, 1431, 1369, 1287, 1261, 1070, 
1050, 1020.  Spectral data consistent with the literature.173 
Benzo[d][1,3]dioxole-5-carbonitrile 313 
The remaining starting material rearranged to give the benzo[d][1,3]dioxole-
5-carbonitrile, of which a sample was isolated from the column. For 
reference: δH (300 MHz, CDCl3) 7.13 (1H, dd, J 8.1, 1.6, H6), 6.96 (1H, d, J 
1.3, H4), 6.85 (1H, d, J 8.4, H7), 5.99 (2H, s, OCH2O); δC (75 MHz, CDCl3) 151.7 (CqO), 148.2 
(CqO), 128.3 (C6), 119.0 (CN), 111.5 (C7), 109.2 (C4), 105.1 (C5), 102.3 (OCH2O). The 1H 
NMR data was consistent with the literature.258 
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6.9 Preparation of imide derivatives 
 
Isoindolo[2,1-b]isoquinoline-5,7-dione 143 
 
A solution of N-methoxybenzamide (302 mg, 2.00 mmol), CsOAc 
(115 mg, 0.600 mmol), [Cp*RhCl2]2 (12 mg, 2.0 mol%) and vinyl 
acetate (277 µL, 3.00 mmol) in MeOH (5 mL, 0.4 M) was heated for 48 
hours at 60 °C.  The reaction mixture was concentrated in vacuo and 
subsequently purified by flash silica chromatography using 50% EtOAc in hexane to afford 
isoindolo[2,1-b]isoquinoline-5,7-dione as a bright yellow amorphous solid (28 mg, 6%). RF 
0.33 (1:1 petrol–EtOAc) strong blue fluorescent trace; δH (500 MHz, CDCl3) 8.51 (1H, d, J 7.9, 
H4), 8.02 (1H, d, J 7.6, H8), 7.81 (1H, d, J 7.6 H11), 7.74 (1H, t, J 7.6, H10), 7.69 (1H, t, J 7.9, 
H2), 7.58 (1H, t, J 7.9, H9), 7.57 (1H, d, J 7.9, H1), 7.53 (1H, t, J 7.6, H3), 6.98 (1H, s, H12); δH 
(500 MHz, DMF-d7) 8.36 (1H, d, J 6.8, ArH), 8.19 (1H, d, J 7.1, ArH), 7.98 (1H, d, J 7.5, ArH), 
7.91 (1H, t, J 7.5, ArH), 7.85-7.77 (2H, m, ArH), 7.71 (1H, t, J 7.0, ArH), 7.63 (1H, t, J 7.5, 
ArH), 7.55 (1H, s);85 δC (75 MHz, CDCl3) 165.1 (C7O), 159.8 (C5O), 135.6 (Cq), 135.1 (Cq), 
134.7 (C10), 134.3 (Cq), 133.9 (C2), 130.6 (C1 or C9), 129.5 (C4), 128.5 (C3), 128.3 (Cq), 127.8 
(Cq), 127.4 (C1 or C9), 125.7 (C8), 120.5 (C11), 103.6 (C12); HRMS: m/z calculated for formula 
C16H9NNaO2 [MNa+]: 270.0525; found 270.0528; IR (νmax, solid, cm-1): 2925, 2852, 1838, 
1759, 1682, 1639, 1607, 1520, 1473, 1380, 1340, 1289, 1277, 1178, 1089, 1030, 957, 928, 860, 
766, 702; Spectral data consistent with the literature.85  
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General procedure (F) for the synthesis of methyl-2-alkynyl benzoates 
 
 
 
Following a modified procedure by Larock et al.,209 a nitrogen degassed solution of the terminal 
alkyne (1.1 eq.), methyl iodobenzoate (1.0 eq.), CuI (0.05 eq.) and PdCl2(PPh3)2 (0.01 eq.) in 
NEt3 (0.5 M) were stirred for 16 hours at room temperature. The reaction solution was 
concentrated in vacuo, rediluted in DCM, washed with saturated sodium thiosulphate, brine, 
dried (MgSO4) and concentrated in vacuo.  The crude material was purified by flash silica 
chromatography to afford the desired product.  The alkynes below are numbered according to 
the following system: 
 
 
General procedure (G) for the synthesis of tetracyclic imides 
 
 
 
 
 
A solution of [Cp*RhCl2]2 (1 mol%), CsOAc (2 eq.), N-(pivaloyloxy)benzamide (1 eq.) and the 
methyl alkynyl benzoate derivative (1.5 eq.) were stirred in MeOH (0.2 M) overnight at room 
temperature. Upon completion of the reaction, the crude mixture was concentrated in vacuo. 
The crude product was purified by various methods depending on the substrate (see below). 
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Methyl 2-(oct-1-yn-1-yl)benzoate 370209 
 
Isolated as a pale yellow oil (3.26 g, 76%) from 1-octyne (3.54 mL, 
24.0 mmol) following general procedure F.  The product was isolated by 
flash silica chromatography using 0-5% EtOAc in hexane. RF 0.4 (10% 
EtOAc in hexane); δH (300 MHz, CDCl3) 7.87 (1H, dd, J 7.8, 1.0, H6), 7.51 
(1H, dd, J 7.7, 1.0, H3), 7.41 (1H, td, J 7.6, 1.4, H4), 7.30 (1H, td, J 7.7, 1.4, H5), 3.91 (3H, s, 
OMe), 2.47 (2H, t, J 7.0, H3’), 1.68-1.57 (2H, m, H4’), 1.48-1.46 (2H, m, H5’), 1.38-1.28 (4H, m, 
H6’ and H7'), 0.90 (3H, t, J 6.8, H8’); δC (75 MHz, CDCl3) 167.2 (CO2Me), 134.4 (C3), 132.1 
(Cq), 131.6 (C4), 130.3 (C6), 127.2 (C5), 124.7 (Cq), 96.2 (C2’), 79.3 (C1’), 52.2 (OMe), 31.6 
(C3’), 28.8 (C4’), 28.8 (C5’), 22.7 (C6’), 20.0 (C7’), 14.2 (C8’); HRMS (ESI+): m/z calculated for 
formula: C16H21O2 [MH+] 245.1536; found 245.1534;  IR (νmax, solid, cm-1): 2952, 2857, 2227, 
1732, 1484, 1447, 1291, 1247, 1128, 1081.  Spectral data was consistent with the literature.209 
 
Purification of the parent imide 372 
 
 
N-(Pivaloyloxy)benzamide (221 mg, 1.00 mmol), [Cp*RhCl2]2 (6 mg, 0.01 mmol), CsOAc 
(382 mg, 2.00 mmol) and methyl 2-(1-octynyl)benzoate (366 mg, 1.50 mmol) were dissolved in 
MeOH (5 mL, 0.2 M). The reaction was stirred at room temperature for 16 hours and 
concentrated in vacuo. The reaction was initially purified by flash silica chromatography (A), 
however, due to the poor recovery an alternative precipitation and crystallisation work up (B) 
was employed. 
 
(A) Purification using flash silica chromatography: 
 
The crude material was purified by flash silica chromatography using 0-40% EtOAc in hexane 
(0-40%) with triethylamine (2.5% v/v), followed by a 10% MeOH in DCM flush to afford three 
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products: 12-hexylisoindolo[2,1-b]-isoquinoline-5,7-dione 372 as a yellow amorphous solid 
(11 mg, 3%); methyl 2-(4-hexyl-1-oxo-1,2-dihydroisoquinolin-3-yl)benzoate 371 (69 mg, 19%) 
as a colourless amorphous solid; and 2-(4-hexyl-1-oxo-1,2-dihydroisoquinolin-3-yl)benzoic 
acid, triethylamine salt 373 as an orange amorphous solid (121 mg, 27%). 
 
(B) Purification using precipitation and crystallisation: 
 
The crude reaction was suspended in cold ether (0 °C) and 2M HCl in ether (5 mL) was added 
to the solution to precipitate the product.  The solid was filtered and redissolved in CHCl3.  
CsOAc was filtered off from the solution, which was concentrated in vacuo and the crude 
product was crystallised from EtOAc.  The desired imide 372 was isolated as yellow needles 
(176 mg, 53%). 
 
12-Hexylisoindolo[2,1-b]isoquinoline-5,7-dione 372 
 
 RF 0.33 (50% EtOAc in hexane); M.p. 172-175 °C (EtOAc); 
δH (300 MHz, CDCl3) 8.56 (1H, d, J 7.9, H4), 8.07 (1H, d, J 7.6, H8), 
7.90 (1H, d, J 7.9, H1 or H11), 7.80-7.71 (3H, m, H3 and ArH), 7.58-
7.52 (2H, m, ArH), 3.19-3.08 (2H, m, H1’), 1.75 (2H, dt, J 10.9, 7.3, 
H2’), 1.67-1.54 (2H, m, H3’), 1.49-1.31 (4H, m, H4’ and H5’), 0.94 (3H, 
t, J 7.0, H6’); δC (75 MHz, CDCl3) 165.4 (C7O), 159.9 (C5O), 136.6 
(Cq) 135.4 (Cq), 135.0, 134.0 (C3), 131.1 (Cq), 129.8 (C4), 129.7, 128.7 (Cq), 128.5, 128.4 (Cq), 
126.0 (C8), 124.1, 123.8, 119.9 (Cq), 31.8 (C4’), 29.9 (C3’), 29.2 (C2’), 26.8 (C1’), 22.8 (C5’), 14.2 
(C6’); HRMS (ESI+): m/z calculated for formula: C22H22NO2 [MH+] 332.1645; found 332.1635; 
IR (νmax, solid, cm-1): 3080, 2952, 2851, 1758, 1673, 1599, 1472, 1293, 1157, 1097, 1034. 
 
Methyl 2-(4-hexyl-1-oxo-1,2-dihydroisoquinolin-3-yl)benzoate 371 
 
RF 0.2 (50% EtOAc in hexane); δH (500 MHz, CDCl3) 10.08 (1H, s, 
NH), 8.43 (1H, d, J 8.0, H8), 8.13 (1H, dd, J 7.9, 1.3, H6’), 7.72-7.71 
(2H, m, H6 and H5), 7.63 (1H, td, J 7.5, 1.5, H4’), 7.58 (1H, td, J 7.6, 
1.3, H5’), 7.52-7.47 (1H, m, H7), 7.40 (1H, dd, J 7.3, 1.2, H3’), 3.62 
(3H, s, OMe), 2.51-2.33 (2H, m, HA), 1.46-1.37 (2H, m, HB), 1.21-1.08 
(6H, m, HC, HD and HE), 0.80 (3H, t, J 7.2, HF); δC (125 MHz, CDCl3) 166.4 (CO2Me), 162.8 
(C1O), 138.1 (Cq), 136.7 (Cq), 135.7 (Cq), 132.7 (C4’), 132.4 (C5 or C6), 131.6 (C3’), 131.1 (C6’), 
130.5 (Cq), 129.5 (C5’), 128.2 (C8), 126.2 (C7), 125.6 (Cq), 123.7 (C5 or C6), 114.5 (Cq), 52.3 
(OMe), 31.5 (CD), 29.8 (CC), 29.5 (CB), 27.6 (CA), 22.6 (CE), 14.1 (CF); HRMS (ESI+): m/z 
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calculated for formula: C23H25NNaO3 [MNa+] 386.1727; found 386.1737; IR (νmax, solid, cm-1): 
2978, 2602, 2496, 1647, 1605, 1552, 1445, 1474, 1376, 1172, 1036. 
 
2-(4-Hexyl-1-oxo-1,2-dihydroisoquinolin-3-yl)benzoic acid, triethylamine salt 373 
 
δH (300 MHz, CDCl3) 9.50 (2H, br s, NH and HNEt3), 8.37 
(1H, d, J 8.0, H6’), 7.86 (1H, dd, J 7.3, 1.6, H8), 7.67-7.66 (2H, 
m, H3’ and H5), 7.44-7.33 (3H, m, H4’, H5’ and H6), 7.28-7.24 
(1H, m, H7), 2.48-2.33 (2H, m, HA), 2.91 (6H, q, J 7.2, N(CH2-
CH3)3) 1.55-1.42 (2H, m, HB), 1.40-1.23 (2H, m, HC), 1.15-1.13 
(13H, m, HD, HE and N(CH2CH3)3), 0.76 (3H, t, J 6.9, HF); δC (75 MHz, CDCl3) 172.0 (CO2-), 
162.1 (C1O), 138.4 (Cq), 138.4 (Cq), 137.2 (Cq), 133.7 (Cq), 132.3 (C3’ or C5), 130.4 (C8), 130.0 
(C7), 129.5, 129.1, 127.8 (C6’), 125.6 (ArH and Cq), 123.5 (C3’ or C5), 114.1 (Cq), 45.4 (N(CH2-
CH3)3), 31.4 (CD), 29.9 (CC), 29.4 (CB), 27.6 (CA), 22.5 (CE), 14.0 (CF), 8.40 (N(CH2CH3)3); 
HRMS (ESI+): m/z calculated for formula: C22H24NO3 [MH+] 350.1751; found 350.1758; IR 
(νmax, solid, cm-1): 2978, 2602, 2496, 1647, 1605, 1552, 1445, 1474, 1376, 1172, 1036. 
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Methyl 2-iodo-6-propoxybenzoate 385 
 
Following a modified procedure by Taylor et al.,213 s-BuLi (7.5 mL, 
11 mmol, 1.4 M in cyclohexane) was added to a solution of TMEDA (1.57 
mL, 10.5 mmol) in THF (20 mL). The resultant yellow solution was cooled 
to −100 °C (ethanol–N2 bath) and 2-propoxybenzoic acid (800 mg, 4.44 mmol) in THF (9 mL) 
was added via a syringe pump over 30 minutes. After a further 30 minutes at −100 °C, the 
orange/brown solution was warmed to −78 °C. Iodine (4.41 g, 17.4 mmol) in THF (5 mL) was 
added dropwise to the stirred solution at −78 °C, and the reaction mixture was subsequently 
stirred for another hour after the addition was complete. The reaction was quenched with 
saturated ammonium chloride solution (5 mL) and the solution was warmed to room 
temperature. The unreacted iodine was quenched with saturated sodium thiosulphate solution 
(40 mL). The phases were separated and the aqueous phase was extracted with Et2O (30 mL) 
and the organic phase was re-extracted with 2N NaOH (10 mL). The aqueous phases were 
combined and acidified to pH 2 with 4N HCl.  The aqueous phase was extracted with DCM (4 × 
50 mL) and dried over MgSO4.  The reaction was filtered and concentrated in vacuo to afford an 
oily yellow solid.  The crude residue was rediluted in DCM (10 mL) with catalytic DMF (10 
µL) and oxalyl chloride (300 µL, 3.54 mmol).  The reaction mixture was concentrated in vacuo 
and methanol was added to the residue.  The solvent was removed in vacuo and the crude 
material was purified by flash silica chromatography, using 10-30% EtOAc in hexane to afford 
a clear oil (454 mg, 32%). RF 0.71 (50% EtOAc in hexane); δH (300 MHz, CDCl3) 7.37 (1H, d, 
J 7.9, H3), 7.02 (1H, t, J 8.1, H4), 6.88 (1H, d, J 8.4, H5), 3.98-3.87 (5H, m, OMe and OCH2), 
1.80-1.71 (2H, m, OCH2CH2), 0.99 (3H, t, J 7.4, O(CH2)2CH3); δC (75 MHz, CDCl3) 168.1 
(CO2Me), 156.5 (C6), 131.6 (C3), 130.8 (C4), 120.2 (C1), 112.0 (C5), 92.4 (C2), 70.7 (OCH2), 
52.8 (OMe), 22.5 (OCH2CH2), 10.5 (O(CH2)2CH3); HRMS (ESI+): m/z calculated for formula 
C11H14IO3 [MH+]: 320.9982; found 320.9985; IR (νmax, solid, cm-1): 2966, 2877, 1753, 1583, 
1567, 1443, 1391, 1265, 1190, 1151, 1106, 1062, 1014. 
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Methyl 2-(oct-1-yn-1-yl)-6-propoxybenzoate 386 
 
The desired compound was isolated as a brown oil (382 mg, 90%) from 
methyl 2-iodo-6-propoxybenzoate (454 mg, 1.41 mmol) and 1-octyne 
(230 µL, 1.56 mmol) following general procedure F.  The product was 
isolated by flash silica chromatography using 0-10% EtOAc in hexane.  
RF 0.49 (10% EtOAc in hexane); δH (500 MHz, CDCl3) 7.23 (1H, t, J 8.1, H4), 6.99 (1H, d, 
J 7.7, H3), 6.83 (1H, d, J 8.4, H5), 3.94 (2H, t, J 6.4, OCH2), 3.90 (3H, s, J 3.2, OMe), 2.38 (2H, 
t, J 7.1, H3’), 1.81-1.72 (2H, m, OCH2CH2), 1.61-1.53 (2H, m, H4’), 1.43 (2H, q, J 7.8, H5’), 
1.36-1.26 (4H, m, H6’ and H7’), 1.00 (3H, t, J 7.4, O(CH2)2CH3), 0.90 (3H, t, J 7.0, 3H8’); 
δC (125 MHz, CDCl3); 167.9 (CO2Me), 155.8 (C6), 130.3 (C4), 126.8 (C1), 124.4 (C3), 123.0 
(C2), 111.9 (C5), 94.4 (C2’), 77.7 (C1’), 70.5 (OCH2), 52.4 (OMe), 31.5 (C6’), 28.8 (C5’), 28.7 
(C4’), 22.7 (C7’), 22.6 (OCH2CH2), 19.6 (C3’), 14.2 (O(CH2)2CH3), 10.5 (C8’); HRMS (ESI+): m/z 
calculated for formula: C19H27O3 [MH+] 303.1955; found 303.1959; IR (νmax, solid, cm-1): 2933, 
2875, 2859, 2246, 1737, 1594, 1574, 1456, 1430, 1390, 1302, 1278, 1261, 1117, 1090, 1067. 
 
12-Hexyl-8-propoxyisoindolo[2,1-b]isoquinoline-5,7-dione 387 
 
 The desired compound was isolated as yellow needles (106 mg, 32%) 
from methyl 2-(oct-1-yn-1-yl)-6-propoxybenzoate (290 mg, 
0.960 mmol, 1.10 eq.) and N-(pivaloyloxybenzamide) (192 mg, 
0.870 mmol) following general procedure G.  The crude reaction 
mixture was treated with 2N HCl in ether (1 mL) and stirred for 2 
hours to convert the methyl ester to the imide.  The solvent was 
removed in vacuo and the product was crystallised from cold MeOH.  RF 0.3 (33% EtOAc in 
hexane); M.p. 142-144 °C (MeOH); δH (500 MHz, CDCl3) 8.55 (1H, dd, J 7.9, 0.8, H4), 7.76-
7.69 (2H, m, H1 and H2), 7.63 (1H, t, J 8.1, H10), 7.51 (1H, ddd, J 8.1, 6.7, 1.5, H3), 7.43 (1H, d, 
J 7.8, H11), 6.97 (1H, d, J 8.3, H9), 4.13 (2H, t, J 6.4, OCH2), 3.13-3.05 (2H, m, H1’), 2.00-1.87 
(2H, m, OCH2CH2), 1.72 (2H, ddd, J 11.6, 10.4, 6.4, H2’), 1.64-1.54 (2H, m, H3’), 1.47-1.31 
(4H, m, H4’ and H5’), 1.13 (3H, t, J 7.4, O(CH2)2CH3), 0.93 (3H, t, J 7.1, H6’); δC (126 MHz, 
CDCl3) 163.2 (C5O), 159.7 (C7O), 159.2 (C8), 137.6 (Cq), 136.6 (Cq), 136.4 (C10), 133.7 (C2 or 
C1), 130.8 (Cq), 129.7 (C4), 128.7 (Cq), 128.2 (C3), 123.9 (C2 or C1), 119.3 (Cq), 115.7 (Cq), 
115.6 (C11), 113.3 (C9), 70.8 (OCH2), 31.8 (C4’), 29.9 (C3’), 29.1 (C2’), 26.7 (C1’), 22.8 (OCH-
2CH2), 22.7 (C5’), 14.2 (C6’), 10.6 (O(CH2)2CH3); HRMS (ESI+): m/z calculated for formula 
C25H27NNaO3 [MNa+]: 412.1883 found 412.1890; IR (νmax, solid, cm-1): 2959, 2921, 2860, 
1759, 1667, 1626, 1601, 1590, 1485, 1472, 1350, 1319, 1282, 1255, 1196, 1099, 1076, 1043. 
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5-Hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one 389215 
 
Thionyl chloride (1.0 mL, 14 mmol) in DME (0.5 mL) was added dropwise to a 
solution of 2,6-dihydroxybenzoic acid (1.5 g, 10 mmol) in DME (3 mL) with 
DMAP (61 mg, 0.50 mmol) and acetone (1 mL).  After four hours the solvents 
were removed in vacuo and the residue was filtered through a silica plug (1:1 
DCM-cyclohexane, 50 mL).  The solvent was removed in vacuo and the residue was diluted in 
hexane and cooled to 0 °C.  The product began to crystallise out and the resulting solid was 
collected by vacuum filtration to afford a colourless crystalline solid (1.10 g, 56%). M.p. 65-
66 °C ([lit.215 59-61 °C] hexane); δH (300 MHz, CDCl3) 10.32 (1H, s, OH), 7.40 (1H, t, J 8.3, 
H7), 6.62 (1H, d, J 8.4, H8), 6.43 (1H, d, J 8.1, H6), 1.74 (6H, s, (Me)2); δC (75 MHz, CDCl3) 
165.6 (C4O), 161.6 (CqO1), 155.7 (C5), 138.0 (C7), 110.9 (C8), 107.4 (C6), 107.3 (C2), 99.5 (Cq-
C4), 25.8 ((Me)2); LRMS (ESI+): m/z 195.0 [MH+]; IR (νmax, film, cm-1): 3203, 3000, 1687, 
1629, 1584, 1486, 1470, 1390, 1379, 1346, 1272, 1199, 1151, 1074, 1054. Spectral data match 
the literature.215 
 
Trifluoromethanesulfonic acid 2,2-dimethyl-4-oxo-4H-1,3-benzodioxin-5-yl ester  390215 
 
Triflic anhydride (780 µL, 4.64 mmol) was added dropwise to a cooled solution 
(0 °C) of 5-hydroxy-2,2-dimethyl-4H-benzo[d][1,3]dioxin-4-one (750 mg, 
3.87 mmol) in DCM (0.5 M) with pyridine (1.13 mL, 13.9 mmol).  After one 
hour, the reaction was diluted with 0.1 M HCl (30 mL) and the aqueous phase 
was extracted three times with diethyl ether (3 × 30 mL).  The organic phases were combined 
and dried over MgSO4.  The solvent was removed in vacuo and purified by flash silica 
chromatography using 25% EtOAc in hexane to afford colourless needles (1.01 g, 87%) which 
were subsequently recrystallised from hexane. M.p. 112-114 °C ([lit.215 115-117 °C], hexane); 
δH (300 MHz, CDCl3) 7.60 (1H, t, J 8.4, H7), 7.05 (1H, d, J 8.5, H6), 7.00 (1H, d, J 8.3, H8), 
1.76 (6H, s, (Me)2); δC (75 MHz, CDCl3) 157.6 (C4), 157.2 (C5), 148.8 (Cq-O1), 136.4 (C7), 
118.9 (q, J 320, CF3), 118.0 (C6), 116.7 (C8), 108.5 (Cq-C4), 107.0 (C2), 25.6 ((Me)2); LRMS 
(ESI+): m/z 326.9 [MH+]; IR (νmax, film, cm-1): 1744, 1621, 1474, 1430, 1323, 1293, 1138, 1074. 
Spectral data match the literature.215 
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2,2-Dimethyl-5-(oct-1-yn-1-yl)-4H-benzo[d][1,3]dioxin-4-one 391 
 
Following a modified procedure by Sakamoto et al.,215 octyne 
(130 µL, 0.86 mmol) was added to a degassed solution of 
2,2-dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl trifluoromethane 
sulfonate (254 mg, 0.780 mmol), PdCl2(PPh3)2 (30 mg, 
0.040 mmol), copper(I) iodide (23 mg, 0.12 mmol) and diethylamine (120 µL, 1.17 mmol) in 
MeCN (16 mL, 0.05 M). The yellow solution was heated to 70 °C for three hours.  The reaction 
solvent was removed in vacuo and the crude mixture was partitioned between EtOAc (25 mL) 
and water (25 mL). The two phases were separated, and then the aqueous phase was extracted 
with EtOAc (25 mL). The organic extracts were combined and washed with water (25 mL), 
brine (25 mL), dried over MgSO4 and concentrated in vacuo. The crude oil was purified using 
flash silica chromatography using 10-30% EtOAc in hexane to afford a brown oil (138 mg, 
62%). δH (500 MHz, CDCl3) 7.40 (1H, t, J 7.9, H7), 7.19 (1H, dd, J 7.7, 0.9, H6), 6.86 (1H, dd, J 
8.2, 0.9, H8), 2.51 (2H, t, J 7.2, H3’), 1.71 (6H, s, (Me)2), 1.66 (2H, app q, J 7.5, H4’), 1.53-1.45 
(2H, m, H5’), 1.37-1.30 (4H, m, H6’ and H7’), 0.90 (3H, t, J 7.0 Hz, H8’); δC (75 MHz, CDCl3); 
13C NMR (126 MHz, CDCl3) δ 159.1 (C4), 156.7 (Cq-O1), 134.9 (C7), 129.0 (C6), 126.6 (C5), 
116.5 (C8), 114.3 (Cq-C4), 105.6 (C2), 98.8 (C2’), 78.8 (C1’), 31.6 (C4’), 28.8 (C5’), 28.6 (C6’), 
25.9 ((Me)2), 22.7 (C7’), 20.2 (C3’), 14.2 (C8’); HRMS (ESI+): m/z calculated for formula 
C18H23O3 [MH+] 287.1641: found 287.1642; IR (νmax, solid, cm-1): 2998, 2931, 2587, 2228, 
1748, 1593, 1578, 1475, 1437, 1389, 1316, 1293, 1271, 1255, 1232, 1205, 1169, 1085, 1039. 
 
3-(2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)-4-hexylisoquinolin-1(2H)-one 392 
 
2,2-Dimethyl-5-(oct-1-yn-1-yl)-4H-benzo[d][1,3]dioxin-4-one (138 mg, 
0.480 mmol) was added to a solution of N-(pivaloyloxy)-benzamide 
(110 mg, 0.500 mmol), CsOAc (30 mg, 0.30 mmol) and [Cp*RhCl2]2 (3 
mg, 0.005 mmol) in MeOH (2.5 mL, 0.20 M).  After 16 hours 
consumption of the starting material was observed by TLC. The reaction 
was concentrated in vacuo and purified by flash silica chromatography 
using 8% isopropanol in toluene to afford an orange-brown solid (195 mg, 96%).  The solid was 
triturated with cold Et2O (3 × 5 mL) to afford a colourless solid (143 mg, 71%).  A sample was 
taken and recrystallised from CHCl3 and pentane using a vapour diffusion to afford colourless 
cubic crystals. M.p. 231-234 °C (CHCl3–pentane); δH (500 MHz, CDCl3) 10.25 (1H, s, NH), 
8.27 (1H, d, J 8.2, H8), 7.71-7.65 (2H, m, H6 and H5), 7.63 (1H, t, J 7.5, H7’), 7.43 (1H, ddd, J 
8.1, 5.9, 2.3, H7), 7.15 (1H, dd, J 8.0, 0.7, H8’), 7.10 (1H, dd, J 7.5, 0.9, H6’), 2.51 (1H, ddd, J 
14.4, 10.0, 6.4, HA), 2.39 (1H, ddd, J 14.3, 9.9, 6.6, Ha), 1.81 (3H, s, Me), 1.74 (3H, s, Me), 
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1.53-1.43 (2H, m, HB), 1.25-1.11 (6H, m, HC, HD and HE), 0.82 (3 H, t, J 7.0, HF); δC (125 MHz, 
CDCl3) 162.8 (C1), 158.4 (C4’), 157.3 (C-O1’), 138.2 (Cq), 137.4 (Cq), 135.6 (C7'), 135.5 (Cq), 
132.4 (C6), 128.0 (C8), 126.0 (C7 and C6’), 123.8 (C5), 118.9 (C8’), 114.0 (Cq), 113.0 (Cq), 106.1 
(C2’), 31.6 (CA), 29.9 (CB), 29.7 (CC), 27.9 (CD), 26.2 (Me), 25.6 (Me), 22.7 (CE), 14.1 (CF), one 
quaternary carbon was not observed; HRMS (ESI+): m/z calculated for formula C25H28NO4 -
[MH+] 406.2013: found 406.2023; IR (νmax, solid, cm-1): 2952, 2926, 2856, 1742, 1647, 1602, 
1583, 1478, 1381, 1311, 1276, 1202, 1044. 
 
12-Hexyl-8-hydroxyisoindolo[2,1-b]isoquinoline-5,7-dione 393 
 
Sodium hydride (100 mg, 2.50 mmol, 60% dispersion in oil) was 
triturated with petrol (2 × 5 mL) under nitrogen and diluted in THF 
(10 mL). In a separate flask, 3-(2,2-dimethyl-4-oxo-4H-benzo[d][1,3]-
dioxin-5-yl)-4-hexylisoquinolin-1(2H)-one (100 mg, 0.250 mmol) was 
dissolved in THF (5 mL) and cooled to 0 °C. An aliquot of the sodium 
hydride solution (1.00 mL, 0.250 mmol) was added dropwise to the 
reaction. The homogeneous solution changed colour from pale yellow to bright orange, 
indicating formation of the phenolate ion. An additional aliquot of the sodium hydride solution 
(1.00 mL, 0.25 mmol) was added in order to achieve full conversion. The reaction mixture was 
quenched with acetic acid (0.5 mL), at which point the solution changed colour from orange to 
bright yellow. The reaction was concentrated in vacuo and the residue was rediluted in acetic 
acid (1 mL). The resultant solid was filtered and washed with Et2O (2 mL) to afford an 
amorphous yellow solid (55 mg, 63%). The solid was recrystallised from AcOH. M.p. 215-
218 °C (AcOH); δH (500 MHz, CDCl3) 8.69 (1H, s, OH), 8.56 (1H, d, J 7.9, H4), 7.77-7.76 (2H, 
m, H2 and H1), 7.63 (1H, t, J 8.0, H10), 7.58-7.55 (1H, m, H3), 7.37 (1H, d, J 7.7, H11), 7.00 (1H, 
d, J 8.2, H9), 3.14-3.07 (2H, m, H1’), 1.77-1.70 (2H, m, 2H2’), 1.59 (2H, q, J 7.5, 2H3’), 1.45-
1.33 (4H, m, 2H4’ and 2H5’), 0.94 (3H, t, J 7.0, H6’); δC (126 MHz, CDCl3) 168.2 (C7O), 159.7 
(C5O), 158.2 (C8O), 137.4 (C10), 136.5 (Cq), 135.2 (Cq), 134.2 (C1 or C2), 131.0 (Cq), 129.9 (C4), 
128.7 (C3), 128.1 (Cq), 124.2 (C1 or C2), 121.4 (Cq), 117.2 (C9), 115.6 (C11), 112.8 (Cq), 31.8 
(C4’), 29.9 (C3’), 29.1 (C2’), 26.9 (C1’), 22.8 (C5’), 14.2 (C6’); HRMS (ESI+): m/z calculated for 
formula C22H22NO3 [MH+]: 348.1594; found 348.1590; IR (νmax, solid, cm-1): 3220, 2959, 2919, 
2854, 1743, 1665, 1612, 1589, 1474, 1458, 1445, 1354, 1341, 1294, 1212, 1189, 1177, 1159, 
1117, 1081, 1064, 1038. 
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N-(pivaloyloxy)-2-naphthamide 396259 
 
Oxalyl chloride (480 µL, 5.50 mmol) was added to a solution of 
2-naphthoic acid (860 mg, 5.00 mmol) in DCM (25 mL, 0.2 M) with 
DMF (2 drops).  The mixture was stirred at room temperature for 2 
hours, then concentrated in vacuo. The crude acid chloride was diluted in EtOAc (5 mL) and 
transferred to a flask containing O-(pivaloyl)-hydroxylammonium triflate34 (1.34 g, 5.00 mmol) 
and NaHCO3 (840 mg, 10.0 mmol) dissolved in a 2:1 mixture of EtOAc–H2O (45 mL, 0.1 M) at 
0 °C.  After 2 hours the reaction was quenched with saturated aqueous NaHCO3 (50 mL) and 
diluted with EtOAc (50 mL).  The two phases were separated and the organic phase was washed 
with brine (50 mL).  The organic phase was dried over MgSO4 and concentrated in vacuo.  The 
solid was crystallised from Et2O–pentane to afford colourless crystals (901 mg, 66%).  M.p. 
110-113 °C (Et2O–pentane); δH (300 MHz, CDCl3) 9.80 (1H, br s, NH), 8.31 (1H, s, H1), 7.90-
7.74 (4H, m, ArH), 7.62-7.44 (2H, m, ArH), 1.36 (9H, s, (CH3)3); δC (75 MHz, CDCl3) δ 177.3 
(CqO), 167.0 (CqO), 135.3 (Cq), 132.5 (Cq), 129.2, 128.8, 128.6, 128.3, 128.1 (Cq), 127.9, 127.0, 
123.5, 38.6 (C(CH3)3), 27.2 (CH3)3); HRMS (ESI+): m/z calculated for formula C16H18NO3 [M-
H+]: 272.1281; found 272.1281; IR (νmax, solid, cm-1): 3146, 2967, 2938,  1782, 1644, 1627, 
1600, 1505, 1479, 1462, 1435, 1387, 1369, 1298, 1269, 1236, 1145, 1117, 1071, 1035, 1012.  
The spectral data was consistent with the literature.259 
 
3-(2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)-4-hexylbenzo[g]isoquinolin-1(2H)-one 
397 
2,2-Dimethyl-5-(oct-1-yn-1-yl)-4H-benzo[d][1,3]dioxin-4-one 
(315 mg, 1.10 mmol) was added to a solution of N-(pivaloyloxy)-
2-napthamide (271 mg, 1.00 mmol), CsOAc (384 mg, 
2.00 mmol) and [Cp*RhCl2]2 (6 mg, 0.01 mmol) in MeOH 
(5 mL, 0.2 M).  After 2 hours the reaction was concentrated in 
vacuo and a 1H NMR of the crude reaction mixture indicated a 
mixture of regioisomers.  The crude material was purified by flash silica chromatography using 
50% EtOAc in pentane to afford an orange-brown solid (231 mg, 51%) and mixed fractions 
containing a mixture of regioisomers (5:2, 397:398, 124 mg, 27%).  A sample from the pure 
fractions were removed and crystallised from slow mixing of THF and pentane to afford 
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colourless crystals.  M.p. 194-197 °C (THF– pentane); δH (500 MHz, CDCl3) 9.77 (1H, s, NH), 
8.89 (1H, s, H10), 8.12 (1H, s, H5), 8.02 (1H, d, J 8.2, H9), 7.97 (1H, d, J 8.3, H6), 7.64 (1H, dd, 
J 8.3, 7.6, H7’), 7.58 (1H, ddd, J 8.2, 6.8, 1.2, H7), 7.51 (1H, ddd, J 8.0, 6.8, 1.1, H8), 7.18-7.15 
(2H, m, H6’ and H8’), 2.66-2.57 (1H, m, HA), 2.55-2.46 (1H, m, HA), 1.80 (3H, s, Me), 1.75 (3H, 
s, Me), 1.60-1.52 (2H, m, HB), 1.31-1.15 (6H, m, HC, HD and HE), 0.84 (3H, t, J 7.0, HF); 
δC (126 MHz, CDCl3) 163.3 (C4’), 158.4 (C1), 157.3 (C-O), 137.7 (Cq), 135.7 (C7’), 135.6 (Cq), 
134.2 (Cq), 134.1 (Cq), 131.3 (Cq), 129.4 (C9), 129.2 (C10), 128.1 (C6 and C7), 126.2 (C8’), 126.0 
(C8), 124.7 (Cq), 122.4 (C5), 118.9 (C6’), 113.7 (Cq), 113.0 (Cq), 106.1 (Cq), 31.6 (CD), 29.7 (CB), 
29.7 (CC), 28.2 (CA), 26.0 (Me), 25.7 (Me), 22.7 (CE), 14.2 (CF); HRMS (ESI+): m/z calculated 
for formula C29H30NO4 [MH+]: 456.2169; found 456.2172; IR (νmax, solid, cm-1): 2927, 2857, 
1746, 1737, 1650, 1622, 1597, 1581, 1476, 1442, 1381, 1362, 1314, 1273, 1240, 1200, 1149, 
1096, 1040. 
 
14-Hexyl-4-hydroxybenzo[g]isoindolo[2,1-b]isoquinoline-5,7-dione 400 
 
Sodium hydride (19 mg, 0.81 mmol, 60% dispersion in oil) was 
triturated with pentane (2 × 1 mL) under nitrogen and diluted in 
THF (0.5 mL).  In a separate vial, 3-(2,2-dimethyl-4-oxo-4H-
benzo[d][1,3]dioxin-5-yl)-4-hexylbenzo[g]isoquinolin-1(2H)-one 
(88 mg, 0.19 mmol) was dissolved in THF (3 mL, 0.06 M) and 
cooled to 0 °C. The sodium hydride solution was added dropwise to the reaction.  The 
homogeneous solution changed colour from pale yellow to bright orange, indicating formation 
of the phenolate ion.  After 30 minutes the reaction was quenched with acetic acid (0.5 mL), at 
which point the solution changed colour from orange to bright yellow.  The reaction mixture 
was concentrated in vacuo and the residue was triturated with water (1 mL) and dissolved into 
DCM (15 mL), dried (MgSO4), filtered and concentrated in vacuo to afford a yellow amorphous 
solid (52 mg, 69%).  The solid was crystallised by slow evaporation of CHCl3 to afford yellow 
needles.  M.p. 244-246 °C (CHCl3); δH (500 MHz, CDCl3) 9.04 (1H, s, H8), 8.73 (1H, s, OH), 
8.14 (1H, s, H13), 8.00 (1H, d, J 8.2, H9), 7.97 (1H, d, J 8.3, H12), 7.65-7.61 (2H, m, H2 and H11), 
7.55 (1H, ddd, J 8.0, 6.8, 1.1, H10), 7.38 (1H, d, J 7.8, H1), 6.96 (1H, d, J 8.3, H3), 3.24-3.17 
(2H, m, H1’), 1.82-1.76 (2H, m, H2’), 1.68-1.61 (2H, m, H3’), 1.49-1.35 (4H, m, H4’ and H5’), 
0.95 (3H, t, J 7.2, H6’); δC (126 MHz, CDCl3) δ 167.9 (CqO), 159.9 (CqO), 157.9 (CqO), 137.1 
(C8), 135.9 (Cq), 135.0 (Cq), 132.2 (Cq), 131.7 (C9), 130.0 (Cq), 129.5 (C2), 129.3 (C11), 128.4 
(C12), 127.6 (C10), 125.0 (Cq), 124.0 (C13), 121.9 (Cq), 116.7 (C3), 115.5 (C1), 112.9 (Cq), 31.7 
(C1’), 29.8 (C2’), 28.9 (C3’), 26.9 (C4’), 22.7 (C5’), 14.1 (C6’), missing a quaternary carbon. 
HRMS (ESI+): m/z calculated for formula C26H23NNaO3 [MNa+]: 420.1570; found 420.1571; IR 
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(νmax, solid, cm-1): 3243, 2950, 2923, 2873, 2854, 1742, 1664, 1619, 1596, 1567, 1490, 1464, 
1440, 1347, 1324, 1308, 1277, 1259, 1232, 1209, 1178, 1164, 1076, 1055, 1015. 
 
 
 
Ethyl 4’-(dimethylamino)-[1,1’-biphenyl]-4-carboxylate 403 
 
Following a modified procedure by Buchwald et al.,217 palladium acetate (25 mg, 
0.11 mmol) and SPhos (130 mg, 0.320 mmol) were charged into an oven-dried 
Schlenk flask and evacuated and refilled with nitrogen (×3). Degassed THF (5 mL) 
was added to the flask and the solution was allowed to stir at room temperature for 
30 minutes. In a separate Schlenk flask, 4-(dimethylamino)-phenylboronic acid 
(2.62 g, 15.9 mmol) and potassium phosphate tribasic (6.74 g, 31.8 mmol) and ethyl 
4-bromobenzoate (1.73 mL, 10.6 mmol) were charged into a flask which was evacuated and 
refilled with nitrogen (×3). Degassed THF (15 mL) was added followed by the palladium 
acetate/SPhos solution. The reaction mixture was stirred for 16 hours at room temperature. The 
reaction mixture was diluted with water (100 mL) and the aqueous phase was extracted with 
DCM (3 × 75 mL). The organic extracts were recombined and washed with brine (50 mL), dried 
over Na2SO4 and concentrated in vacuo. The crude material was purified by flash silica 
chromatography using 10% EtOAc in pentane to afford a colourless solid (2.24 g, 79%). A 
sample was taken and recrystallized from EtOAc.  RF 0.66 (20% EtOAc in hexane); M.p. 180-
182 °C (EtOAc); δH (300 MHz, CDCl3) 8.06 (2H, d, J 8.3, H3), 7.62 (2H, d, J 8.3, H4), 7.56 
(1H, d, J 8.8, H2’), 6.84 (1H, d, J 8.6, H3’), 4.39 (2H, q, J 7.1, OCH2CH3), 3.02 (6H, s, NMe2), 
1.41 (3H, t, J 7.1, OCH2CH3); δC (75 MHz, CDCl3) 166.9 (CO2Et), 150.6 (Cq), 145.6 (Cq), 130.2 
(C2’), 128.1 (C2), 128.0 (2Cq), 125.9 (C3), 113.0 (C3’), 60.9 (OCH2CH3), 40.8 (NMe2), 14.5 
(OCH2CH3); LRMS (ESI+): m/z 270.1 [MH+]; found 270.1; IR (νmax, solid, cm-1): 2981, 1702, 
1603, 1536, 1500, 1467, 1444, 1402, 1365, 1313, 1280, 1221, 1184, 1169, 1106, 1064, 1026.  
The spectral data corresponds to the literature values.260 
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4’-(Dimethylamino)-[1, 1’-biphenyl]-4-carboxylic acid 404 
 
The biphenyl ester (X) (2.24 g, 8.30 mmol) was heated to reflux in a solution of 
ethanol–water (2:1, 60 mL, 0.1 M) with KOH (1.0 g, 18 mmol) for 16 hours, after 
which time the reaction solution was neutralised with sat. NH4Cl solution. The 
resulting precipitate was filtered and washed with water. The amorphous solid was 
dried at 70 °C in vacuo to afford a brown solid (2.00 g, quant.). δH (300 MHz, 
DMSO-d6) 7.93 (2H, d, J 7.9, H3), 7.68 (2H, d, J 8.0, H2), 7.59 (2H, d, J 8.3, H2’), 
6.81 (2H, d, J 8.6, H3’), 3.55 (1H, br s, OH), 2.95 (6H, s, NMe2); δC (75 MHz, DMSO) 167.6 (C-
O2H), 150.3 (Cq), 143.8 (Cq), 129.9 (C2’), 127.4 (C2), 126.2 (Cq), 126.1 (Cq), 125.0 (C3), 112.5 
(C3’), 39.9 (NMe2); LRMS (ESI+): m/z 242.1 [MH+]; found 242.0. The spectral data was 
consistent with the literature.260   
 
4’-(Dimethylamino)-N-(pivaloyloxy)-[1, 1’-biphenyl]-4-carboxamide 405 
 
Oxalyl chloride (1.31 mL, 15.0 mmol) was added to a solution of the 
biphenyl acid X (2.0 g, 8.3 mmol) in DCM (50 mL, 3.3 M) with cat. DMF 
(10 µL). After two hours the reaction was concentrated in vacuo to afford the 
crude acid chloride. The crude intermediate was transferred to a separate flask 
containing N-(pivaloyl)ammonium triflate (2.94 g, 11.0 mmol) in a biphasic 
solution of EtOAc–water (2:1, 100 mL, 0.1 M) with NaHCO3 (1.68 g, 
20.0 mmol) at 0 °C. After 16 hours the reaction mixture was diluted with 
EtOAc (100 mL) and the phases were separated. The organic phase was washed with brine 
(50 mL) and dried over Na2SO4 and concentrated in vacuo. The crude material was purified by 
flash silica chromatography using 10-50% EtOAc in hexane to afford an orange solid (1.10 g, 
39%). A sample was recrystallized from EtOAc.  RF 0.9 (50% EtOAc in hexane); M.p. 90-92 °C 
(EtOAc); δH (300 MHz, CDCl3) 9.36 (1H, s, NH), 7.84 (2H, d, J 8.3, H3), 7.64 (2H, d, J 8.2, 
H2), 7.54 (2H, d, J 8.9, H2’), 6.80 (2H, d, J 8.8, H3’), 3.02 (6H, s, NMe2), 1.38 (9H, s, (CH3)3); δC 
(75 MHz, CDCl3) 177.3 (CO2tBu), 167.1 (CONH), 150.7 (Cq), 145.8 (Cq), 128.1 (C2’ and C2), 
128.0 (Cq), 127.3 (Cq), 126.3 (C3), 112.8 (C3’), 40.6 (NMe2), 38.6 (C(CH3)3), 27.1 (C(CH3)3); 
HRMS (ESI+): m/z calculated for formula C20H24N2NaO3 [MNa+] 363.1679; found 363.1685; IR 
(νmax, solid, cm-1):  3187, 2959, 2933, 2904, 1779, 1734, 1697, 1653, 1598, 1535, 1501, 1478, 
1397, 1361, 1269, 1220, 1168, 1142, 1075, 1028. 
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3-(2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl-)-6-(4-dimethylamino)phenyl)-4-
hexylisoquinolin-1(2H)-one 406 – major regioisomer 
 
2,2-Dimethyl-5-(oct-1-yn-1-yl)-4H-benzo[d][1,3]dioxin-4-one 
(315 mg, 1.10 mmol) was added to a solution of 
4’-(dimethylamino)-N-(pivaloyloxy)-[1,1’-biphenyl]-4-
carboxamide (340 mg, 1.00 mmol), CsOAc (382 mg, 
2.00 mmol) and [Cp*RhCl2]2 (6 mg, 0.01 mmol) in MeOH 
(5.0 mL, 0.2 M). After 16 hours the reaction mixture was 
concentrated in vacuo and a 1H NMR of the crude reaction mixture indicated a 4:1 mixture 
between the major regioisomer X and the minor regioisomer X. The crude material was purified 
by flash silica chromatography using 50% EtOAc in pentane to afford the minor regioisomer X 
as an amorphous tan solid (63 mg, 12%) and the major regioisomer as a tan amorphous solid X 
(222 mg, 42%) (combined yield: 54%, ratio 3.5:1).  A sample from the pure fractions of the 
major regioisomer were removed and crystallised from slow mixing of THF and pentane to 
afford colourless crystals. M.p. 247-248 °C (THF–pentane); δH (300 MHz, CDCl3) 10.04 (1H, s, 
NH), 8.28 (1H, d, J 8.0, H8), 7.82 (1H, s, H5), 7.66-7.58 (4H, m, H7, H7’ and H2’’), 7.15 (1H, d, J 
7.7, H8’), 7.11 (1H, d, J 7.7, H6’), 6.84 (2H, d, J 8.7, H3’’), 3.03 (6H, s, NMe2), 2.63-2.35 (2H, m, 
HA), 1.82 (3H, s, Me), 1.75 (3H, s, Me), 1.59-1.46 (2H, m, HB), 1.33-1.10 (6H, m, HC, HD and 
HE), 0.83 (3H, t, J 6.5, HF); δC (75 MHz, CDCl3) 162.7 (C4’), 158.4 (Cq-O1’), 157.2 (C1), 150.6 
(C4’’-NMe2), 145.2 (Cq), 138.5 (Cq), 137.5 (Cq), 135.6 (C7), 128.5 (C8), 128.3 (C2’’), 126.1 (C6’), 
124.7 (C7’), 123.9 (Cq), 120.7 (C5), 118.8 (C8’), 114.1 (Cq), 113.1 (Cq), 112.8 (C3’’), 106.1 (Cq), 
40.6 (NMe2), 31.5 (CD), 29.9 (CC), 29.7 (CB), 27.9 (CA), 26.2 (Me), 25.6 (Me), 22.7 (CE), 14.2 
(CF), two quaternary carbons were obscured; HRMS (ESI+): m/z calculated for formula C33H37-
N2O4 [MH+] 525.2748; found 525.2758; IR (νmax, solid, cm-1):  2926, 2856, 1746, 1647, 1601, 
1584, 1546, 1503, 1478, 1444, 1361, 1330, 1309, 1279, 1201, 1044. 
 
4-(2,2-Dimethyl-4-oxo-4H-benzo[d][1,3]dioxin-5-yl)-6-(4-dimethylamino)phenyl-3-
hexylisoquinoline-1-(2H)-one 407 – minor regioisomer 
 
M.p. >250 °C (DCM–pentane); δH (300 MHz, CDCl3) 
10.32 (1H, s, NH), 8.43 (1H, d, J 8.4, H8), 7.62 (1H, t, 
J 7.9, H5’), 7.58 (1H, dd, J 8.2, 1.8, H7), 7.34 (2H, d, J 8.8, 
H2’’), 7.09 (1H, dd, J 8.2, 0.8, H6’), 7.02 (1H, dd, J 7.5, 
0.8, H4’), 6.95 (1H, d, J 1.4, H5), 6.70 (2H, d, J 8.8, H3’’), 
2.96 (6H, s, NMe2), 2.47-2.24 (2H, m, HA), 1.75 (3H, s, Me), 1.74 (3H, s, Me), 1.65-1.55 (2H, 
m, HB), 1.38-1.11 (6H, m, HC, HD and HE), 0.84 (3H, t, J 6.6, HF); δC (75 MHz, CDCl3) 163.8 
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(C4’), 158.5 (Cq-O1’), 157.3 (C1), 150.4 (C4’’), 145.3 (Cq), 140.0 (Cq), 139.3 (Cq), 137.8 (Cq), 
135.6 (C5’), 128.4 (Cq), 128.2 (C2’’), 128.0 (C4’), 127.9 (C8), 124.5 (C7), 122.6 (Cq), 121.1 (C5), 
117.6 (C6’), 114.9 (Cq), 114.5 (Cq), 112.6 (C3’’), 105.5 (Cq), 40.5 (NMe2), 31.8 (CD), 31.4 (CC), 
29.3 (CB), 28.5 (CA), 25.9 (Me), 25.9 (Me), 22.6 (CE), 14.2 (CF); HRMS (ESI+): m/z calculated 
for formula C33H37N2O4 [MH+] 525.2748; found 525.2765; IR (νmax, solid, cm-1): 2924, 2854, 
2806, 1738, 1647, 1626, 1597, 1578, 1544, 1530, 1504, 1475, 1459, 1435, 1358, 1315, 1271, 
1205, 1167, 1111, 1042. 
 
2-(4-(Dimethylamino)phenyl-12-hexyl-8-hydroxyisoindolo[2,1–b]isoquinoline-5,7-dione 
408 
 
 Sodium hydride (19 mg, 0.81 mmol, 60% dispersion in oil) 
was triturated with pentane (2 × 1 mL) under nitrogen and 
diluted in THF (1 mL).  In a separate vial, 4-(2,2-dimethyl-4-
oxo-4H-benzo[d][1,3]dioxin-5-yl)-6-(4-dimethylamino)-
phenyl-3-hexylisoquinoline-1-(2H)-one (X) (100 mg, 
0.190 mmol) was dissolved in THF (5 mL, 0.04 M) and cooled 
to 0 °C. The sodium hydride solution was added to the reaction solution, which was allowed to 
warm to room temperature and stirred overnight. The reaction was acidified with 2N HCl in 
ether (2 mL) and the solvents were removed in vacuo. The crude reaction mixture was dissolved 
in DCM (5 mL) and the solid was filtered from the reaction.  The filtrate was concentrated in 
vacuo and precipitated using diethyl ether (2 mL) to afford a red amorphous solid (49 mg, 
50%). The solid was crystallised from DMSO. M.p. >250 °C; δH (500 MHz, DMSO-d6, 343 K) 
8.33 (1H, d, J 8.3, H4), 7.96 (1H, s, H1), 7.82 (1H, d, J 8.3, H3), 7.72 (2H, d, J 8.7, H2’), 7.65 
(1H, t, J 7.9, H10), 7.46 (1H, d, J, 7.7, H11), 7.14 (1H, d, J 8.2, H9), 7.04 (2H, d, J 7.7, H3’), 3.22-
3.15 (2H, m, HA), 3.02 (6H, s, NMe2), 1.75-1.66 (2H, m, HB), 1.63-1.54 (2H, m, HC), 1.44-1.36 
(2H, m, HD), 1.36-1.27 (2H, m, HE), 0.89 (3H, t, J 7.1, HF); δC (126 MHz, DMSO-d6, 343 K) 
162.9 (C7O), 158.2 (C5O), 157.5 (C8O), 145.2 (Cq), 136.4 (Cq), 136.3 (C10), 135.8 (Cq), 128.7 
(C4), 127.6 (C2’), 125.4 (C3), 125.1 (Cq), 120.4 (C1), 118.4 (Cq), 117.6 (C9), 114.4 (C11), 113.7 
(C3’), 112.5 (Cq), 40.4 (NMe2), 30.7 (CD), 28.3 (CC), 28.1 (CB), 25.2 (CA), 21.6 (CE), 13.4 (CF), 
three quaternary carbons obscured; HRMS (ESI+): m/z calculated for formula C30H30N2NaO3 -
[MNa+] 489.2149; found 489.2151; IR (νmax, solid, cm-1): 3309, 2951, 2921, 2853, 1743, 1592, 
1530, 1486, 1450, 1356, 1311, 1168, 1084, 1068, 1043. 
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2-Iodo-4-methoxy benzoic acid 410214  
 
s-BuLi (20 mL, 28 mmol, 1.4 M in hexane) was added to a cooled solution 
(−78 °C) of TMEDA (4.14 mL, 27.7 mmol) in THF (60 mL). The yellow 
solution was stirred for 30 minutes at −78 °C. p-Anisic acid (2.0 g, 
13 mmol), dissolved in THF (15 mL) was added dropwise to the s-BuLi/TMEDA solution 
whilst keeping the temperature of the reaction mixture at −70 °C.  The solution was stirred at 
−78 °C for 2 hours, then the mixture was treated with an excess of iodine (10.0 g, 20.0 mmol) 
dissolved in THF (10 mL) after which the reaction was stirred for a further 30 minutes.  The 
resulting solution was then allowed to warm to ambient temperature and saturated NH4Cl (50 
mL) was added to the reaction. The aqueous phase was treated with saturated sodium 
thiosulphate (50 mL) and washed with diethyl ether (2 × 30 mL).  The aqueous layer was 
acidified to pH 1 using 2 M HCl.  The aqueous phase was then extracted with diethyl ether 
(4 × 100 mL) and the organic phases were combined and dried over MgSO4.  The solution was 
concentrated in vacuo and the crude product was crystallised from CHCl3–Et2O to afford a 
colourless crystalline solid (1.54 g, 78%). δH (300 MHz, CDCl3) 8.05 (1H, d, J 8.8, H6), 7.58 
(1H, d, J 2.5, H3), 6.95 (1H, dd, J 8.8, 2.5, H5), 3.86 (3H, s, OMe); δC (75 MHz, CDCl3) 170.2 
(CO2H), 162.8 (C4), 133.9 (C6), 132.6 (C1), 127.8 (C3), 113.8 (C5), 96.5 (C2), 55.9 (OMe); 
LRMS (ESI-): m/z  276.9 [M-H-]; found 276.7.  Spectral data consistent with the literature.214  
 
Methyl 2-iodo-4-(methoxymethoxy)benzoate 413 
 
Boron tribromide (1 M solution in DCM, 4.3 mL, 4.3 mmol) was 
added dropwise to a solution of 2-iodo-4-methoxy benzoic acid 
(400 mg, 1.44 mmol) in DCM (15 mL, 0.10 M) at 0 °C. After 16 
hours, the reaction was cooled to 0 °C and quenched by the dropwise addition of MeOH 
(20 mL). The solvents were removed in vacuo. To achieve full conversion to the methyl ester 
from the benzoic acid, conc. HCl (5 mL) was added to the crude material in a solution of MeOH 
(15 mL) and the reaction was heated to reflux for a further 24 hours. The reaction was 
concentrated in vacuo and the reaction was rediluted with DCM (30 mL). The organic layers 
were combined and washed with water (25 mL) and brine (25 mL), dried with MgSO4 and 
concentrated in vacuo. The solid was washed with cold DCM–pentane (1:4, 30 mL) to give 
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methyl 2-iodo-4-hydroxybenzoate as a colourless amorphous solid (300 mg, 76%). 
δH (500 MHz, CDCl3) 7.84 (1H, d, J 8.6, H6), 7.51 (1H, d, J 2.6, H3), 6.86 (1H, dd, J 8.6, 2.6, 
H5), 5.35 (1H, s, OH), 3.89 (3H, s, OMe).  Methyl 2-iodo-4-hydroxybenzoate (300 mg, 1.08 
mmol) was dissolved in THF (10 mL, 0.10 M) with triethylamine (2.8 mL, 20 mmol).  The 
solution was cooled to 0 °C and chloromethylmethyl ether (800 mL, 10.5 mmol) was added 
dropwise to the solution, which was allowed to stir for one hour.  Water (5 mL) was added to 
quench the reaction and the THF was removed in vacuo.  The residue was redissolved in EtOAc 
(30 mL), washed with 1N HCl (20 mL), water (20 mL), brine (20 mL), dried over MgSO4 and 
concentrated in vacuo to afford a crude oil which was purified by flash silica chromatography 
using 0-50% EtOAc in hexane to give a colourless oil (273 mg, 79%). δH (500 MHz, CDCl3) 
7.83 (1H, d, J 8.7, H6), 7.68 (1H, d, J 2.5, H3), 7.04 (1H, dd, J 8.7, 2.5, H5), 5.19 (2H, s, 
OCH2O), 3.90 (3H, s, OMe), 3.47 (3H, s, OCH2OCH3); δC (125 MHz, CDCl3) 166.2 (CO2Me), 
159.8 (C4), 132.6 (C6), 131.7 (C1), 129.3 (C3), 115.5 (C5), 95.4 (C2), 94.4 (OCH2O), 56.5 
(OCH2OCH3), 52.4 (OMe); HRMS (ESI+): m/z calculated for formula C10H12IO4 [MH+]: 
322.9775; found 322.9775; IR (νmax, film, cm-1): 2951, 2904, 2828, 1725, 1590, 1559, 1486, 
1433, 1292, 1258, 1229, 1195, 1152, 1115, 1083. 
 
Methyl 4-(methoxymethoxy)-2-(oct-1-yn-1-yl)benzoate 414 
 
The desired compound was isolated as a colourless oil (206 mg, 
67%) from methyl 2-iodo-4-(methoxymethoxy)benzoate (278 mg, 
1.00 mmol) and 1-octyne (221 mL, 1.50 mmol) following general 
procedure F. The product was isolated by flash silica 
chromatography using 10-40% EtOAc in hexane. RF 0.68 (50% EtOAc in hexane); δH (300 
MHz, CDCl3) 7.87 (1H, d, J 8.8, H6), 7.14 (1H, d, J 2.6, H3), 6.95 (1H, dd, J 8.8, 2.6, H5), 5.20 
(2H, s, OCH2O), 3.88 (3H, s, OMe), 3.47 (3H, s, OCH2OCH3), 2.47 (2H, t, J 7.1, H3’), 1.69-1.57 
(2H, m, H4’), 1.52-1.41 (2H, m, H5’), 1.36-1.29 (4H, m, H6’ and H7’), 0.90 (3H, t, J 6.9, H8’); δC 
(75 MHz, CDCl3) 166.6 (CO2Me), 159.7 (C4), 132.5 (C6), 126.7 (C2), 125.3 (C1), 121.3 (C3), 
115.3 (C5), 96.4 (C2’), 94.3 (OCH2O), 79.4 (C1’), 56.4 (OCH2OCH3), 52.0 (OMe), 31.6 (C6’), 
28.8 (C5’ and C4’), 22.7 (C7’), 20.0 (C3’), 14.2 (C8’); HRMS (ESI+): m/z calculated for formula 
C18H25O4 [MH+]: 305.1747; found 305.1750; IR (νmax, film, cm-1): 2952, 2930, 2858, 2230, 
1730, 1712, 1598, 1563, 1491, 1434, 1318, 1287, 1256, 1217, 1180, 1154, 1140, 1093, 1080, 
1016. 
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12-Hexyl-10-(methoxymethoxy)isoindolo[2,1-b]isoquinoline-5,7-dione 415 
 
The desired compound was isolated as a colourless crystalline solid 
(138 mg, 40%) from methyl 4-(methoxymethoxy)-2-(oct-1-yn-
1-yl)benzoate (345 mg, 1.13 mmol) following general procedure G. 
After 16 hours the reaction was concentrated in vacuo and THF 
(5 mL) was added to dissolve the product and precipitate the 
CsOAc. The solid was removed by filtration and the filtrate was 
cooled to 0 °C and acidified with 2N HCl in ether (5.0 mL, 2.5 mmol).  After one hour the solid, 
which had precipitated from the solution, was collected by filtration to afford a cream 
amorphous solid (138 mg, 35%).  A sample was taken and recrystallized from slow diffusion of 
pentane into a solution of the compound in DMF. M.p. 149-151 °C (DMF–pentane); δH (500 
MHz, CDCl3) 8.56 (1H, d, J 7.3, H4), 7.97 (1H, d, J 8.5, H8), 7.78-7.72 (2H, m, H1 and H2), 7.58 
(1H, d, J 2.0, H11), 7.54 (1H, ddd, J 8.1, 6.6, 1.7, H3), 7.18 (1H, dd, J 8.4, 2.0, H9), 5.32 (2H, s, 
OCH2O), 3.54 (3H, s, OCH2OCH3), 3.12-3.06 (2H, m, H1’), 1.78-1.71 (2H, m, H2’), 1.66-1.58 
(2H, m, H3’), 1.47-1.34 (4H, m, H4’ and H5’), 0.94 (3H, t, J 7.1, H6’); δC (125 MHz, CDCl3) 
164.9 (C7), 163.1 (C10), 159.8 (C5), 137.4 (Cq), 136.5 (Cq), 133.9 (C1 or C2), 130.9 (Cq), 129.8 
(C4), 128.6 (Cq), 128.5 (C3), 127.5 (C8), 124.0 (C1 or C2), 122.2 (Cq), 120.0 (Cq), 118.4 (C9), 
110.9 (C11), 94.9 (OCH2O), 56.6 (OCH2OCH3), 31.9 (C4’), 29.8 (C3’), 29.3 (C2’), 26.8 (C1’), 22.8 
(C5’), 14.2 (C6’); HRMS (ESI+): m/z calculated for formula C24H26NO4 [MH+]: 392.1856; found 
392.1855; IR (νmax, solid, cm-1): 2954, 2922, 2857, 1751, 1669, 1618, 1600, 1479, 1347, 1299, 
1274, 1255, 1242, 1229, 1152, 1109, 1076, 1032, 1016. 
 
12-Hexyl-10-hydroxyisoindolo[2,1-b]isoquinoline-5,7-dione 416 
 
12-Hexyl-10-(methoxymethoxy)isoindolo[2,1-b]-isoquinoline-5,7-
dione (140 mg, 0.35 mmol) was dissolved in MeCN (2.5 mL) and 
cooled to 0 °C.  2 N HCl in ether (5 mL) was added to the reaction 
mixture, which was stirred overnight.  The solvents were removed in 
vacuo and the remaining solid was washed with THF–Et2O (5 mL) to 
afford the desired product (76 mg, 62%).  A sample was recrystallized 
from (DMF–pentane) to afford colourless crystals.  M.p. >270 °C (DMF–pentane); δH (500 
MHz, DMSO-d6) 10.92 (1H, s, OH), 8.33 (1H, dd, J 7.9, 1.3, H4), 7.95 (1H, d, J 8.1, H1), 7.86 
(1H, t, J 7.6, H2), 7.81 (1H, d, J 8.3, H8), 7.62 (1H, t, J 7.2, H3), 7.36 (1H, d, J 1.8, H11), 7.03 
(1H, dd, J 8.4, 1.9, H9), 3.11-3.04 (2H, m, H1’), 1.68 (4H, m, H2’ and H3’), 1.42-1.29 (4H, m, H4’ 
and H5’), 0.90 (3H, t, J 7.1, H6’); δC (125 MHz, DMSO-d6) 164.0 (C7 and C10), 158.5 (C5), 137.0 
(Cq), 136.0 (Cq), 134.2 (C2), 130.5 (Cq), 128.5 (C3), 128.4 (C4), 127.7 (Cq), 127.2 (C8), 124.6 
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(C1), 119.0 (Cq), 118.7 (Cq), 117.8 (C9), 110.1 (C11), 31.2 (C4’), 28.8 (C3’), 28.7 (C2’), 25.6 (C1’), 
22.1 (C5’), 13.9 (C6’); HRMS (ESI+): m/z calculated for formula C22H22NO3 [MH+]: 348.1594; 
found 348.1593; IR (νmax, film, cm-1): 2959, 2924, 2853, 1741, 1667, 1640, 1628, 1592, 1475, 
1433, 1416, 1391, 1352, 1322, 1295, 1277, 1262, 1239, 1204, 1153, 1089, 1032, 1010. 
 
6.10 Imide stability studies 
 
 
 
A solution of the imide 372 in MeOD-d6 (0.5 mL, 0.2 M) was monitored over six hours (at 30 
minute intervals) at room temperature (23 °C, 296 K) and 50 °C (323 K) to compare the rate of 
alcoholysis of the imide. 
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6.11 Absorbance and fluorescent studies 
 
UV-Vis absorbance measurements were recorded on a Perkin-Elmer UV/VIS/NIR Spectrometer 
Lambda 900. Fluorescence measurements were performed using Jobin Yvon Horiba 
FluoroMax-3 in a 1 cm-pathlength cell without an incident ray filter and the Xenon lamp 
calibrated to 467 nm and water peak to 397 nm.  The excitation and emission slit widths were 
set to 1 nm. Spectrophotometric grade solvents were purchased from Sigma-Aldrich. Solvents 
were undegassed during the measurements. 9,10-Diphenylanthracene (97%) was purchased 
from Sigma-Aldrich and subsequently recrystallised from toluene to afford yellow needles.  
Solutions for absorbance and fluorescence studies were prepared prior to the experiment and 
used within 8 hours.  The solutions were stored at 0 °C in the dark to prevent photodegradation.  
 
Solvent correction 
 
9,10-Diphenylanthracene was selected as a reference compound, based on the absorbance and 
fluorescence within the same region as the imide 372. The literature value for 
9,10-diphenylanthracene is specified in cyclohexane (ΦF = 0.9233), therefore a correction for 
measurements performed in DCM was required. Absorbance and fluorescence data for 
9,10-diphenylanthracene in DCM and cyclohexane were recorded using solutions prepared from 
serial dilutions using stock solutions in the corresponding solvent (4.33 × 10-6 M). The emission 
for 9,10-diphenylanthracene in DCM and cyclohexane (Cy) was integrated from 363-552 nm, 
with excitation at 375 nm. The relative slope gradients, obtained from a plot of absorbance 
versus integrated fluorescence, were used to calculated the quantum yield of 9,10-
diphenylanthracene in DCM (ΦF) using the following equation: 
 𝜙!"# =   𝜙!" 𝐺𝑟𝑎𝑑𝑖𝑒𝑛𝑡!"#𝐺𝑟𝑎𝑑𝑖𝑒𝑛𝑡!" 𝜂!"#!𝜂!"!  
 𝜙!"# =   0.90 2.55×10!  2.37×10! 1.424!1.426!  
 𝜙!"# =   0.97   
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Quantum yield of 12-hexylisoindolo[2,1-b]isoquinoline-5,7-dione 372 
 
The quantum yield of fluorescence was determined by comparison of the integrated area of the 
corrected emission spectrum of the imide 372 to that of 9,10-diphenylanthracene as a standard 
fluorescence reference.  Absorbance and fluorescence data for 9,10-diphenylanthracene and the 
imide 372 were recorded using solutions in DCM prepared from serial dilutions from stock 
solutions (Standard: 5.19 × 10-6 M; imide: 4.33 × 10-6 M). The emission for 9,10-
diphenylanthracene and 12-hexylisoindolo-[2,1-b]isoquinoline-5,7-dione 372 was integrated 
from 380-545 nm with excitation at 383 nm and 375 nm, respectively.   
 𝜙! =   0.97 1.22×10!  2.71×10!  𝜙! = 0.44 
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6.12 Cyclic voltammetry 
 
Electrochemical measurements were conducted using an Autolab PGSTAT20 voltammetric 
analyser under an argon atmosphere, solvated in pre-dried CH3CN containing 0.10 M 
[nBu4N]BF4 as supporting electrolyte. Voltammetric experiments utilised a Pt disk working 
electrode, a Pt rod auxiliary electrode and an Ag/AgCl reference electrode. All potentials quoted 
are referenced to an internal ferrocene/ferrocenium standard and were obtained at various scan 
rates (ν) of 10-1000 mVs-1. The ferrocene/ferrocenium couple under these conditions was 
observed at + 0.45 ≤ E1/2 ≤ 0.47 V vs Ag/AgCl. 
 
 
Cyclic voltammogram of 372 (1.0 mM) in non-aqueous media (CH3CN/[nBu4N]BF4 0.10 M), T = 298 K, 
[Fc] = 1.0 mM. 
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Cyclic voltammogram of 387 (1.0 mM) in non-aqueous media (CH3CN/[nBu4N]BF4 0.10 M), T = 298 K, 
[Fc] = 1.0 mM. 
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Cyclic voltammogram of 423 (1.0 mM) in non-aqueous media (CH3CN/[nBu4N]BF4 0.10 M), T = 298 K, 
[Fc] = 1.0 mM. 
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Cyclic voltammogram of 424 (1.0 mM) in non-aqueous media (CH3CN/[nBu4N]BF4 0.10 M), T = 298 K, 
[Fc] = 1.0 mM. 
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Appendix 
 
A1. NMR Studies 
 
Appendix 1.1 
 
 
 500 MHz 1H NMR NOESY of 130 in deuterated CDCl3. 
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500 MHz 1H NMR NOESY of 123 in deuterated CDCl3. 
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500 MHz 1H NMR NOESY of 122 in deuterated CDCl3. 
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A2. X-ray crystal structures 
 
Appendix 2.1 
 
Compound 123 
 
Crystal data and structure refinement. 
 
Identification code Compound 123                                      
Formula C11H11NO2 
Formula weight 189.21 
Size 0.5284 x 0.2603 x 0.1529 mm 
Crystal morphology Colourless block 
Temperature 100.00(10) K 
Wavelength 0.7107 Å  [Mo -Ka] 
Crystal system Orthorhombic 
Space group Pna21 
Unit cell dimensions a = 7.2675(4) Å a = 90° 
 b = 12.9319(6) Å b = 90° 
 c = 9.6419(5) Å g = 90° 
Volume 906.18(8) Å3 
Z 4 
Density (calculated) 1.387 Mg/m3 
Absorption coefficient 0.096 mm-1 
F(000) 400 
Data collection range 3.15 ≤ q ≤ 26.35° 
Index ranges -7 ≤ h ≤9,  -16 ≤ k ≤ 15,  -12 ≤ l ≤ 10 
	   215 
Reflections collected 3228 
Independent reflections 1560 [R(int) = 0.0632] 
Observed reflections 1315 [I >2s(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.46407 
Refinement method Full 
Data / restraints / parameters 1560 / 1 / 127 
Goodness of fit 1.07 
Final R indices  [I >2s(I)] R1 = 0.0529, wR2 = 0.1146 
R indices (all data) R1 = 0.0661, wR2 = 0.1307 
Largest diff. peak and hole 0.235 and -0.27e.Å-3 
Absolute structure parameter -1(2) 
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Appendix 2.2 
 
Compound 267 
 
Identification code Compound 267                                           
Formula C32H41N4O6.50 
Formula weight 585.69 
Size 0.3092 x 0.2031 x 0.1568 mm 
Crystal morphology Colourless block 
Temperature 100.00(10) K 
Wavelength 0.7107 Å  [Mo -Ka] 
Crystal system Monoclinic 
Space group P21/n 
Unit cell dimensions a = 10.1273(5) Å a = 90° 
 b = 12.4095(5) Å b = 91.343(4)° 
 c = 24.1328(9) Å g = 90° 
Volume 3032.0(2) Å3 
Z 4 
Density (calculated) 1.283 Mg/m3 
Absorption coefficient 0.09 mm-1 
F(000) 1252 
Data collection range 1.85 ≤ q ≤ 29.88° 
Index ranges -10 ≤ h ≤14,  -16 ≤ k ≤ 14,  -32 ≤ l ≤ 32 
Reflections collected 18513 
	   217 
Independent reflections 7396 [R(int) = 0.034] 
Observed reflections 6032 [I >2s(I)] 
Absorption correction multi-scan 
Max. and min. transmission 1 and 0.87787 
Refinement method Full 
Data / restraints / parameters 7396 / 0 / 551 
Goodness of fit 1.016 
Final R indices  [I >2s(I)] R1 = 0.0461, wR2 = 0.1063 
R indices (all data) R1 = 0.0594, wR2 = 0.1149 
Largest diff. peak and hole 0.295 and -0.275e.Å-3 
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Appendix 2.3 
 
Compound 372 
 
  
Identification code Compound 372                                         
Formula C22H21NO2 
Formula weight 331.4 
Size 0.16 x 0.07 x 0.03 mm 
Crystal morphology Colourless plate 
Temperature 99.9(5) K 
Wavelength 1.54184 Å  [Cu-Kα] 
Crystal system Monoclinic 
Space group P2(1)/c 
Unit cell dimensions a = 4.90124(14) Å α = 90° 
 b = 21.2010(5) Å β = 93.043(2)° 
 c = 16.3443(4) Å γ = 90° 
Volume 1695.96(8) Å3 
Z 4 
Density (calculated) 1.298 Mg/m3 
Absorption coefficient 0.654 mm-1 
F(000) 704 
Data collection range 3.42 ≤ θ ≤ 66.6° 
Index ranges -5 ≤ h ≤5,  -25 ≤ k ≤ 25,  -19 ≤ l ≤ 19 
Reflections collected 11979 
Independent reflections 2989 [R(int) = 0.0348] 
Observed reflections 2590 [I >2σ(I)] 
Absorption correction analytical 
	   219 
Max. and min. transmission 0.981 and 0.947 
Refinement method Full 
Data / restraints / parameters 2989 / 0 / 227 
Goodness of fit 1.045 
Final R indices  [I >2σ(I)] R1 = 0.0417, wR2 = 0.0994 
R indices (all data) R1 = 0.0497, wR2 = 0.1044 
Largest diff. peak and hole 0.439 and -0.197e.Å-3 
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Appendix 2.4 
 
Compound 440 
 
 
Identification code Compound 440                                         
Formula C49H48F6N2O11S2Zn 
Formula weight 1084.38 
Size 0.16 x 0.1 x 0.07 mm 
Crystal morphology Yellow Fragments 
Temperature 120.01(13) K 
Wavelength 0.71073 Å  [Mo-Kα] 
Crystal system Triclinic 
Space group P! 
Unit cell dimensions a = 6.6901(4) Å α = 78.707(4)° 
 b = 12.7594(7) Å β = 84.883(4)° 
 c = 14.8752(6) Å γ = 75.297(5)° 
Volume 1203.36(10) Å3 
Z 1 
Density (calculated) 1.496 Mg/m3 
Absorption coefficient 0.683 mm-1 
F(000) 560 
Data collection range 3.15 ≤ θ ≤ 26.37° 
	   221 
Index ranges -8 ≤ h ≤8,  -15 ≤ k ≤ 15,  -18 ≤ l ≤ 17 
Reflections collected 13053 
Independent reflections 4910 [R(int) = 0.0451] 
Observed reflections 3789 [I >2σ(I)] 
Absorption correction analytical 
Max. and min. transmission 0.965 and 0.94 
Refinement method Full 
Data / restraints / parameters 4910 / 1 / 341 
Goodness of fit 1.052 
Final R indices  [I >2σ(I)] R1 = 0.0479, wR2 = 0.0976 
R indices (all data) R1 = 0.0713, wR2 = 0.1077 
Largest diff. peak and hole 0.724 and -0.462e.Å-3 
 
 
